<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="21.06.1">
<page number="1" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="0" size="18" family="BCDEEE+TimesNewRomanPSMT" color="#000000"/>
	<fontspec id="1" size="29" family="BCDFEE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="2" size="20" family="BCDFEE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="3" size="18" family="BCDHEE+ArialMT" color="#000000"/>
	<fontspec id="4" size="24" family="BCDFEE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="5" size="18" family="BCDGEE+SymbolMT" color="#000000"/>
	<fontspec id="6" size="18" family="Times" color="#000000"/>
<text top="55" left="108" width="693" height="20" font="0">Aetna Medicare Advantra Central Value (PPO), Aetna Medicare Advantra Credit Value (PPO), </text>
<text top="79" left="108" width="694" height="20" font="0">Aetna Medicare Advantra Preferred Plan (PPO), Aetna Medicare Advantra Silver (PPO), Aetna </text>
<text top="102" left="108" width="703" height="20" font="0">Medicare Advantra Value (PPO), Aetna Medicare Choice II Plan (PPO), Aetna Medicare Choice </text>
<text top="126" left="108" width="678" height="20" font="0">Plan (PPO), Aetna Medicare Credit Plan (PPO), Aetna Medicare Discover Value Plan (PPO), </text>
<text top="150" left="108" width="675" height="20" font="0">Aetna Medicare DMG Prime (PPO), Aetna Medicare Elite (PPO), Aetna Medicare Elite Plan </text>
<text top="174" left="108" width="699" height="20" font="0">(PPO), Aetna Medicare Elite Plan 2 (PPO), Aetna Medicare Elite Plan 3 (PPO), Aetna Medicare </text>
<text top="198" left="108" width="704" height="20" font="0">Essential Elite Plan (PPO), Aetna Medicare Essential Plan (PPO), Aetna Medicare Explorer Elite </text>
<text top="221" left="108" width="682" height="20" font="0">(PPO), Aetna Medicare Explorer Plan (PPO), Aetna Medicare Explorer Premier (PPO), Aetna </text>
<text top="245" left="108" width="656" height="20" font="0">Medicare Explorer Premier 2 (PPO), Aetna Medicare Explorer Premier Plan (PPO), Aetna </text>
<text top="269" left="108" width="700" height="20" font="0">Medicare Explorer Premier Plus (PPO), Aetna Medicare Explorer Value (PPO), Aetna Medicare </text>
<text top="293" left="108" width="666" height="20" font="0">Freedom Core Plan (PPO), Aetna Medicare Freedom Plan (PPO), Aetna Medicare Freedom </text>
<text top="317" left="108" width="693" height="20" font="0">Preferred Plan (PPO), Aetna Medicare Gold Plan (PPO), Aetna Medicare Platinum Plan (PPO), </text>
<text top="340" left="108" width="646" height="20" font="0">Aetna Medicare Plus Plan (PPO), Aetna Medicare Preferred Premium Plan (PPO), Aetna </text>
<text top="364" left="108" width="688" height="20" font="0">Medicare Premier (PPO), Aetna Medicare Premier (Regional PPO), Aetna Medicare Premier 1 </text>
<text top="388" left="108" width="695" height="20" font="0">(PPO), Aetna Medicare Premier 2 (PPO), Aetna Medicare Premier Plan (PPO), Aetna Medicare </text>
<text top="412" left="108" width="666" height="20" font="0">Premier Plus (PPO), Aetna Medicare Premier Plus 2 (PPO), Aetna Medicare Premier Plus 2 </text>
<text top="436" left="108" width="700" height="20" font="0">(Regional PPO), Aetna Medicare Premier Plus Plan (PPO), Aetna Medicare Prime (PPO), Aetna </text>
<text top="459" left="108" width="687" height="20" font="0">Medicare Prime 1 (PPO), Aetna Medicare Prime Credit (PPO), Aetna Medicare Prime Premier </text>
<text top="483" left="108" width="655" height="20" font="0">(PPO), Aetna Medicare Select Plan (PPO), Aetna Medicare SNJ Prime Elite (PPO), Aetna </text>
<text top="507" left="108" width="673" height="20" font="0">Medicare The Valley Plan (PPO), Aetna Medicare Value (PPO), Aetna Medicare Value Plan </text>
<text top="531" left="108" width="343" height="20" font="0">(PPO), Aetna Medicare Value Plus Plan (PPO) </text>
<text top="555" left="108" width="193" height="20" font="0">Last Updated: 04/01/2022 </text>
<text top="603" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="608" left="130" width="167" height="27" font="4"><b>BIRATERONE </b></text>
<text top="659" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="683" left="122" width="8" height="22" font="5">•</text>
<text top="682" left="130" width="5" height="23" font="6"> </text>
<text top="685" left="149" width="150" height="20" font="0">Abiraterone Acetate </text>
<text top="705" left="122" width="8" height="22" font="5">•</text>
<text top="704" left="130" width="5" height="23" font="6"> </text>
<text top="707" left="149" width="162" height="20" font="0">Zytiga TABS 500MG </text>
<text top="1018" left="108" width="179" height="20" font="0">NR_0009_3741 09/2014</text>
<text top="1016" left="287" width="9" height="23" font="6"> </text>
<text top="1057" left="108" width="244" height="20" font="0">Formulary ID: 22007: version 12 </text>
<text top="1057" left="801" width="14" height="20" font="0">1 </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="7" size="18" family="BCDFEE+TimesNewRomanPS" color="#000000"/>
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="414" height="20" font="0">Node-positive (N1), non-metastatic (M0) prostate cancer </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="499" height="20" font="0">The requested drug will be used in combination with a gonadotropin-</text>
<text top="332" left="274" width="473" height="20" font="0">releasing hormone (GnRH) analog or after bilateral orchiectomy. </text>
<text top="391" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="391" left="274" width="35" height="20" font="0">N/A </text>
<text top="430" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="450" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="430" left="274" width="35" height="20" font="0">N/A </text>
<text top="489" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="510" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="489" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="548" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="548" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">2 </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="8" size="18" family="BCDFEE+TimesNewRomanPS" color="#7e7e7e"/>
	<fontspec id="9" size="18" family="BCDEEE+TimesNewRomanPSMT" color="#7e7e7e"/>
	<fontspec id="10" size="24" family="Times" color="#000000"/>
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="119" height="27" font="4"><b>CITRETIN</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Acitretin </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="537" height="20" font="0">Prevention of non-melanoma skin cancers in high risk individuals, Lichen </text>
<text top="378" left="274" width="334" height="20" font="0">planus, Keratosis follicularis (Darier Disease) </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="528" height="20" font="0">Psoriasis: The patient has experienced an inadequate treatment response, </text>
<text top="497" left="274" width="487" height="20" font="0">intolerance, or the patient has a contraindication to methotrexate or </text>
<text top="518" left="274" width="101" height="20" font="0">cyclosporine. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">3 </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="139" height="27" font="4"><b>CTIMMUNE</b></text>
<text top="119" left="268" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="89" height="20" font="0">Actimmune </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="279" height="20" font="0">Mycosis fungoides, Sezary syndrome. </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">4 </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="101" height="27" font="4"><b>DEMPAS</b></text>
<text top="119" left="231" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Adempas </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="525" height="20" font="0">For pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="476" left="274" width="532" height="20" font="0">[WHO] Group 1): PAH was confirmed by right heart catheterization. For </text>
<text top="497" left="274" width="536" height="20" font="0">PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is </text>
<text top="518" left="274" width="531" height="20" font="0">greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge </text>
<text top="538" left="274" width="469" height="20" font="0">pressure is less than or equal to 15 mmHg, AND 3) pretreatment </text>
<text top="559" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="580" left="274" width="518" height="20" font="0">For chronic thromboembolic pulmonary hypertension (CTEPH) (WHO </text>
<text top="600" left="274" width="521" height="20" font="0">Group 4): 1) Patient has persistent or recurrent CTEPH after pulmonary </text>
<text top="621" left="274" width="508" height="20" font="0">endarterectomy (PEA), OR 2) Patient has inoperable CTEPH with the </text>
<text top="642" left="274" width="504" height="20" font="0">diagnosis confirmed by right heart catheterization AND by computed </text>
<text top="662" left="274" width="503" height="20" font="0">tomography (CT), magnetic resonance imaging (MRI), or pulmonary </text>
<text top="683" left="274" width="99" height="20" font="0">angiography. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="760" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="781" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="760" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="879" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="879" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">5 </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="96" height="27" font="4"><b>IMOVIG</b></text>
<text top="119" left="226" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Aimovig </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="525" height="20" font="0">1) The patient received at least 3 months of treatment with the requested </text>
<text top="476" left="274" width="510" height="20" font="0">drug, and the patient had a reduction in migraine days per month from </text>
<text top="497" left="274" width="538" height="20" font="0">baseline, OR 2) The patient experienced an inadequate treatment response </text>
<text top="518" left="274" width="523" height="20" font="0">with a 4-week trial of any of the following: Antiepileptic drugs (AEDs), </text>
<text top="538" left="274" width="501" height="20" font="0">Beta-adrenergic blocking agents, Antidepressants, OR 3) The patient </text>
<text top="559" left="274" width="534" height="20" font="0">experienced an intolerance or has a contraindication that would prohibit a </text>
<text top="580" left="274" width="513" height="20" font="0">4-week trial of any of the following: Antiepileptic drugs (AEDs), Beta-</text>
<text top="600" left="274" width="327" height="20" font="0">adrenergic blocking agents, Antidepressants. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="318" height="20" font="0">Initial 3 months, Reauthorization Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">6 </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="113" height="27" font="4"><b>LECENSA</b></text>
<text top="119" left="243" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Alecensa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="495" height="20" font="0">Recurrent ALK-positive non-small cell lung cancer (NSCLC), brain </text>
<text top="378" left="274" width="292" height="20" font="0">metastases from ALK-positive NSCLC. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">7 </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="133" height="27" font="4"><b>LOSETRON</b></text>
<text top="119" left="263" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="185" height="20" font="0">Alosetron Hydrochloride </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="503" height="20" font="0">1) The requested drug is being prescribed for a biological female or a </text>
<text top="476" left="274" width="529" height="20" font="0">person that self-identifies as a female with a diagnosis of severe diarrhea-</text>
<text top="497" left="274" width="483" height="20" font="0">predominant irritable bowel syndrome (IBS) AND 2) Chronic IBS </text>
<text top="518" left="274" width="475" height="20" font="0">symptoms lasting at least 6 months AND 3) Gastrointestinal tract </text>
<text top="538" left="274" width="511" height="20" font="0">abnormalities have been ruled out AND 4) Inadequate response to one </text>
<text top="559" left="274" width="435" height="20" font="0">conventional therapy (e.g., antispasmodics, antidepressants, </text>
<text top="580" left="274" width="113" height="20" font="0">antidiarrheals). </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">8 </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="67" height="27" font="4"><b>LPHA</b></text>
<text top="118" left="196" width="25" height="33" font="1"><b>1-</b></text>
<text top="123" left="221" width="162" height="27" font="4"><b>PROTEINASE </b></text>
<text top="118" left="383" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="395" width="123" height="27" font="4"><b>NHIBITOR</b></text>
<text top="119" left="518" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="83" height="20" font="0">Prolastin-c </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="536" height="20" font="0">For alpha1-proteinase inhibitor deficiency: Patient must have 1) clinically </text>
<text top="476" left="274" width="541" height="20" font="0">evident emphysema and 2) pretreatment serum alpha1-proteinase inhibitor </text>
<text top="497" left="274" width="540" height="20" font="0">level less than 11 micromol/L (80 mg/dL by radial immunodiffusion or 50 </text>
<text top="518" left="274" width="189" height="20" font="0">mg/dL by nephelometry). </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="801" width="14" height="20" font="0">9 </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="112" height="27" font="4"><b>LUNBRIG</b></text>
<text top="119" left="242" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Alunbrig </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="495" height="20" font="0">Recurrent ALK-positive non-small cell lung cancer (NSCLC), brain </text>
<text top="378" left="274" width="292" height="20" font="0">metastases from ALK-positive NSCLC. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">10 </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="163" height="27" font="4"><b>MBRISENTAN</b></text>
<text top="119" left="292" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="97" height="20" font="0">Ambrisentan </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="496" height="20" font="0">Pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="476" left="274" width="538" height="20" font="0">[WHO] Group 1): Diagnosis was confirmed by right heart catheterization. </text>
<text top="497" left="274" width="486" height="20" font="0">For PAH new starts only: 1) Pretreatment mean pulmonary arterial </text>
<text top="518" left="274" width="518" height="20" font="0">pressure is greater than 20 mmHg, 2) Pretreatment pulmonary capillary </text>
<text top="538" left="274" width="509" height="20" font="0">wedge pressure is less than or equal to 15 mmHg, and 3) Pretreatment </text>
<text top="559" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">11 </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="115" height="27" font="4"><b>RCALYST</b></text>
<text top="119" left="244" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Arcalyst </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="474" height="20" font="0">Prevention of gout flares in patients initiating or continuing urate-</text>
<text top="378" left="274" width="131" height="20" font="0">lowering therapy. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="503" height="20" font="0">For prevention of gout flares in patients initiating or continuing urate-</text>
<text top="497" left="274" width="500" height="20" font="0">lowering therapy (e.g., allopurinol) (new starts): 1) two or more gout </text>
<text top="518" left="274" width="490" height="20" font="0">flares within the previous 12 months, AND 2) inadequate response, </text>
<text top="538" left="274" width="498" height="20" font="0">intolerance or contraindication to maximum tolerated doses of a non-</text>
<text top="559" left="274" width="487" height="20" font="0">steroidal anti-inflammatory drug (NSAID) and colchicine, AND 3) </text>
<text top="580" left="274" width="531" height="20" font="0">concurrent use with urate-lowering therapy. For prevention of gout flares </text>
<text top="600" left="274" width="459" height="20" font="0">in patients initiating or continuing urate-lowering therapy (e.g., </text>
<text top="621" left="274" width="537" height="20" font="0">allopurinol) (continuation): 1) patient must have achieved or maintained a </text>
<text top="642" left="274" width="523" height="20" font="0">clinical benefit (i.e., a fewer number of gout attacks or fewer flare days) </text>
<text top="662" left="274" width="517" height="20" font="0">compared to baseline, AND 2) continued use of urate-lowering therapy </text>
<text top="683" left="274" width="274" height="20" font="0">concurrently with the requested drug. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="760" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="781" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="760" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="418" height="20" font="0">For prevention of gout flares: 4 months. Other: Plan Year </text>
<text top="879" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="879" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">12 </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="160" height="27" font="4"><b>RMODAFINIL</b></text>
<text top="119" left="290" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="94" height="20" font="0">Armodafinil </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="467" height="20" font="0">1) The patient has a diagnosis of narcolepsy and the diagnosis is </text>
<text top="476" left="274" width="516" height="20" font="0">confirmed by sleep lab evaluation OR 2) The patient has a diagnosis of </text>
<text top="497" left="274" width="477" height="20" font="0">Shift Work Disorder (SWD) OR 3) The patient has a diagnosis of </text>
<text top="518" left="274" width="472" height="20" font="0">obstructive sleep apnea (OSA) and the diagnosis is confirmed by </text>
<text top="538" left="274" width="139" height="20" font="0">polysomnography. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">13 </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="109" height="27" font="4"><b>SPARLAS</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Asparlas </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="200" height="20" font="0">Patient age 21 years or less </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">14 </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="99" height="27" font="4"><b>USTEDO</b></text>
<text top="119" left="228" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Austedo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="151" height="20" font="0">Tourette's syndrome </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">15 </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="87" height="27" font="4"><b>VONEX</b></text>
<text top="119" left="216" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="210" height="20" font="0">Avonex INJ 30MCG/0.5ML </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="93" height="20" font="0">Avonex Pen </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="35" height="20" font="0">N/A </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">16 </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>A</b></text>
<text top="123" left="130" width="96" height="27" font="4"><b>YVAKIT</b></text>
<text top="119" left="226" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Ayvakit </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="498" height="20" font="0">Myeloid and lymphoid neoplasms with eosinophilia, gastrointestinal </text>
<text top="378" left="274" width="514" height="20" font="0">stromal tumor (GIST) for unresectable, recurrent, or metastatic disease </text>
<text top="399" left="274" width="535" height="20" font="0">without platelet-derived growth factor receptor alpha (PDGFRA) exon 18 </text>
<text top="419" left="274" width="69" height="20" font="0">mutation </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="537" height="20" font="0">For myeloid and lymphoid neoplasms with eosinophilia, the patient meets </text>
<text top="538" left="274" width="463" height="20" font="0">all of the following criteria: 1) the disease is FIP1L1- PDGFRA </text>
<text top="559" left="274" width="532" height="20" font="0">rearrangement-positive, AND 2) The disease harbors a PDGFRA D842A </text>
<text top="580" left="274" width="498" height="20" font="0">mutation, AND 3) The disease is resistant to imatinib. For GIST, the </text>
<text top="600" left="274" width="493" height="20" font="0">patient meets either of the following criteria: 1) The disease harbors </text>
<text top="621" left="274" width="526" height="20" font="0">PDGFRA exon 18 mutation, including PDGFRA D842V mutations, OR </text>
<text top="642" left="274" width="524" height="20" font="0">2) The requested drug will be used after failure on at least two Food and </text>
<text top="662" left="274" width="467" height="20" font="0">Drug Administration (FDA)-approved therapies in unresectable, </text>
<text top="683" left="274" width="527" height="20" font="0">recurrent, or metastatic disease without PDGFRA exon 18 mutation. For </text>
<text top="704" left="274" width="529" height="20" font="0">advanced systemic mastocytosis (AdvSM): 1) the patient has a diagnosis </text>
<text top="724" left="274" width="477" height="20" font="0">of advanced systemic mastocytosis including aggressive systemic </text>
<text top="745" left="274" width="437" height="20" font="0">mastocytosis (ASM), systemic mastocytosis with associated </text>
<text top="766" left="274" width="541" height="20" font="0">hematological neoplasm (SM-AHN), and mast cell leukemia (MCL) AND </text>
<text top="787" left="274" width="530" height="20" font="0">2) the patient has a platelet count of greater than or equal to 50,000/mcL. </text>
<text top="825" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="825" left="274" width="35" height="20" font="0">N/A </text>
<text top="864" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="885" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="864" left="274" width="35" height="20" font="0">N/A </text>
<text top="923" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="944" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="923" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="983" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="983" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">17 </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="115" height="27" font="4"><b>ALVERSA</b></text>
<text top="119" left="243" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Balversa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">18 </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="83" height="27" font="4"><b>ANZEL</b></text>
<text top="119" left="211" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="105" height="20" font="0">Banzel TABS </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="89" height="20" font="0">Rufinamide </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="35" height="20" font="0">N/A </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="159" height="20" font="0">1 year of age or older </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">19 </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>ELEODAQ</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Beleodaq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="523" height="20" font="0">Adult T-cell leukemia/lymphoma, mycosis fungoides/Sezary syndrome, </text>
<text top="378" left="274" width="536" height="20" font="0">extranodal NK/T-cell lymphoma (nasal type), hepatosplenic gamma-delta </text>
<text top="399" left="274" width="531" height="20" font="0">T-cell lymphoma, and primary cutaneous anaplastic large cell lymphoma </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">20 </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="113" height="27" font="4"><b>ENLYSTA</b></text>
<text top="119" left="241" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Benlysta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="522" height="20" font="0">For patients new to therapy: severe active central nervous system lupus. </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="534" height="20" font="0">For systemic lupus erythematosus (SLE): 1) Patient is currently receiving </text>
<text top="476" left="274" width="532" height="20" font="0">a stable standard therapy regimen (e.g., corticosteroid or antimalarial) for </text>
<text top="497" left="274" width="494" height="20" font="0">SLE OR 2) patient is not currently receiving stable standard therapy </text>
<text top="518" left="274" width="530" height="20" font="0">regimen for SLE because patient tried and had an inadequate response or </text>
<text top="538" left="274" width="506" height="20" font="0">intolerance to stable standard therapy regimen. For lupus nephritis: 1) </text>
<text top="559" left="274" width="499" height="20" font="0">Patient is currently receiving a stable standard therapy regimen (e.g., </text>
<text top="580" left="274" width="533" height="20" font="0">corticosteroid) for lupus nephritis OR 2) patient is not currently receiving </text>
<text top="600" left="274" width="535" height="20" font="0">a stable standard therapy regimen for lupus nephritis because patient tried </text>
<text top="621" left="274" width="538" height="20" font="0">and had an inadequate response or intolerance to a stable standard therapy </text>
<text top="642" left="274" width="68" height="20" font="0">regimen. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">21 </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="95" height="27" font="4"><b>ESREMI</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Besremi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">22 </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="132" height="27" font="4"><b>ETASERON</b></text>
<text top="119" left="260" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="77" height="20" font="0">Betaseron </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">23 </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="167" height="27" font="4"><b>EVACIZUMAB</b></text>
<text top="119" left="295" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Zirabev </text>
<text top="1096" left="792" width="23" height="20" font="0">24 </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="540" height="20" font="0">Breast cancer, central nervous system (CNS) tumor types: adult low-grade </text>
<text top="234" left="274" width="308" height="20" font="0">(WHO Grade II) infiltrative supratentorial </text>
<text top="254" left="274" width="444" height="20" font="0">astrocytoma/oligodendroglioma, adult intracranial and spinal </text>
<text top="275" left="274" width="537" height="20" font="0">ependymoma, anaplastic gliomas, adult medulloblastoma, primary central </text>
<text top="296" left="274" width="508" height="20" font="0">nervous system lymphoma, meningiomas, limited and extensive brain </text>
<text top="316" left="274" width="536" height="20" font="0">metastases, and metastatic spine tumors, malignant pleural mesothelioma, </text>
<text top="337" left="274" width="503" height="20" font="0">ovarian cancer/fallopian tube cancer/primary peritoneal cancer types: </text>
<text top="358" left="274" width="460" height="20" font="0">carcinosarcoma (malignant mixed Mullerian tumors), clear cell </text>
<text top="378" left="274" width="518" height="20" font="0">carcinoma, mucinous carcinoma, grade 1 endometrioid carcinoma, low-</text>
<text top="399" left="274" width="479" height="20" font="0">grade serous carcinoma, ovarian borderline epithelial tumors (low </text>
<text top="420" left="274" width="496" height="20" font="0">malignant potential) with invasive implants, and malignant sex cord-</text>
<text top="440" left="274" width="500" height="20" font="0">stromal tumors, soft tissue sarcoma types: angiosarcoma and solitary </text>
<text top="461" left="274" width="494" height="20" font="0">fibrous tumor/hemangiopericytoma, uterine neoplasms, endometrial </text>
<text top="482" left="274" width="468" height="20" font="0">cancer, vulvar squamous cell carcinoma, and ophthalmic-related </text>
<text top="503" left="274" width="535" height="20" font="0">disorders: diabetic macular edema, neovascular (wet) age-related macular </text>
<text top="523" left="274" width="537" height="20" font="0">degeneration including polypoidal choroidopathy and retinal angiomatous </text>
<text top="544" left="274" width="519" height="20" font="0">proliferation subtypes, macular edema following retinal vein occlusion, </text>
<text top="565" left="274" width="462" height="20" font="0">proliferative diabetic retinopathy, choroidal neovascularization, </text>
<text top="585" left="274" width="486" height="20" font="0">neovascular glaucoma and retinopathy of prematurity, small bowel </text>
<text top="606" left="274" width="127" height="20" font="0">adenocarcinoma. </text>
<text top="645" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="666" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="645" left="274" width="35" height="20" font="0">N/A </text>
<text top="704" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="725" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="746" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="704" left="274" width="35" height="20" font="0">N/A </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="844" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="942" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="942" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="963" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="983" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="792" width="23" height="20" font="0">25 </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="152" height="27" font="4"><b>EXAROTENE</b></text>
<text top="119" left="280" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="87" height="20" font="0">Bexarotene </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="527" height="20" font="0">Mycosis fungoides, Sezary syndrome, CD30-positive primary cutaneous </text>
<text top="378" left="274" width="530" height="20" font="0">anaplastic large cell lymphoma, CD30-positive lymphomatoid papulosis. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">26 </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="97" height="27" font="4"><b>LENREP</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Blenrep </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">27 </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="116" height="27" font="4"><b>OSENTAN</b></text>
<text top="119" left="244" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Bosentan </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="115" height="20" font="0">Tracleer TBSO </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="525" height="20" font="0">For pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="498" left="274" width="538" height="20" font="0">[WHO] Group 1): Diagnosis was confirmed by right heart catheterization. </text>
<text top="519" left="274" width="486" height="20" font="0">For PAH new starts only: 1) Pretreatment mean pulmonary arterial </text>
<text top="539" left="274" width="518" height="20" font="0">pressure is greater than 20 mmHg, 2) Pretreatment pulmonary capillary </text>
<text top="560" left="274" width="509" height="20" font="0">wedge pressure is less than or equal to 15 mmHg, and 3) Pretreatment </text>
<text top="581" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">28 </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="89" height="27" font="4"><b>OSULIF</b></text>
<text top="119" left="217" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Bosulif </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="512" height="20" font="0">Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ </text>
<text top="378" left="274" width="45" height="20" font="0">ALL) </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="516" height="20" font="0">For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia </text>
<text top="497" left="274" width="477" height="20" font="0">(ALL): Diagnosis was confirmed by detection of the Philadelphia </text>
<text top="518" left="274" width="501" height="20" font="0">chromosome or BCR-ABL gene. For CML, including patients newly </text>
<text top="538" left="274" width="507" height="20" font="0">diagnosed with CML and patients who have received a hematopoietic </text>
<text top="559" left="274" width="521" height="20" font="0">stem cell transplant: patient has experienced resistance or intolerance to </text>
<text top="580" left="274" width="515" height="20" font="0">imatinib or dasatinib. If patient experienced resistance to an alternative </text>
<text top="600" left="274" width="482" height="20" font="0">tyrosine kinase inhibitor for CML, patient is negative for all of the </text>
<text top="621" left="274" width="415" height="20" font="0">following mutations: T315I, G250E, V299L, and F317L. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">29 </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="111" height="27" font="4"><b>RAFTOVI</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="166" height="20" font="0">Braftovi CAPS 75MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="379" height="20" font="0">Adjuvant systemic therapy for cutaneous melanoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="483" height="20" font="0">For colorectal cancer: The patient must meet both of the following </text>
<text top="476" left="274" width="469" height="20" font="0">criteria: 1) Tumor is positive for BRAF V600E mutation, 2) The </text>
<text top="497" left="274" width="521" height="20" font="0">requested drug will be used for either of the following: a) as subsequent </text>
<text top="518" left="274" width="532" height="20" font="0">therapy for advanced or metastatic disease, or b) as primary treatment for </text>
<text top="538" left="274" width="509" height="20" font="0">unresectable metachronous metastases. For cutaneous melanoma: The </text>
<text top="559" left="274" width="512" height="20" font="0">patient must meet all of the following criteria: 1) Tumor is positive for </text>
<text top="580" left="274" width="476" height="20" font="0">BRAF V600 activating mutation (e.g., V600E or V600K), 2) The </text>
<text top="600" left="274" width="526" height="20" font="0">requested drug will be used in combination with binimetinib, and 3) The </text>
<text top="621" left="274" width="531" height="20" font="0">requested drug will be used for either of the following: a) unresectable or </text>
<text top="642" left="274" width="374" height="20" font="0">metastatic disease, or b) adjuvant systemic therapy. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">30 </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="104" height="27" font="4"><b>RIVIACT</b></text>
<text top="119" left="232" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="167" height="20" font="0">Briviact ORAL SOLN </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="113" height="20" font="0">Briviact TABS </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="474" height="20" font="0">1) The patient has experienced an inadequate treatment response, </text>
<text top="498" left="274" width="534" height="20" font="0">intolerance, or contraindication to a generic anticonvulsant AND 2) If the </text>
<text top="519" left="274" width="462" height="20" font="0">patient is 4 years of age or older, the patient has experienced an </text>
<text top="539" left="274" width="525" height="20" font="0">inadequate treatment response, intolerance, or contraindication to any of </text>
<text top="560" left="274" width="358" height="20" font="0">the following: Aptiom, Vimpat, Xcopri, Spritam. </text>
<text top="599" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="599" left="274" width="174" height="20" font="0">1 month of age or older </text>
<text top="638" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="658" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="638" left="274" width="35" height="20" font="0">N/A </text>
<text top="697" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="718" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="697" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="756" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="756" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">31 </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="110" height="27" font="4"><b>RIVIACT </b></text>
<text top="118" left="238" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="250" width="29" height="27" font="4"><b>NJ</b></text>
<text top="119" left="279" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="93" height="20" font="0">Briviact INJ </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="474" height="20" font="0">1) The patient has experienced an inadequate treatment response, </text>
<text top="476" left="274" width="534" height="20" font="0">intolerance, or contraindication to a generic anticonvulsant AND 2) If the </text>
<text top="497" left="274" width="462" height="20" font="0">patient is 4 years of age or older, the patient has experienced an </text>
<text top="518" left="274" width="525" height="20" font="0">inadequate treatment response, intolerance, or contraindication to any of </text>
<text top="538" left="274" width="358" height="20" font="0">the following: Aptiom, Vimpat, Xcopri, Spritam. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="174" height="20" font="0">1 month of age or older </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">32 </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="111" height="27" font="4"><b>RUKINSA</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Brukinsa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">33 </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="195" height="27" font="4"><b>UPRENORPHINE</b></text>
<text top="119" left="323" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="194" height="20" font="0">Buprenorphine Hcl SUBL </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="507" height="20" font="0">The requested drug is being prescribed for the treatment of opioid use </text>
<text top="476" left="274" width="485" height="20" font="0">disorder AND patient meets one of the following: 1) The patient is </text>
<text top="497" left="274" width="527" height="20" font="0">pregnant or breastfeeding, and the requested drug is being prescribed for </text>
<text top="518" left="274" width="537" height="20" font="0">induction therapy and/or subsequent maintenance therapy for treatment of </text>
<text top="538" left="274" width="501" height="20" font="0">opioid use disorder OR 2) The requested drug is being prescribed for </text>
<text top="559" left="274" width="537" height="20" font="0">induction therapy for transition from opioid use to treatment of opioid use </text>
<text top="580" left="274" width="517" height="20" font="0">disorder OR 3) The requested drug is being prescribed for maintenance </text>
<text top="600" left="274" width="528" height="20" font="0">therapy for treatment of opioid use disorder in a patient who is intolerant </text>
<text top="621" left="274" width="94" height="20" font="0">to naloxone. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="80" height="20" font="0">12 months </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">34 </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="128" width="201" height="27" font="4"><b>UPRENORPHINE </b></text>
<text top="118" left="329" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="347" width="69" height="27" font="4"><b>ATCH</b></text>
<text top="119" left="416" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="168" height="20" font="0">Buprenorphine PTWK </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="535" height="20" font="0">1) The requested drug is being prescribed for pain associated with cancer, </text>
<text top="476" left="274" width="521" height="20" font="0">sickle cell disease, a terminal condition, or pain being managed through </text>
<text top="497" left="274" width="500" height="20" font="0">palliative care OR 2) The requested drug is being prescribed for pain </text>
<text top="518" left="274" width="538" height="20" font="0">severe enough to require daily, around-the-clock, long-term treatment in a </text>
<text top="538" left="274" width="538" height="20" font="0">patient who has been taking an opioid AND 3) The patient can safely take </text>
<text top="559" left="274" width="520" height="20" font="0">the requested dose based on their history of opioid use [Note: This drug </text>
<text top="580" left="274" width="452" height="20" font="0">should be prescribed only by healthcare professionals who are </text>
<text top="600" left="274" width="540" height="20" font="0">knowledgeable in the use of potent opioids for the management of chronic </text>
<text top="621" left="274" width="500" height="20" font="0">pain.] AND 4) The patient has been evaluated and the patient will be </text>
<text top="642" left="274" width="489" height="20" font="0">monitored for the development of opioid use disorder AND 5) This </text>
<text top="662" left="274" width="536" height="20" font="0">request is for continuation of therapy for a patient who has been receiving </text>
<text top="683" left="274" width="519" height="20" font="0">an extended-release opioid agent for at least 30 days OR the patient has </text>
<text top="704" left="274" width="410" height="20" font="0">taken an immediate-release opioid for at least one week. </text>
<text top="742" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="742" left="274" width="35" height="20" font="0">N/A </text>
<text top="781" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="802" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="781" left="274" width="35" height="20" font="0">N/A </text>
<text top="841" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="861" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="841" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="900" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="900" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">35 </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="141" height="27" font="4"><b>ABOMETYX</b></text>
<text top="119" left="271" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="88" height="20" font="0">Cabometyx </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="199" height="20" font="0">Non-small cell lung cancer </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="525" height="20" font="0">For renal cell carcinoma: The disease is advanced, relapsed, or stage IV. </text>
<text top="476" left="274" width="487" height="20" font="0">For non-small cell lung cancer: 1) The disease is rearranged during </text>
<text top="497" left="274" width="534" height="20" font="0">transfection (RET) positive AND 2) the disease is recurrent, advanced, or </text>
<text top="518" left="274" width="531" height="20" font="0">metastatic. For hepatocellular carcinoma: the requested drug will be used </text>
<text top="538" left="274" width="181" height="20" font="0">as subsequent treatment. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">36 </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="185" height="27" font="4"><b>ALCIPOTRIENE</b></text>
<text top="119" left="315" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="154" height="20" font="0">Calcipotriene CREA </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="149" height="20" font="0">Calcipotriene OINT </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="153" height="20" font="0">Calcipotriene SOLN </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="9" height="23" font="6">  </text>
<text top="266" left="149" width="213" height="20" font="0">Calcipotriene/betamethasone </text>
<text top="286" left="149" width="147" height="20" font="0">Dipropionate OINT </text>
<text top="306" left="122" width="8" height="22" font="5">•</text>
<text top="306" left="130" width="9" height="23" font="6">  </text>
<text top="308" left="149" width="120" height="20" font="0">Calcitriol OINT </text>
<text top="328" left="122" width="8" height="22" font="5">•</text>
<text top="328" left="130" width="9" height="23" font="6">  </text>
<text top="330" left="149" width="61" height="20" font="0">Enstilar </text>
<text top="407" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="407" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="449" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="449" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="488" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="488" left="274" width="35" height="20" font="0">N/A </text>
<text top="527" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="547" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="527" left="274" width="35" height="20" font="0">N/A </text>
<text top="586" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="607" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="627" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="586" left="274" width="515" height="20" font="0">1) The requested drug is being prescribed for the treatment of psoriasis </text>
<text top="607" left="274" width="489" height="20" font="0">AND 2) The patient experienced an inadequate treatment response, </text>
<text top="627" left="274" width="493" height="20" font="0">intolerance, or the patient has a contraindication to a topical steroid. </text>
<text top="666" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="666" left="274" width="35" height="20" font="0">N/A </text>
<text top="705" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="726" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="705" left="274" width="35" height="20" font="0">N/A </text>
<text top="764" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="785" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="764" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="824" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="824" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">37 </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="136" height="27" font="4"><b>ALQUENCE</b></text>
<text top="119" left="266" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="80" height="20" font="0">Calquence </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="473" height="20" font="0">Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="523" height="20" font="0">For chronic lymphocytic leukemia or small lymphocytic lymphoma: the </text>
<text top="476" left="274" width="487" height="20" font="0">patient has experienced an intolerable adverse event with ibrutinib. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">38 </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="99" height="27" font="4"><b>APLYTA</b></text>
<text top="119" left="228" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Caplyta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="534" height="20" font="0">The patient experienced an inadequate treatment response, intolerance, or </text>
<text top="476" left="274" width="538" height="20" font="0">contraindication to one of the following generic products: A) aripiprazole, </text>
<text top="497" left="274" width="539" height="20" font="0">B) asenapine, C) olanzapine, D) quetiapine, E) risperidone, F) ziprasidone </text>
<text top="518" left="274" width="463" height="20" font="0">AND the patient experienced an inadequate treatment response, </text>
<text top="538" left="274" width="540" height="20" font="0">intolerance, or contraindication to one of the following brand products: A) </text>
<text top="559" left="274" width="236" height="20" font="0">Latuda, B) Rexulti, C) Secuado. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">39 </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="112" height="27" font="4"><b>APRELSA</b></text>
<text top="119" left="242" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Caprelsa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="519" height="20" font="0">Differentiated thyroid carcinoma: papillary, follicular, and Hurthle cell. </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">40 </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="69" height="27" font="4"><b>ARAC</b></text>
<text top="119" left="199" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="188" height="20" font="0">Fluorouracil CREA 0.5% </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="476" height="20" font="0">Patients who are pregnant or may become pregnant. Patients with </text>
<text top="417" left="274" width="449" height="20" font="0">dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="517" height="20" font="0">If being used as part of a compounded product, all active ingredients in </text>
<text top="476" left="274" width="434" height="20" font="0">the compounded product are FDA approved for topical use. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="71" height="20" font="0">3 months </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">41 </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="120" height="27" font="4"><b>ARBAGLU</b></text>
<text top="119" left="250" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Carbaglu </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="533" height="20" font="0">For N-acetylglutamate synthase (NAGS) deficiency: Diagnosis of NAGS </text>
<text top="476" left="274" width="424" height="20" font="0">deficiency was confirmed by enzymatic or genetic testing. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">42 </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="100" height="27" font="4"><b>AYSTON</b></text>
<text top="119" left="230" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Cayston </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="491" height="20" font="0">For treatment of respiratory symptoms in cystic fibrosis patients: 1) </text>
<text top="476" left="274" width="531" height="20" font="0">Pseudomonas aeruginosa is present in the patient's airway cultures OR 2) </text>
<text top="497" left="274" width="474" height="20" font="0">The patient has a history of pseudomonas aeruginosa infection or </text>
<text top="518" left="274" width="203" height="20" font="0">colonization in the airways. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">43 </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="119" height="27" font="4"><b>ERDELGA</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Cerdelga </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="514" height="20" font="0">For Gaucher disease, the diagnosis was confirmed by an enzyme assay </text>
<text top="476" left="274" width="536" height="20" font="0">demonstrating a deficiency of beta-glucocerebrosidase enzyme activity or </text>
<text top="497" left="274" width="505" height="20" font="0">by genetic testing. The patient's CYP2D6 metabolizer status has been </text>
<text top="518" left="274" width="540" height="20" font="0">established using an FDA-cleared test. The patient is a CYP2D6 extensive </text>
<text top="538" left="274" width="467" height="20" font="0">metabolizer, an intermediate metabolizer, or a poor metabolizer. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">44 </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="96" height="27" font="4"><b>HANTIX</b></text>
<text top="119" left="226" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="121" height="20" font="0">Apo-varenicline </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="215" height="20" font="0">Chantix TABS 0.5MG, 1MG </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="231" height="20" font="0">Chantix Continuing Month Pak </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="207" height="20" font="0">Chantix Starting Month Pak </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="5" height="23" font="6"> </text>
<text top="288" left="149" width="150" height="20" font="0">Varenicline Tartrate </text>
<text top="365" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="365" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="407" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="407" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="445" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="445" left="274" width="35" height="20" font="0">N/A </text>
<text top="484" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="505" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="484" left="274" width="35" height="20" font="0">N/A </text>
<text top="543" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="564" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="585" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="543" left="274" width="35" height="20" font="0">N/A </text>
<text top="623" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="623" left="274" width="35" height="20" font="0">N/A </text>
<text top="662" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="683" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="662" left="274" width="35" height="20" font="0">N/A </text>
<text top="722" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="742" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="722" left="274" width="71" height="20" font="0">6 months </text>
<text top="781" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="781" left="274" width="484" height="20" font="0">This Prior Authorization requirement applies after the member has </text>
<text top="802" left="274" width="424" height="20" font="0">received a cumulative 24 weeks of therapy in a Plan Year. </text>
<text top="1096" left="792" width="23" height="20" font="0">45 </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="11" size="29" family="Times" color="#000000"/>
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="246" height="27" font="4"><b>HLORDIAZEPOXIDE </b></text>
<text top="118" left="376" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="422" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="268" height="20" font="0">Chlordiazepoxide Hcl CAPS 10MG, </text>
<text top="221" left="149" width="42" height="20" font="0">5MG </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="237" height="20" font="0">Chlordiazepoxide Hydrochloride</text>
<text top="240" left="386" width="9" height="23" font="6"> </text>
<text top="263" left="149" width="96" height="20" font="0">CAPS 25MG</text>
<text top="260" left="245" width="9" height="23" font="6"> </text>
<text top="340" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="340" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="382" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="382" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="421" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="421" left="274" width="35" height="20" font="0">N/A </text>
<text top="459" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="480" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="459" left="274" width="35" height="20" font="0">N/A </text>
<text top="519" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="539" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="560" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="519" left="274" width="483" height="20" font="0">For all indications: the prescriber must acknowledge the benefit of </text>
<text top="539" left="274" width="522" height="20" font="0">therapy with the prescribed medication outweighs the potential risks for </text>
<text top="560" left="274" width="527" height="20" font="0">the patient.  (Note: The American Geriatrics Society identifies the use of </text>
<text top="581" left="274" width="526" height="20" font="0">this medication as potentially inappropriate in older adults, meaning it is </text>
<text top="602" left="274" width="487" height="20" font="0">best avoided, prescribed at reduced dosage, or used with caution or </text>
<text top="622" left="274" width="513" height="20" font="0">carefully monitored.)  For the management of anxiety disorders: 1) the </text>
<text top="643" left="274" width="493" height="20" font="0">requested drug is being used concurrently with a selective serotonin </text>
<text top="664" left="274" width="526" height="20" font="0">reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor </text>
<text top="684" left="274" width="528" height="20" font="0">(SNRI) until SSRI/SNRI is effective for the symptoms of anxiety, OR 2) </text>
<text top="705" left="274" width="537" height="20" font="0">the patient has experienced an inadequate treatment response, intolerance, </text>
<text top="726" left="274" width="526" height="20" font="0">or has a contraindication to AT LEAST TWO agents from the following </text>
<text top="747" left="274" width="472" height="20" font="0">classes: a) selective serotonin reuptake inhibitors (SSRIs), OR b) </text>
<text top="767" left="274" width="395" height="20" font="0">serotonin-norepinephrine reuptake inhibitors (SNRIs). </text>
<text top="806" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="806" left="274" width="35" height="20" font="0">N/A </text>
<text top="845" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="865" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="845" left="274" width="35" height="20" font="0">N/A </text>
<text top="904" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="925" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="904" left="274" width="477" height="20" font="0">Short-term relief anxiety-preop apprehens and anx-1 mo, Anxiety </text>
<text top="925" left="274" width="297" height="20" font="0">Disorder-4 mo, Alc Withdrawal-PlanYR </text>
<text top="963" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="963" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="984" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="792" width="23" height="20" font="0">46 </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="124" height="27" font="4"><b>LOBAZAM</b></text>
<text top="119" left="254" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="78" height="20" font="0">Clobazam </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="166" height="20" font="0">2 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">47 </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="181" height="27" font="4"><b>LOMIPRAMINE</b></text>
<text top="119" left="311" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="189" height="20" font="0">Clomipramine Hcl CAPS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="202" height="20" font="0">Depression, Panic Disorder </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="485" height="20" font="0">1) The requested drug is being prescribed for one of the following: </text>
<text top="476" left="274" width="519" height="20" font="0">Obsessive-Compulsive Disorder (OCD) or Panic Disorder AND 2) The </text>
<text top="497" left="274" width="530" height="20" font="0">patient has experienced an inadequate treatment response, intolerance, or </text>
<text top="518" left="274" width="531" height="20" font="0">the patient has a contraindication to any of the following: a serotonin and </text>
<text top="538" left="274" width="475" height="20" font="0">norepinephrine reuptake inhibitor (SNRI) or a selective serotonin </text>
<text top="559" left="274" width="520" height="20" font="0">reuptake inhibitor (SSRI) OR 3) The requested drug is being prescribed </text>
<text top="580" left="274" width="484" height="20" font="0">for Depression AND 4) The patient has experienced an inadequate </text>
<text top="600" left="274" width="514" height="20" font="0">treatment response, intolerance, or the patient has a contraindication to </text>
<text top="621" left="274" width="512" height="20" font="0">two of the following: serotonin and norepinephrine reuptake inhibitors </text>
<text top="642" left="274" width="508" height="20" font="0">(SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, </text>
<text top="662" left="274" width="83" height="20" font="0">bupropion. </text>
<text top="701" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="701" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">48 </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="165" height="27" font="4"><b>LORAZEPATE</b></text>
<text top="119" left="295" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="236" height="20" font="0">Clorazepate Dipotassium TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="483" height="20" font="0">For all indications: the prescriber must acknowledge the benefit of </text>
<text top="476" left="274" width="495" height="20" font="0">therapy with the requested drug outweighs the potential risks for the </text>
<text top="497" left="274" width="527" height="20" font="0">patient. (Note: The American Geriatrics Society identifies the use of this </text>
<text top="518" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="538" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="559" left="274" width="513" height="20" font="0">monitored.) For the management of anxiety disorders: 1) the requested </text>
<text top="580" left="274" width="486" height="20" font="0">drug is being used concurrently with a selective serotonin reuptake </text>
<text top="600" left="274" width="517" height="20" font="0">inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) </text>
<text top="621" left="274" width="524" height="20" font="0">until the SSRI/SNRI becomes effective for the symptoms of anxiety OR </text>
<text top="642" left="274" width="468" height="20" font="0">2) the patient has experienced an inadequate treatment response, </text>
<text top="662" left="274" width="540" height="20" font="0">intolerance, or has a contraindication to AT LEAST TWO agents from the </text>
<text top="683" left="274" width="522" height="20" font="0">following classes: a) selective serotonin reuptake inhibitors (SSRIs) OR </text>
<text top="704" left="274" width="415" height="20" font="0">b) serotonin-norepinephrine reuptake inhibitors (SNRIs). </text>
<text top="742" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="742" left="274" width="35" height="20" font="0">N/A </text>
<text top="781" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="802" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="781" left="274" width="35" height="20" font="0">N/A </text>
<text top="841" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="861" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="841" left="274" width="535" height="20" font="0">Short-term relief anxiety-1 month, Anxiety Disorders-4 months, All other </text>
<text top="861" left="274" width="157" height="20" font="0">Diagnoses-Plan Year </text>
<text top="900" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="900" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="921" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="792" width="23" height="20" font="0">49 </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="131" height="27" font="4"><b>LOZAPINE </b></text>
<text top="118" left="261" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="284" width="33" height="27" font="4"><b>DT</b></text>
<text top="119" left="318" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="109" height="20" font="0">Clozapine Odt </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">50 </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="52" height="27" font="4"><b>OLY</b></text>
<text top="118" left="182" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="192" width="84" height="27" font="4"><b>MYCIN</b></text>
<text top="119" left="276" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="200" height="20" font="0">Colistimethate Sodium INJ </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="529" height="20" font="0">Intravenous (IV) or intramuscular (IM) use only. Administration will not </text>
<text top="476" left="274" width="478" height="20" font="0">be via nebulizer. (Note: CMS endorsed compendia do not support </text>
<text top="497" left="274" width="502" height="20" font="0">inhalation/nebulization of colistimethate.). The infection is proven or </text>
<text top="518" left="274" width="492" height="20" font="0">strongly suspected to be caused by susceptible bacteria based on: 1) </text>
<text top="538" left="274" width="497" height="20" font="0">culture and susceptibility information OR 2) local epidemiology and </text>
<text top="559" left="274" width="167" height="20" font="0">susceptibility patterns. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="495" height="20" font="0">Prescribed by or in consultation with an infectious disease specialist </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="344" height="20" font="0">Initial approval: 3 months, Renewal: Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">51 </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="119" height="27" font="4"><b>OMETRIQ</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Cometriq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="520" height="20" font="0">Non-small cell lung cancer (NSCLC), differentiated thyroid carcinoma: </text>
<text top="378" left="274" width="273" height="20" font="0">papillary, follicular, and Hurthle cell. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="499" height="20" font="0">For NSCLC: The requested medication is used for NSCLC when the </text>
<text top="497" left="274" width="505" height="20" font="0">patient's disease expresses rearranged during transfection (RET) gene </text>
<text top="518" left="274" width="120" height="20" font="0">rearrangements. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">52 </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="112" height="27" font="4"><b>OPIKTRA</b></text>
<text top="119" left="242" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Copiktra </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="538" height="20" font="0">Gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal </text>
<text top="378" left="274" width="368" height="20" font="0">zone lymphoma, splenic marginal zone lymphoma </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="521" height="20" font="0">For follicular lymphoma, gastric MALT lymphoma, non-gastric MALT </text>
<text top="497" left="274" width="516" height="20" font="0">lymphoma, nodal marginal zone lymphoma, and splenic marginal zone </text>
<text top="518" left="274" width="533" height="20" font="0">lymphoma: the requested drug will be used as subsequent therapy after at </text>
<text top="538" left="274" width="164" height="20" font="0">least 2 prior therapies. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">53 </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="109" height="27" font="4"><b>OTELLIC</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Cotellic </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="471" height="20" font="0">Central nervous system (CNS) cancer (i.e., glioma, meningioma, </text>
<text top="378" left="274" width="98" height="20" font="0">astrocytoma) </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="523" height="20" font="0">For adjuvant treatment of melanoma, and central nervous system (CNS) </text>
<text top="497" left="274" width="515" height="20" font="0">cancer (i.e., glioma, meningioma, astrocytoma): The patient must meet </text>
<text top="518" left="274" width="516" height="20" font="0">both of the following criteria: 1) The tumor is positive for BRAF V600 </text>
<text top="538" left="274" width="521" height="20" font="0">activating mutation (e.g., V600E or V600K), and 2) The requested drug </text>
<text top="559" left="274" width="484" height="20" font="0">will be used in combination with vemurafenib. For unresectable or </text>
<text top="580" left="274" width="484" height="20" font="0">metastatic melanoma: The patient must meet both of the following </text>
<text top="600" left="274" width="503" height="20" font="0">criteria: 1) The tumor is positive for BRAF V600 activating mutation </text>
<text top="621" left="274" width="487" height="20" font="0">(e.g., V600E or V600K), and 2) The requested drug will be used in </text>
<text top="642" left="274" width="459" height="20" font="0">combination with vemurafenib (with or without atezolizumab). </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">54 </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="119" height="27" font="4"><b>YSTAGON</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Cystagon </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="511" height="20" font="0">For nephropathic cystinosis: Diagnosis of nephropathic cystinosis was </text>
<text top="476" left="274" width="463" height="20" font="0">confirmed by the presence of increased cystine concentration in </text>
<text top="497" left="274" width="237" height="20" font="0">leukocytes or by genetic testing. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">55 </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="130" width="116" height="27" font="4"><b>YSTARAN</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Cystaran </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="528" height="20" font="0">For cystinosis: 1) Diagnosis of cystinosis was confirmed by the presence </text>
<text top="476" left="274" width="536" height="20" font="0">of increased cystine concentration in leukocytes or by genetic testing, and </text>
<text top="497" left="274" width="374" height="20" font="0">2) Patient has corneal cystine crystal accumulation. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">56 </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="189" height="27" font="4"><b>ALFAMPRIDINE</b></text>
<text top="119" left="319" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="131" height="20" font="0">Dalfampridine Er </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="514" height="20" font="0">For multiple sclerosis, patient must meet the following: For new starts, </text>
<text top="476" left="274" width="450" height="20" font="0">prior to initiating therapy, patient meets the following: patient </text>
<text top="497" left="274" width="532" height="20" font="0">demonstrates sustained walking impairment. For continuation of therapy, </text>
<text top="518" left="274" width="450" height="20" font="0">patient meets the following: patient must have experienced an </text>
<text top="538" left="274" width="515" height="20" font="0">improvement in walking speed OR other objective measure of walking </text>
<text top="559" left="274" width="292" height="20" font="0">ability since starting the requested drug. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">57 </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="116" height="27" font="4"><b>AURISMO</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="76" height="20" font="0">Daurismo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="515" height="20" font="0">Post induction therapy following response to previous therapy with the </text>
<text top="378" left="274" width="514" height="20" font="0">same regimen for acute myeloid leukemia (AML). Relapsed/refractory </text>
<text top="399" left="274" width="476" height="20" font="0">AML as a component of repeating the initial successful induction </text>
<text top="419" left="274" width="68" height="20" font="0">regimen. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="99" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="532" height="20" font="0">For acute myeloid leukemia: 1) the requested medication must be used in </text>
<text top="538" left="274" width="535" height="20" font="0">combination with cytarabine, 2) the patient is 75 years of age or older OR </text>
<text top="559" left="274" width="487" height="20" font="0">has comorbidities that preclude intensive chemotherapy, and 3) the </text>
<text top="580" left="274" width="502" height="20" font="0">requested medication will be used as treatment for induction therapy, </text>
<text top="600" left="274" width="411" height="20" font="0">post-induction therapy, or relapsed or refractory disease. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">58 </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="157" height="27" font="4"><b>EFERASIROX</b></text>
<text top="119" left="287" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="90" height="20" font="0">Deferasirox </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="524" height="20" font="0">For chronic iron overload due to blood transfusions: pretreatment serum </text>
<text top="476" left="274" width="297" height="20" font="0">ferritin level is greater than 1000 mcg/L. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">59 </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="85" height="27" font="4"><b>EMSER</b></text>
<text top="119" left="215" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="87" height="20" font="0">Metyrosine </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">60 </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="205" height="27" font="4"><b>ESVENLAFAXINE</b></text>
<text top="119" left="335" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="138" height="20" font="0">Desvenlafaxine Er </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="531" height="20" font="0">Patient has experienced an inadequate treatment response, intolerance, or </text>
<text top="476" left="274" width="534" height="20" font="0">the patient has a contraindication to TWO of the following: serotonin and </text>
<text top="497" left="274" width="528" height="20" font="0">norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake </text>
<text top="518" left="274" width="316" height="20" font="0">inhibitors (SSRIs), mirtazapine, bupropion. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">61 </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="41" height="27" font="4"><b>HE </b></text>
<text top="118" left="170" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="192" width="64" height="27" font="4"><b>ASAL</b></text>
<text top="119" left="256" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="216" height="20" font="0">Dihydroergotamine Mesylate </text>
<text top="221" left="149" width="116" height="20" font="0">NASAL SOLN </text>
<text top="297" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="297" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="339" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="339" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="378" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="378" left="274" width="35" height="20" font="0">N/A </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="518" height="20" font="0">1) The patient has experienced an inadequate treatment response to one </text>
<text top="497" left="274" width="500" height="20" font="0">triptan 5-HT1 receptor agonist OR 2) The patient has experienced an </text>
<text top="518" left="274" width="533" height="20" font="0">intolerance to one triptan 5-HT1 receptor agonist OR 3) The patient has a </text>
<text top="538" left="274" width="497" height="20" font="0">contraindication that would prohibit a trial of triptan 5-HT1 receptor </text>
<text top="559" left="274" width="68" height="20" font="0">agonists. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">62 </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="111" height="27" font="4"><b>IACOMIT</b></text>
<text top="119" left="240" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Diacomit </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">63 </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="113" height="27" font="4"><b>IAZEPAM</b></text>
<text top="119" left="243" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="132" height="20" font="0">Diazepam CONC </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="182" height="20" font="0">Diazepam INJ 5MG/ML </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="266" height="20" font="0">Diazepam ORAL SOLN 5MG/5ML </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="128" height="20" font="0">Diazepam TABS </text>
<text top="343" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="343" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="385" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="385" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="423" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="423" left="274" width="35" height="20" font="0">N/A </text>
<text top="462" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="483" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="462" left="274" width="35" height="20" font="0">N/A </text>
<text top="521" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="542" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="563" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="521" left="274" width="483" height="20" font="0">For all indications: the prescriber must acknowledge the benefit of </text>
<text top="542" left="274" width="495" height="20" font="0">therapy with the requested drug outweighs the potential risks for the </text>
<text top="563" left="274" width="527" height="20" font="0">patient. (Note: The American Geriatrics Society identifies the use of this </text>
<text top="583" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="604" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="625" left="274" width="513" height="20" font="0">monitored.) For the management of anxiety disorders: 1) the requested </text>
<text top="646" left="274" width="486" height="20" font="0">drug is being used concurrently with a selective serotonin reuptake </text>
<text top="666" left="274" width="517" height="20" font="0">inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) </text>
<text top="687" left="274" width="529" height="20" font="0">until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR </text>
<text top="708" left="274" width="474" height="20" font="0">2) The patient has experienced an inadequate treatment response, </text>
<text top="728" left="274" width="540" height="20" font="0">intolerance, or has a contraindication to AT LEAST TWO agents from the </text>
<text top="749" left="274" width="517" height="20" font="0">following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) </text>
<text top="770" left="274" width="395" height="20" font="0">serotonin-norepinephrine reuptake inhibitors (SNRIs). </text>
<text top="808" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="808" left="274" width="35" height="20" font="0">N/A </text>
<text top="847" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="868" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="847" left="274" width="35" height="20" font="0">N/A </text>
<text top="907" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="927" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="907" left="274" width="539" height="20" font="0">Short-term relief anx-1 mo, skeletal muscle spasm-3 mo, Anx Disorders-4 </text>
<text top="927" left="274" width="220" height="20" font="0">mo, Other Diagnoses-PlanYR </text>
<text top="966" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="966" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="987" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="792" width="23" height="20" font="0">64 </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="150" height="27" font="4"><b>ICLOFENAC </b></text>
<text top="118" left="280" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="303" width="38" height="27" font="4"><b>EL </b></text>
<text top="118" left="341" width="45" height="33" font="1"><b>1%</b></text>
<text top="113" left="386" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="212" height="20" font="0">Diclofenac Sodium GEL 1% </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="540" height="20" font="0">The patient has osteoarthritis pain in joints susceptible to topical treatment </text>
<text top="476" left="274" width="380" height="20" font="0">such as feet, ankles, knees, hands, wrists, or elbows. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">65 </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="150" height="27" font="4"><b>ICLOFENAC </b></text>
<text top="118" left="280" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="296" width="52" height="27" font="4"><b>OLN</b></text>
<text top="119" left="348" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="149" height="20" font="0">Pennsaid SOLN 2% </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">66 </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="113" height="27" font="4"><b>OPTELET</b></text>
<text top="119" left="243" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="67" height="20" font="0">Doptelet </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="504" height="20" font="0">For thrombocytopenia associated with chronic liver disease: Baseline </text>
<text top="476" left="274" width="535" height="20" font="0">platelet count prior to a scheduled procedure is less than 50,000/mcL. For </text>
<text top="497" left="274" width="538" height="20" font="0">chronic immune thrombocytopenia (ITP): 1) For new starts: a) Patient has </text>
<text top="518" left="274" width="497" height="20" font="0">had an inadequate response or is intolerant to a prior therapy such as </text>
<text top="538" left="274" width="531" height="20" font="0">corticosteroids or immunoglobulins, AND b) Untransfused platelet count </text>
<text top="559" left="274" width="531" height="20" font="0">at any point prior to the initiation of the requested medication is less than </text>
<text top="580" left="274" width="537" height="20" font="0">30,000/mcL OR 30,000 to 50,000/mcL with symptomatic bleeding or risk </text>
<text top="600" left="274" width="503" height="20" font="0">factor(s) for bleeding (e.g., undergoing a medical or dental procedure </text>
<text top="621" left="274" width="537" height="20" font="0">where blood loss is anticipated, comorbidities such as peptic ulcer disease </text>
<text top="642" left="274" width="504" height="20" font="0">and hypertension, anticoagulation therapy, profession or lifestyle that </text>
<text top="662" left="274" width="509" height="20" font="0">predisposes patient to trauma). 2) For continuation of therapy, platelet </text>
<text top="683" left="274" width="536" height="20" font="0">count response to the requested drug: a) Current platelet count is less than </text>
<text top="704" left="274" width="499" height="20" font="0">or equal to 200,000/mcL OR b) Current platelet count is greater than </text>
<text top="724" left="274" width="518" height="20" font="0">200,000/mcL and less than or equal to 400,000/mcL and dosing will be </text>
<text top="745" left="274" width="479" height="20" font="0">adjusted to a platelet count sufficient to avoid clinically important </text>
<text top="766" left="274" width="71" height="20" font="0">bleeding. </text>
<text top="805" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="805" left="274" width="175" height="20" font="0">18 years of age or older </text>
<text top="843" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="864" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="843" left="274" width="35" height="20" font="0">N/A </text>
<text top="903" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="923" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="903" left="274" width="538" height="20" font="0">Chronic liver disease: 1 month, ITP initial: 6 months, ITP reauthorization: </text>
<text top="923" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="962" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="962" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">67 </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="116" height="27" font="4"><b>RIZALMA</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="137" height="20" font="0">Drizalma Sprinkle </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="390" height="20" font="0">Cancer pain, chemotherapy-induced neuropathic pain </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="540" height="20" font="0">1) The patient has tried duloxetine capsules OR 2) The patient is unable to </text>
<text top="476" left="274" width="488" height="20" font="0">take duloxetine capsules for any reason (e.g., difficulty swallowing </text>
<text top="497" left="274" width="337" height="20" font="0">capsules, requires nasogastric administration). </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="398" height="20" font="0">Generalized Anxiety Disorder - 7 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">68 </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="148" height="27" font="4"><b>RONABINOL</b></text>
<text top="119" left="278" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="86" height="20" font="0">Dronabinol </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="520" height="20" font="0">For chemotherapy-induced nausea and vomiting (CINV): The patient is </text>
<text top="476" left="274" width="497" height="20" font="0">receiving cancer chemotherapy AND has experienced an inadequate </text>
<text top="497" left="274" width="508" height="20" font="0">treatment response, intolerance, or contraindication to one oral 5-HT3 </text>
<text top="518" left="274" width="146" height="20" font="0">receptor antagonist. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="71" height="20" font="0">6 months </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="734" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="755" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="792" width="23" height="20" font="0">69 </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="130" width="73" height="27" font="4"><b>UEXIS</b></text>
<text top="119" left="203" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="55" height="20" font="0">Duexis </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="158" height="20" font="0">Ibuprofen/famotidine </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="526" height="20" font="0">The patient has tried two different regimens containing any combination </text>
<text top="498" left="274" width="515" height="20" font="0">of a nonsteroidal anti-inflammatory drug (NSAID) and an acid blocker </text>
<text top="519" left="274" width="525" height="20" font="0">from any of the following drug classes: H2-receptor antagonist (H2RA), </text>
<text top="539" left="274" width="210" height="20" font="0">proton pump inhibitor (PPI). </text>
<text top="578" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="578" left="274" width="35" height="20" font="0">N/A </text>
<text top="617" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="638" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="617" left="274" width="35" height="20" font="0">N/A </text>
<text top="676" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="697" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="676" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="736" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="736" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">70 </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="76" height="27" font="4"><b>MSAM</b></text>
<text top="119" left="204" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="59" height="20" font="0">Emsam </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="531" height="20" font="0">1) Patient has experienced an inadequate treatment response, intolerance, </text>
<text top="476" left="274" width="523" height="20" font="0">or the patient has a contraindication to TWO of the following: serotonin </text>
<text top="497" left="274" width="492" height="20" font="0">and norepinephrine reuptake inhibitors (SNRIs), selective serotonin </text>
<text top="518" left="274" width="498" height="20" font="0">reuptake inhibitors (SSRIs), mirtazapine, bupropion OR 2) Patient is </text>
<text top="538" left="274" width="269" height="20" font="0">unable to swallow oral formulations. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">71 </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="83" height="27" font="4"><b>NBREL</b></text>
<text top="119" left="211" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="52" height="20" font="0">Enbrel </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="92" height="20" font="0">Enbrel Mini </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="125" height="20" font="0">Enbrel Sureclick </text>
<text top="1096" left="792" width="23" height="20" font="0">72 </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="182" height="20" font="0">Hidradenitis suppurativa </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="523" height="20" font="0">For moderately to severely active rheumatoid arthritis (new starts only): </text>
<text top="332" left="274" width="517" height="20" font="0">1) Inadequate response, intolerance or contraindication to methotrexate </text>
<text top="352" left="274" width="494" height="20" font="0">(MTX) OR 2) Inadequate response or intolerance to a prior biologic </text>
<text top="373" left="274" width="526" height="20" font="0">disease-modifying antirheumatic drug (DMARD) or a targeted synthetic </text>
<text top="394" left="274" width="470" height="20" font="0">DMARD. For active ankylosing spondylitis (new starts only): 1) </text>
<text top="414" left="274" width="526" height="20" font="0">Inadequate response to a non-steroidal anti-inflammatory drug (NSAID) </text>
<text top="435" left="274" width="522" height="20" font="0">trial, OR 2) Intolerance or contraindication to NSAIDs. For moderate to </text>
<text top="456" left="274" width="525" height="20" font="0">severe plaque psoriasis (new starts only): 1) At least 3% of body surface </text>
<text top="476" left="274" width="540" height="20" font="0">area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, </text>
<text top="497" left="274" width="525" height="20" font="0">groin, intertriginous areas) are affected at the time of diagnosis, AND 2) </text>
<text top="518" left="274" width="471" height="20" font="0">Patient meets any of the following: a) Patient has experienced an </text>
<text top="539" left="274" width="505" height="20" font="0">inadequate response or intolerance to either phototherapy (e.g., UVB, </text>
<text top="559" left="274" width="523" height="20" font="0">PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or </text>
<text top="580" left="274" width="441" height="20" font="0">acitretin, OR b) Pharmacologic treatment with methotrexate, </text>
<text top="601" left="274" width="502" height="20" font="0">cyclosporine, or acitretin is contraindicated, OR c) Patient has severe </text>
<text top="621" left="274" width="507" height="20" font="0">psoriasis that warrants a biologic DMARD as first-line therapy (i.e. at </text>
<text top="642" left="274" width="525" height="20" font="0">least 10% of the BSA or crucial body areas (e.g., hands, feet, face, neck, </text>
<text top="663" left="274" width="521" height="20" font="0">scalp, genitals/groin, intertriginous areas) are affected). For hidradenitis </text>
<text top="684" left="274" width="492" height="20" font="0">suppurativa (new starts only): patient has severe, refractory disease. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="761" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="782" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="761" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="880" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="880" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">73 </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="103" height="27" font="4"><b>NHERTU</b></text>
<text top="119" left="231" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Enhertu </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="531" height="20" font="0">Non-small cell lung cancer with human epidermal growth factor receptor </text>
<text top="378" left="274" width="505" height="20" font="0">2 (HER2) mutations, HER2-amplified and RAS and BRAF wild-type </text>
<text top="399" left="274" width="131" height="20" font="0">colorectal cancer. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="755" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="776" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="792" width="23" height="20" font="0">74 </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="96" height="27" font="4"><b>PCLUSA</b></text>
<text top="119" left="224" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Epclusa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="511" height="20" font="0">For hepatitis C virus (HCV): Infection confirmed by presence of HCV </text>
<text top="476" left="274" width="532" height="20" font="0">RNA in the serum prior to starting treatment. Planned treatment regimen, </text>
<text top="497" left="274" width="480" height="20" font="0">genotype, prior treatment history, presence or absence of cirrhosis </text>
<text top="518" left="274" width="505" height="20" font="0">(compensated or decompensated [Child Turcotte Pugh class B or C]), </text>
<text top="538" left="274" width="540" height="20" font="0">presence or absence of human immunodeficiency virus (HIV) coinfection, </text>
<text top="559" left="274" width="467" height="20" font="0">presence or absence of resistance-associated substitutions where </text>
<text top="580" left="274" width="533" height="20" font="0">applicable, liver and kidney transplantation status if applicable. Coverage </text>
<text top="600" left="274" width="506" height="20" font="0">conditions and specific durations of approval will be based on current </text>
<text top="621" left="274" width="220" height="20" font="0">AASLD treatment guidelines. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="526" height="20" font="0">Criteria will be applied consistent with current AASLD-IDSA guidance. </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">75 </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="119" height="27" font="4"><b>PIDIOLEX</b></text>
<text top="119" left="247" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="75" height="20" font="0">Epidiolex </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">76 </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="33" height="27" font="4"><b>PO</b></text>
<text top="119" left="161" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="54" height="20" font="0">Procrit </text>
<text top="1096" left="792" width="23" height="20" font="0">77 </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="531" height="20" font="0">Anemia due to myelodysplastic syndromes (MDS), anemia in congestive </text>
<text top="234" left="274" width="521" height="20" font="0">heart failure (CHF), anemia in rheumatoid arthritis (RA), anemia due to </text>
<text top="254" left="274" width="529" height="20" font="0">hepatitis C treatment (ribavirin in combination with either interferon alfa </text>
<text top="275" left="274" width="158" height="20" font="0">or peginterferon alfa) </text>
<text top="314" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="334" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="314" left="274" width="486" height="20" font="0">Patients receiving chemotherapy with curative intent. Patients with </text>
<text top="334" left="274" width="119" height="20" font="0">myeloid cancer. </text>
<text top="373" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="394" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="414" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="373" left="274" width="539" height="20" font="0">Requirements regarding hemoglobin (Hgb) values exclude values due to a </text>
<text top="394" left="274" width="527" height="20" font="0">recent transfusion. For initial approval: 1) for all uses except anemia due </text>
<text top="414" left="274" width="484" height="20" font="0">to chemotherapy or myelodysplastic syndrome (MDS): patient has </text>
<text top="435" left="274" width="516" height="20" font="0">adequate iron stores (defined as a transferrin saturation [TSAT] greater </text>
<text top="456" left="274" width="517" height="20" font="0">than or equal to 20%) AND 2) for all uses except surgery: pretreatment </text>
<text top="476" left="274" width="529" height="20" font="0">(no erythropoietin treatment in previous month) Hgb is less than 10 g/dL </text>
<text top="497" left="274" width="498" height="20" font="0">(less than 9 g/dL for anemia in congestive heart failure), AND 3) for </text>
<text top="518" left="274" width="537" height="20" font="0">MDS: pretreatment serum erythropoietin level is 500 international units/L </text>
<text top="539" left="274" width="528" height="20" font="0">or less. For reauthorizations (patient received erythropoietin treatment in </text>
<text top="559" left="274" width="536" height="20" font="0">previous month) in all uses except surgery: 1) patient has received at least </text>
<text top="580" left="274" width="474" height="20" font="0">12 weeks of erythropoietin therapy, AND 2) patient responded to </text>
<text top="601" left="274" width="535" height="20" font="0">erythropoietin therapy, AND 3) current Hgb is less than 12 g/dL, AND 4) </text>
<text top="621" left="274" width="497" height="20" font="0">for all uses except anemia due to chemotherapy or MDS: patient has </text>
<text top="642" left="274" width="514" height="20" font="0">adequate iron stores (defined as a TSAT greater than or equal to 20%). </text>
<text top="681" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="681" left="274" width="35" height="20" font="0">N/A </text>
<text top="720" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="720" left="274" width="35" height="20" font="0">N/A </text>
<text top="779" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="800" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="779" left="274" width="72" height="20" font="0">16 weeks </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="539" height="20" font="0">Coverage includes use in anemia in patients whose religious beliefs forbid </text>
<text top="859" left="274" width="519" height="20" font="0">blood transfusions. Coverage under Part D will be denied if coverage is </text>
<text top="880" left="274" width="492" height="20" font="0">available under Part A or Part B as the medication is prescribed and </text>
<text top="900" left="274" width="518" height="20" font="0">dispensed or administered for the individual (e.g., used for treatment of </text>
<text top="921" left="274" width="537" height="20" font="0">anemia for a patient with chronic renal failure who is undergoing dialysis, </text>
<text top="942" left="274" width="501" height="20" font="0">or furnished from physician's supply incident to a physician service). </text>
<text top="1096" left="792" width="23" height="20" font="0">78 </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="112" height="27" font="4"><b>RIVEDGE</b></text>
<text top="119" left="240" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Erivedge </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="174" height="20" font="0">Adult medulloblastoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="538" height="20" font="0">For adult medulloblastoma: patient has received chemotherapy previously </text>
<text top="476" left="274" width="478" height="20" font="0">AND has tumor(s) with mutations in the sonic hedgehog pathway </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">79 </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="101" height="27" font="4"><b>RLEADA</b></text>
<text top="119" left="229" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Erleada </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="499" height="20" font="0">The requested drug will be used in combination with a gonadotropin-</text>
<text top="476" left="274" width="473" height="20" font="0">releasing hormone (GnRH) analog or after bilateral orchiectomy. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">80 </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>RLOTINIB</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="178" height="20" font="0">Erlotinib Hydrochloride </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="511" height="20" font="0">Recurrent or advanced non-small cell lung cancer (NSCLC), recurrent </text>
<text top="378" left="274" width="479" height="20" font="0">chordoma, relapsed or stage IV renal cell carcinoma (RCC), brain </text>
<text top="399" left="274" width="188" height="20" font="0">metastases from NSCLC. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="525" height="20" font="0">For NSCLC (including brain metastases from NSCLC): 1) the disease is </text>
<text top="518" left="274" width="538" height="20" font="0">recurrent, advanced, or metastatic and 2) the patient has sensitizing EGFR </text>
<text top="538" left="274" width="510" height="20" font="0">mutation-positive disease. For pancreatic cancer: the disease is locally </text>
<text top="559" left="274" width="277" height="20" font="0">advanced, unresectable, or metastatic. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">81 </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="88" height="27" font="4"><b>SBRIET</b></text>
<text top="119" left="216" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="55" height="20" font="0">Esbriet </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="481" height="20" font="0">For idiopathic pulmonary fibrosis (Initial Review Only): 1) a high-</text>
<text top="476" left="274" width="507" height="20" font="0">resolution computed tomography (HRCT) study of the chest or a lung </text>
<text top="497" left="274" width="492" height="20" font="0">biopsy reveals the usual interstitial pneumonia (UIP) pattern, OR 2) </text>
<text top="518" left="274" width="528" height="20" font="0">HRCT study of the chest reveals a result other than the UIP pattern (e.g., </text>
<text top="538" left="274" width="541" height="20" font="0">probable UIP, indeterminate for UIP) and the diagnosis is supported either </text>
<text top="559" left="274" width="517" height="20" font="0">by a lung biopsy or by a multidisciplinary discussion between at least a </text>
<text top="580" left="274" width="469" height="20" font="0">radiologist and pulmonologist who are experienced in idiopathic </text>
<text top="600" left="274" width="435" height="20" font="0">pulmonary fibrosis if a lung biopsy has not been conducted. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">82 </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="148" height="27" font="4"><b>VEROLIMUS</b></text>
<text top="119" left="276" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="164" height="20" font="0">Afinitor TABS 10MG </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="123" height="20" font="0">Afinitor Disperz </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="254" height="20" font="0">Everolimus TABS 10MG, 2.5MG, </text>
<text top="264" left="149" width="103" height="20" font="0">5MG, 7.5MG </text>
<text top="284" left="122" width="8" height="22" font="5">•</text>
<text top="284" left="130" width="9" height="23" font="6">  </text>
<text top="286" left="149" width="138" height="20" font="0">Everolimus TBSO </text>
<text top="363" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="363" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="405" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="405" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="444" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="444" left="274" width="465" height="20" font="0">Classic Hodgkin lymphoma, thymomas and thymic carcinomas, </text>
<text top="465" left="274" width="520" height="20" font="0">Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft </text>
<text top="485" left="274" width="486" height="20" font="0">tissue sarcoma (perivascular epithelioid cell tumors (PEComa) and </text>
<text top="506" left="274" width="514" height="20" font="0">lymphangioleiomyomatosis subtypes), gastrointestinal stromal tumors, </text>
<text top="527" left="274" width="494" height="20" font="0">neuroendocrine tumors of the thymus, thyroid carcinoma (papillary, </text>
<text top="547" left="274" width="380" height="20" font="0">Hurthle cell, and follicular), endometrial carcinoma. </text>
<text top="586" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="607" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="586" left="274" width="35" height="20" font="0">N/A </text>
<text top="646" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="666" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="687" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="646" left="274" width="493" height="20" font="0">For breast cancer: 1) The disease is recurrent or metastatic hormone </text>
<text top="666" left="274" width="481" height="20" font="0">receptor (HR)-positive, human epidermal growth factor receptor 2 </text>
<text top="687" left="274" width="501" height="20" font="0">(HER2)-negative, AND 2) The requested medication is prescribed in </text>
<text top="708" left="274" width="507" height="20" font="0">combination with exemestane, fulvestrant, or tamoxifen, AND 3) The </text>
<text top="728" left="274" width="499" height="20" font="0">requested medication is used for subsequent treatment. For renal cell </text>
<text top="749" left="274" width="454" height="20" font="0">carcinoma: The disease is relapsed, advanced, or stage IV. For </text>
<text top="770" left="274" width="500" height="20" font="0">subependymal giant cell astrocytoma (SEGA): The requested drug is </text>
<text top="790" left="274" width="207" height="20" font="0">given as adjuvant treatment. </text>
<text top="829" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="829" left="274" width="35" height="20" font="0">N/A </text>
<text top="868" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="889" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="868" left="274" width="35" height="20" font="0">N/A </text>
<text top="927" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="948" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="927" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="987" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="987" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">83 </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="128" width="105" height="27" font="4"><b>XKIVITY</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="67" height="20" font="0">Exkivity </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">84 </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="83" height="27" font="4"><b>ANAPT</b></text>
<text top="119" left="209" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="53" height="20" font="0">Fanapt </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="161" height="20" font="0">Fanapt Titration Pack </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="534" height="20" font="0">The patient experienced an inadequate treatment response, intolerance, or </text>
<text top="498" left="274" width="538" height="20" font="0">contraindication to one of the following generic products: A) aripiprazole, </text>
<text top="519" left="274" width="539" height="20" font="0">B) asenapine, C) olanzapine, D) quetiapine, E) risperidone, F) ziprasidone </text>
<text top="539" left="274" width="463" height="20" font="0">AND the patient experienced an inadequate treatment response, </text>
<text top="560" left="274" width="540" height="20" font="0">intolerance, or contraindication to one of the following brand products: A) </text>
<text top="581" left="274" width="236" height="20" font="0">Latuda, B) Rexulti, C) Secuado. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">85 </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="105" height="27" font="4"><b>ARYDAK</b></text>
<text top="119" left="232" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Farydak </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">86 </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="99" height="27" font="4"><b>ASENRA</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Fasenra </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="92" height="20" font="0">Fasenra Pen </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="513" height="20" font="0">For severe asthma: For initial therapy: 1) Either a) Patient has baseline </text>
<text top="498" left="274" width="536" height="20" font="0">blood eosinophil count of at least 150 cells per microliter OR b) Patient is </text>
<text top="519" left="274" width="503" height="20" font="0">dependent on systemic corticosteroids, and 2) Patient has a history of </text>
<text top="539" left="274" width="483" height="20" font="0">severe asthma despite current treatment with both of the following </text>
<text top="560" left="274" width="541" height="20" font="0">medications at optimized doses: a) inhaled corticosteroid and b) additional </text>
<text top="581" left="274" width="522" height="20" font="0">controller (long-acting beta2-agonist, leukotriene modifier, or sustained-</text>
<text top="602" left="274" width="511" height="20" font="0">release theophylline). For continuation of therapy: Asthma control has </text>
<text top="622" left="274" width="503" height="20" font="0">improved on treatment with the requested drug, as demonstrated by a </text>
<text top="643" left="274" width="538" height="20" font="0">reduction in the frequency and/or severity of symptoms and exacerbations </text>
<text top="664" left="274" width="463" height="20" font="0">or a reduction in the daily maintenance oral corticosteroid dose. </text>
<text top="702" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="702" left="274" width="175" height="20" font="0">12 years of age or older </text>
<text top="741" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="762" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="741" left="274" width="35" height="20" font="0">N/A </text>
<text top="801" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="821" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="801" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="860" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="860" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">87 </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="123" height="27" font="4"><b>ENTANYL </b></text>
<text top="118" left="250" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="268" width="69" height="27" font="4"><b>ATCH</b></text>
<text top="119" left="337" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="111" height="20" font="0">Fentanyl PT72 </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="535" height="20" font="0">1) The requested drug is being prescribed for pain associated with cancer, </text>
<text top="476" left="274" width="521" height="20" font="0">sickle cell disease, a terminal condition, or pain being managed through </text>
<text top="497" left="274" width="500" height="20" font="0">palliative care OR 2) The requested drug is being prescribed for pain </text>
<text top="518" left="274" width="538" height="20" font="0">severe enough to require daily, around-the-clock, long-term treatment in a </text>
<text top="538" left="274" width="538" height="20" font="0">patient who has been taking an opioid AND 3) The patient can safely take </text>
<text top="559" left="274" width="520" height="20" font="0">the requested dose based on their history of opioid use [Note: This drug </text>
<text top="580" left="274" width="452" height="20" font="0">should be prescribed only by healthcare professionals who are </text>
<text top="600" left="274" width="540" height="20" font="0">knowledgeable in the use of potent opioids for the management of chronic </text>
<text top="621" left="274" width="500" height="20" font="0">pain.] AND 4) The patient has been evaluated and the patient will be </text>
<text top="642" left="274" width="489" height="20" font="0">monitored for the development of opioid use disorder AND 5) This </text>
<text top="662" left="274" width="536" height="20" font="0">request is for continuation of therapy for a patient who has been receiving </text>
<text top="683" left="274" width="519" height="20" font="0">an extended-release opioid agent for at least 30 days OR the patient has </text>
<text top="704" left="274" width="410" height="20" font="0">taken an immediate-release opioid for at least one week. </text>
<text top="742" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="742" left="274" width="35" height="20" font="0">N/A </text>
<text top="781" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="802" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="781" left="274" width="35" height="20" font="0">N/A </text>
<text top="841" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="861" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="841" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="900" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="900" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">88 </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="97" height="27" font="4"><b>ETZIMA</b></text>
<text top="119" left="224" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Fetzima </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="170" height="20" font="0">Fetzima Titration Pack </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="454" height="20" font="0">The patient has experienced an inadequate treatment response, </text>
<text top="498" left="274" width="540" height="20" font="0">intolerance, or the patient has a contraindication to TWO of the following: </text>
<text top="519" left="274" width="492" height="20" font="0">serotonin and norepinephrine reuptake inhibitors (SNRIs), selective </text>
<text top="539" left="274" width="454" height="20" font="0">serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion. </text>
<text top="578" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="578" left="274" width="35" height="20" font="0">N/A </text>
<text top="617" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="638" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="617" left="274" width="35" height="20" font="0">N/A </text>
<text top="676" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="697" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="676" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="736" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="736" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">89 </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="107" height="27" font="4"><b>INTEPLA</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Fintepla </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">90 </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="183" height="27" font="4"><b>LUOROURACIL</b></text>
<text top="119" left="309" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="136" height="20" font="0">Fluoroplex CREA </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="174" height="20" font="0">Fluorouracil CREA 5% </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="534" height="20" font="0">Patients who are pregnant or may become pregnant. Fluorouracil cream 5 </text>
<text top="439" left="274" width="501" height="20" font="0">percent only: Patients with dihydropyrimidine dehydrogenase (DPD) </text>
<text top="459" left="274" width="145" height="20" font="0">enzyme deficiency. </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="541" height="20" font="0">Applies to new starts only. If being used as part of a compounded product, </text>
<text top="519" left="274" width="520" height="20" font="0">all active ingredients in the compounded product are FDA approved for </text>
<text top="539" left="274" width="87" height="20" font="0">topical use. </text>
<text top="578" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="578" left="274" width="35" height="20" font="0">N/A </text>
<text top="617" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="638" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="617" left="274" width="35" height="20" font="0">N/A </text>
<text top="676" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="697" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="676" left="274" width="71" height="20" font="0">3 months </text>
<text top="736" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="736" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">91 </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="124" height="27" font="4"><b>ORTAMET</b></text>
<text top="118" left="250" width="8" height="33" font="1"><b>/</b></text>
<text top="123" left="259" width="140" height="27" font="4"><b>GLUMETZA</b></text>
<text top="119" left="399" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="259" height="20" font="0">Metformin Hydrochloride Er TB24 </text>
<text top="221" left="149" width="60" height="20" font="0">500MG </text>
<text top="297" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="297" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="339" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="339" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="378" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="378" left="274" width="35" height="20" font="0">N/A </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="513" height="20" font="0">The patient has experienced an intolerance to generic Glucophage XR. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">92 </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="87" height="27" font="4"><b>ORTEO</b></text>
<text top="119" left="213" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="218" height="20" font="0">Forteo INJ 620MCG/2.48ML </text>
<text top="1096" left="792" width="23" height="20" font="0">93 </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="532" height="20" font="0">For postmenopausal osteoporosis: patient has ONE of the following (1 or </text>
<text top="332" left="274" width="536" height="20" font="0">2): 1) a history of fragility fracture, OR 2) A pre-treatment T-score of less </text>
<text top="352" left="274" width="515" height="20" font="0">than or equal to -2.5 or pre-treatment T-score greater than -2.5 and less </text>
<text top="373" left="274" width="536" height="20" font="0">than -1 with a high pre-treatment Fracture Risk Assessment Tool (FRAX) </text>
<text top="394" left="274" width="532" height="20" font="0">fracture probability AND patient has ANY of the following: a) indicators </text>
<text top="414" left="274" width="540" height="20" font="0">for higher fracture risk (e.g., advanced age, frailty, glucocorticoid therapy, </text>
<text top="435" left="274" width="517" height="20" font="0">very low T-scores, or increased fall risk), OR b) patient has failed prior </text>
<text top="456" left="274" width="485" height="20" font="0">treatment with or is intolerant to a previous injectable osteoporosis </text>
<text top="476" left="274" width="512" height="20" font="0">therapy OR c) patient has had an oral bisphosphonate trial of at least 1-</text>
<text top="497" left="274" width="524" height="20" font="0">year duration or there is a clinical reason to avoid treatment with an oral </text>
<text top="518" left="274" width="536" height="20" font="0">bisphosphonate. For primary or hypogonadal osteoporosis in men: patient </text>
<text top="539" left="274" width="499" height="20" font="0">has one of the following: 1) a history of osteoporotic vertebral or hip </text>
<text top="559" left="274" width="529" height="20" font="0">fracture, OR 2) pre-treatment T-score of less than or equal to -2.5, OR 3) </text>
<text top="580" left="274" width="516" height="20" font="0">pre-treatment T-score greater than -2.5 and less than -1 with a high pre-</text>
<text top="601" left="274" width="474" height="20" font="0">treatment FRAX fracture probability. For glucocorticoid-induced </text>
<text top="621" left="274" width="506" height="20" font="0">osteoporosis: Patient has had an oral bisphosphonate trial of at least 1-</text>
<text top="642" left="274" width="509" height="20" font="0">year duration unless patient has a contraindication or intolerance to an </text>
<text top="663" left="274" width="539" height="20" font="0">oral bisphosphonate, AND patient meets ANY of the following: 1) patient </text>
<text top="684" left="274" width="516" height="20" font="0">has a history of fragility fracture, OR 2) a pre-treatment T-score of less </text>
<text top="704" left="274" width="518" height="20" font="0">than or equal to -2.5, OR 3) pre-treatment T-score greater than -2.5 and </text>
<text top="725" left="274" width="475" height="20" font="0">less than -1 with a high pre-treatment FRAX fracture probability. </text>
<text top="764" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="764" left="274" width="35" height="20" font="0">N/A </text>
<text top="802" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="823" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="802" left="274" width="35" height="20" font="0">N/A </text>
<text top="862" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="882" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="862" left="274" width="509" height="20" font="0">24 months total unless the patient remains at high risk for fracture and </text>
<text top="882" left="274" width="164" height="20" font="0">benefit outweighs risk </text>
<text top="921" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="921" left="274" width="516" height="20" font="0">Patient has high FRAX fracture probability if the 10 year probability is </text>
<text top="942" left="274" width="493" height="20" font="0">either greater than or equal to 20 percent for any major osteoporotic </text>
<text top="963" left="274" width="457" height="20" font="0">fracture or greater than or equal to 3 percent for hip fracture. If </text>
<text top="983" left="274" width="517" height="20" font="0">glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) </text>
<text top="1004" left="274" width="474" height="20" font="0">per day, the estimated risk score generated with FRAX should be </text>
<text top="1025" left="274" width="538" height="20" font="0">multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture. </text>
<text top="1096" left="792" width="23" height="20" font="0">94 </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="96" height="27" font="4"><b>OTIVDA</b></text>
<text top="119" left="222" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Fotivda </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="537" height="20" font="0">For advanced renal cell carcinoma: The following criteria must be met: 1) </text>
<text top="476" left="274" width="540" height="20" font="0">The disease is relapsed or refractory, 2) The requested medication must be </text>
<text top="497" left="274" width="507" height="20" font="0">used after at least two prior systemic therapies, and 3) The patient has </text>
<text top="518" left="274" width="511" height="20" font="0">experienced disease progression or an intolerable adverse event with a </text>
<text top="538" left="274" width="154" height="20" font="0">trial of cabozantinib. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">95 </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="126" width="108" height="27" font="4"><b>YCOMPA</b></text>
<text top="119" left="234" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Fycompa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="502" height="20" font="0">For treatment of partial-onset seizures: 1) The patient experienced an </text>
<text top="476" left="274" width="488" height="20" font="0">inadequate treatment response, intolerance, or contraindication to a </text>
<text top="497" left="274" width="540" height="20" font="0">generic anticonvulsant AND 2) The patient has experienced an inadequate </text>
<text top="518" left="274" width="469" height="20" font="0">treatment response, intolerance, or contraindication to any of the </text>
<text top="538" left="274" width="532" height="20" font="0">following: Aptiom, Vimpat, Xcopri, Spritam. For adjunctive treatment of </text>
<text top="559" left="274" width="525" height="20" font="0">primary generalized tonic-clonic seizures: 1) The patient experienced an </text>
<text top="580" left="274" width="488" height="20" font="0">inadequate treatment response, intolerance, or contraindication to a </text>
<text top="600" left="274" width="511" height="20" font="0">generic anticonvulsant AND 2) The patient experienced an inadequate </text>
<text top="621" left="274" width="469" height="20" font="0">treatment response, intolerance, or contraindication to one of the </text>
<text top="642" left="274" width="208" height="20" font="0">following: Vimpat, Spritam. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="525" height="20" font="0">Partial-onset seizures: 4 years of age or older. Primary generalized tonic-</text>
<text top="701" left="274" width="291" height="20" font="0">clonic seizures: 12 years of age or older </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">96 </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="83" height="27" font="4"><b>ATTEX</b></text>
<text top="119" left="214" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="53" height="20" font="0">Gattex </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="498" height="20" font="0">For short bowel syndrome (SBS) initial therapy: Adult patients were </text>
<text top="476" left="274" width="467" height="20" font="0">dependent on parenteral support for at least 12 months. For SBS </text>
<text top="497" left="274" width="501" height="20" font="0">continuation: Requirement for parenteral support has decreased from </text>
<text top="518" left="274" width="414" height="20" font="0">baseline while on therapy with the requested medication. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">97 </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="103" height="27" font="4"><b>AVRETO</b></text>
<text top="119" left="234" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Gavreto </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="440" height="20" font="0">Recurrent or advanced rearranged during transfection (RET) </text>
<text top="378" left="274" width="366" height="20" font="0">rearrangement-positive non-small cell lung cancer </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="529" height="20" font="0">For non-small cell lung cancer, patient must meet all of the following: 1) </text>
<text top="497" left="274" width="504" height="20" font="0">The disease is recurrent, advanced, or metastatic, and 2) The tumor is </text>
<text top="518" left="274" width="443" height="20" font="0">rearranged during transfection (RET) fusion-positive or RET </text>
<text top="538" left="274" width="176" height="20" font="0">rearrangement-positive. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="519" height="20" font="0">Non-small cell lung cancer: 18 years of age or older. Medullary thyroid </text>
<text top="598" left="274" width="374" height="20" font="0">cancer and thyroid cancer: 12 years of age or older. </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">98 </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="93" height="27" font="4"><b>ILENYA</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="167" height="20" font="0">Gilenya CAPS 0.5MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="792" width="23" height="20" font="0">99 </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="101" height="27" font="4"><b>ILOTRIF</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="59" height="20" font="0">Gilotrif </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="496" height="20" font="0">For non-small cell lung cancer (NSCLC): Patient meets either of the </text>
<text top="476" left="274" width="80" height="20" font="0">following: </text>
<text top="497" left="274" width="470" height="20" font="0">1) Patient has metastatic squamous NSCLC that progressed after </text>
<text top="518" left="274" width="490" height="20" font="0">platinum-based chemotherapy, OR 2) Patient has sensitizing EGFR </text>
<text top="538" left="274" width="193" height="20" font="0">mutation-positive disease. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">100 </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="149" height="27" font="4"><b>LATIRAMER</b></text>
<text top="119" left="281" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="280" height="20" font="0">Copaxone INJ 20MG/ML, 40MG/ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">101 </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>G</b></text>
<text top="123" left="131" width="101" height="27" font="4"><b>ROWTH </b></text>
<text top="118" left="232" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="255" width="111" height="27" font="4"><b>ORMONE</b></text>
<text top="119" left="366" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="87" height="20" font="0">Genotropin </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="166" height="20" font="0">Genotropin Miniquick </text>
<text top="1096" left="783" width="32" height="20" font="0">102 </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="263" height="20" font="0">All Medically-accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="516" height="20" font="0">Pediatric patients with closed epiphyses (except in patients with PWS). </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="540" height="20" font="0">Pediatric growth hormone deficiency (GHD): Patient (pt) meets any of the </text>
<text top="332" left="274" width="527" height="20" font="0">following: 1) younger than 2.5 years old (yo) with pre-treatment (pre-tx) </text>
<text top="352" left="274" width="515" height="20" font="0">height (ht) more than 2 standard deviations (SD) below mean and slow </text>
<text top="373" left="274" width="524" height="20" font="0">growth velocity OR 2) 2.5 yo or older AND one of the following: a) pre-</text>
<text top="394" left="274" width="516" height="20" font="0">tx 1-year ht velocity more than 2 SD below mean OR b) pre-tx ht more </text>
<text top="414" left="274" width="497" height="20" font="0">than 2 SD below mean and 1-year ht velocity more than 1 SD below </text>
<text top="435" left="274" width="529" height="20" font="0">mean, AND patient meets any of the following: 1) failed 2 pre-tx growth </text>
<text top="456" left="274" width="461" height="20" font="0">hormone (GH) stimulation tests (peak below 10 ng/mL), OR 2) </text>
<text top="476" left="274" width="508" height="20" font="0">pituitary/central nervous system (CNS) disorder (e.g., genetic defects, </text>
<text top="497" left="274" width="523" height="20" font="0">CNS tumors, congenital structural abnormalities) and pre-tx insulin-like </text>
<text top="518" left="274" width="488" height="20" font="0">growth factor-1 (IGF-1) more than 2 SD below mean, OR 3) pt is a </text>
<text top="539" left="274" width="520" height="20" font="0">neonate or was diagnosed with GHD as a neonate. Turner syndrome: 1) </text>
<text top="559" left="274" width="538" height="20" font="0">Confirmed by karyotyping AND 2) pre-tx ht is less than the 5th percentile </text>
<text top="580" left="274" width="507" height="20" font="0">for age. Small for gestational age (GA): 1) Birth weight (wt) less than </text>
<text top="601" left="274" width="500" height="20" font="0">2500g at GA greater than 37 weeks, OR birth wt or length below 3rd </text>
<text top="621" left="274" width="517" height="20" font="0">percentile for GA or at least 2 SD below mean for GA, AND 2) did not </text>
<text top="642" left="274" width="258" height="20" font="0">manifest catch-up growth by age 2. </text>
<text top="681" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="681" left="274" width="211" height="20" font="0">SGA: 2 years of age or older </text>
<text top="720" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="720" left="274" width="479" height="20" font="0">Endocrinologist, pediatric endocrinologist, pediatric nephrologist, </text>
<text top="740" left="274" width="480" height="20" font="0">infectious disease specialist, gastroenterologist/nutritional support </text>
<text top="761" left="274" width="154" height="20" font="0">specialist, geneticist. </text>
<text top="800" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="800" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="472" height="20" font="0">Adult GHD: Pt meets any of the following: 1) failed 2 pre-tx GH </text>
<text top="880" left="274" width="525" height="20" font="0">stimulation tests, OR 2) pre-tx IGF-1 more than 2 SD below mean AND </text>
<text top="900" left="274" width="513" height="20" font="0">failed 1 pre-tx GH stimulation test. (Note: Stimulation tests include: a) </text>
<text top="921" left="274" width="531" height="20" font="0">insulin tolerance test [ITT] [peak GH less than or equal to 5 ng/ml], or b) </text>
<text top="942" left="274" width="485" height="20" font="0">Macrelin-stimulation test [peak GH level less than 2.8ng/ml], or c) </text>
<text top="963" left="274" width="514" height="20" font="0">glucagon-stimulation test [GST] [peak GH level less than or equal to 3 </text>
<text top="983" left="274" width="538" height="20" font="0">ng/ml] for pt with a body mass index [BMI] 25-30 kg/m2 and high pretest </text>
<text top="1004" left="274" width="524" height="20" font="0">probability of GHD [e.g., acquired structural abnormalities] or BMI less </text>
<text top="1025" left="274" width="538" height="20" font="0">than 25 kg/m2, or d) GST [peak GH level less than or equal to 1 ng/ml] in </text>
<text top="1045" left="274" width="509" height="20" font="0">pt with BMI 25-30 kg/m2 and low pretest probability of GHD or BMI </text>
<text top="1096" left="783" width="32" height="20" font="0">103 </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1188" width="918">
<text top="127" left="274" width="507" height="20" font="0">greater than 30 kg/m2), OR 3) organic hypothalamic-pituitary disease </text>
<text top="147" left="274" width="531" height="20" font="0">(e.g., suprasellar mass with previous surgery and cranial irradiation) with </text>
<text top="168" left="274" width="529" height="20" font="0">3 or more pituitary hormone deficiencies AND pre-tx IGF-1 more than 2 </text>
<text top="189" left="274" width="491" height="20" font="0">SD below mean, OR 4) genetic or structural hypothalamic-pituitary </text>
<text top="210" left="274" width="471" height="20" font="0">defects, OR 5) childhood-onset GHD with congenital (genetic or </text>
<text top="230" left="274" width="525" height="20" font="0">structural) abnormality of the hypothalamus/pituitary/CNS. Renewal for </text>
<text top="251" left="274" width="478" height="20" font="0">pediatric GHD, TS, SGA, and adult GHD: Patient is experiencing </text>
<text top="272" left="274" width="105" height="20" font="0">improvement. </text>
<text top="1096" left="783" width="32" height="20" font="0">104 </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="121" height="27" font="4"><b>AEGARDA</b></text>
<text top="119" left="253" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Haegarda </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="529" height="20" font="0">The requested drug is being used for the prevention of acute angioedema </text>
<text top="476" left="274" width="493" height="20" font="0">attacks. Patient has hereditary angioedema (HAE) with C1 inhibitor </text>
<text top="497" left="274" width="532" height="20" font="0">deficiency or dysfunction confirmed by laboratory testing OR patient has </text>
<text top="518" left="274" width="532" height="20" font="0">hereditary angioedema with normal C1 inhibitor confirmed by laboratory </text>
<text top="538" left="274" width="501" height="20" font="0">testing. For patients with HAE with normal C1 inhibitor, EITHER 1) </text>
<text top="559" left="274" width="481" height="20" font="0">Patient tested positive for an F12, angiopoietin-1, plasminogen, or </text>
<text top="580" left="274" width="533" height="20" font="0">kininogen-1 (KNG1) gene mutation OR 2) Patient has a family history of </text>
<text top="600" left="274" width="453" height="20" font="0">angioedema and the angioedema was refractory to a trial of an </text>
<text top="621" left="274" width="267" height="20" font="0">antihistamine for at least one month. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="290" height="20" font="0">Immunologist, allergist, rheumatologist </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">105 </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="97" height="27" font="4"><b>ARVONI</b></text>
<text top="119" left="229" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Harvoni </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="511" height="20" font="0">For hepatitis C virus (HCV): Infection confirmed by presence of HCV </text>
<text top="476" left="274" width="532" height="20" font="0">RNA in the serum prior to starting treatment. Planned treatment regimen, </text>
<text top="497" left="274" width="480" height="20" font="0">genotype, prior treatment history, presence or absence of cirrhosis </text>
<text top="518" left="274" width="505" height="20" font="0">(compensated or decompensated [Child Turcotte Pugh class B or C]), </text>
<text top="538" left="274" width="540" height="20" font="0">presence or absence of human immunodeficiency virus (HIV) coinfection, </text>
<text top="559" left="274" width="467" height="20" font="0">presence or absence of resistance-associated substitutions where </text>
<text top="580" left="274" width="533" height="20" font="0">applicable, liver and kidney transplantation status if applicable. Coverage </text>
<text top="600" left="274" width="506" height="20" font="0">conditions and specific durations of approval will be based on current </text>
<text top="621" left="274" width="220" height="20" font="0">AASLD treatment guidelines. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="533" height="20" font="0">Criteria applied consistent w/ current AASLD-IDSA guidance. Reminder </text>
<text top="778" left="274" width="218" height="20" font="0">for 8wk option if appropriate. </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">106 </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="130" height="27" font="4"><b>ERCEPTIN </b></text>
<text top="118" left="261" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="285" width="100" height="27" font="4"><b>YLECTA</b></text>
<text top="119" left="385" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="136" height="20" font="0">Herceptin Hylecta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="503" height="20" font="0">Neoadjuvant treatment for human epidermal growth factor receptor 2 </text>
<text top="378" left="274" width="535" height="20" font="0">(HER2)-positive breast cancer, recurrent or advanced unresectable HER2-</text>
<text top="399" left="274" width="165" height="20" font="0">positive breast cancer. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="491" height="20" font="0">Neoadjuvant therapy for breast cancer: 6 months, Other: Plan Year. </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="755" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="776" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">107 </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="92" height="27" font="4"><b>ETLIOZ</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Hetlioz </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="477" height="20" font="0">For Non-24-Hour Sleep-Wake Disorder: 1) for initial therapy and </text>
<text top="476" left="274" width="529" height="20" font="0">continuation of therapy: a) diagnosis of total blindness in both eyes (e.g., </text>
<text top="497" left="274" width="538" height="20" font="0">nonfunctioning retinas) and b) unable to perceive light in either eye, AND </text>
<text top="518" left="274" width="514" height="20" font="0">2) if currently on therapy with the requested drug, patient must meet at </text>
<text top="538" left="274" width="475" height="20" font="0">least one of the following: a) increased total nighttime sleep or b) </text>
<text top="559" left="274" width="495" height="20" font="0">decreased daytime nap duration. For nighttime sleep disturbances in </text>
<text top="580" left="274" width="526" height="20" font="0">Smith-Magenis Syndrome (SMS): 1) for initial therapy and continuation </text>
<text top="600" left="274" width="473" height="20" font="0">therapy, the patient has a confirmed diagnosis of SMS AND 2) if </text>
<text top="621" left="274" width="498" height="20" font="0">currently on therapy with the requested drug, the patient experiences </text>
<text top="642" left="274" width="424" height="20" font="0">improvement in the quality of sleep since starting therapy. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="464" height="20" font="0">Non-24: 18 years of age or older. SMS: 16 years of age or older </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="284" height="20" font="0">Sleep disorder specialist or neurologist </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="301" height="20" font="0">Initiation: 6 Months, Renewal: Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">108 </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="98" height="27" font="4"><b>ETLIOZ </b></text>
<text top="118" left="230" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="250" width="19" height="27" font="4"><b>Q</b></text>
<text top="119" left="268" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="82" height="20" font="0">Hetlioz Lq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="529" height="20" font="0">For nighttime sleep disturbances in Smith-Magenis Syndrome (SMS): 1) </text>
<text top="476" left="274" width="518" height="20" font="0">for initial therapy and continuation therapy, the patient has a confirmed </text>
<text top="497" left="274" width="540" height="20" font="0">diagnosis of SMS AND 2) if currently on therapy with the requested drug, </text>
<text top="518" left="274" width="530" height="20" font="0">the patient experiences improvement in the quality of sleep since starting </text>
<text top="538" left="274" width="63" height="20" font="0">therapy. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="146" height="20" font="0">3 to 15 years of age </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="284" height="20" font="0">Sleep disorder specialist or neurologist </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="306" height="20" font="0">Initiation: 6 Months, Renewal: Plan Year. </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">109 </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="53" height="27" font="4"><b>IGH </b></text>
<text top="118" left="184" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="206" width="47" height="27" font="4"><b>ISK </b></text>
<text top="118" left="253" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="281" width="145" height="27" font="4"><b>EDICATION </b></text>
<text top="118" left="426" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="472" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="230" height="20" font="0">Chlordiazepoxide/amitriptyline </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="179" height="20" font="0">Dicyclomine Hcl SOLN </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="256" height="20" font="0">Dicyclomine Hydrochloride CAPS </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="9" height="23" font="6">  </text>
<text top="266" left="149" width="238" height="20" font="0">Dicyclomine Hydrochloride INJ </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="9" height="23" font="6">  </text>
<text top="288" left="149" width="257" height="20" font="0">Dicyclomine Hydrochloride TABS </text>
<text top="308" left="122" width="8" height="22" font="5">•</text>
<text top="307" left="130" width="9" height="23" font="6">  </text>
<text top="310" left="149" width="247" height="20" font="0">Dihydroergotamine Mesylate INJ </text>
<text top="330" left="122" width="8" height="22" font="5">•</text>
<text top="329" left="130" width="9" height="23" font="6">  </text>
<text top="332" left="149" width="279" height="20" font="0">Diphenhydramine Hcl INJ 50MG/ML </text>
<text top="352" left="122" width="8" height="22" font="5">•</text>
<text top="351" left="130" width="9" height="23" font="6">  </text>
<text top="354" left="149" width="155" height="20" font="0">Dipyridamole TABS </text>
<text top="374" left="122" width="8" height="22" font="5">•</text>
<text top="373" left="130" width="9" height="23" font="6">  </text>
<text top="376" left="149" width="234" height="20" font="0">Disopyramide Phosphate CAPS </text>
<text top="396" left="122" width="8" height="22" font="5">•</text>
<text top="395" left="130" width="9" height="23" font="6">  </text>
<text top="398" left="149" width="248" height="20" font="0">Guanfacine Er TB24 1MG, 2MG, </text>
<text top="418" left="149" width="42" height="20" font="0">4MG </text>
<text top="438" left="122" width="8" height="22" font="5">•</text>
<text top="438" left="130" width="9" height="23" font="6">  </text>
<text top="440" left="149" width="118" height="20" font="0">Guanfacine Hcl </text>
<text top="460" left="122" width="8" height="22" font="5">•</text>
<text top="459" left="130" width="9" height="23" font="6">  </text>
<text top="462" left="149" width="243" height="20" font="0">Guanfacine Hydrochloride TB24 </text>
<text top="483" left="149" width="42" height="20" font="0">3MG </text>
<text top="503" left="122" width="8" height="22" font="5">•</text>
<text top="502" left="130" width="9" height="23" font="6">  </text>
<text top="505" left="149" width="216" height="20" font="0">Ketorolac Tromethamine INJ </text>
<text top="526" left="149" width="172" height="20" font="0">15MG/ML, 30MG/ML </text>
<text top="546" left="122" width="8" height="22" font="5">•</text>
<text top="545" left="130" width="9" height="23" font="6">  </text>
<text top="548" left="149" width="236" height="20" font="0">Ketorolac Tromethamine TABS </text>
<text top="568" left="122" width="8" height="22" font="5">•</text>
<text top="567" left="130" width="9" height="23" font="6">  </text>
<text top="570" left="149" width="104" height="20" font="0">Meprobamate </text>
<text top="590" left="122" width="8" height="22" font="5">•</text>
<text top="589" left="130" width="9" height="23" font="6">  </text>
<text top="592" left="149" width="251" height="20" font="0">Methscopolamine Bromide TABS </text>
<text top="612" left="122" width="8" height="22" font="5">•</text>
<text top="611" left="130" width="9" height="23" font="6">  </text>
<text top="614" left="149" width="267" height="20" font="0">Methyldopa TABS 250MG, 500MG </text>
<text top="634" left="122" width="8" height="22" font="5">•</text>
<text top="633" left="130" width="9" height="23" font="6">  </text>
<text top="636" left="149" width="199" height="20" font="0">Perphenazine/amitriptyline </text>
<text top="656" left="122" width="8" height="22" font="5">•</text>
<text top="655" left="130" width="9" height="23" font="6">  </text>
<text top="658" left="149" width="242" height="20" font="0">Thioridazine Hcl TABS 100MG, </text>
<text top="678" left="149" width="163" height="20" font="0">10MG, 25MG, 50MG </text>
<text top="698" left="122" width="8" height="22" font="5">•</text>
<text top="698" left="130" width="9" height="23" font="6">  </text>
<text top="700" left="149" width="259" height="20" font="0">Trimethobenzamide Hydrochloride </text>
<text top="1096" left="783" width="32" height="20" font="0">110 </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="35" height="20" font="0">N/A </text>
<text top="391" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="391" left="274" width="35" height="20" font="0">N/A </text>
<text top="430" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="450" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="430" left="274" width="35" height="20" font="0">N/A </text>
<text top="489" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="510" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="489" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="548" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="548" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="569" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="590" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="611" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="631" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="652" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="673" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">111 </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="46" height="27" font="4"><b>RM </b></text>
<text top="118" left="177" width="38" height="33" font="1"><b>- A</b></text>
<text top="123" left="215" width="230" height="27" font="4"><b>NTICONVULSANTS </b></text>
<text top="118" left="445" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="491" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="242" height="20" font="0">Phenobarbital ELIX 20MG/5ML </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="276" height="20" font="0">Phenobarbital TABS 100MG, 15MG, </text>
<text top="242" left="149" width="251" height="20" font="0">16.2MG, 30MG, 32.4MG, 60MG, </text>
<text top="263" left="149" width="134" height="20" font="0">64.8MG, 97.2MG </text>
<text top="283" left="122" width="8" height="22" font="5">•</text>
<text top="282" left="130" width="9" height="23" font="6">  </text>
<text top="285" left="149" width="195" height="20" font="0">Phenobarbital Sodium INJ </text>
<text top="282" left="344" width="5" height="23" font="6"></text>
<text top="306" left="149" width="176" height="20" font="0">130MG/ML, 65MG/ML</text>
<text top="303" left="325" width="9" height="23" font="6"> </text>
<text top="383" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="383" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="425" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="425" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="463" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="463" left="274" width="68" height="20" font="0">Epilepsy </text>
<text top="502" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="523" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="502" left="274" width="35" height="20" font="0">N/A </text>
<text top="561" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="582" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="603" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="561" left="274" width="35" height="20" font="0">N/A </text>
<text top="642" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="642" left="274" width="35" height="20" font="0">N/A </text>
<text top="680" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="701" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="760" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="740" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="799" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="799" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="820" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="840" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="861" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="882" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="903" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="923" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">112 </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="46" height="27" font="4"><b>RM </b></text>
<text top="118" left="177" width="39" height="33" font="1"><b>- H</b></text>
<text top="123" left="217" width="130" height="27" font="4"><b>YPNOTICS </b></text>
<text top="118" left="347" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="393" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="92" height="20" font="0">Eszopiclone </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="69" height="20" font="0">Zaleplon </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="187" height="20" font="0">Zolpidem Tartrate TABS </text>
<text top="321" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="321" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="363" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="363" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="401" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="401" left="274" width="35" height="20" font="0">N/A </text>
<text top="440" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="461" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="440" left="274" width="35" height="20" font="0">N/A </text>
<text top="499" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="520" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="541" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="499" left="274" width="508" height="20" font="0">1) The patient has a contraindication to the non-HRM (non-High Risk </text>
<text top="520" left="274" width="501" height="20" font="0">Medication) alternative drug doxepin (3 mg or 6 mg) OR 2) The non-</text>
<text top="541" left="274" width="515" height="20" font="0">HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 </text>
<text top="561" left="274" width="482" height="20" font="0">mg) has been tried AND 3) The patient experienced an inadequate </text>
<text top="582" left="274" width="494" height="20" font="0">treatment response OR intolerance to the non-HRM (non-High Risk </text>
<text top="603" left="274" width="492" height="20" font="0">Medication) alternative drug doxepin (3 mg or 6 mg) AND 4) If the </text>
<text top="624" left="274" width="503" height="20" font="0">patient is using two or more additional central nervous system (CNS) </text>
<text top="644" left="274" width="519" height="20" font="0">active medications (e.g., lorazepam, quetiapine, sertraline, clonazepam, </text>
<text top="665" left="274" width="501" height="20" font="0">escitalopram, alprazolam) with the requested drug, the prescriber has </text>
<text top="686" left="274" width="499" height="20" font="0">determined that taking multiple central nervous system (CNS) active </text>
<text top="706" left="274" width="530" height="20" font="0">medications is medically necessary for the patient [Note: Use of multiple </text>
<text top="727" left="274" width="484" height="20" font="0">central nervous system (CNS) active medications in older adults is </text>
<text top="748" left="274" width="310" height="20" font="0">associated with an increased risk of falls.]. </text>
<text top="786" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="786" left="274" width="35" height="20" font="0">N/A </text>
<text top="825" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="846" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="825" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="905" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="885" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="944" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="944" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="965" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="985" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="1006" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="1027" left="274" width="532" height="20" font="0">monitored.) Prescriber must acknowledge that the benefit of therapy with </text>
<text top="1047" left="274" width="519" height="20" font="0">this prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">113 </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">114</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="46" height="27" font="4"><b>RM </b></text>
<text top="118" left="177" width="33" height="33" font="1"><b>- S</b></text>
<text top="123" left="210" width="174" height="27" font="4"><b>COPOLAMINE </b></text>
<text top="118" left="384" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="430" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="247" height="20" font="0">Scopolamine PT72 1MG/3DAYS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="151" height="20" font="0">Excessive salivation </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="714" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="734" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="755" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="776" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="796" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="817" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">115 </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="210" height="27" font="4"><b>ANTIPARKINSON </b></text>
<text top="118" left="391" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="437" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="193" height="20" font="0">Benztropine Mesylate INJ </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="213" height="20" font="0">Benztropine Mesylate TABS </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="207" height="20" font="0">Trihexyphenidyl Hcl SOLN </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="234" height="20" font="0">Trihexyphenidyl Hydrochloride </text>
<text top="343" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="343" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="385" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="385" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="423" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="423" left="274" width="35" height="20" font="0">N/A </text>
<text top="462" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="483" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="462" left="274" width="35" height="20" font="0">N/A </text>
<text top="521" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="542" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="563" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="521" left="274" width="503" height="20" font="0">EPS (extrapyramidal symptoms): 1) The patient has not tried the non-</text>
<text top="542" left="274" width="441" height="20" font="0">HRM alternative drug amantadine AND 2) The patient has a </text>
<text top="563" left="274" width="532" height="20" font="0">contraindication to the non-HRM alternative drug amantadine OR 3) The </text>
<text top="583" left="274" width="525" height="20" font="0">patient has tried the non-HRM alternative drug amantadine AND 4) The </text>
<text top="604" left="274" width="521" height="20" font="0">patient experienced an inadequate treatment response OR intolerance to </text>
<text top="625" left="274" width="541" height="20" font="0">the non-HRM alternative drug amantadine. Parkinson's: 1) The patient has </text>
<text top="646" left="274" width="490" height="20" font="0">tried two of the following non-HRM alternative drugs: amantadine, </text>
<text top="666" left="274" width="498" height="20" font="0">carbidopa/levodopa, pramipexole, or ropinirole. AND 2) The patient </text>
<text top="687" left="274" width="519" height="20" font="0">experienced an inadequate treatment response OR intolerance to two of </text>
<text top="708" left="274" width="401" height="20" font="0">the following non-HRM alternative drugs: amantadine, </text>
<text top="728" left="274" width="349" height="20" font="0">carbidopa/levodopa, pramipexole, or ropinirole. </text>
<text top="767" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="767" left="274" width="35" height="20" font="0">N/A </text>
<text top="806" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="826" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="806" left="274" width="35" height="20" font="0">N/A </text>
<text top="865" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="886" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="865" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="925" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="925" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="945" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="966" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="987" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="1007" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="1028" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="1049" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">116 </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">117</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="234" height="27" font="4"><b>CYPROHEPTADINE </b></text>
<text top="118" left="415" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="461" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="200" height="20" font="0">Cyproheptadine Hcl SYRP </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="279" height="20" font="0">Cyproheptadine Hydrochloride TABS </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="319" height="20" font="0">Pruritus, spasticity due to spinal cord injury </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="492" height="20" font="0">For rhinitis: 1) The patient has tried two of the following non-HRM </text>
<text top="498" left="274" width="507" height="20" font="0">alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or </text>
<text top="519" left="274" width="540" height="20" font="0">flunisolide nasal AND 2) The patient experienced an inadequate treatment </text>
<text top="539" left="274" width="511" height="20" font="0">response OR intolerance to two of the following non-HRM alternative </text>
<text top="560" left="274" width="508" height="20" font="0">drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide </text>
<text top="581" left="274" width="46" height="20" font="0">nasal. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="798" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="819" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="839" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="860" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="881" left="274" width="505" height="20" font="0">The prescriber must acknowledge that the benefit of therapy with this </text>
<text top="901" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">118 </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="117" height="27" font="4"><b>DOXEPIN </b></text>
<text top="118" left="298" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="344" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="263" height="20" font="0">Doxepin Hcl CAPS 150MG, 75MG </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="151" height="20" font="0">Doxepin Hcl CONC </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="225" height="20" font="0">Doxepin Hydrochloride CAPS </text>
<text top="241" left="374" width="5" height="23" font="6"></text>
<text top="264" left="149" width="224" height="20" font="0">100MG, 10MG, 25MG, 50MG</text>
<text top="262" left="372" width="9" height="23" font="6"> </text>
<text top="1096" left="783" width="32" height="20" font="0">119 </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="541" height="20" font="0">For depression: 1) The patient tried two of the following alternative drugs: </text>
<text top="332" left="274" width="477" height="20" font="0">SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-</text>
<text top="352" left="274" width="536" height="20" font="0">norepinephrine reuptake inhibitors), bupropion, mirtazapine, or trazodone </text>
<text top="373" left="274" width="514" height="20" font="0">AND 2) The patient experienced an inadequate treatment response OR </text>
<text top="394" left="274" width="508" height="20" font="0">intolerance to two of the following alternative drugs: SSRIs (selective </text>
<text top="414" left="274" width="533" height="20" font="0">serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake </text>
<text top="435" left="274" width="504" height="20" font="0">inhibitors), bupropion, mirtazapine, or trazodone. For anxiety: 1) The </text>
<text top="456" left="274" width="481" height="20" font="0">patient has tried two of the following alternative drugs: buspirone, </text>
<text top="476" left="274" width="539" height="20" font="0">duloxetine, escitalopram, sertraline, or venlafaxine extended-release AND </text>
<text top="497" left="274" width="470" height="20" font="0">2) The patient experienced an inadequate treatment response OR </text>
<text top="518" left="274" width="465" height="20" font="0">intolerance to two of the following alternative drugs: buspirone, </text>
<text top="539" left="274" width="500" height="20" font="0">duloxetine, escitalopram, sertraline, or venlafaxine extended-release. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="637" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="735" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="735" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="756" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="776" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="797" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="818" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="838" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="859" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">120 </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="189" height="27" font="4"><b>HYDROXYZINE </b></text>
<text top="118" left="370" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="416" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="178" height="20" font="0">Hydroxyzine Hcl SYRP </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="231" height="20" font="0">Hydroxyzine Hcl TABS 50MG </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="258" height="20" font="0">Hydroxyzine Hydrochloride TABS </text>
<text top="264" left="149" width="107" height="20" font="0">10MG, 25MG </text>
<text top="284" left="122" width="8" height="22" font="5">•</text>
<text top="284" left="130" width="9" height="23" font="6">  </text>
<text top="286" left="149" width="214" height="20" font="0">Hydroxyzine Pamoate CAPS </text>
<text top="1096" left="783" width="32" height="20" font="0">121 </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="496" height="20" font="0">For anxiety: 1) The patient has tried two of the following alternative </text>
<text top="332" left="274" width="499" height="20" font="0">drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine </text>
<text top="352" left="274" width="470" height="20" font="0">extended-release AND 2) The patient experienced an inadequate </text>
<text top="373" left="274" width="505" height="20" font="0">treatment response OR intolerance to two of the following alternative </text>
<text top="394" left="274" width="499" height="20" font="0">drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine </text>
<text top="414" left="274" width="506" height="20" font="0">extended-release OR 3) The patient has not tried two of the following </text>
<text top="435" left="274" width="487" height="20" font="0">alternative drugs: buspirone, duloxetine, escitalopram, sertraline or </text>
<text top="456" left="274" width="539" height="20" font="0">venlafaxine extended-release AND 4) The patient has acute anxiety. If the </text>
<text top="476" left="274" width="532" height="20" font="0">patient is taking one or more additional anticholinergic medications (e.g., </text>
<text top="497" left="274" width="455" height="20" font="0">oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, </text>
<text top="518" left="274" width="524" height="20" font="0">cyclobenzaprine) with the requested drug, the prescriber has determined </text>
<text top="539" left="274" width="516" height="20" font="0">that taking multiple anticholinergic medications is medically necessary </text>
<text top="559" left="274" width="536" height="20" font="0">for the patient [Note: Use of multiple anticholinergic medications in older </text>
<text top="580" left="274" width="467" height="20" font="0">adults is associated with an increased risk of cognitive decline.]. </text>
<text top="619" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="619" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="717" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="717" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="797" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="818" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="838" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="859" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="880" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="900" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">122 </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="189" height="27" font="4"><b>HYDROXYZINE </b></text>
<text top="118" left="370" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="382" width="35" height="27" font="4"><b>NJ </b></text>
<text top="118" left="417" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="463" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="243" height="20" font="0">Hydroxyzine Hcl INJ 25MG/ML </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="239" height="20" font="0">Hydroxyzine Hydrochloride INJ </text>
<text top="1096" left="783" width="32" height="20" font="0">123 </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="511" height="20" font="0">Alcohol Withdrawal Syndrome: 1) The patient has not tried one of the </text>
<text top="332" left="274" width="539" height="20" font="0">following alternative drugs: clorazepate or lorazepam AND 2) The patient </text>
<text top="352" left="274" width="462" height="20" font="0">has a contraindication to one of the following alternative drugs: </text>
<text top="373" left="274" width="537" height="20" font="0">clorazepate or lorazepam OR 3) The patient has tried one of the following </text>
<text top="394" left="274" width="464" height="20" font="0">alternative drugs: clorazepate or lorazepam AND 4) The patient </text>
<text top="414" left="274" width="518" height="20" font="0">experienced an inadequate treatment response OR intolerance to one of </text>
<text top="435" left="274" width="540" height="20" font="0">the following alternative drugs: clorazepate or lorazepam. Anxiety: 1) The </text>
<text top="456" left="274" width="481" height="20" font="0">patient has tried two of the following alternative drugs: buspirone, </text>
<text top="476" left="274" width="534" height="20" font="0">duloxetine, escitalopram, sertraline or venlafaxine extended-release AND </text>
<text top="497" left="274" width="470" height="20" font="0">2) The patient experienced an inadequate treatment response OR </text>
<text top="518" left="274" width="465" height="20" font="0">intolerance to two of the following alternative drugs: buspirone, </text>
<text top="539" left="274" width="540" height="20" font="0">duloxetine, escitalopram, sertraline or venlafaxine extended-release OR 3) </text>
<text top="559" left="274" width="461" height="20" font="0">The patient has not tried two of the following alternative drugs: </text>
<text top="580" left="274" width="516" height="20" font="0">buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-</text>
<text top="601" left="274" width="336" height="20" font="0">release AND 4) The patient has acute anxiety. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="699" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="738" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="738" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="797" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="797" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="818" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="838" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="859" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="880" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="900" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="921" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">124 </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="206" height="27" font="4"><b>PROMETHAZINE </b></text>
<text top="118" left="387" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="433" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="165" height="20" font="0">Promethazine Hcl INJ </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="251" height="20" font="0">Promethazine Hcl SUPP 12.5MG, </text>
<text top="219" left="400" width="5" height="23" font="6"></text>
<text top="242" left="149" width="47" height="20" font="0">25MG</text>
<text top="240" left="195" width="9" height="23" font="6"> </text>
<text top="262" left="122" width="8" height="22" font="5">•</text>
<text top="262" left="130" width="9" height="23" font="6">  </text>
<text top="264" left="149" width="249" height="20" font="0">Promethazine Hcl TABS 12.5MG </text>
<text top="284" left="122" width="8" height="22" font="5">•</text>
<text top="284" left="130" width="9" height="23" font="6">  </text>
<text top="286" left="149" width="176" height="20" font="0">Promethazine Hcl Plain </text>
<text top="306" left="122" width="8" height="22" font="5">•</text>
<text top="306" left="130" width="9" height="23" font="6">  </text>
<text top="308" left="149" width="264" height="20" font="0">Promethazine Hydrochloride TABS </text>
<text top="329" left="149" width="107" height="20" font="0">25MG, 50MG </text>
<text top="349" left="122" width="8" height="22" font="5">•</text>
<text top="348" left="130" width="9" height="23" font="6">  </text>
<text top="351" left="149" width="99" height="20" font="0">Promethegan </text>
<text top="428" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="428" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="470" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="470" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="509" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="509" left="274" width="35" height="20" font="0">N/A </text>
<text top="547" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="568" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="547" left="274" width="35" height="20" font="0">N/A </text>
<text top="607" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="627" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="648" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="607" left="274" width="468" height="20" font="0">Rhinitis: 1) The patient has tried two of the following non-HRM </text>
<text top="627" left="274" width="507" height="20" font="0">alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or </text>
<text top="648" left="274" width="540" height="20" font="0">flunisolide nasal AND 2) The patient experienced an inadequate treatment </text>
<text top="669" left="274" width="511" height="20" font="0">response OR intolerance to two of the following non-HRM alternative </text>
<text top="690" left="274" width="508" height="20" font="0">drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide </text>
<text top="710" left="274" width="46" height="20" font="0">nasal. </text>
<text top="749" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="749" left="274" width="35" height="20" font="0">N/A </text>
<text top="788" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="808" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="788" left="274" width="35" height="20" font="0">N/A </text>
<text top="847" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="868" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="847" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="906" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="906" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="927" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="948" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="969" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="989" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="1010" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="1031" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">125 </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">126</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="59" height="27" font="4"><b>RMS </b></text>
<text top="118" left="191" width="38" height="33" font="1"><b>- A</b></text>
<text top="123" left="228" width="215" height="27" font="4"><b>NTIDEPRESSANTS</b></text>
<text top="119" left="443" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="249" height="20" font="0">Amitriptyline Hcl TABS 100MG, </text>
<text top="197" left="397" width="5" height="23" font="6"></text>
<text top="221" left="149" width="112" height="20" font="0">150MG, 75MG</text>
<text top="218" left="260" width="9" height="23" font="6"> </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="258" height="20" font="0">Amitriptyline Hydrochloride TABS</text>
<text top="240" left="407" width="9" height="23" font="6"> </text>
<text top="263" left="149" width="159" height="20" font="0">10MG, 25MG, 50MG</text>
<text top="260" left="307" width="9" height="23" font="6"> </text>
<text top="283" left="122" width="8" height="22" font="5">•</text>
<text top="282" left="130" width="9" height="23" font="6">  </text>
<text top="285" left="149" width="206" height="20" font="0">Desipramine Hydrochloride </text>
<text top="305" left="122" width="8" height="22" font="5">•</text>
<text top="304" left="130" width="9" height="23" font="6">  </text>
<text top="307" left="149" width="277" height="20" font="0">Imipramine Hcl TABS 25MG, 50MG </text>
<text top="327" left="122" width="8" height="22" font="5">•</text>
<text top="326" left="130" width="9" height="23" font="6">  </text>
<text top="329" left="149" width="244" height="20" font="0">Imipramine Hydrochloride TABS</text>
<text top="326" left="392" width="9" height="23" font="6"> </text>
<text top="350" left="149" width="47" height="20" font="0">10MG</text>
<text top="347" left="195" width="9" height="23" font="6"> </text>
<text top="370" left="122" width="8" height="22" font="5">•</text>
<text top="369" left="130" width="9" height="23" font="6">  </text>
<text top="372" left="149" width="155" height="20" font="0">Imipramine Pamoate </text>
<text top="1096" left="783" width="32" height="20" font="0">127 </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="129" height="20" font="0">Neuropathic pain </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="525" height="20" font="0">If the requested drug is being prescribed for the treatment of depression: </text>
<text top="332" left="274" width="474" height="20" font="0">1) The patient tried two of the following alternative drugs: SSRIs </text>
<text top="352" left="274" width="540" height="20" font="0">(selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine </text>
<text top="373" left="274" width="518" height="20" font="0">reuptake inhibitors), bupropion, mirtazapine, or trazodone AND 2) The </text>
<text top="394" left="274" width="521" height="20" font="0">patient experienced an inadequate treatment response OR intolerance to </text>
<text top="414" left="274" width="476" height="20" font="0">two of the following alternative drugs: SSRIs (selective serotonin </text>
<text top="435" left="274" width="462" height="20" font="0">reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake </text>
<text top="456" left="274" width="360" height="20" font="0">inhibitors), bupropion, mirtazapine, or trazodone. </text>
<text top="494" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="494" left="274" width="35" height="20" font="0">N/A </text>
<text top="533" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="554" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="533" left="274" width="35" height="20" font="0">N/A </text>
<text top="593" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="613" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="593" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="652" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="652" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="673" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="693" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="714" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="735" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="756" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="776" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">128 </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="59" height="27" font="4"><b>RMS </b></text>
<text top="118" left="191" width="38" height="33" font="1"><b>- C</b></text>
<text top="123" left="228" width="196" height="27" font="4"><b>ARBINOXAMINE</b></text>
<text top="119" left="424" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="229" height="20" font="0">Carbinoxamine Maleate SOLN </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="228" height="20" font="0">Carbinoxamine Maleate TABS </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="468" height="20" font="0">Rhinitis: 1) The patient has tried two of the following non-HRM </text>
<text top="498" left="274" width="507" height="20" font="0">alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or </text>
<text top="519" left="274" width="540" height="20" font="0">flunisolide nasal AND 2) The patient experienced an inadequate treatment </text>
<text top="539" left="274" width="511" height="20" font="0">response OR intolerance to two of the following non-HRM alternative </text>
<text top="560" left="274" width="508" height="20" font="0">drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide </text>
<text top="581" left="274" width="46" height="20" font="0">nasal. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="798" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="819" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="839" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="860" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="881" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="901" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">129 </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="59" height="27" font="4"><b>RMS </b></text>
<text top="118" left="191" width="38" height="33" font="1"><b>- C</b></text>
<text top="123" left="228" width="144" height="27" font="4"><b>LEMASTINE</b></text>
<text top="118" left="372" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="418" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="273" height="20" font="0">Clemastine Fumarate TABS 2.68MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="468" height="20" font="0">Rhinitis: 1) The patient has tried two of the following non-HRM </text>
<text top="476" left="274" width="507" height="20" font="0">alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or </text>
<text top="497" left="274" width="540" height="20" font="0">flunisolide nasal AND 2) The patient experienced an inadequate treatment </text>
<text top="518" left="274" width="511" height="20" font="0">response OR intolerance to two of the following non-HRM alternative </text>
<text top="538" left="274" width="508" height="20" font="0">drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide </text>
<text top="559" left="274" width="46" height="20" font="0">nasal. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="776" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="796" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="817" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="838" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="859" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="879" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">130 </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="59" height="27" font="4"><b>RMS </b></text>
<text top="118" left="191" width="44" height="33" font="1"><b>- M</b></text>
<text top="123" left="235" width="124" height="27" font="4"><b>ECLIZINE </b></text>
<text top="118" left="358" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="404" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="223" height="20" font="0">Meclizine Hcl TABS 12.5MG </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="236" height="20" font="0">Meclizine Hydrochloride TABS </text>
<text top="242" left="149" width="51" height="20" font="0">25MG </text>
<text top="319" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="319" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="361" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="361" left="274" width="263" height="20" font="0">All Medically-accepted Indications. </text>
<text top="400" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="400" left="274" width="35" height="20" font="0">N/A </text>
<text top="439" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="459" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="439" left="274" width="35" height="20" font="0">N/A </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="35" height="20" font="0">N/A </text>
<text top="578" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="578" left="274" width="35" height="20" font="0">N/A </text>
<text top="617" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="638" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="617" left="274" width="35" height="20" font="0">N/A </text>
<text top="676" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="697" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="676" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="736" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="736" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="756" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="777" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="798" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="819" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="839" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="860" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">131 </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="59" height="27" font="4"><b>RMS </b></text>
<text top="118" left="191" width="36" height="33" font="1"><b>- T</b></text>
<text top="123" left="227" width="48" height="27" font="4"><b>CAS</b></text>
<text top="119" left="275" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="126" height="20" font="0">Protriptyline Hcl </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="216" height="20" font="0">Trimipramine Maleate CAPS </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="474" height="20" font="0">1) The patient tried two of the following alternative drugs: SSRIs </text>
<text top="498" left="274" width="540" height="20" font="0">(selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine </text>
<text top="519" left="274" width="518" height="20" font="0">reuptake inhibitors), bupropion, mirtazapine, or trazodone AND 2) The </text>
<text top="539" left="274" width="521" height="20" font="0">patient experienced an inadequate treatment response OR intolerance to </text>
<text top="560" left="274" width="476" height="20" font="0">two of the following alternative drugs: SSRIs (selective serotonin </text>
<text top="581" left="274" width="462" height="20" font="0">reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake </text>
<text top="602" left="274" width="360" height="20" font="0">inhibitors), bupropion, mirtazapine, or trazodone. </text>
<text top="640" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="679" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="700" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="679" left="274" width="35" height="20" font="0">N/A </text>
<text top="738" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="759" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="738" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="798" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="798" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="819" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="839" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="860" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="881" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="901" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="922" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">132 </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="40" height="27" font="4"><b>RM</b></text>
<text top="118" left="171" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="181" width="135" height="27" font="4"><b>SKELETAL </b></text>
<text top="118" left="317" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="345" width="86" height="27" font="4"><b>USCLE </b></text>
<text top="118" left="431" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="453" width="137" height="27" font="4"><b>ELAXANTS </b></text>
<text top="118" left="589" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="635" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="224" height="20" font="0">Chlorzoxazone TABS 500MG </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="236" height="20" font="0">Cyclobenzaprine Hydrochloride </text>
<text top="242" left="149" width="149" height="20" font="0">TABS 10MG, 5MG </text>
<text top="319" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="319" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="361" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="361" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="400" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="400" left="274" width="35" height="20" font="0">N/A </text>
<text top="439" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="459" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="439" left="274" width="35" height="20" font="0">N/A </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="528" height="20" font="0">If the patient is using one or more additional anticholinergic medications </text>
<text top="519" left="274" width="496" height="20" font="0">(e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, </text>
<text top="539" left="274" width="527" height="20" font="0">hydroxyzine) with the requested drug, the prescriber has determined that </text>
<text top="560" left="274" width="536" height="20" font="0">taking multiple anticholinergic medications is medically necessary for the </text>
<text top="581" left="274" width="532" height="20" font="0">patient [Note: Use of multiple anticholinergic medications in older adults </text>
<text top="602" left="274" width="419" height="20" font="0">is associated with an increased risk of cognitive decline.]. </text>
<text top="640" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="679" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="700" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="679" left="274" width="35" height="20" font="0">N/A </text>
<text top="738" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="759" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="738" left="274" width="71" height="20" font="0">3 months </text>
<text top="798" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="798" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="819" left="274" width="519" height="20" font="0">age or older. (The American Geriatrics Society identifies the use of this </text>
<text top="839" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="860" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="881" left="274" width="89" height="20" font="0">monitored.) </text>
<text top="901" left="274" width="474" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with this </text>
<text top="922" left="274" width="489" height="20" font="0">prescribed medication outweighs the potential risks for this patient. </text>
<text top="1096" left="783" width="32" height="20" font="0">133 </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="84" height="27" font="4"><b>UMIRA</b></text>
<text top="119" left="215" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="201" height="20" font="0">Humira INJ 10MG/0.1ML, </text>
<text top="197" left="349" width="5" height="23" font="6"></text>
<text top="221" left="149" width="221" height="20" font="0">20MG/0.2ML, 40MG/0.4ML, </text>
<text top="218" left="370" width="5" height="23" font="6"></text>
<text top="241" left="149" width="102" height="20" font="0">40MG/0.8ML</text>
<text top="238" left="250" width="9" height="23" font="6"> </text>
<text top="261" left="122" width="8" height="22" font="5">•</text>
<text top="260" left="130" width="9" height="23" font="6">  </text>
<text top="263" left="149" width="245" height="20" font="0">Humira Pediatric Crohns Disease </text>
<text top="260" left="393" width="5" height="23" font="6"></text>
<text top="284" left="149" width="242" height="20" font="0">Starter Pack INJ 0, 80MG/0.8ML</text>
<text top="281" left="391" width="9" height="23" font="6"> </text>
<text top="304" left="122" width="8" height="22" font="5">•</text>
<text top="303" left="130" width="9" height="23" font="6">  </text>
<text top="306" left="149" width="91" height="20" font="0">Humira Pen </text>
<text top="326" left="122" width="8" height="22" font="5">•</text>
<text top="325" left="130" width="9" height="23" font="6">  </text>
<text top="328" left="149" width="209" height="20" font="0">Humira Pen-cd/uc/hs Starter </text>
<text top="348" left="122" width="8" height="22" font="5">•</text>
<text top="347" left="130" width="9" height="23" font="6">  </text>
<text top="350" left="149" width="277" height="20" font="0">Humira Pen-pediatric Uc Starter Pack </text>
<text top="370" left="122" width="8" height="22" font="5">•</text>
<text top="369" left="130" width="9" height="23" font="6">  </text>
<text top="372" left="149" width="188" height="20" font="0">Humira Pen-ps/uv Starter </text>
<text top="1096" left="783" width="32" height="20" font="0">134 </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="316" height="20" font="0">Axial spondyloarthritis, Behcet's syndrome </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="523" height="20" font="0">For moderately to severely active rheumatoid arthritis (new starts only): </text>
<text top="332" left="274" width="517" height="20" font="0">1) Inadequate response, intolerance or contraindication to methotrexate </text>
<text top="352" left="274" width="494" height="20" font="0">(MTX) OR 2) Inadequate response or intolerance to a prior biologic </text>
<text top="373" left="274" width="526" height="20" font="0">disease-modifying antirheumatic drug (DMARD) or a targeted synthetic </text>
<text top="394" left="274" width="516" height="20" font="0">DMARD. For active ankylosing spondylitis and axial spondyloarthritis </text>
<text top="414" left="274" width="464" height="20" font="0">(new starts only): 1) Inadequate response to a non-steroidal anti-</text>
<text top="435" left="274" width="539" height="20" font="0">inflammatory drug (NSAID) trial OR 2) Intolerance or contraindication to </text>
<text top="456" left="274" width="533" height="20" font="0">NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) At </text>
<text top="476" left="274" width="512" height="20" font="0">least 3% of body surface area (BSA) is affected OR crucial body areas </text>
<text top="497" left="274" width="539" height="20" font="0">(e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the </text>
<text top="518" left="274" width="526" height="20" font="0">time of diagnosis, AND 2) Patient meets any of the following: a) Patient </text>
<text top="539" left="274" width="459" height="20" font="0">has experienced an inadequate response or intolerance to either </text>
<text top="559" left="274" width="487" height="20" font="0">phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with </text>
<text top="580" left="274" width="525" height="20" font="0">methotrexate, cyclosporine, or acitretin, OR b) Pharmacologic treatment </text>
<text top="601" left="274" width="508" height="20" font="0">with methotrexate, cyclosporine, or acitretin is contraindicated, OR c) </text>
<text top="621" left="274" width="533" height="20" font="0">Patient has severe psoriasis that warrants a biologic DMARD as first-line </text>
<text top="642" left="274" width="516" height="20" font="0">therapy (i.e. at least 10% of the BSA or crucial body areas (e.g., hands, </text>
<text top="663" left="274" width="520" height="20" font="0">feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected). </text>
<text top="684" left="274" width="512" height="20" font="0">For moderately to severely active Crohn's disease (new starts only): 1) </text>
<text top="704" left="274" width="452" height="20" font="0">Inadequate response to at least one conventional therapy (e.g., </text>
<text top="725" left="274" width="512" height="20" font="0">corticosteroids), OR 2) Intolerance or contraindication to conventional </text>
<text top="746" left="274" width="516" height="20" font="0">therapy. For moderately to severely active ulcerative colitis (new starts </text>
<text top="766" left="274" width="519" height="20" font="0">only): 1) Inadequate response to at least one conventional therapy (e.g., </text>
<text top="787" left="274" width="512" height="20" font="0">corticosteroids), OR 2) Intolerance or contraindication to conventional </text>
<text top="808" left="274" width="63" height="20" font="0">therapy. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="906" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="945" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="945" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1004" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1004" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">135 </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="131" width="111" height="27" font="4"><b>YPNOTIC</b></text>
<text top="118" left="242" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="252" width="237" height="27" font="4"><b>BENZODIAZEPINES </b></text>
<text top="118" left="489" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="535" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="267" height="20" font="0">Temazepam CAPS 15MG, 22.5MG, </text>
<text top="221" left="149" width="56" height="20" font="0">7.5MG </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="78" height="20" font="0">Triazolam </text>
<text top="319" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="319" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="361" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="361" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="400" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="400" left="274" width="35" height="20" font="0">N/A </text>
<text top="439" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="459" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="439" left="274" width="35" height="20" font="0">N/A </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="512" height="20" font="0">Prescriber must acknowledge the benefit of therapy with the requested </text>
<text top="519" left="274" width="521" height="20" font="0">drug outweighs the potential risks for the patient.  (Note: The American </text>
<text top="539" left="274" width="496" height="20" font="0">Geriatrics Society identifies the use of this medication as potentially </text>
<text top="560" left="274" width="506" height="20" font="0">inappropriate in older adults, meaning it is best avoided, prescribed at </text>
<text top="581" left="274" width="539" height="20" font="0">reduced dosage, or used with caution or carefully monitored.)  The patient </text>
<text top="602" left="274" width="518" height="20" font="0">has experienced an inadequate treatment response, intolerance, or has a </text>
<text top="622" left="274" width="320" height="20" font="0">contraindication to doxepin (3 mg or 6 mg). </text>
<text top="661" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="661" left="274" width="35" height="20" font="0">N/A </text>
<text top="700" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="720" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="700" left="274" width="35" height="20" font="0">N/A </text>
<text top="759" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="780" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="759" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="819" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="819" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="839" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="783" width="32" height="20" font="0">136 </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="101" height="27" font="4"><b>BRANCE</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Ibrance </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="494" height="20" font="0">Unresectable well-differentiated/dedifferentiated liposarcoma of the </text>
<text top="378" left="274" width="125" height="20" font="0">retroperitoneum. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">137 </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="127" height="27" font="4"><b>CATIBANT</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="127" height="20" font="0">Icatibant Acetate </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="55" height="20" font="0">Sajazir </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="524" height="20" font="0">For hereditary angioedema (HAE): The requested drug is being used for </text>
<text top="498" left="274" width="498" height="20" font="0">the treatment of acute angioedema attacks. Patient has HAE with C1 </text>
<text top="519" left="274" width="516" height="20" font="0">inhibitor deficiency or dysfunction confirmed by laboratory testing OR </text>
<text top="539" left="274" width="487" height="20" font="0">patient has HAE with normal C1 inhibitor confirmed by laboratory </text>
<text top="560" left="274" width="501" height="20" font="0">testing. For patients with HAE with normal C1 inhibitor, EITHER 1) </text>
<text top="581" left="274" width="481" height="20" font="0">Patient tested positive for an F12, angiopoietin-1, plasminogen, or </text>
<text top="602" left="274" width="533" height="20" font="0">kininogen-1 (KNG1) gene mutation OR 2) Patient has a family history of </text>
<text top="622" left="274" width="453" height="20" font="0">angioedema and the angioedema was refractory to a trial of an </text>
<text top="643" left="274" width="267" height="20" font="0">antihistamine for at least one month. </text>
<text top="682" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="682" left="274" width="175" height="20" font="0">18 years of age or older </text>
<text top="720" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="741" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="720" left="274" width="290" height="20" font="0">Immunologist, allergist, rheumatologist </text>
<text top="780" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="801" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="780" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="839" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="839" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">138 </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="92" height="27" font="4"><b>CLUSIG</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="53" height="20" font="0">Iclusig </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="499" height="20" font="0">Therapy after hematopoietic stem cell transplant (HSCT) for chronic </text>
<text top="378" left="274" width="491" height="20" font="0">myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) </text>
<text top="399" left="274" width="60" height="20" font="0">patients </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="516" height="20" font="0">For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia </text>
<text top="518" left="274" width="473" height="20" font="0">(ALL): diagnosis was confirmed by detection of the Philadelphia </text>
<text top="538" left="274" width="527" height="20" font="0">chromosome or BCR-ABL gene. For CML, including patients who have </text>
<text top="559" left="274" width="540" height="20" font="0">received a hematopoietic stem cell transplant: 1) patient has accelerated or </text>
<text top="580" left="274" width="533" height="20" font="0">blast phase CML and no other kinase inhibitor is indicated, OR 2) patient </text>
<text top="600" left="274" width="524" height="20" font="0">has chronic phase CML and has experienced resistance or intolerance to </text>
<text top="621" left="274" width="539" height="20" font="0">at least 2 prior kinase inhibitors AND at least one of those was imatinib or </text>
<text top="642" left="274" width="428" height="20" font="0">dasatinib, OR 3) patient is positive for the T315I mutation. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">139 </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="77" height="27" font="4"><b>DHIFA</b></text>
<text top="119" left="197" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="48" height="20" font="0">Idhifa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="308" height="20" font="0">Newly-diagnosed acute myeloid leukemia </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="519" height="20" font="0">For acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 </text>
<text top="476" left="274" width="508" height="20" font="0">(IDH2) mutation: 1) patient has a physiologic age of 60 years or older </text>
<text top="497" left="274" width="530" height="20" font="0">with newly-diagnosed AML and meets one of the following: a) patient is </text>
<text top="518" left="274" width="500" height="20" font="0">not a candidate for intensive induction therapy, or b) patient declines </text>
<text top="538" left="274" width="534" height="20" font="0">intensive induction chemotherapy, OR 2) patient has a physiologic age of </text>
<text top="559" left="274" width="513" height="20" font="0">60 years or older and the requested drug will be used as post-induction </text>
<text top="580" left="274" width="524" height="20" font="0">therapy following response to induction therapy with the requested drug </text>
<text top="600" left="274" width="339" height="20" font="0">OR 3) patient has relapsed or refractory AML. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">140 </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="108" height="27" font="4"><b>MATINIB</b></text>
<text top="119" left="228" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="136" height="20" font="0">Imatinib Mesylate </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="539" height="20" font="0">Desmoid tumors, pigmented villonodular synovitis/tenosynovial giant cell </text>
<text top="378" left="274" width="502" height="20" font="0">tumor (PVNS/TGCT), recurrent chordoma, melanoma, AIDS-related </text>
<text top="399" left="274" width="531" height="20" font="0">Kaposi sarcoma, chronic myelomonocytic leukemia, chronic graft versus </text>
<text top="419" left="274" width="524" height="20" font="0">host disease (cGVHD), T-cell acute lymphoblastic leukemia, aggressive </text>
<text top="440" left="274" width="471" height="20" font="0">systemic mastocytosis when eosinophilia is present with FIP1L1-</text>
<text top="461" left="274" width="164" height="20" font="0">PDGFRA fusion gene </text>
<text top="500" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="520" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="500" left="274" width="35" height="20" font="0">N/A </text>
<text top="559" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="580" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="600" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="559" left="274" width="489" height="20" font="0">For chronic myeloid leukemia (CML) or Philadelphia chromosome </text>
<text top="580" left="274" width="476" height="20" font="0">positive acute lymphoblastic leukemia (Ph+ ALL): diagnosis was </text>
<text top="600" left="274" width="511" height="20" font="0">confirmed by detection of the Philadelphia chromosome or BCR-ABL </text>
<text top="621" left="274" width="530" height="20" font="0">gene. For CML: patient did not fail (excluding failure due to intolerance) </text>
<text top="642" left="274" width="486" height="20" font="0">prior therapy with a tyrosine kinase inhibitor. For melanoma: c-Kit </text>
<text top="662" left="274" width="151" height="20" font="0">mutation is positive. </text>
<text top="701" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="701" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">141 </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="135" height="27" font="4"><b>MBRUVICA</b></text>
<text top="119" left="254" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="79" height="20" font="0">Imbruvica </text>
<text top="1096" left="783" width="32" height="20" font="0">142 </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="539" height="20" font="0">Hairy cell leukemia, lymphoplasmacytic lymphoma, follicular lymphoma, </text>
<text top="234" left="274" width="467" height="20" font="0">primary central nervous system lymphoma, AIDS-related B-cell </text>
<text top="254" left="274" width="524" height="20" font="0">lymphoma, histologic transformation of nodal marginal zone lymphoma </text>
<text top="275" left="274" width="513" height="20" font="0">to diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, post-</text>
<text top="296" left="274" width="516" height="20" font="0">transplant lymphoproliferative disorders, high-grade B-cell lymphoma. </text>
<text top="334" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="355" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="334" left="274" width="35" height="20" font="0">N/A </text>
<text top="394" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="414" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="435" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="394" left="274" width="533" height="20" font="0">For mantle cell lymphoma: 1) the requested drug will be used in a patient </text>
<text top="414" left="274" width="536" height="20" font="0">who has received at least one prior therapy, OR 2) the requested drug will </text>
<text top="435" left="274" width="489" height="20" font="0">be used in combination with rituximab as pretreatment to induction </text>
<text top="456" left="274" width="521" height="20" font="0">therapy with RHyperCVAD (rituximab, cyclophosphamide, vincristine, </text>
<text top="476" left="274" width="534" height="20" font="0">doxorubicin, and dexamethasone) regimen. For marginal zone lymphoma </text>
<text top="497" left="274" width="457" height="20" font="0">(including gastric mucosa-associated lymphoid tissue [MALT] </text>
<text top="518" left="274" width="464" height="20" font="0">lymphoma, non-gastric MALT lymphoma, nodal marginal zone </text>
<text top="539" left="274" width="480" height="20" font="0">lymphoma, and splenic marginal zone lymphoma): the patient has </text>
<text top="559" left="274" width="530" height="20" font="0">received at least one prior therapy. For hairy cell leukemia: the requested </text>
<text top="580" left="274" width="518" height="20" font="0">drug will be used as a single agent for disease progression. For primary </text>
<text top="601" left="274" width="534" height="20" font="0">central nervous system lymphoma: 1) the disease is relapsed or refractory </text>
<text top="621" left="274" width="524" height="20" font="0">OR 2) the requested drug is used for induction therapy as a single agent. </text>
<text top="642" left="274" width="541" height="20" font="0">For histologic transformation of nodal marginal zone lymphoma to diffuse </text>
<text top="663" left="274" width="519" height="20" font="0">large B-cell lymphoma: the requested drug will be used in patients who </text>
<text top="684" left="274" width="487" height="20" font="0">have received prior chemoimmunotherapy. For diffuse large B-cell </text>
<text top="704" left="274" width="526" height="20" font="0">lymphoma: the requested drug will be used as second-line or subsequent </text>
<text top="725" left="274" width="520" height="20" font="0">therapy. For AIDS-related B-cell lymphoma: the requested drug will be </text>
<text top="746" left="274" width="486" height="20" font="0">used as a single agent and as second-line or subsequent therapy for </text>
<text top="766" left="274" width="517" height="20" font="0">relapsed disease. For post-transplant lymphoproliferative disorders: the </text>
<text top="787" left="274" width="460" height="20" font="0">requested drug will be used in patients who have received prior </text>
<text top="808" left="274" width="518" height="20" font="0">chemoimmunotherapy. For high-grade B-cell lymphoma: the requested </text>
<text top="828" left="274" width="503" height="20" font="0">drug will be used as second-line or subsequent therapy. For follicular </text>
<text top="849" left="274" width="443" height="20" font="0">lymphoma: the requested drug will be used as a single agent. </text>
<text top="888" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="888" left="274" width="35" height="20" font="0">N/A </text>
<text top="927" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="947" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="927" left="274" width="35" height="20" font="0">N/A </text>
<text top="986" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="1007" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="986" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1045" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1045" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">143 </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">144</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="101" height="27" font="4"><b>MLYGIC</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Imlygic </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="412" height="20" font="0">Limited resectable or incompletely resectable melanoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="493" height="20" font="0">For melanoma: The requested drug will be used for the treatment of </text>
<text top="476" left="274" width="511" height="20" font="0">unresectable, limited resectable, or incompletely resectable cutaneous, </text>
<text top="497" left="274" width="240" height="20" font="0">subcutaneous, and nodal lesions. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">145 </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="117" height="27" font="4"><b>NCRELEX</b></text>
<text top="119" left="237" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Increlex </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="291" height="20" font="0">Pediatric patients with closed epiphyses </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="501" height="20" font="0">For growth failure due to severe primary insulin-like growth factor-1 </text>
<text top="476" left="274" width="537" height="20" font="0">(IGF-1) deficiency or growth hormone gene deletion in patients who have </text>
<text top="497" left="274" width="515" height="20" font="0">developed neutralizing antibodies to growth hormone, must meet all of </text>
<text top="518" left="274" width="508" height="20" font="0">the following prior to beginning therapy with the requested drug (new </text>
<text top="538" left="274" width="535" height="20" font="0">starts only): 1) height 3 or more standard deviations (SD) below the mean </text>
<text top="559" left="274" width="515" height="20" font="0">for children of the same age and gender AND 2) basal IGF-1 level 3 or </text>
<text top="580" left="274" width="540" height="20" font="0">more SD below the mean for children of the same age and gender AND 3) </text>
<text top="600" left="274" width="516" height="20" font="0">provocative growth hormone test showing a normal or elevated growth </text>
<text top="621" left="274" width="480" height="20" font="0">hormone level. For renewal, patient is experiencing improvement. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">146 </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="84" height="27" font="4"><b>NLYTA</b></text>
<text top="119" left="204" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="46" height="20" font="0">Inlyta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="416" height="20" font="0">Thyroid carcinoma (papillary, Hurthle cell, or follicular). </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="519" height="20" font="0">For renal cell carcinoma: the disease is advanced, relapsed, or stage IV. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">147 </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="81" height="27" font="4"><b>NQOVI</b></text>
<text top="119" left="201" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="51" height="20" font="0">Inqovi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">148 </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="93" height="27" font="4"><b>NREBIC</b></text>
<text top="119" left="213" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="56" height="20" font="0">Inrebic </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="513" height="20" font="0">Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and </text>
<text top="378" left="274" width="273" height="20" font="0">janus kinase 2 (JAK2) rearrangement </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="541" height="20" font="0">For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and </text>
<text top="497" left="274" width="444" height="20" font="0">JAK2 rearrangement: the disease is in chronic or blast phase. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">149 </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="23" height="27" font="4"><b>R </b></text>
<text top="118" left="143" width="20" height="33" font="1"><b>B</b></text>
<text top="123" left="163" width="89" height="27" font="4"><b>EFORE </b></text>
<text top="118" left="252" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="272" width="17" height="27" font="4"><b>R</b></text>
<text top="119" left="289" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="243" height="20" font="0">Hydrocodone Bitartrate Er T24A </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="91" height="20" font="0">Hysingla Er </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="147" height="20" font="0">Methadone Hcl INJ </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="221" height="20" font="0">Methadone Hcl ORAL SOLN </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="5" height="23" font="6"> </text>
<text top="288" left="149" width="166" height="20" font="0">Methadone Hcl TABS </text>
<text top="308" left="122" width="8" height="22" font="5">•</text>
<text top="307" left="130" width="5" height="23" font="6"> </text>
<text top="310" left="149" width="249" height="20" font="0">Methadone Hydrochloride CONC </text>
<text top="330" left="122" width="8" height="22" font="5">•</text>
<text top="329" left="130" width="5" height="23" font="6"> </text>
<text top="332" left="149" width="197" height="20" font="0">Morphine Sulfate Er CP24 </text>
<text top="352" left="122" width="8" height="22" font="5">•</text>
<text top="351" left="130" width="5" height="23" font="6"> </text>
<text top="354" left="149" width="204" height="20" font="0">Morphine Sulfate Er TBCR </text>
<text top="374" left="122" width="8" height="22" font="5">•</text>
<text top="373" left="130" width="5" height="23" font="6"> </text>
<text top="376" left="149" width="172" height="20" font="0">Tramadol Hcl Er TB24 </text>
<text top="1096" left="783" width="32" height="20" font="0">150 </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="535" height="20" font="0">1) The requested drug is being prescribed for pain associated with cancer, </text>
<text top="332" left="274" width="521" height="20" font="0">sickle cell disease, a terminal condition, or pain being managed through </text>
<text top="352" left="274" width="500" height="20" font="0">palliative care OR 2) The requested drug is being prescribed for pain </text>
<text top="373" left="274" width="538" height="20" font="0">severe enough to require daily, around-the-clock, long-term treatment in a </text>
<text top="394" left="274" width="538" height="20" font="0">patient who has been taking an opioid AND 3) The patient can safely take </text>
<text top="414" left="274" width="520" height="20" font="0">the requested dose based on their history of opioid use [Note: This drug </text>
<text top="435" left="274" width="452" height="20" font="0">should be prescribed only by healthcare professionals who are </text>
<text top="456" left="274" width="540" height="20" font="0">knowledgeable in the use of potent opioids for the management of chronic </text>
<text top="476" left="274" width="500" height="20" font="0">pain.] AND 4) The patient has been evaluated and the patient will be </text>
<text top="497" left="274" width="489" height="20" font="0">monitored for the development of opioid use disorder AND 5) This </text>
<text top="518" left="274" width="536" height="20" font="0">request is for continuation of therapy for a patient who has been receiving </text>
<text top="539" left="274" width="519" height="20" font="0">an extended-release opioid agent for at least 30 days OR the patient has </text>
<text top="559" left="274" width="410" height="20" font="0">taken an immediate-release opioid for at least one week. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="637" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="637" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="717" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="756" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="756" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">151 </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="1188" width="918">
</page>
<page number="153" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="169" height="27" font="4"><b>SOTRETINOIN</b></text>
<text top="128" left="289" width="6" height="22" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="203" left="130" width="5" height="16" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Accutane </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="90" height="20" font="0">Amnesteem </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="65" height="20" font="0">Claravis </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="137" height="20" font="0">Isotretinoin CAPS </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="5" height="23" font="6"> </text>
<text top="288" left="149" width="74" height="20" font="0">Myorisan </text>
<text top="308" left="122" width="8" height="22" font="5">•</text>
<text top="307" left="130" width="5" height="23" font="6"> </text>
<text top="310" left="149" width="71" height="20" font="0">Zenatane </text>
<text top="387" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="387" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="429" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="429" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="467" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="467" left="274" width="490" height="20" font="0">Refractory acne vulgaris, severe refractory rosacea, neuroblastoma, </text>
<text top="488" left="274" width="506" height="20" font="0">cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary </text>
<text top="509" left="274" width="532" height="20" font="0">syndrome), high risk for developing skin cancer (squamous cell cancers), </text>
<text top="529" left="274" width="535" height="20" font="0">transient acantholytic dermatosis (Grover's Disease), keratosis follicularis </text>
<text top="550" left="274" width="440" height="20" font="0">(Darier Disease), lamellar ichthyosis, pityriasis rubra pilaris. </text>
<text top="589" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="609" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="589" left="274" width="35" height="20" font="0">N/A </text>
<text top="648" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="669" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="690" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="648" left="274" width="35" height="20" font="0">N/A </text>
<text top="728" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="728" left="274" width="35" height="20" font="0">N/A </text>
<text top="767" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="788" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="767" left="274" width="35" height="20" font="0">N/A </text>
<text top="826" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="847" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="826" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="886" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="886" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">153 </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="188" height="27" font="4"><b>TRACONAZOLE</b></text>
<text top="119" left="308" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="143" height="20" font="0">Itraconazole CAPS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="525" height="20" font="0">Coccidioidomycosis, Coccidioidomycosis prophylaxis in HIV infection, </text>
<text top="378" left="274" width="516" height="20" font="0">Cryptococcosis, Histoplasmosis prophylaxis in HIV infection, invasive </text>
<text top="399" left="274" width="536" height="20" font="0">fungal infection prophylaxis in liver transplant patients, Microsporidiosis, </text>
<text top="419" left="274" width="481" height="20" font="0">Talaromycosis (formerly Penicilliosis), Pityriasis versicolor/Tinea </text>
<text top="440" left="274" width="504" height="20" font="0">versicolor, Sporotrichosis, Tinea corporis, Tinea cruris, Tinea capitis, </text>
<text top="461" left="274" width="205" height="20" font="0">Tinea manuum, Tinea pedis </text>
<text top="500" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="520" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="500" left="274" width="35" height="20" font="0">N/A </text>
<text top="559" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="580" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="600" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="559" left="274" width="488" height="20" font="0">If for the treatment of onychomycosis due to dermatophytes (Tinea </text>
<text top="580" left="274" width="517" height="20" font="0">unguium), the diagnosis has been confirmed by a fungal diagnostic test </text>
<text top="600" left="274" width="503" height="20" font="0">(e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail </text>
<text top="621" left="274" width="63" height="20" font="0">biopsy). </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="524" height="20" font="0">Disseminated/CNS histoplasmosis, Histoplasmosis/Coccidioidomycosis </text>
<text top="778" left="274" width="214" height="20" font="0">ppx: 12 mths. Others: 6 mths </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">154 </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="155" height="27" font="4"><b>VERMECTIN </b></text>
<text top="118" left="275" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="295" width="33" height="27" font="4"><b>AB</b></text>
<text top="119" left="328" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="133" height="20" font="0">Ivermectin TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="452" height="20" font="0">Ascariasis, Cutaneous larva migrans, Mansonelliasis, Scabies, </text>
<text top="378" left="274" width="216" height="20" font="0">Gnathostomiasis, Pediculosis </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="537" height="20" font="0">The requested drug is not being prescribed for the prevention or treatment </text>
<text top="497" left="274" width="308" height="20" font="0">of coronavirus disease 2019 (COVID-19). </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="64" height="20" font="0">1 month </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">155 </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="120" width="45" height="27" font="4"><b>VIG</b></text>
<text top="119" left="165" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="232" height="20" font="0">Bivigam INJ 10%, 5GM/50ML </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="127" height="20" font="0">Flebogamma Dif </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="9" height="23" font="6">  </text>
<text top="244" left="149" width="146" height="20" font="0">Gammagard Liquid </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="9" height="23" font="6">  </text>
<text top="266" left="149" width="228" height="20" font="0">Gammagard S/d Iga Less Than </text>
<text top="286" left="149" width="69" height="20" font="0">1mcg/ml </text>
<text top="306" left="122" width="8" height="22" font="5">•</text>
<text top="306" left="130" width="9" height="23" font="6">  </text>
<text top="308" left="149" width="233" height="20" font="0">Gammaked INJ 10GM/100ML, </text>
<text top="329" left="149" width="212" height="20" font="0">1GM/10ML, 20GM/200ML, </text>
<text top="350" left="149" width="93" height="20" font="0">5GM/50ML </text>
<text top="370" left="122" width="8" height="22" font="5">•</text>
<text top="369" left="130" width="9" height="23" font="6">  </text>
<text top="372" left="149" width="238" height="20" font="0">Gammaplex INJ 10GM/100ML, </text>
<text top="393" left="149" width="230" height="20" font="0">10GM/200ML, 20GM/200ML, </text>
<text top="413" left="149" width="221" height="20" font="0">20GM/400ML, 5GM/100ML, </text>
<text top="434" left="149" width="93" height="20" font="0">5GM/50ML </text>
<text top="454" left="122" width="8" height="22" font="5">•</text>
<text top="453" left="130" width="9" height="23" font="6">  </text>
<text top="456" left="149" width="89" height="20" font="0">Gamunex-c </text>
<text top="476" left="122" width="8" height="22" font="5">•</text>
<text top="475" left="130" width="9" height="23" font="6">  </text>
<text top="478" left="149" width="215" height="20" font="0">Octagam INJ 10GM/100ML, </text>
<text top="499" left="149" width="226" height="20" font="0">10GM/200ML, 2.5GM/50ML, </text>
<text top="519" left="149" width="230" height="20" font="0">20GM/200ML, 25GM/500ML, </text>
<text top="540" left="149" width="212" height="20" font="0">2GM/20ML, 30GM/300ML, </text>
<text top="561" left="149" width="199" height="20" font="0">5GM/100ML, 5GM/50ML </text>
<text top="581" left="122" width="8" height="22" font="5">•</text>
<text top="580" left="130" width="9" height="23" font="6">  </text>
<text top="583" left="149" width="65" height="20" font="0">Panzyga </text>
<text top="603" left="122" width="8" height="22" font="5">•</text>
<text top="602" left="130" width="9" height="23" font="6">  </text>
<text top="605" left="149" width="66" height="20" font="0">Privigen </text>
<text top="1096" left="783" width="32" height="20" font="0">156 </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="263" height="20" font="0">All Medically-accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="524" height="20" font="0">For B-cell chronic lymphocytic leukemia (CLL): 1) serum IgG less than </text>
<text top="332" left="274" width="504" height="20" font="0">500 mg/dL OR 2) a history of recurrent bacterial infections. For bone </text>
<text top="352" left="274" width="518" height="20" font="0">marrow transplant/hematopoietic stem cell transplant (BMT/HSCT): 1) </text>
<text top="373" left="274" width="521" height="20" font="0">IVIG is requested within the first 100 days post-transplant OR 2) serum </text>
<text top="394" left="274" width="518" height="20" font="0">IgG less than 400 mg/dL. For pediatric human immunodeficiency virus </text>
<text top="414" left="274" width="501" height="20" font="0">(HIV) infection: 1) serum IgG less than 400 mg/dL, OR 2) history of </text>
<text top="435" left="274" width="540" height="20" font="0">recurrent bacterial infections. For dermatomyositis and polymyositis: 1) at </text>
<text top="456" left="274" width="401" height="20" font="0">least one standard first-line treatment (corticosteroid or </text>
<text top="476" left="274" width="530" height="20" font="0">immunosuppressant) has been tried but was unsuccessful or not tolerated </text>
<text top="497" left="274" width="464" height="20" font="0">OR 2) patient is unable to receive standard therapy because of a </text>
<text top="518" left="274" width="474" height="20" font="0">contraindication or other clinical reason. For pure red cell aplasia </text>
<text top="539" left="274" width="422" height="20" font="0">(PRCA): PRCA is secondary to parvovirus B19 infection. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="637" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="735" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="735" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="756" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="776" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">157 </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="15" height="33" font="1"><b>J</b></text>
<text top="123" left="123" width="77" height="27" font="4"><b>AKAFI</b></text>
<text top="119" left="200" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="48" height="20" font="0">Jakafi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="515" height="20" font="0">Lower-risk myelofibrosis, accelerated phase myelofibrosis, blast phase </text>
<text top="378" left="274" width="504" height="20" font="0">myelofibrosis/acute myeloid leukemia, acute lymphoblastic leukemia </text>
<text top="399" left="274" width="484" height="20" font="0">(ALL), chronic myelomonocytic leukemia (CMML)-2, BCR-ABL </text>
<text top="419" left="274" width="454" height="20" font="0">negative atypical chronic myeloid leukemia (aCML), essential </text>
<text top="440" left="274" width="514" height="20" font="0">thrombocythemia, and myeloid, lymphoid or mixed lineage neoplasms </text>
<text top="461" left="274" width="314" height="20" font="0">with eosinophilia and JAK2 rearrangement </text>
<text top="500" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="520" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="500" left="274" width="35" height="20" font="0">N/A </text>
<text top="559" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="580" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="600" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="559" left="274" width="532" height="20" font="0">For polycythemia vera: patient had an inadequate response or intolerance </text>
<text top="580" left="274" width="526" height="20" font="0">to interferon therapy or hydroxyurea. For acute lymphoblastic leukemia: </text>
<text top="600" left="274" width="488" height="20" font="0">patient has a cytokine receptor-like factor 2 (CRLF2) mutation or a </text>
<text top="621" left="274" width="534" height="20" font="0">mutation associated with activation of the Janus kinase/signal transducers </text>
<text top="642" left="274" width="525" height="20" font="0">and activators of transcription (JAK/STAT) pathway. For CMML-2: the </text>
<text top="662" left="274" width="531" height="20" font="0">requested drug is used in combination with a hypomethylating agent. For </text>
<text top="683" left="274" width="538" height="20" font="0">BCR-ABL negative aCML: the requested drug is used as a single agent or </text>
<text top="704" left="274" width="432" height="20" font="0">in combination with a hypomethylating agent. For essential </text>
<text top="724" left="274" width="531" height="20" font="0">thrombocythemia: patient had an inadequate response or loss of response </text>
<text top="745" left="274" width="536" height="20" font="0">to hydroxyurea, interferon therapy, or anagrelide. For myeloid, lymphoid, </text>
<text top="766" left="274" width="525" height="20" font="0">or mixed lineage neoplasms with eosinophilia and JAK2 rearrangement: </text>
<text top="787" left="274" width="284" height="20" font="0">the disease is in chronic or blast phase. </text>
<text top="825" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="825" left="274" width="35" height="20" font="0">N/A </text>
<text top="864" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="885" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="864" left="274" width="35" height="20" font="0">N/A </text>
<text top="923" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="944" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="923" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="983" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="983" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">158 </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="120" height="27" font="4"><b>ALYDECO</b></text>
<text top="119" left="251" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Kalydeco </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="506" height="20" font="0">For cystic fibrosis (CF): The requested medication will not be used in </text>
<text top="476" left="274" width="417" height="20" font="0">combination with other medications containing ivacaftor. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="181" height="20" font="0">4 months of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">159 </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="109" height="27" font="4"><b>ESIMPTA</b></text>
<text top="119" left="241" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Kesimpta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">160 </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="188" height="27" font="4"><b>ETOCONAZOLE</b></text>
<text top="119" left="319" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="154" height="20" font="0">Ketoconazole TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="150" height="20" font="0">Cushing's syndrome </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="477" height="20" font="0">Acute or chronic liver disease. Concurrent use with drugs that are </text>
<text top="417" left="274" width="539" height="20" font="0">contraindicated with ketoconazole tablets: dofetilide, quinidine, pimozide, </text>
<text top="437" left="274" width="493" height="20" font="0">cisapride, methadone, disopyramide, dronedarone, ranolazine, ergot </text>
<text top="458" left="274" width="526" height="20" font="0">alkaloids, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, </text>
<text top="479" left="274" width="524" height="20" font="0">felodipine, nisoldipine, tolvaptan, eplerenone, lovastatin, simvastatin, or </text>
<text top="500" left="274" width="83" height="20" font="0">colchicine. </text>
<text top="538" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="559" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="580" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="538" left="274" width="459" height="20" font="0">The potential benefits outweigh the risks of treatment with oral </text>
<text top="559" left="274" width="516" height="20" font="0">ketoconazole. For systemic fungal infections, the patient has any of the </text>
<text top="580" left="274" width="533" height="20" font="0">following diagnoses: blastomycosis, coccidioidomycosis, histoplasmosis, </text>
<text top="600" left="274" width="537" height="20" font="0">chromomycosis, or paracoccidioidomycosis. For Cushing's syndrome: the </text>
<text top="621" left="274" width="489" height="20" font="0">requested drug is being prescribed for a patient who cannot tolerate </text>
<text top="642" left="274" width="346" height="20" font="0">surgery or where surgery has not been curative. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="71" height="20" font="0">6 months </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">161 </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="119" height="27" font="4"><b>EYTRUDA</b></text>
<text top="119" left="250" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="203" height="20" font="0">Keytruda INJ 100MG/4ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="263" height="20" font="0">All Medically-accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">162 </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="84" height="27" font="4"><b>ISQALI</b></text>
<text top="119" left="215" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="57" height="20" font="0">Kisqali </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="188" height="20" font="0">Kisqali Femara 200 Dose </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="188" height="20" font="0">Kisqali Femara 400 Dose </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="188" height="20" font="0">Kisqali Femara 600 Dose </text>
<text top="343" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="343" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="385" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="385" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="423" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="423" left="274" width="35" height="20" font="0">N/A </text>
<text top="462" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="483" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="462" left="274" width="35" height="20" font="0">N/A </text>
<text top="521" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="542" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="563" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="521" left="274" width="35" height="20" font="0">N/A </text>
<text top="601" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="601" left="274" width="35" height="20" font="0">N/A </text>
<text top="640" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="661" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="700" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="720" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="700" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="759" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="759" left="274" width="519" height="20" font="0">For treatment of breast cancer using Kisqali (ribociclib) in combination </text>
<text top="780" left="274" width="513" height="20" font="0">with an aromatase inhibitor or Kisqali Femara Co-Pack (ribociclib and </text>
<text top="800" left="274" width="437" height="20" font="0">letrozole) as initial endocrine-based therapy: if the patient is </text>
<text top="821" left="274" width="497" height="20" font="0">postmenopausal OR male, the patient has experienced an intolerable </text>
<text top="842" left="274" width="513" height="20" font="0">adverse event to Ibrance (palbociclib) AND Verzenio (abemaciclib) or </text>
<text top="862" left="274" width="450" height="20" font="0">has a contraindication to Ibrance (palbociclib) AND Verzenio </text>
<text top="883" left="274" width="525" height="20" font="0">(abemaciclib). For treatment of breast cancer with Kisqali (ribociclib) in </text>
<text top="904" left="274" width="519" height="20" font="0">combination with fulvestrant, one of the following criteria must met: 1) </text>
<text top="925" left="274" width="497" height="20" font="0">the requested drug is being used with fulvestrant as initial endocrine-</text>
<text top="945" left="274" width="479" height="20" font="0">based therapy in a postmenopausal patient or in a male, OR 2) the </text>
<text top="966" left="274" width="527" height="20" font="0">requested drug is being used following disease progression on endocrine </text>
<text top="987" left="274" width="492" height="20" font="0">therapy in a postmenopausal patient or in a male and the patient has </text>
<text top="1007" left="274" width="514" height="20" font="0">experienced an intolerable adverse event to Ibrance (palbociclib) AND </text>
<text top="1028" left="274" width="539" height="20" font="0">Verzenio (abemaciclib) OR has a contraindication to Ibrance (palbociclib) </text>
<text top="1049" left="274" width="222" height="20" font="0">AND Verzenio (abemaciclib). </text>
<text top="1096" left="783" width="32" height="20" font="0">163 </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">164</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="92" height="27" font="4"><b>ORLYM</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Korlym </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="120" height="20" font="0">Endocrinologist </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">165 </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="137" height="27" font="4"><b>RISTALOSE</b></text>
<text top="119" left="269" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="77" height="20" font="0">Kristalose </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="531" height="20" font="0">1) The patient has experienced an inadequate treatment response to a one </text>
<text top="476" left="274" width="455" height="20" font="0">month trial of generic lactulose solution OR 2) The patient has </text>
<text top="497" left="274" width="486" height="20" font="0">experienced an intolerance that would prohibit a one month trial of </text>
<text top="518" left="274" width="193" height="20" font="0">generic lactulose solution. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">166 </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="69" height="27" font="4"><b>UVAN</b></text>
<text top="119" left="201" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="212" height="20" font="0">Sapropterin Dihydrochloride </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="536" height="20" font="0">For phenylketonuria: For patients who have not yet received a therapeutic </text>
<text top="476" left="274" width="508" height="20" font="0">trial of the requested drug, the patient's pretreatment, including before </text>
<text top="497" left="274" width="510" height="20" font="0">dietary management, phenylalanine level is greater than 6 mg/dL (360 </text>
<text top="518" left="274" width="482" height="20" font="0">micromol/L). For patients who completed a therapeutic trial of the </text>
<text top="538" left="274" width="497" height="20" font="0">requested drug, the patient must have experienced improvement (for </text>
<text top="559" left="274" width="482" height="20" font="0">example, reduction in blood phenylalanine levels, improvement in </text>
<text top="580" left="274" width="214" height="20" font="0">neuropsychiatric symptoms). </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="289" height="20" font="0">Initial: 2 months. All others: Plan Year. </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">167 </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>K</b></text>
<text top="123" left="131" width="101" height="27" font="4"><b>YNMOBI</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Kynmobi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="507" height="20" font="0">For continuation treatment of off episodes in Parkinson's disease: The </text>
<text top="476" left="274" width="432" height="20" font="0">patient is experiencing improvement on the requested drug. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">168 </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="117" height="27" font="4"><b>APATINIB</b></text>
<text top="119" left="245" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="152" height="20" font="0">Lapatinib Ditosylate </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="474" height="20" font="0">Brain metastases from human epidermal growth factor receptor 2 </text>
<text top="378" left="274" width="539" height="20" font="0">(HER2)-positive breast cancer, recurrent epidermal growth factor receptor </text>
<text top="399" left="274" width="521" height="20" font="0">(EGFR)-positive chordoma, HER2-amplified and RAS and BRAF wild-</text>
<text top="419" left="274" width="409" height="20" font="0">type colorectal cancer in combination with trastuzumab. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="493" height="20" font="0">For HER2-positive breast cancer, the requested drug will be used in </text>
<text top="538" left="274" width="474" height="20" font="0">combination with any of the following: 1) aromatase inhibitor, 2) </text>
<text top="559" left="274" width="245" height="20" font="0">capecitabine, OR 3) trastuzumab. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">169 </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="100" height="27" font="4"><b>ENVIMA</b></text>
<text top="119" left="228" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="207" height="20" font="0">Lenvima 10 Mg Daily Dose </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="200" height="20" font="0">Lenvima 12mg Daily Dose </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="207" height="20" font="0">Lenvima 14 Mg Daily Dose </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="207" height="20" font="0">Lenvima 18 Mg Daily Dose </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="5" height="23" font="6"> </text>
<text top="288" left="149" width="207" height="20" font="0">Lenvima 20 Mg Daily Dose </text>
<text top="308" left="122" width="8" height="22" font="5">•</text>
<text top="307" left="130" width="5" height="23" font="6"> </text>
<text top="310" left="149" width="207" height="20" font="0">Lenvima 24 Mg Daily Dose </text>
<text top="330" left="122" width="8" height="22" font="5">•</text>
<text top="329" left="130" width="5" height="23" font="6"> </text>
<text top="332" left="149" width="198" height="20" font="0">Lenvima 4 Mg Daily Dose </text>
<text top="352" left="122" width="8" height="22" font="5">•</text>
<text top="351" left="130" width="5" height="23" font="6"> </text>
<text top="354" left="149" width="198" height="20" font="0">Lenvima 8 Mg Daily Dose </text>
<text top="431" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="431" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="473" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="473" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="511" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="511" left="274" width="459" height="20" font="0">Medullary thyroid carcinoma, recurrent endometrial carcinoma </text>
<text top="550" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="571" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="550" left="274" width="35" height="20" font="0">N/A </text>
<text top="609" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="630" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="651" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="609" left="274" width="513" height="20" font="0">For differentiated thyroid cancer (follicular, papillary, or Hurthle cell): </text>
<text top="630" left="274" width="514" height="20" font="0">disease is not amenable to radioactive iodine therapy and unresectable, </text>
<text top="651" left="274" width="527" height="20" font="0">locally recurrent, persistent, or metastatic. For hepatocellular carcinoma: </text>
<text top="671" left="274" width="522" height="20" font="0">disease is unresectable or inoperable, local, metastatic or with extensive </text>
<text top="692" left="274" width="479" height="20" font="0">liver tumor burden. For renal cell carcinoma: disease is advanced, </text>
<text top="713" left="274" width="528" height="20" font="0">relapsed, or stage IV. For endometrial carcinoma, the patient meets ALL </text>
<text top="734" left="274" width="525" height="20" font="0">of the following: 1) The disease is advanced or recurrent, 2) The disease </text>
<text top="754" left="274" width="536" height="20" font="0">is not microsatellite instability-high (MSI-H) or mismatch repair deficient </text>
<text top="775" left="274" width="530" height="20" font="0">(dMMR), 3) The patient experienced disease progression following prior </text>
<text top="796" left="274" width="497" height="20" font="0">systemic therapy, AND 4) The patient is not a candidate for curative </text>
<text top="816" left="274" width="151" height="20" font="0">surgery or radiation. </text>
<text top="855" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="855" left="274" width="35" height="20" font="0">N/A </text>
<text top="894" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="914" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="894" left="274" width="35" height="20" font="0">N/A </text>
<text top="953" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="974" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="953" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1013" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1013" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">170 </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="143" height="27" font="4"><b>EUPROLIDE</b></text>
<text top="119" left="271" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="270" height="20" font="0">Leuprolide Acetate INJ 1MG/0.2ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="538" height="20" font="0">Use in combination with growth hormone for children with growth failure </text>
<text top="378" left="274" width="500" height="20" font="0">and advancing puberty, recurrent androgen receptor positive salivary </text>
<text top="399" left="274" width="103" height="20" font="0">gland tumors. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">171 </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="95" height="27" font="4"><b>IBTAYO</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Libtayo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="526" height="20" font="0">Inoperable or incompletely resected cutaneous squamous cell carcinoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="480" height="20" font="0">For cutaneous squamous cell carcinoma: patient meets both of the </text>
<text top="476" left="274" width="501" height="20" font="0">following: 1) disease is one of the following: a) metastatic, b) locally </text>
<text top="497" left="274" width="525" height="20" font="0">advanced, or c) regional and inoperable or incompletely resected, and 2) </text>
<text top="518" left="274" width="485" height="20" font="0">patient is not a candidate for curative surgery or curative radiation. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">172 </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="129" height="27" font="4"><b>IDOCAINE </b></text>
<text top="118" left="257" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="275" width="99" height="27" font="4"><b>ATCHES</b></text>
<text top="119" left="374" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="155" height="20" font="0">Lidocaine PTCH 5% </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="506" height="20" font="0">Pain associated with diabetic neuropathy, pain associated with cancer-</text>
<text top="378" left="274" width="471" height="20" font="0">related neuropathy (including treatment-related neuropathy [e.g., </text>
<text top="399" left="274" width="484" height="20" font="0">neuropathy associated with radiation treatment or chemotherapy]). </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">173 </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>INEZOLID</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Linezolid </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="530" height="20" font="0">The infection is proven or strongly suspected to be caused by susceptible </text>
<text top="476" left="274" width="453" height="20" font="0">bacteria. The patient will be using the requested drug orally or </text>
<text top="497" left="274" width="107" height="20" font="0">intravenously. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="503" height="20" font="0">Prescribed or directed by an Infectious Disease specialist when being </text>
<text top="595" left="274" width="370" height="20" font="0">converted from intravenous (IV) linezolid (Zyvox) </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="60" height="20" font="0">28 days </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">174 </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="99" height="27" font="4"><b>ONSURF</b></text>
<text top="119" left="227" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Lonsurf </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="523" height="20" font="0">For colorectal cancer: The disease is advanced or metastatic. For gastric </text>
<text top="476" left="274" width="537" height="20" font="0">or gastroesophageal junction adenocarcinoma, all of the following criteria </text>
<text top="497" left="274" width="541" height="20" font="0">must be met: 1) The disease is unresectable locally advanced, recurrent, or </text>
<text top="518" left="274" width="510" height="20" font="0">metastatic, and 2) The patient has been previously treated with at least </text>
<text top="538" left="274" width="240" height="20" font="0">two prior lines of chemotherapy. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">175 </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>ORBRENA</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Lorbrena </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="524" height="20" font="0">Anaplastic lymphoma kinase (ALK)-positive recurrent or advanced non-</text>
<text top="378" left="274" width="473" height="20" font="0">small cell lung cancer (NSCLC). Repressor of silencing (ROS)-1 </text>
<text top="399" left="274" width="482" height="20" font="0">rearrangement-positive recurrent, advanced, or metastatic NSCLC </text>
<text top="419" left="274" width="438" height="20" font="0">following progression on crizotinib, entrectinib, or ceritinib. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="67" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="35" height="20" font="0">N/A </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">176 </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="124" height="27" font="4"><b>UMAKRAS</b></text>
<text top="119" left="252" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="77" height="20" font="0">Lumakras </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">177 </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="111" height="27" font="4"><b>UMOXITI</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Lumoxiti </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="532" height="20" font="0">For hairy cell leukemia, the patient will not receive more than 6 cycles of </text>
<text top="476" left="274" width="251" height="20" font="0">treatment with the requested drug. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="71" height="20" font="0">6 months </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">178 </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="91" height="27" font="4"><b>UPRON </b></text>
<text top="118" left="219" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="238" width="33" height="27" font="4"><b>ED</b></text>
<text top="119" left="271" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="216" height="20" font="0">Lupron Depot-ped (1-month) </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="216" height="20" font="0">Lupron Depot-ped (3-month) </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="507" height="20" font="0">For central precocious puberty (CPP), patients not currently receiving </text>
<text top="498" left="274" width="525" height="20" font="0">therapy must meet all of the following criteria: 1) Diagnosis of CPP was </text>
<text top="519" left="274" width="514" height="20" font="0">confirmed by a pubertal response to a gonadotropin releasing hormone </text>
<text top="539" left="274" width="527" height="20" font="0">(GnRH) agonist test OR a pubertal level of a third generation luteinizing </text>
<text top="560" left="274" width="538" height="20" font="0">hormone (LH) assay, 2) Assessment of bone age versus chronological age </text>
<text top="581" left="274" width="497" height="20" font="0">supports the diagnosis of CPP, and 3) The onset of secondary sexual </text>
<text top="602" left="274" width="507" height="20" font="0">characteristics occurred prior to 8 years of age for female patients OR </text>
<text top="622" left="274" width="293" height="20" font="0">prior to 9 years of age for male patients. </text>
<text top="661" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="661" left="274" width="505" height="20" font="0">CPP: Patient must be less than 12 years old if female and less than 13 </text>
<text top="682" left="274" width="130" height="20" font="0">years old if male. </text>
<text top="720" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="741" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="720" left="274" width="35" height="20" font="0">N/A </text>
<text top="780" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="801" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="780" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="839" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="839" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">179 </text>
</page>
<page number="180" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="85" height="27" font="4"><b>UPRON</b></text>
<text top="118" left="213" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="223" width="205" height="27" font="4"><b>ENDOMETRIOSIS</b></text>
<text top="119" left="429" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="214" height="20" font="0">Lupron Depot (1-month) INJ </text>
<text top="221" left="149" width="65" height="20" font="0">3.75MG </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="214" height="20" font="0">Lupron Depot (3-month) INJ </text>
<text top="263" left="149" width="74" height="20" font="0">11.25MG </text>
<text top="340" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="340" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="382" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="382" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="421" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="421" left="274" width="497" height="20" font="0">Breast cancer, malignant sex cord-stromal tumors, epithelial ovarian </text>
<text top="441" left="274" width="397" height="20" font="0">cancer/fallopian tube cancer/primary peritoneal cancer </text>
<text top="480" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="501" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="480" left="274" width="35" height="20" font="0">N/A </text>
<text top="539" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="560" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="581" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="539" left="274" width="533" height="20" font="0">For uterine fibroids, patient must meet one of the following: 1) Diagnosis </text>
<text top="560" left="274" width="477" height="20" font="0">of anemia (e.g., hematocrit less than or equal to 30 percent and/or </text>
<text top="581" left="274" width="539" height="20" font="0">hemoglobin less than or equal to 10g/dL), OR 2) the requested medication </text>
<text top="602" left="274" width="353" height="20" font="0">will be used prior to surgery for uterine fibroids. </text>
<text top="640" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="679" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="700" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="679" left="274" width="35" height="20" font="0">N/A </text>
<text top="738" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="759" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="738" left="274" width="519" height="20" font="0">Fibroids: 3 months (mo), max 6 mo total. Endometriosis: 6 mo, max 12 </text>
<text top="759" left="274" width="202" height="20" font="0">mo total. Others: Plan Year </text>
<text top="798" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="798" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">180 </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="117" height="27" font="4"><b>YNPARZA</b></text>
<text top="119" left="245" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="123" height="20" font="0">Lynparza TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="513" height="20" font="0">Recurrent HER2-negative, BRCA 1/2-germline mutated breast cancer, </text>
<text top="378" left="274" width="497" height="20" font="0">recurrent or metastatic HER2-positive, BRCA 1/2-germline mutated </text>
<text top="399" left="274" width="99" height="20" font="0">breast cancer </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="515" height="20" font="0">For breast cancer the disease must be: 1) BRCA 1/2-germline mutated, </text>
<text top="518" left="274" width="483" height="20" font="0">and 2) recurrent or metastatic. For prostate cancer: The patient has </text>
<text top="538" left="274" width="537" height="20" font="0">progressed on prior treatment with an androgen receptor-directed therapy. </text>
<text top="559" left="274" width="538" height="20" font="0">For epithelial ovarian, fallopian tube, or primary peritoneal cancer: 1) The </text>
<text top="580" left="274" width="472" height="20" font="0">requested drug is used for maintenance therapy for stage II-IV or </text>
<text top="600" left="274" width="539" height="20" font="0">recurrent disease who are in complete or partial response to chemotherapy </text>
<text top="621" left="274" width="493" height="20" font="0">OR 2) The patient has deleterious or suspected deleterious germline </text>
<text top="642" left="274" width="506" height="20" font="0">BRCA-mutated advanced, recurrent, or persistent disease after two or </text>
<text top="662" left="274" width="262" height="20" font="0">more prior chemotherapy regimens. </text>
<text top="701" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="701" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">181 </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="128" width="85" height="27" font="4"><b>YRICA </b></text>
<text top="118" left="213" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="234" width="17" height="27" font="4"><b>R</b></text>
<text top="119" left="252" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="103" height="20" font="0">Pregabalin Er </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="468" height="20" font="0">The patient has experienced an inadequate treatment response to </text>
<text top="476" left="274" width="539" height="20" font="0">gabapentin, or the patient has experienced an intolerance to gabapentin, or </text>
<text top="497" left="274" width="349" height="20" font="0">the patient has a contraindication to gabapentin. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">182 </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="101" height="27" font="4"><b>AVYRET</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Mavyret </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="522" height="20" font="0">Decompensated cirrhosis/moderate or severe hepatic impairment (Child </text>
<text top="417" left="274" width="259" height="20" font="0">Turcotte Pugh [CTP] class B or C). </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="511" height="20" font="0">For hepatitis C virus (HCV): Infection confirmed by presence of HCV </text>
<text top="476" left="274" width="532" height="20" font="0">RNA in the serum prior to starting treatment. Planned treatment regimen, </text>
<text top="497" left="274" width="480" height="20" font="0">genotype, prior treatment history, presence or absence of cirrhosis </text>
<text top="518" left="274" width="540" height="20" font="0">(compensated or decompensated [CTP class B or C]), presence or absence </text>
<text top="538" left="274" width="540" height="20" font="0">of human immunodeficiency virus (HIV) coinfection, presence or absence </text>
<text top="559" left="274" width="523" height="20" font="0">of resistance-associated substitutions where applicable, liver and kidney </text>
<text top="580" left="274" width="499" height="20" font="0">transplantation status if applicable. Coverage conditions and specific </text>
<text top="600" left="274" width="526" height="20" font="0">durations of approval will be based on current American Association for </text>
<text top="621" left="274" width="435" height="20" font="0">the Study of Liver Diseases (AASLD) treatment guidelines. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="521" height="20" font="0">Criteria will be applied consistent with current AASLD-IDSA guidance </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">183 </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="100" height="27" font="4"><b>EKINIST</b></text>
<text top="119" left="236" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Mekinist </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="492" height="20" font="0">Brain metastases from melanoma, uveal melanoma, central nervous </text>
<text top="378" left="274" width="531" height="20" font="0">system (CNS) cancer (i.e., glioma, meningioma, astrocytoma), low grade </text>
<text top="399" left="274" width="165" height="20" font="0">serous ovarian cancer. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="515" height="20" font="0">For brain metastasis from melanoma, adjuvant treatment of melanoma, </text>
<text top="518" left="274" width="498" height="20" font="0">and central nervous system (CNS) cancer (i.e., glioma, meningioma, </text>
<text top="538" left="274" width="490" height="20" font="0">astrocytoma): 1) The tumor is positive for a BRAF V600 activating </text>
<text top="559" left="274" width="537" height="20" font="0">mutation (e.g., V600E or V600K), and 2) The requested drug will be used </text>
<text top="580" left="274" width="541" height="20" font="0">in combination with dabrafenib. For unresectable or metastatic melanoma: </text>
<text top="600" left="274" width="496" height="20" font="0">1) The tumor is positive for a BRAF V600 activating mutation (e.g., </text>
<text top="621" left="274" width="507" height="20" font="0">V600E or V600K), and 2) The requested drug will be used as a single </text>
<text top="642" left="274" width="527" height="20" font="0">agent or in combination with dabrafenib. For non-small cell lung cancer, </text>
<text top="662" left="274" width="487" height="20" font="0">and anaplastic thyroid cancer: 1) The tumor is positive for a BRAF </text>
<text top="683" left="274" width="526" height="20" font="0">V600E mutation, and 2) The requested drug will be used in combination </text>
<text top="704" left="274" width="540" height="20" font="0">with dabrafenib. For uveal melanoma, the requested drug will be used as a </text>
<text top="724" left="274" width="510" height="20" font="0">single agent. For low grade serous ovarian cancer: The requested drug </text>
<text top="745" left="274" width="370" height="20" font="0">will be used to treat persistent or recurrent disease. </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="843" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="941" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="941" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">184 </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="96" height="27" font="4"><b>EKTOVI</b></text>
<text top="119" left="232" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Mektovi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="379" height="20" font="0">Adjuvant systemic therapy for cutaneous melanoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="498" height="20" font="0">For cutaneous melanoma: The patient must meet all of the following </text>
<text top="476" left="274" width="518" height="20" font="0">criteria: 1) Tumor is positive for BRAF V600 activating mutation (e.g., </text>
<text top="497" left="274" width="510" height="20" font="0">V600E or V600K), 2) The requested drug will be used in combination </text>
<text top="518" left="274" width="532" height="20" font="0">with encorafenib, and 3) The requested drug will be used for either of the </text>
<text top="538" left="274" width="523" height="20" font="0">following: a) unresectable or metastatic disease, or b) adjuvant systemic </text>
<text top="559" left="274" width="63" height="20" font="0">therapy. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">185 </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="132" height="27" font="4"><b>EMANTINE</b></text>
<text top="119" left="268" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="216" height="20" font="0">Memantine Hcl Titration Pak </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="247" height="20" font="0">Memantine Hydrochloride SOLN </text>
<text top="242" left="149" width="75" height="20" font="0">2MG/ML </text>
<text top="262" left="122" width="8" height="22" font="5">•</text>
<text top="262" left="130" width="9" height="23" font="6">  </text>
<text top="264" left="149" width="247" height="20" font="0">Memantine Hydrochloride TABS </text>
<text top="284" left="122" width="8" height="22" font="5">•</text>
<text top="284" left="130" width="9" height="23" font="6">  </text>
<text top="286" left="149" width="217" height="20" font="0">Memantine Hydrochloride Er </text>
<text top="363" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="363" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="405" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="405" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="444" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="444" left="274" width="35" height="20" font="0">N/A </text>
<text top="483" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="503" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="483" left="274" width="35" height="20" font="0">N/A </text>
<text top="542" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="563" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="583" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="542" left="274" width="35" height="20" font="0">N/A </text>
<text top="622" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="622" left="274" width="35" height="20" font="0">N/A </text>
<text top="661" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="682" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="661" left="274" width="35" height="20" font="0">N/A </text>
<text top="720" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="741" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="720" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="780" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="780" left="274" width="424" height="20" font="0">This edit only applies to patients less than 30 years of age. </text>
<text top="1096" left="783" width="32" height="20" font="0">186 </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="84" height="27" font="4"><b>EPRON</b></text>
<text top="119" left="220" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="140" height="20" font="0">Atovaquone SUSP </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="457" height="20" font="0">Babesiosis, Toxoplasmosis, Pneumocystis jirovecii pneumonia </text>
<text top="378" left="274" width="540" height="20" font="0">prophylaxis in pediatric patients, mild-to-moderate Pneumocystis jirovecii </text>
<text top="399" left="274" width="308" height="20" font="0">pneumonia treatment in pediatric patients. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="527" height="20" font="0">For the treatment of mild-to-moderate Pneumocystis jiroveci pneumonia </text>
<text top="518" left="274" width="470" height="20" font="0">(PCP): the patient had an intolerance or has a contraindication to </text>
<text top="538" left="274" width="528" height="20" font="0">sulfamethoxazole/trimethoprim (SMX-TMP). For the prevention of PCP </text>
<text top="559" left="274" width="533" height="20" font="0">and primary toxoplasmosis prophylaxis indications: A) the patient had an </text>
<text top="580" left="274" width="522" height="20" font="0">intolerance or has a contraindication to SMX-TMP, AND B) the patient </text>
<text top="600" left="274" width="491" height="20" font="0">has had a CD4 cell count of less than 200 cells per cubic millimeter </text>
<text top="621" left="274" width="521" height="20" font="0">within the past 3 months. For secondary toxoplasmosis prophylaxis: the </text>
<text top="642" left="274" width="465" height="20" font="0">patient has had a CD4 cell count of less than 200 cells per cubic </text>
<text top="662" left="274" width="482" height="20" font="0">millimeter within the past 6 months.  For babesiosis treatment: the </text>
<text top="683" left="274" width="524" height="20" font="0">requested drug is used concurrently with azithromycin OR clindamycin. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="760" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="781" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="760" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="529" height="20" font="0">Secondary toxoplasmosis prophylaxis: 6 months, All other indications: 3 </text>
<text top="841" left="274" width="58" height="20" font="0">months </text>
<text top="879" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="879" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">187 </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="120" height="27" font="4"><b>ODAFINIL</b></text>
<text top="119" left="256" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="77" height="20" font="0">Modafinil </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="467" height="20" font="0">1) The patient has a diagnosis of narcolepsy and the diagnosis is </text>
<text top="476" left="274" width="516" height="20" font="0">confirmed by sleep lab evaluation OR 2) The patient has a diagnosis of </text>
<text top="497" left="274" width="477" height="20" font="0">Shift Work Disorder (SWD) OR 3) The patient has a diagnosis of </text>
<text top="518" left="274" width="472" height="20" font="0">obstructive sleep apnea (OSA) and the diagnosis is confirmed by </text>
<text top="538" left="274" width="139" height="20" font="0">polysomnography. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">188 </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="92" height="27" font="4"><b>ONJUVI</b></text>
<text top="119" left="228" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="67" height="20" font="0">Monjuvi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">189 </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="28" height="33" font="1"><b>M</b></text>
<text top="123" left="136" width="121" height="27" font="4"><b>YLOTARG</b></text>
<text top="119" left="258" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Mylotarg </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="277" height="20" font="0">Acute promyelocytic leukemia (APL) </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">190 </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="119" height="27" font="4"><b>APROXEN</b></text>
<text top="118" left="248" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="258" width="203" height="27" font="4"><b>ESOMEPRAZOLE</b></text>
<text top="119" left="461" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="269" height="20" font="0">Naproxen/esomeprazole Magnesium </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="526" height="20" font="0">The patient has tried two different regimens containing any combination </text>
<text top="476" left="274" width="515" height="20" font="0">of a nonsteroidal anti-inflammatory drug (NSAID) and an acid blocker </text>
<text top="497" left="274" width="525" height="20" font="0">from any of the following drug classes: H2-receptor antagonist (H2RA), </text>
<text top="518" left="274" width="210" height="20" font="0">proton pump inhibitor (PPI). </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">191 </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="100" height="27" font="4"><b>ATPARA</b></text>
<text top="119" left="230" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Natpara </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="530" height="20" font="0">Acute postsurgical hypoparathyroidism (within 6 months of surgery) and </text>
<text top="417" left="274" width="329" height="20" font="0">expected recovery from hypoparathyroidism. </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">192 </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="116" height="27" font="4"><b>AYZILAM</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="74" height="20" font="0">Nayzilam </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="175" height="20" font="0">12 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">193 </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="101" height="27" font="4"><b>ERLYNX</b></text>
<text top="119" left="231" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Nerlynx </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="509" height="20" font="0">Recurrent human epidermal growth factor receptor 2 (HER2)-positive </text>
<text top="378" left="274" width="485" height="20" font="0">breast cancer, Brain metastases from HER2-positive breast cancer. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">194 </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="103" height="27" font="4"><b>EXAVAR</b></text>
<text top="119" left="232" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="65" height="20" font="0">Nexavar </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="508" height="20" font="0">Acute myeloid leukemia, soft tissue sarcoma (angiosarcoma, desmoid </text>
<text top="378" left="274" width="504" height="20" font="0">tumors/aggressive fibromatosis, and solitary fibrous tumor subtypes), </text>
<text top="399" left="274" width="443" height="20" font="0">gastrointestinal stromal tumor, medullary thyroid carcinoma, </text>
<text top="419" left="274" width="512" height="20" font="0">osteosarcoma, recurrent chordoma, epithelial ovarian cancer, fallopian </text>
<text top="440" left="274" width="285" height="20" font="0">tube cancer, primary peritoneal cancer. </text>
<text top="479" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="500" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="479" left="274" width="35" height="20" font="0">N/A </text>
<text top="538" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="559" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="580" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="538" left="274" width="520" height="20" font="0">For thyroid carcinoma: Histology is follicular, papillary, Hurthle cell or </text>
<text top="559" left="274" width="538" height="20" font="0">medullary. For acute myeloid leukemia, any of the following criteria must </text>
<text top="580" left="274" width="526" height="20" font="0">be met: 1) The requested drug is used in combination with azacitidine or </text>
<text top="600" left="274" width="535" height="20" font="0">decitabine for low-intensity treatment induction or post-induction therapy </text>
<text top="621" left="274" width="535" height="20" font="0">AND the patient is 60 years of age or older with FLT3-ITD mutation, OR </text>
<text top="642" left="274" width="475" height="20" font="0">2) The disease is relapsed/refractory AND the requested drug is a </text>
<text top="662" left="274" width="501" height="20" font="0">component of repeating the initial successful induction if late relapse </text>
<text top="683" left="274" width="422" height="20" font="0">(greater than or equal to 12 months), OR 3) The disease is </text>
<text top="704" left="274" width="525" height="20" font="0">relapsed/refractory AND the requested drug is used in combination with </text>
<text top="724" left="274" width="538" height="20" font="0">azacitidine or decitabine if the patient is FLT3-ITD mutation positive. For </text>
<text top="745" left="274" width="498" height="20" font="0">renal cell carcinoma, the patient meets ALL of the following: 1) The </text>
<text top="766" left="274" width="475" height="20" font="0">disease is advanced, AND 2) The patient has experienced disease </text>
<text top="787" left="274" width="532" height="20" font="0">progression or an intolerable adverse event with a trial of cabozantinib or </text>
<text top="807" left="274" width="64" height="20" font="0">axitinib. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="905" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="944" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="944" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1003" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1003" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">195 </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="96" height="27" font="4"><b>INLARO</b></text>
<text top="119" left="226" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Ninlaro </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="349" height="20" font="0">Systemic light chain amyloidosis, Waldenstrom </text>
<text top="378" left="274" width="372" height="20" font="0">macroglobulinemia/lymphoplasmacytic lymphoma </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="518" height="20" font="0">For multiple myeloma: The requested drug will be used in combination </text>
<text top="497" left="274" width="449" height="20" font="0">with lenalidomide and dexamethasone OR pomalidomide and </text>
<text top="518" left="274" width="460" height="20" font="0">dexamethasone OR dexamethasone OR cyclophosphamide and </text>
<text top="538" left="274" width="272" height="20" font="0">dexamethasone OR as a single agent. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">196 </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="127" height="27" font="4"><b>ITISINONE</b></text>
<text top="119" left="256" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="80" height="20" font="0">Nitisinone </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="513" height="20" font="0">For hereditary tyrosinemia type 1: Diagnosis of hereditary tyrosinemia </text>
<text top="476" left="274" width="528" height="20" font="0">type 1 is confirmed by one of the following: 1) biochemical testing (e.g., </text>
<text top="497" left="274" width="485" height="20" font="0">detection of succinylacetone in urine) or 2) DNA testing (mutation </text>
<text top="518" left="274" width="73" height="20" font="0">analysis). </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">197 </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="121" height="27" font="4"><b>ORTHERA</b></text>
<text top="119" left="251" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="81" height="20" font="0">Droxidopa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="512" height="20" font="0">For neurogenic orthostatic hypotension (nOH): Prior to initial therapy, </text>
<text top="476" left="274" width="540" height="20" font="0">patient has a persistent, consistent decrease in systolic blood pressure of at </text>
<text top="497" left="274" width="501" height="20" font="0">least 20 mmHg OR decrease in diastolic blood pressure of at least 10 </text>
<text top="518" left="274" width="529" height="20" font="0">mmHg within 3 minutes of standing or head-up tilt test. For continuation </text>
<text top="538" left="274" width="498" height="20" font="0">of therapy for nOH, patient experienced benefit from therapy (e.g., a </text>
<text top="559" left="274" width="507" height="20" font="0">sustained decrease in dizziness, lightheadedness, or feeling faint). For </text>
<text top="580" left="274" width="525" height="20" font="0">both initial and continuation of therapy for nOH, the requested drug will </text>
<text top="600" left="274" width="517" height="20" font="0">be used for patients with neurogenic orthostatic hypotension associated </text>
<text top="621" left="274" width="531" height="20" font="0">with one of the following diagnoses: 1) Primary autonomic failure due to </text>
<text top="642" left="274" width="523" height="20" font="0">Parkinson's disease, multiple system atrophy, or pure autonomic failure, </text>
<text top="662" left="274" width="489" height="20" font="0">OR 2) Dopamine beta-hydroxylase deficiency, OR 3) Non-diabetic </text>
<text top="683" left="274" width="171" height="20" font="0">autonomic neuropathy. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="760" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="781" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="760" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="71" height="20" font="0">3 months </text>
<text top="879" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="879" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">198 </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="85" height="27" font="4"><b>UBEQA</b></text>
<text top="119" left="215" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Nubeqa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="499" height="20" font="0">The requested drug will be used in combination with a gonadotropin-</text>
<text top="476" left="274" width="473" height="20" font="0">releasing hormone (GnRH) analog or after bilateral orchiectomy. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">199 </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="117" height="27" font="4"><b>UEDEXTA</b></text>
<text top="119" left="247" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Nuedexta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">200 </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>N</b></text>
<text top="123" left="130" width="108" height="27" font="4"><b>UPLAZID</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="120" height="20" font="0">Nuplazid CAPS </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="172" height="20" font="0">Nuplazid TABS 10MG </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="496" height="20" font="0">For hallucinations and delusions associated with Parkinson's disease </text>
<text top="498" left="274" width="530" height="20" font="0">psychosis, the diagnosis of Parkinson's disease must be made prior to the </text>
<text top="519" left="274" width="219" height="20" font="0">onset of psychotic symptoms. </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">201 </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="144" height="27" font="4"><b>CTREOTIDE</b></text>
<text top="119" left="275" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="170" height="20" font="0">Octreotide Acetate INJ </text>
<text top="221" left="149" width="227" height="20" font="0">1000MCG/ML, 100MCG/ML, </text>
<text top="241" left="149" width="218" height="20" font="0">200MCG/ML, 500MCG/ML, </text>
<text top="262" left="149" width="95" height="20" font="0">50MCG/ML </text>
<text top="339" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="339" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="381" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="381" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="419" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="419" left="274" width="384" height="20" font="0">Tumor control of thymomas and thymic carcinomas. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="514" height="20" font="0">For acromegaly (initial): 1) patient has a high pretreatment insulin-like </text>
<text top="538" left="274" width="470" height="20" font="0">growth factor-1 (IGF-1) level for age and/or gender based on the </text>
<text top="559" left="274" width="507" height="20" font="0">laboratory reference range, and 2) patient had an inadequate or partial </text>
<text top="580" left="274" width="528" height="20" font="0">response to surgery or radiotherapy OR there is a clinical reason for why </text>
<text top="600" left="274" width="462" height="20" font="0">the patient has not had surgery or radiotherapy. For acromegaly </text>
<text top="621" left="274" width="465" height="20" font="0">(continuation of therapy): patient's IGF-1 level has decreased or </text>
<text top="642" left="274" width="541" height="20" font="0">normalized since initiation of therapy. For tumor control of thymomas and </text>
<text top="662" left="274" width="481" height="20" font="0">thymic carcinomas, the requested drug will be used as second-line </text>
<text top="683" left="274" width="531" height="20" font="0">systemic therapy in patients with unresectable or extrathoracic metastatic </text>
<text top="704" left="274" width="61" height="20" font="0">disease. </text>
<text top="742" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="742" left="274" width="35" height="20" font="0">N/A </text>
<text top="781" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="802" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="781" left="274" width="35" height="20" font="0">N/A </text>
<text top="841" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="861" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="841" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="900" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="900" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">202 </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="93" height="27" font="4"><b>DOMZO</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Odomzo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">203 </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="48" height="27" font="4"><b>FEV</b></text>
<text top="119" left="179" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="40" height="20" font="0">Ofev </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">204 </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="115" height="27" font="4"><b>NCASPAR</b></text>
<text top="119" left="246" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Oncaspar </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="507" height="20" font="0">Extranodal natural killer/T-cell lymphoma (nasal type), hepatosplenic </text>
<text top="378" left="274" width="227" height="20" font="0">gamma-delta T-cell lymphoma </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="472" height="20" font="0">For extranodal natural killer/T-cell lymphoma (nasal type), acute </text>
<text top="497" left="274" width="461" height="20" font="0">lymphoblastic leukemia, and hepatosplenic gamma-delta T-cell </text>
<text top="518" left="274" width="511" height="20" font="0">lymphoma: the requested drug must be used in conjunction with multi-</text>
<text top="538" left="274" width="154" height="20" font="0">agent chemotherapy. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">205 </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="87" height="27" font="4"><b>NUREG</b></text>
<text top="119" left="218" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Onureg </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">206 </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="93" height="27" font="4"><b>PSUMIT</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="67" height="20" font="0">Opsumit </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="525" height="20" font="0">For pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="476" left="274" width="538" height="20" font="0">[WHO] Group 1): Diagnosis was confirmed by right heart catheterization. </text>
<text top="497" left="274" width="486" height="20" font="0">For PAH new starts only: 1) Pretreatment mean pulmonary arterial </text>
<text top="518" left="274" width="518" height="20" font="0">pressure is greater than 20 mmHg, 2) Pretreatment pulmonary capillary </text>
<text top="538" left="274" width="509" height="20" font="0">wedge pressure is less than or equal to 15 mmHg, and 3) Pretreatment </text>
<text top="559" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">207 </text>
</page>
<page number="208" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="85" height="27" font="4"><b>RACEA</b></text>
<text top="119" left="217" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="148" height="20" font="0">Doxycycline CPDR </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="55" height="20" font="0">Oracea </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="472" height="20" font="0">Patient must have experienced an inadequate treatment response, </text>
<text top="498" left="274" width="477" height="20" font="0">intolerance, or has a contraindication to formulary generic topical </text>
<text top="519" left="274" width="112" height="20" font="0">metronidazole. </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">208 </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="51" height="27" font="4"><b>RAL</b></text>
<text top="118" left="182" width="10" height="33" font="1"><b>-</b></text>
<text top="123" left="192" width="165" height="27" font="4"><b>INTRANASAL </b></text>
<text top="118" left="357" width="18" height="33" font="1"><b>F</b></text>
<text top="123" left="375" width="117" height="27" font="4"><b>ENTANYL</b></text>
<text top="119" left="492" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="263" height="20" font="0">Fentanyl Citrate Oral Transmucosal </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="494" height="20" font="0">1) The requested drug is indicated for the treatment of breakthrough </text>
<text top="476" left="274" width="518" height="20" font="0">CANCER-related pain only. The requested drug is being prescribed for </text>
<text top="497" left="274" width="477" height="20" font="0">the management of breakthrough pain in a CANCER patient with </text>
<text top="518" left="274" width="510" height="20" font="0">underlying CANCER pain AND 2) The International Classification of </text>
<text top="538" left="274" width="465" height="20" font="0">Diseases (ICD) diagnosis code provided supports the CANCER-</text>
<text top="559" left="274" width="530" height="20" font="0">RELATED diagnosis. [Note: For drug coverage approval, ICD diagnosis </text>
<text top="580" left="274" width="538" height="20" font="0">code provided MUST support the CANCER-RELATED diagnosis.] AND </text>
<text top="600" left="274" width="532" height="20" font="0">3) The patient is currently receiving, and will continue to receive, around-</text>
<text top="621" left="274" width="497" height="20" font="0">the-clock opioid therapy for underlying CANCER pain AND 4) The </text>
<text top="642" left="274" width="510" height="20" font="0">requested drug is intended only for use in opioid tolerant patients. The </text>
<text top="662" left="274" width="514" height="20" font="0">patient can safely take the requested dose based on their current opioid </text>
<text top="683" left="274" width="523" height="20" font="0">use history. [Note: Patients considered opioid tolerant are those who are </text>
<text top="704" left="274" width="501" height="20" font="0">taking around-the-clock medicine consisting of at least 60 mg of oral </text>
<text top="724" left="274" width="508" height="20" font="0">morphine per day, at least 25 mcg per hour of transdermal fentanyl, at </text>
<text top="745" left="274" width="541" height="20" font="0">least 30 mg of oral oxycodone per day, at least 60 mg of oral hydrocodone </text>
<text top="766" left="274" width="517" height="20" font="0">per day, at least 8 mg of oral hydromorphone per day, at least 25 mg of </text>
<text top="787" left="274" width="509" height="20" font="0">oral oxymorphone per day, or an equianalgesic dose of another opioid </text>
<text top="807" left="274" width="308" height="20" font="0">medication daily for one week or longer.]. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="905" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="944" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="944" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1003" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1003" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">209 </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="107" height="27" font="4"><b>RGOVYX</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Orgovyx </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="72" height="20" font="0">Plan year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">210 </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="101" height="27" font="4"><b>RKAMBI</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Orkambi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="506" height="20" font="0">For cystic fibrosis (CF): The requested medication will not be used in </text>
<text top="476" left="274" width="417" height="20" font="0">combination with other medications containing ivacaftor. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="166" height="20" font="0">2 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">211 </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="173" height="27" font="4"><b>XANDROLONE</b></text>
<text top="119" left="305" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="149" height="20" font="0">Oxandrolone TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="508" height="20" font="0">Cachexia associated with AIDS (HIV wasting), To enhance growth in </text>
<text top="378" left="274" width="236" height="20" font="0">patients with Turners Syndrome </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="445" height="20" font="0">Turners Syndrome: Plan Year, All other diagnoses: 6 months </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="501" height="20" font="0">Coverage will be denied if request is for an indication excluded from </text>
<text top="734" left="274" width="128" height="20" font="0">Medicare Part D. </text>
<text top="1096" left="783" width="32" height="20" font="0">212 </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>O</b></text>
<text top="123" left="131" width="127" height="27" font="4"><b>XAZEPAM </b></text>
<text top="118" left="259" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="305" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="81" height="20" font="0">Oxazepam </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="483" height="20" font="0">For all indications: the prescriber must acknowledge the benefit of </text>
<text top="476" left="274" width="495" height="20" font="0">therapy with the requested drug outweighs the potential risks for the </text>
<text top="497" left="274" width="531" height="20" font="0">patient.  (Note: The American Geriatrics Society identifies the use of this </text>
<text top="518" left="274" width="529" height="20" font="0">medication as potentially inappropriate in older adults, meaning it is best </text>
<text top="538" left="274" width="522" height="20" font="0">avoided, prescribed at reduced dosage, or used with caution or carefully </text>
<text top="559" left="274" width="534" height="20" font="0">monitored.)  For the management of anxiety disorders, anxiety associated </text>
<text top="580" left="274" width="516" height="20" font="0">with depression, and the management of anxiety, tension, agitation and </text>
<text top="600" left="274" width="458" height="20" font="0">irritability in older patients: 1) the requested drug is being used </text>
<text top="621" left="274" width="490" height="20" font="0">concurrently with a selective serotonin reuptake inhibitor (SSRI) or </text>
<text top="642" left="274" width="529" height="20" font="0">serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI </text>
<text top="662" left="274" width="504" height="20" font="0">becomes effective for the symptoms of anxiety, OR 2) the patient has </text>
<text top="683" left="274" width="502" height="20" font="0">experienced an inadequate treatment response, intolerance, or a has a </text>
<text top="704" left="274" width="525" height="20" font="0">contraindication to AT LEAST TWO agents from the following classes: </text>
<text top="724" left="274" width="456" height="20" font="0">a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-</text>
<text top="745" left="274" width="322" height="20" font="0">norepinephrine reuptake inhibitors (SNRIs). </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="843" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="529" height="20" font="0">Short-term relief anxiety-1 month, Anxiety Disorders-4 months, Alcohol </text>
<text top="903" left="274" width="167" height="20" font="0">Withdrawal-Plan Year </text>
<text top="941" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="941" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="962" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="783" width="32" height="20" font="0">213 </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="85" height="27" font="4"><b>ADCEV</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="56" height="20" font="0">Padcev </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="485" height="20" font="0">Recurrent primary carcinoma of the urethra, recurrent or persistent </text>
<text top="378" left="274" width="262" height="20" font="0">urothelial carcinoma of the bladder. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="520" height="20" font="0">For urothelial carcinoma, the requested drug will be used as subsequent </text>
<text top="497" left="274" width="481" height="20" font="0">therapy for any of the following: a) locally advanced or metastatic </text>
<text top="518" left="274" width="526" height="20" font="0">urothelial carcinoma, b) urothelial carcinoma of the bladder with muscle </text>
<text top="538" left="274" width="521" height="20" font="0">invasive local recurrence or persistent disease in a preserved bladder, c) </text>
<text top="559" left="274" width="511" height="20" font="0">urothelial carcinoma of the bladder with metastatic or local recurrence </text>
<text top="580" left="274" width="481" height="20" font="0">post cystectomy, or d) recurrent primary carcinoma of the urethra. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">214 </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="96" height="27" font="4"><b>EGASYS</b></text>
<text top="119" left="222" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Pegasys </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="525" height="20" font="0">Myeloproliferative neoplasm (essential thrombocythemia, polycythemia </text>
<text top="378" left="274" width="524" height="20" font="0">vera, symptomatic low risk myelofibrosis), systemic mastocytosis, adult </text>
<text top="399" left="274" width="539" height="20" font="0">T-cell leukemia/lymphoma, mycosis fungoides/Sezary syndrome, primary </text>
<text top="419" left="274" width="405" height="20" font="0">cutaneous CD30+ T-cell lymphoproliferative disorders. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="524" height="20" font="0">For chronic hepatitis C: Hepatitis C virus (HCV) confirmed by presence </text>
<text top="538" left="274" width="540" height="20" font="0">of hepatitis C virus HCV RNA in serum prior to starting treatment and the </text>
<text top="559" left="274" width="202" height="20" font="0">planned treatment regimen. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="515" height="20" font="0">HCV: 12-48 weeks depending on regimen. HBV: 48 weeks. All Other: </text>
<text top="716" left="274" width="81" height="20" font="0">Plan Year. </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">215 </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="123" height="27" font="4"><b>EMAZYRE</b></text>
<text top="119" left="249" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="76" height="20" font="0">Pemazyre </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">216 </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="100" height="27" font="4"><b>EPAXTO</b></text>
<text top="119" left="226" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Pepaxto </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">217 </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="219" height="27" font="4"><b>HENYLBUTYRATE</b></text>
<text top="119" left="345" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="231" height="20" font="0">Sodium Phenylbutyrate POWD </text>
<text top="221" left="149" width="79" height="20" font="0">3GM/TSP </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="224" height="20" font="0">Sodium Phenylbutyrate TABS </text>
<text top="319" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="319" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="361" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="361" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="400" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="400" left="274" width="35" height="20" font="0">N/A </text>
<text top="439" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="459" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="439" left="274" width="35" height="20" font="0">N/A </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="500" height="20" font="0">For urea cycle disorder: Diagnosis of urea cycle disorder (UCD) was </text>
<text top="519" left="274" width="409" height="20" font="0">confirmed by enzymatic, biochemical or genetic testing. </text>
<text top="578" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="578" left="274" width="35" height="20" font="0">N/A </text>
<text top="617" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="638" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="617" left="274" width="35" height="20" font="0">N/A </text>
<text top="676" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="697" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="676" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="736" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="736" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">218 </text>
</page>
<page number="219" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="85" height="27" font="4"><b>HESGO</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="57" height="20" font="0">Phesgo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="509" height="20" font="0">Recurrent human epidermal growth factor receptor 2 (HER2)-positive </text>
<text top="378" left="274" width="99" height="20" font="0">breast cancer </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="486" height="20" font="0">Neoadjuvant therapy for breast cancer: 6 months. Other: Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">219 </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="80" height="27" font="4"><b>IQRAY</b></text>
<text top="119" left="206" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="192" height="20" font="0">Piqray 200mg Daily Dose </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="192" height="20" font="0">Piqray 250mg Daily Dose </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="192" height="20" font="0">Piqray 300mg Daily Dose </text>
<text top="321" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="321" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="363" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="363" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="401" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="401" left="274" width="502" height="20" font="0">Recurrent hormone receptor (HR)-positive, human epidermal growth </text>
<text top="422" left="274" width="505" height="20" font="0">factor receptor 2 (HER2)-negative, PIK3CA-mutated breast cancer in </text>
<text top="443" left="274" width="217" height="20" font="0">combination with fulvestrant. </text>
<text top="481" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="502" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="481" left="274" width="35" height="20" font="0">N/A </text>
<text top="541" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="561" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="582" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="541" left="274" width="35" height="20" font="0">N/A </text>
<text top="621" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="621" left="274" width="35" height="20" font="0">N/A </text>
<text top="660" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="680" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="740" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="719" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="778" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="778" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">220 </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="79" height="27" font="4"><b>OLIVY</b></text>
<text top="119" left="205" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="52" height="20" font="0">Polivy </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="522" height="20" font="0">High-grade B-cell lymphomas, histologic transformation of follicular to </text>
<text top="378" left="274" width="533" height="20" font="0">diffuse large B-cell lymphoma without translocations of MYC and BCL2 </text>
<text top="399" left="274" width="539" height="20" font="0">and/or BCL6, monomorphic post-transplant lymphoproliferative disorders </text>
<text top="419" left="274" width="513" height="20" font="0">(B-cell type), acquired immunodeficiency syndrome (AIDS)-related B-</text>
<text top="440" left="274" width="517" height="20" font="0">cell lymphomas (AIDS-related diffuse large B-cell lymphoma, primary </text>
<text top="461" left="274" width="518" height="20" font="0">effusion lymphoma, and human herpesvirus-8 (HHV8)-positive diffuse </text>
<text top="482" left="274" width="538" height="20" font="0">large B-cell lymphoma), histologic transformation of nodal marginal zone </text>
<text top="502" left="274" width="486" height="20" font="0">lymphoma to diffuse large B-cell lymphoma, follicular lymphoma. </text>
<text top="541" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="562" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="541" left="274" width="35" height="20" font="0">N/A </text>
<text top="600" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="621" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="642" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="600" left="274" width="536" height="20" font="0">For diffuse large B-cell lymphomas and high-grade B-cell lymphomas: 1) </text>
<text top="621" left="274" width="489" height="20" font="0">The requested drug is used as a single agent or in combination with </text>
<text top="642" left="274" width="517" height="20" font="0">bendamustine with or without a rituximab product, AND 2) Patient has </text>
<text top="662" left="274" width="265" height="20" font="0">received at least two prior therapies. </text>
<text top="701" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="701" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">221 </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="121" height="27" font="4"><b>OMALYST</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Pomalyst </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="530" height="20" font="0">Systemic light chain amyloidosis, primary central nervous system (CNS) </text>
<text top="378" left="274" width="231" height="20" font="0">lymphoma, POEMS syndrome. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="517" height="20" font="0">For multiple myeloma: The patient has previously received at least two </text>
<text top="497" left="274" width="516" height="20" font="0">prior therapies for multiple myeloma, including an immunomodulatory </text>
<text top="518" left="274" width="512" height="20" font="0">agent AND a proteasome inhibitor. For Kaposi sarcoma, patient meets </text>
<text top="538" left="274" width="539" height="20" font="0">one of the following: 1) patient has acquired immunodeficiency syndrome </text>
<text top="559" left="274" width="496" height="20" font="0">(AIDS), or 2) patient is negative for human immunodeficiency virus </text>
<text top="580" left="274" width="53" height="20" font="0">(HIV). </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">222 </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="130" height="27" font="4"><b>OTELIGEO</b></text>
<text top="119" left="256" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Poteligeo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="245" height="20" font="0">Adult T-cell leukemia/lymphoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">223 </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="117" height="27" font="4"><b>RALUENT</b></text>
<text top="119" left="244" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Praluent </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">224 </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="146" height="27" font="4"><b>REGABALIN</b></text>
<text top="119" left="272" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="131" height="20" font="0">Pregabalin CAPS </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="133" height="20" font="0">Pregabalin SOLN </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="539" height="20" font="0">Cancer-Related Neuropathic Pain, Cancer Treatment-Related Neuropathic </text>
<text top="400" left="274" width="37" height="20" font="0">Pain </text>
<text top="439" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="459" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="439" left="274" width="35" height="20" font="0">N/A </text>
<text top="498" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="519" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="539" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="498" left="274" width="471" height="20" font="0">1) The requested drug is being prescribed for the management of </text>
<text top="519" left="274" width="514" height="20" font="0">postherpetic neuralgia, the management of neuropathic pain associated </text>
<text top="539" left="274" width="521" height="20" font="0">with diabetic peripheral neuropathy, cancer-related neuropathic pain, or </text>
<text top="560" left="274" width="481" height="20" font="0">cancer treatment-related neuropathic pain AND 2) The patient has </text>
<text top="581" left="274" width="448" height="20" font="0">experienced an inadequate treatment response, intolerance, or </text>
<text top="602" left="274" width="477" height="20" font="0">contraindication to gabapentin OR 3) The requested drug is being </text>
<text top="622" left="274" width="536" height="20" font="0">prescribed as adjunctive therapy for the treatment of partial onset seizures </text>
<text top="643" left="274" width="501" height="20" font="0">OR 4) The requested drug is being prescribed for the management of </text>
<text top="664" left="274" width="499" height="20" font="0">fibromyalgia or the management of neuropathic pain associated with </text>
<text top="684" left="274" width="136" height="20" font="0">spinal cord injury. </text>
<text top="723" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="723" left="274" width="35" height="20" font="0">N/A </text>
<text top="762" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="783" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="762" left="274" width="35" height="20" font="0">N/A </text>
<text top="821" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="842" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="821" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="881" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="881" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">225 </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="152" height="27" font="4"><b>RETOMANID</b></text>
<text top="119" left="278" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="87" height="20" font="0">Pretomanid </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">226 </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="127" height="27" font="4"><b>ROMACTA</b></text>
<text top="119" left="253" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="72" height="20" font="0">Promacta </text>
<text top="1096" left="783" width="32" height="20" font="0">227 </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="35" height="20" font="0">N/A </text>
<text top="252" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="272" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="252" left="274" width="35" height="20" font="0">N/A </text>
<text top="311" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="332" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="352" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="311" left="274" width="512" height="20" font="0">For chronic or persistent immune thrombocytopenia (ITP): 1) For new </text>
<text top="332" left="274" width="531" height="20" font="0">starts: a) Patient has had an inadequate response or is intolerant to a prior </text>
<text top="352" left="274" width="501" height="20" font="0">therapy such as corticosteroids or immunoglobulins, b) Untransfused </text>
<text top="373" left="274" width="500" height="20" font="0">platelet (plt) count at any point prior to the initiation of the requested </text>
<text top="394" left="274" width="473" height="20" font="0">medication is less than 30,000/mcL OR 30,000-50,000/mcL with </text>
<text top="414" left="274" width="512" height="20" font="0">symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a </text>
<text top="435" left="274" width="540" height="20" font="0">medical or dental procedure where blood loss is anticipated, comorbidities </text>
<text top="456" left="274" width="513" height="20" font="0">such as peptic ulcer disease and hypertension, anticoagulation therapy, </text>
<text top="476" left="274" width="505" height="20" font="0">profession or lifestyle that predisposes patient to trauma) AND c) For </text>
<text top="497" left="274" width="538" height="20" font="0">chronic ITP only: patient has had an inadequate response or intolerance to </text>
<text top="518" left="274" width="518" height="20" font="0">avatrombopag. 2) For continuation of therapy, plt count response to the </text>
<text top="539" left="274" width="528" height="20" font="0">requested drug: a) Current plt count is less than or equal to 200,000/mcL </text>
<text top="559" left="274" width="532" height="20" font="0">OR b) Current plt count is greater than 200,000/mcL to less than or equal </text>
<text top="580" left="274" width="511" height="20" font="0">to 400,000/mcL and dosing will be adjusted to a plt count sufficient to </text>
<text top="601" left="274" width="505" height="20" font="0">avoid clinically important bleeding. For thrombocytopenia associated </text>
<text top="621" left="274" width="530" height="20" font="0">with chronic hepatitis C: 1) For new starts: the requested drug is used for </text>
<text top="642" left="274" width="449" height="20" font="0">initiation and maintenance of interferon-based therapy. 2) For </text>
<text top="663" left="274" width="534" height="20" font="0">continuation of therapy: patient is receiving interferon-based therapy. For </text>
<text top="684" left="274" width="517" height="20" font="0">severe aplastic anemia (AA): For continuation of therapy following the </text>
<text top="704" left="274" width="540" height="20" font="0">initial 6 month approval for severe aplastic anemia: The patient must meet </text>
<text top="725" left="274" width="525" height="20" font="0">one of the following: 1) Current plt count is 50,000-200,000/mcL OR 2) </text>
<text top="746" left="274" width="508" height="20" font="0">Current plt count is less than 50,000/mcL and patient has not received </text>
<text top="766" left="274" width="503" height="20" font="0">appropriately titrated therapy for at least 16 weeks, OR 3) Current plt </text>
<text top="787" left="274" width="533" height="20" font="0">count is less than 50,000/mcL and patient is transfusion-independent, OR </text>
<text top="808" left="274" width="521" height="20" font="0">4) Current plt count is greater than 200,000/mcL to less than or equal to </text>
<text top="828" left="274" width="500" height="20" font="0">400,000/mcL and dosing will be adjusted to achieve and maintain an </text>
<text top="849" left="274" width="204" height="20" font="0">appropriate target plt count. </text>
<text top="888" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="888" left="274" width="35" height="20" font="0">N/A </text>
<text top="927" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="947" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="927" left="274" width="35" height="20" font="0">N/A </text>
<text top="986" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="1007" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="986" left="274" width="536" height="20" font="0">HCV: 6mo, ITP/AA initial: 6mo, ITP reauth: Plan Year, AA reauth: APR-</text>
<text top="1007" left="274" width="170" height="20" font="0">Plan Year, IPR-16 wks </text>
<text top="1096" left="783" width="32" height="20" font="0">228 </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="1188" width="918">
<text top="127" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="127" left="274" width="474" height="20" font="0">APR: adequate platelet response (greater than 50,000/mcL), IPR: </text>
<text top="147" left="274" width="383" height="20" font="0">inadequate platelet response (less than 50,000/mcL). </text>
<text top="1096" left="783" width="32" height="20" font="0">229 </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="147" height="27" font="4"><b>ULMOZYME</b></text>
<text top="119" left="273" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="252" height="20" font="0">Pulmozyme SOLN 2.5MG/2.5ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="474" height="20" font="0">For cystic fibrosis: Diagnosis of cystic fibrosis was confirmed by </text>
<text top="476" left="274" width="298" height="20" font="0">appropriate diagnostic or genetic testing. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="714" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="734" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">230 </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>Q</b></text>
<text top="123" left="131" width="97" height="27" font="4"><b>INLOCK</b></text>
<text top="119" left="229" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Qinlock </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">231 </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>Q</b></text>
<text top="123" left="131" width="139" height="27" font="4"><b>UETIAPINE </b></text>
<text top="118" left="271" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="292" width="17" height="27" font="4"><b>R</b></text>
<text top="119" left="310" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="177" height="20" font="0">Quetiapine Fumarate Er </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="521" height="20" font="0">Maintenance monotherapy treatment in bipolar I disorder, monotherapy </text>
<text top="378" left="274" width="496" height="20" font="0">treatment of generalized anxiety disorder, monotherapy treatment of </text>
<text top="399" left="274" width="190" height="20" font="0">major depressive disorder </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="535" height="20" font="0">For schizophrenia, acute treatment of manic or mixed episodes associated </text>
<text top="518" left="274" width="530" height="20" font="0">with bipolar I disorder, both as monotherapy and as an adjunct to lithium </text>
<text top="538" left="274" width="528" height="20" font="0">or divalproex, the acute treatment of depressive episodes associated with </text>
<text top="559" left="274" width="486" height="20" font="0">bipolar disorder, maintenance treatment of bipolar I disorder, as an </text>
<text top="580" left="274" width="536" height="20" font="0">adjunct to lithium or divalproex, adjunctive treatment of major depressive </text>
<text top="600" left="274" width="540" height="20" font="0">disorder, or maintenance monotherapy treatment in bipolar I disorder: The </text>
<text top="621" left="274" width="502" height="20" font="0">patient experienced an inadequate treatment response, intolerance, or </text>
<text top="642" left="274" width="538" height="20" font="0">contraindication to one of the following generic products: A) aripiprazole, </text>
<text top="662" left="274" width="477" height="20" font="0">B) asenapine, C) olanzapine, D) quetiapine immediate-release, E) </text>
<text top="683" left="274" width="540" height="20" font="0">risperidone, F) ziprasidone. For all indications: If the patient is 65 years of </text>
<text top="704" left="274" width="532" height="20" font="0">age or older AND is using two or more additional central nervous system </text>
<text top="724" left="274" width="486" height="20" font="0">(CNS) active medications (e.g., lorazepam, sertraline, clonazepam, </text>
<text top="745" left="274" width="472" height="20" font="0">escitalopram, alprazolam, zolpidem) with the requested drug, the </text>
<text top="766" left="274" width="528" height="20" font="0">prescriber determined that taking multiple central nervous system (CNS) </text>
<text top="787" left="274" width="530" height="20" font="0">active medications is medically necessary. [Note: Use of multiple central </text>
<text top="807" left="274" width="509" height="20" font="0">nervous system (CNS) active medications in older adults is associated </text>
<text top="828" left="274" width="232" height="20" font="0">with an increased risk of falls.]. </text>
<text top="867" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="867" left="274" width="35" height="20" font="0">N/A </text>
<text top="905" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="926" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="905" left="274" width="35" height="20" font="0">N/A </text>
<text top="965" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="985" left="126" width="75" height="20" font="7"><b>Duration </b></text>
<text top="965" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1024" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1024" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">232 </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="23" height="33" font="1"><b>Q</b></text>
<text top="123" left="131" width="93" height="27" font="4"><b>UININE </b></text>
<text top="118" left="224" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="241" width="97" height="27" font="4"><b>ULFATE</b></text>
<text top="119" left="338" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="228" height="20" font="0">Quinine Sulfate CAPS 324MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="394" height="20" font="0">Babesiosis, uncomplicated Plasmodium vivax malaria </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="64" height="20" font="0">1 month </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">233 </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="120" height="27" font="4"><b>EGRANEX</b></text>
<text top="119" left="250" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="74" height="20" font="0">Regranex </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="497" height="20" font="0">For the treatment of lower extremity diabetic neuropathic ulcers that </text>
<text top="476" left="274" width="540" height="20" font="0">extend into the subcutaneous tissue or beyond and have an adequate blood </text>
<text top="497" left="274" width="57" height="20" font="0">supply. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="72" height="20" font="0">20 weeks </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">234 </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="107" height="27" font="4"><b>ETEVMO</b></text>
<text top="119" left="236" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Retevmo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="442" height="20" font="0">Recurrent or advanced rearranged during transfection (RET)-</text>
<text top="378" left="274" width="365" height="20" font="0">rearrangement positive non-small cell lung cancer </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="529" height="20" font="0">For non-small cell lung cancer, patient must meet all of the following: 1) </text>
<text top="497" left="274" width="512" height="20" font="0">The disease is recurrent, advanced or metastatic, and 2) Tumor is RET </text>
<text top="518" left="274" width="347" height="20" font="0">fusion-positive or RET rearrangement-positive. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="519" height="20" font="0">Non-small cell lung cancer: 18 years of age or older. Medullary thyroid </text>
<text top="577" left="274" width="374" height="20" font="0">cancer and thyroid cancer: 12 years of age or older. </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">235 </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="108" height="27" font="4"><b>EVLIMID</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Revlimid </text>
<text top="1096" left="783" width="32" height="20" font="0">236 </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="466" height="20" font="0">Systemic light chain amyloidosis, classical Hodgkin lymphoma, </text>
<text top="234" left="274" width="455" height="20" font="0">myelodysplastic syndrome without the 5q deletion cytogenetic </text>
<text top="254" left="274" width="485" height="20" font="0">abnormality, myelofibrosis-associated anemia, POEMS syndrome, </text>
<text top="275" left="274" width="479" height="20" font="0">myeloproliferative neoplasms, non-Hodgkin's lymphoma with the </text>
<text top="296" left="274" width="488" height="20" font="0">following subtypes: acquired immunodeficiency syndrome (AIDS)-</text>
<text top="316" left="274" width="494" height="20" font="0">related non-germinal center diffuse large B-cell lymphoma, primary </text>
<text top="337" left="274" width="524" height="20" font="0">central nervous system (CNS) lymphoma, monomorphic post-transplant </text>
<text top="358" left="274" width="534" height="20" font="0">lymphoproliferative disorder, chronic lymphocytic leukemia (CLL)/small </text>
<text top="378" left="274" width="459" height="20" font="0">lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, </text>
<text top="399" left="274" width="488" height="20" font="0">multicentric Castleman's disease, adult T-cell leukemia/lymphoma, </text>
<text top="420" left="274" width="521" height="20" font="0">mycosis fungoides (MF)/Sezary syndrome (SS), angioimmunoblastic T-</text>
<text top="440" left="274" width="482" height="20" font="0">cell lymphoma (AITL), peripheral T-cell lymphoma not otherwise </text>
<text top="461" left="274" width="478" height="20" font="0">specified (PTCL NOS), enteropathy-associated T-cell lymphoma, </text>
<text top="482" left="274" width="541" height="20" font="0">monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral </text>
<text top="503" left="274" width="500" height="20" font="0">T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma </text>
<text top="523" left="274" width="529" height="20" font="0">(ALCL), hepatosplenic T-cell lymphoma, high-grade B-cell lymphomas, </text>
<text top="544" left="274" width="511" height="20" font="0">histologic transformation of nodal marginal zone lymphoma to diffuse </text>
<text top="565" left="274" width="532" height="20" font="0">large B-cell lymphoma, histologic transformation of follicular lymphoma </text>
<text top="585" left="274" width="474" height="20" font="0">to diffuse large B-cell lymphoma, AIDS-related Kaposi sarcoma, </text>
<text top="606" left="274" width="157" height="20" font="0">smoldering myeloma </text>
<text top="645" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="666" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="645" left="274" width="35" height="20" font="0">N/A </text>
<text top="704" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="725" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="746" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="704" left="274" width="450" height="20" font="0">For myelodysplastic syndrome (MDS): Lower risk MDS with </text>
<text top="725" left="274" width="509" height="20" font="0">symptomatic anemia per the Revised International Prognostic Scoring </text>
<text top="746" left="274" width="505" height="20" font="0">System (IPSS-R), International Prognostic Scoring System (IPSS), or </text>
<text top="766" left="274" width="485" height="20" font="0">World Health organization (WHO) classification-based Prognostic </text>
<text top="787" left="274" width="186" height="20" font="0">Scoring System (WPSS). </text>
<text top="826" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="826" left="274" width="35" height="20" font="0">N/A </text>
<text top="864" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="885" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="864" left="274" width="35" height="20" font="0">N/A </text>
<text top="924" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="945" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="924" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="983" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="983" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">237 </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="121" height="27" font="4"><b>EZUROCK</b></text>
<text top="119" left="251" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Rezurock </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="175" height="20" font="0">12 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">238 </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="81" height="27" font="4"><b>INVOQ</b></text>
<text top="119" left="211" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Rinvoq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="523" height="20" font="0">For moderately to severely active rheumatoid arthritis (new starts only): </text>
<text top="476" left="274" width="516" height="20" font="0">1) inadequate response, intolerance or contraindication to methotrexate </text>
<text top="497" left="274" width="493" height="20" font="0">(MTX) OR 2) inadequate response or intolerance to a prior biologic </text>
<text top="518" left="274" width="526" height="20" font="0">disease-modifying antirheumatic drug (DMARD) or a targeted synthetic </text>
<text top="538" left="274" width="76" height="20" font="0">DMARD. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">239 </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="101" height="27" font="4"><b>ITUXAN </b></text>
<text top="118" left="230" width="23" height="33" font="1"><b>H</b></text>
<text top="123" left="254" width="84" height="27" font="4"><b>YCELA</b></text>
<text top="119" left="338" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="117" height="20" font="0">Rituxan Hycela </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="486" height="20" font="0">Castleman's disease (CD), high-grade B-cell lymphoma, histologic </text>
<text top="378" left="274" width="525" height="20" font="0">transformation of nodal marginal zone lymphoma to diffuse large B-cell </text>
<text top="399" left="274" width="525" height="20" font="0">lymphoma, marginal zone lymphomas (nodal marginal zone lymphoma, </text>
<text top="419" left="274" width="464" height="20" font="0">gastric mucosa-associated lymphoid tissue (MALT) lymphoma, </text>
<text top="440" left="274" width="506" height="20" font="0">nongastric MALT lymphoma, and splenic marginal zone lymphoma), </text>
<text top="461" left="274" width="493" height="20" font="0">mantle cell lymphoma, post-transplant lymphoproliferative disorder </text>
<text top="482" left="274" width="520" height="20" font="0">(PTLD), primary cutaneous B-cell lymphoma (e.g., cutaneous marginal </text>
<text top="502" left="274" width="491" height="20" font="0">zone lymphoma or cutaneous follicle center lymphomas), hairy cell </text>
<text top="523" left="274" width="347" height="20" font="0">leukemia, small lymphocytic lymphoma (SLL). </text>
<text top="562" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="582" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="562" left="274" width="35" height="20" font="0">N/A </text>
<text top="621" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="642" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="662" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="621" left="274" width="512" height="20" font="0">Malignancies must be CD20 positive. Patient must receive at least one </text>
<text top="642" left="274" width="467" height="20" font="0">full dose of a rituximab product by intravenous infusion without </text>
<text top="662" left="274" width="281" height="20" font="0">experiencing severe adverse reactions. </text>
<text top="701" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="701" left="274" width="35" height="20" font="0">N/A </text>
<text top="740" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="760" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="740" left="274" width="35" height="20" font="0">N/A </text>
<text top="799" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="820" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="799" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="859" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="859" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">240 </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="125" height="27" font="4"><b>ITUXIMAB</b></text>
<text top="119" left="255" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Rituxan </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="72" height="20" font="0">Ruxience </text>
<text top="1096" left="783" width="32" height="20" font="0">241 </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="489" height="20" font="0">Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma </text>
<text top="234" left="274" width="533" height="20" font="0">(SLL), mantle cell lymphoma, marginal zone lymphomas (nodal, splenic, </text>
<text top="254" left="274" width="528" height="20" font="0">gastric mucosa-associated lymphoid tissue [MALT], nongastric MALT), </text>
<text top="275" left="274" width="514" height="20" font="0">Burkitt lymphoma, primary cutaneous B-cell lymphoma, high-grade B-</text>
<text top="296" left="274" width="496" height="20" font="0">cell lymphoma with translocations of MYC and BCL2 and/or BCL6 </text>
<text top="316" left="274" width="533" height="20" font="0">(double/triple hit lymphoma), high-grade B-cell lymphoma not otherwise </text>
<text top="337" left="274" width="537" height="20" font="0">specified, histological transformation from follicular lymphoma to diffuse </text>
<text top="358" left="274" width="526" height="20" font="0">large B-cell lymphoma, histological transformation from nodal marginal </text>
<text top="378" left="274" width="520" height="20" font="0">zone lymphoma to diffuse large B-cell lymphoma, Castleman's disease, </text>
<text top="399" left="274" width="529" height="20" font="0">acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, </text>
<text top="420" left="274" width="536" height="20" font="0">hairy cell leukemia, post-transplant lymphoproliferative disorder (PTLD), </text>
<text top="440" left="274" width="482" height="20" font="0">B-cell lymphoblastic lymphoma], refractory immune or idiopathic </text>
<text top="461" left="274" width="476" height="20" font="0">thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, </text>
<text top="482" left="274" width="488" height="20" font="0">Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, </text>
<text top="503" left="274" width="538" height="20" font="0">chronic graft-versus-host disease (GVHD), Sjogren syndrome, thrombotic </text>
<text top="523" left="274" width="493" height="20" font="0">thrombocytopenic purpura, refractory myasthenia gravis, Hodgkin's </text>
<text top="544" left="274" width="520" height="20" font="0">lymphoma (nodular lymphocyte-predominant), primary central nervous </text>
<text top="565" left="274" width="521" height="20" font="0">system (CNS) lymphoma, leptomeningeal metastases from lymphomas, </text>
<text top="585" left="274" width="516" height="20" font="0">acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-</text>
<text top="606" left="274" width="489" height="20" font="0">related PTLD, multiple sclerosis, and immune checkpoint inhibitor-</text>
<text top="627" left="274" width="124" height="20" font="0">related toxicities </text>
<text top="666" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="686" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="666" left="274" width="35" height="20" font="0">N/A </text>
<text top="725" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="746" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="766" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="725" left="274" width="523" height="20" font="0">For moderately to severely active rheumatoid arthritis (new starts only): </text>
<text top="746" left="274" width="528" height="20" font="0">1) patient meets ANY of the following: a) requested drug will be used in </text>
<text top="766" left="274" width="521" height="20" font="0">combination with methotrexate (MTX) OR b) patient has intolerance or </text>
<text top="787" left="274" width="539" height="20" font="0">contraindication to MTX, AND 2) patient meets ANY of the following: a) </text>
<text top="808" left="274" width="496" height="20" font="0">inadequate response, intolerance, or contraindication to MTX OR b) </text>
<text top="828" left="274" width="525" height="20" font="0">inadequate response or intolerance to a prior biologic disease-modifying </text>
<text top="849" left="274" width="464" height="20" font="0">antirheumatic drug (DMARD) or a targeted synthetic DMARD. </text>
<text top="870" left="274" width="538" height="20" font="0">Hematologic malignancies must be CD20-positive. For multiple sclerosis: </text>
<text top="891" left="274" width="528" height="20" font="0">1) patient has a diagnosis of relapsing remitting multiple sclerosis and 2) </text>
<text top="911" left="274" width="533" height="20" font="0">patient has had an inadequate response to two or more disease-modifying </text>
<text top="932" left="274" width="479" height="20" font="0">drugs indicated for multiple sclerosis despite adequate duration of </text>
<text top="953" left="274" width="77" height="20" font="0">treatment. </text>
<text top="991" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="991" left="274" width="35" height="20" font="0">N/A </text>
<text top="1030" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="1051" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="1030" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">242 </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="1188" width="918">
<text top="127" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="147" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="127" left="274" width="531" height="20" font="0">Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan </text>
<text top="147" left="274" width="39" height="20" font="0">Year </text>
<text top="186" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="186" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">243 </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="136" height="27" font="4"><b>OZLYTREK</b></text>
<text top="119" left="266" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="76" height="20" font="0">Rozlytrek </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="474" height="20" font="0">Recurrent or advanced ROS1-positive non-small cell lung cancer </text>
<text top="378" left="274" width="482" height="20" font="0">(NSCLC), advanced, recurrent, or persistent neurotrophic tyrosine </text>
<text top="399" left="274" width="495" height="20" font="0">receptor kinase (NTRK) gene fusion-positive solid tumors, first-line </text>
<text top="419" left="274" width="395" height="20" font="0">treatment of NTRK gene fusion-positive solid tumors. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="67" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="480" height="20" font="0">For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-</text>
<text top="538" left="274" width="527" height="20" font="0">positive solid tumors, the disease is without a known acquired resistance </text>
<text top="559" left="274" width="73" height="20" font="0">mutation. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">244 </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="103" height="27" font="4"><b>UBRACA</b></text>
<text top="119" left="232" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Rubraca </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="540" height="20" font="0">For metastatic castration-resistant prostate cancer with a deleterious breast </text>
<text top="476" left="274" width="540" height="20" font="0">cancer susceptibility gene (BRCA) mutation (germline and/or somatic): 1) </text>
<text top="497" left="274" width="492" height="20" font="0">patient has been treated with androgen receptor-directed therapy, 2) </text>
<text top="518" left="274" width="527" height="20" font="0">patient has been treated with a taxane-based chemotherapy or the patient </text>
<text top="538" left="274" width="468" height="20" font="0">is not fit for chemotherapy, 3) the requested drug will be used in </text>
<text top="559" left="274" width="519" height="20" font="0">combination with a gonadotropin-releasing hormone (GnRH) analog or </text>
<text top="580" left="274" width="515" height="20" font="0">after bilateral orchiectomy, and 4) patient experienced an unacceptable </text>
<text top="600" left="274" width="531" height="20" font="0">toxicity with a trial of Lynparza (olaparib). For maintenance treatment of </text>
<text top="621" left="274" width="490" height="20" font="0">patients with recurrent epithelial ovarian, fallopian tube, or primary </text>
<text top="642" left="274" width="517" height="20" font="0">peritoneal cancer who are in a complete or partial response to platinum-</text>
<text top="662" left="274" width="530" height="20" font="0">based chemotherapy, patient experienced an unacceptable toxicity with a </text>
<text top="683" left="274" width="520" height="20" font="0">trial of Lynparza (olaparib). For treatment of patients with a deleterious </text>
<text top="704" left="274" width="497" height="20" font="0">breast cancer susceptibility gene (BRCA) mutation (germline and/or </text>
<text top="724" left="274" width="470" height="20" font="0">somatic)-associated epithelial ovarian, fallopian tube, or primary </text>
<text top="745" left="274" width="423" height="20" font="0">peritoneal cancer who have been treated with two or more </text>
<text top="766" left="274" width="512" height="20" font="0">chemotherapies: if prescribed for deleterious germline BRCA-mutated </text>
<text top="787" left="274" width="526" height="20" font="0">advanced ovarian cancer treated with two or more prior chemotherapies, </text>
<text top="807" left="274" width="525" height="20" font="0">the patient experienced an unacceptable toxicity with a trial of Lynparza </text>
<text top="828" left="274" width="80" height="20" font="0">(olaparib). </text>
<text top="867" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="867" left="274" width="35" height="20" font="0">N/A </text>
<text top="905" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="926" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="905" left="274" width="35" height="20" font="0">N/A </text>
<text top="965" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="985" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="965" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1024" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1024" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">245 </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="130" width="83" height="27" font="4"><b>YDAPT</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="57" height="20" font="0">Rydapt </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="471" height="20" font="0">Relapsed or refractory acute myeloid leukemia (AML), myeloid, </text>
<text top="378" left="274" width="521" height="20" font="0">lymphoid, or mixed lineage neoplasms with eosinophilia and FGFR1 or </text>
<text top="399" left="274" width="498" height="20" font="0">FLT3 rearrangements, post-remission maintenance therapy for acute </text>
<text top="419" left="274" width="492" height="20" font="0">myeloid leukemia (AML), re-induction in residual disease for acute </text>
<text top="440" left="274" width="190" height="20" font="0">myeloid leukemia (AML) </text>
<text top="479" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="500" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="479" left="274" width="35" height="20" font="0">N/A </text>
<text top="538" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="559" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="580" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="538" left="274" width="488" height="20" font="0">For acute myeloid leukemia (AML): AML must be FLT3 mutation-</text>
<text top="559" left="274" width="484" height="20" font="0">positive. For myeloid, lymphoid, or mixed lineage neoplasms with </text>
<text top="580" left="274" width="485" height="20" font="0">eosinophilia and FGFR1 or FLT3 rearrangements: the disease is in </text>
<text top="600" left="274" width="167" height="20" font="0">chronic or blast phase. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">246 </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="166" height="27" font="4"><b>ANDOSTATIN </b></text>
<text top="118" left="291" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="311" width="35" height="27" font="4"><b>AR</b></text>
<text top="119" left="346" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="166" height="20" font="0">Sandostatin Lar Depot </text>
<text top="1096" left="783" width="32" height="20" font="0">247 </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="500" height="20" font="0">Tumor control of thymomas and thymic carcinomas, neuroendocrine </text>
<text top="234" left="274" width="526" height="20" font="0">tumors (NETs) of the gastrointestinal (GI) tract, lung, thymus (carcinoid </text>
<text top="254" left="274" width="492" height="20" font="0">tumors), unresected primary gastrinoma, NETs of the pancreas, and </text>
<text top="275" left="274" width="264" height="20" font="0">pheochromocytoma/paraganglioma. </text>
<text top="314" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="334" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="314" left="274" width="35" height="20" font="0">N/A </text>
<text top="373" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="394" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="414" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="373" left="274" width="514" height="20" font="0">For acromegaly (initial): 1) patient has a high pretreatment insulin-like </text>
<text top="394" left="274" width="470" height="20" font="0">growth factor-1 (IGF-1) level for age and/or gender based on the </text>
<text top="414" left="274" width="507" height="20" font="0">laboratory reference range, and 2) patient had an inadequate or partial </text>
<text top="435" left="274" width="528" height="20" font="0">response to surgery or radiotherapy OR there is a clinical reason for why </text>
<text top="456" left="274" width="462" height="20" font="0">the patient has not had surgery or radiotherapy. For acromegaly </text>
<text top="476" left="274" width="465" height="20" font="0">(continuation of therapy): patient's IGF-1 level has decreased or </text>
<text top="497" left="274" width="516" height="20" font="0">normalized since initiation of therapy. For tumor control, the requested </text>
<text top="518" left="274" width="520" height="20" font="0">drug will be used for any of the following: 1) neuroendocrine tumors of </text>
<text top="539" left="274" width="474" height="20" font="0">the gastrointestinal tract or pancreas in patients with locoregional </text>
<text top="559" left="274" width="536" height="20" font="0">advanced disease and/or distant metastatic disease, OR 2) neuroendocrine </text>
<text top="580" left="274" width="518" height="20" font="0">tumors of the thymus or lung in patients with locoregional unresectable </text>
<text top="601" left="274" width="490" height="20" font="0">disease and/or distant metastatic disease, OR 3) unresected primary </text>
<text top="621" left="274" width="496" height="20" font="0">gastrinoma, OR 4) thymomas and thymic carcinomas as second-line </text>
<text top="642" left="274" width="531" height="20" font="0">systemic therapy in patients with unresectable or extrathoracic metastatic </text>
<text top="663" left="274" width="526" height="20" font="0">disease, OR 5) pheochromocytomas and paragangliomas, used for either </text>
<text top="684" left="274" width="482" height="20" font="0">of the following: a) symptomatic locally unresectable disease with </text>
<text top="704" left="274" width="480" height="20" font="0">somatostatin receptor positive imaging, OR b) secreting tumors in </text>
<text top="725" left="274" width="138" height="20" font="0">metastatic disease. </text>
<text top="764" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="764" left="274" width="35" height="20" font="0">N/A </text>
<text top="802" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="823" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="802" left="274" width="35" height="20" font="0">N/A </text>
<text top="862" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="882" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="862" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="921" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="921" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">248 </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="108" height="27" font="4"><b>ARCLISA</b></text>
<text top="119" left="233" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Sarclisa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">249 </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="115" height="27" font="4"><b>CEMBLIX</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Scemblix </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="477" height="20" font="0">For chronic myeloid leukemia (CML) in the chronic phase: 1) the </text>
<text top="476" left="274" width="534" height="20" font="0">diagnosis was confirmed by detection of the Philadelphia chromosome or </text>
<text top="497" left="274" width="512" height="20" font="0">BCR-ABL gene AND the patient meets either of the following: A) the </text>
<text top="518" left="274" width="478" height="20" font="0">patient has previously been treated with 2 or more tyrosine kinase </text>
<text top="538" left="274" width="538" height="20" font="0">inhibitors (TKIs) AND at least one of those was imatinib or dasatinib, OR </text>
<text top="559" left="274" width="354" height="20" font="0">B) the patient is positive for the T315I mutation. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">250 </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="105" height="27" font="4"><b>IGNIFOR</b></text>
<text top="119" left="230" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Signifor </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="120" height="20" font="0">Endocrinologist </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">251 </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="133" height="27" font="4"><b>ILDENAFIL</b></text>
<text top="119" left="258" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="105" height="20" font="0">Sildenafil INJ </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="230" height="20" font="0">Sildenafil Citrate TABS 20MG </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="525" height="20" font="0">For pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="498" left="274" width="538" height="20" font="0">[WHO] Group 1): Diagnosis was confirmed by right heart catheterization. </text>
<text top="519" left="274" width="486" height="20" font="0">For PAH new starts only: 1) Pretreatment mean pulmonary arterial </text>
<text top="539" left="274" width="518" height="20" font="0">pressure is greater than 20 mmHg, 2) Pretreatment pulmonary capillary </text>
<text top="560" left="274" width="509" height="20" font="0">wedge pressure is less than or equal to 15 mmHg, and 3) Pretreatment </text>
<text top="581" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">252 </text>
</page>
<page number="253" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="96" height="27" font="4"><b>IRTURO</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="55" height="20" font="0">Sirturo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="499" height="20" font="0">Prescribed by or in consultation with an infectious disease specialist. </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">253 </text>
</page>
<page number="254" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="88" height="27" font="4"><b>KYRIZI</b></text>
<text top="119" left="213" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="57" height="20" font="0">Skyrizi </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="88" height="20" font="0">Skyrizi Pen </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="523" height="20" font="0">For moderate to severe plaque psoriasis (new starts only): 1) at least 3% </text>
<text top="498" left="274" width="523" height="20" font="0">of body surface area (BSA) is affected OR crucial body areas (e.g., feet, </text>
<text top="519" left="274" width="518" height="20" font="0">hands, face, neck, groin, intertriginous areas) are affected at the time of </text>
<text top="539" left="274" width="496" height="20" font="0">diagnosis, AND 2) patient meets any of the following: a) patient has </text>
<text top="560" left="274" width="530" height="20" font="0">experienced an inadequate response or intolerance to either phototherapy </text>
<text top="581" left="274" width="490" height="20" font="0">(e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, </text>
<text top="602" left="274" width="448" height="20" font="0">cyclosporine, or acitretin, or b) pharmacologic treatment with </text>
<text top="622" left="274" width="515" height="20" font="0">methotrexate, cyclosporine, or acitretin is contraindicated, or c) patient </text>
<text top="643" left="274" width="458" height="20" font="0">has severe psoriasis that warrants a biologic disease-modifying </text>
<text top="664" left="274" width="540" height="20" font="0">antirheumatic drug (DMARD) as first-line therapy (i.e. at least 10% of the </text>
<text top="684" left="274" width="496" height="20" font="0">body surface area or crucial body areas [e.g., hands, feet, face, neck, </text>
<text top="705" left="274" width="402" height="20" font="0">scalp, genitals/groin, intertriginous areas] are affected). </text>
<text top="744" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="744" left="274" width="35" height="20" font="0">N/A </text>
<text top="783" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="803" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="783" left="274" width="35" height="20" font="0">N/A </text>
<text top="842" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="863" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="842" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="901" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="901" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">254 </text>
</page>
<page number="255" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="157" height="27" font="4"><b>OMATULINE </b></text>
<text top="118" left="281" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="303" width="65" height="27" font="4"><b>EPOT</b></text>
<text top="119" left="368" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="135" height="20" font="0">Somatuline Depot </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="502" height="20" font="0">Tumor control of neuroendocrine tumors (NETs) of the lung, thymus </text>
<text top="378" left="274" width="420" height="20" font="0">(carcinoid tumors) or unresected primary gastrinoma, and </text>
<text top="399" left="274" width="264" height="20" font="0">pheochromocytoma/paraganglioma. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="514" height="20" font="0">For acromegaly (initial): 1) patient has a high pretreatment insulin-like </text>
<text top="518" left="274" width="470" height="20" font="0">growth factor-1 (IGF-1) level for age and/or gender based on the </text>
<text top="538" left="274" width="507" height="20" font="0">laboratory reference range, and 2) patient had an inadequate or partial </text>
<text top="559" left="274" width="528" height="20" font="0">response to surgery or radiotherapy OR there is a clinical reason for why </text>
<text top="580" left="274" width="462" height="20" font="0">the patient has not had surgery or radiotherapy. For acromegaly </text>
<text top="600" left="274" width="538" height="20" font="0">continuation of therapy: patient's IGF-1 level has decreased or normalized </text>
<text top="621" left="274" width="522" height="20" font="0">since initiation of therapy. For tumor control, the requested drug will be </text>
<text top="642" left="274" width="525" height="20" font="0">used for any of the following: 1) neuroendocrine tumor of the thymus or </text>
<text top="662" left="274" width="500" height="20" font="0">lung in patients with locoregional unresectable disease and/or distant </text>
<text top="683" left="274" width="463" height="20" font="0">metastatic disease, OR 2) unresected primary carcinoma, OR 3) </text>
<text top="704" left="274" width="462" height="20" font="0">pheochromocytomas and paragangliomas, used for either of the </text>
<text top="724" left="274" width="532" height="20" font="0">following: a) symptomatic locally unresectable disease with somatostatin </text>
<text top="745" left="274" width="511" height="20" font="0">receptor positive imaging OR b) secreting tumor in metastatic disease. </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="843" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="941" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="941" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">255 </text>
</page>
<page number="256" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="125" height="27" font="4"><b>OMAVERT</b></text>
<text top="119" left="250" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="74" height="20" font="0">Somavert </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="514" height="20" font="0">For acromegaly (initial): 1) patient has a high pretreatment insulin-like </text>
<text top="476" left="274" width="470" height="20" font="0">growth factor-1 (IGF-1) level for age and/or gender based on the </text>
<text top="497" left="274" width="507" height="20" font="0">laboratory reference range, and 2) patient had an inadequate or partial </text>
<text top="518" left="274" width="528" height="20" font="0">response to surgery or radiotherapy OR there is a clinical reason for why </text>
<text top="538" left="274" width="462" height="20" font="0">the patient has not had surgery or radiotherapy. For acromegaly </text>
<text top="559" left="274" width="538" height="20" font="0">continuation of therapy: patient's IGF-1 level has decreased or normalized </text>
<text top="580" left="274" width="193" height="20" font="0">since initiation of therapy. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">256 </text>
</page>
<page number="257" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="97" height="27" font="4"><b>PRITAM</b></text>
<text top="119" left="222" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Spritam </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="516" height="20" font="0">Partial-Onset Seizures: 4 years of age or older. Myoclonic Seizures: 12 </text>
<text top="556" left="274" width="538" height="20" font="0">years of age or older. Primary Generalized Tonic-Clonic Seizures: 6 years </text>
<text top="577" left="274" width="114" height="20" font="0">of age or older. </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">257 </text>
</page>
<page number="258" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="99" height="27" font="4"><b>PRYCEL</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Sprycel </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="491" height="20" font="0">Gastrointestinal stromal tumor (GIST), metastatic chondrosarcoma, </text>
<text top="378" left="274" width="473" height="20" font="0">recurrent chordoma, T-cell acute lymphoblastic leukemia (ALL), </text>
<text top="399" left="274" width="220" height="20" font="0">Philadelphia (Ph)-like B-ALL </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="489" height="20" font="0">For chronic myeloid leukemia (CML), including patients who have </text>
<text top="518" left="274" width="540" height="20" font="0">received a hematopoietic stem cell transplant: diagnosis was confirmed by </text>
<text top="538" left="274" width="505" height="20" font="0">detection of the Philadelphia (Ph) chromosome or BCR-ABL gene. If </text>
<text top="559" left="274" width="520" height="20" font="0">patient experienced resistance to an alternative tyrosine kinase inhibitor </text>
<text top="580" left="274" width="494" height="20" font="0">for CML, patient is negative for T315I/A, F317L/V/I/C, and V299L </text>
<text top="600" left="274" width="506" height="20" font="0">mutations. For acute lymphoblastic leukemia (ALL), the patient has a </text>
<text top="621" left="274" width="521" height="20" font="0">diagnosis of one of the following: 1) Philadelphia chromosome positive </text>
<text top="642" left="274" width="496" height="20" font="0">ALL that has been confirmed by detection of the Ph chromosome or </text>
<text top="662" left="274" width="540" height="20" font="0">BCR-ABL gene, OR 2) Ph-like B-ALL with ABL-class kinase fusion, OR </text>
<text top="683" left="274" width="515" height="20" font="0">3) relapsed or refractory T-cell ALL with ABL-class translocation. For </text>
<text top="704" left="274" width="457" height="20" font="0">GIST, patient must have progressed on imatinib, sunitinib, and </text>
<text top="724" left="274" width="92" height="20" font="0">regorafenib. </text>
<text top="763" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="763" left="274" width="35" height="20" font="0">N/A </text>
<text top="802" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="823" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="802" left="274" width="35" height="20" font="0">N/A </text>
<text top="861" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="882" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="861" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="921" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="921" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">258 </text>
</page>
<page number="259" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="100" height="27" font="4"><b>TELARA</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="279" height="20" font="0">Stelara INJ 45MG/0.5ML, 90MG/ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="528" height="20" font="0">For moderate to severe plaque psoriasis (new starts only): 1) At least 3% </text>
<text top="476" left="274" width="523" height="20" font="0">of body surface area (BSA) is affected OR crucial body areas (e.g., feet, </text>
<text top="497" left="274" width="518" height="20" font="0">hands, face, neck, groin, intertriginous areas) are affected at the time of </text>
<text top="518" left="274" width="492" height="20" font="0">diagnosis and 2) Patient had an inadequate response, intolerance, or </text>
<text top="538" left="274" width="511" height="20" font="0">contraindication to two of the following products: Enbrel (etanercept), </text>
<text top="559" left="274" width="523" height="20" font="0">Humira (adalimumab), Skyrizi (risankizumab-rzaa). For active psoriatic </text>
<text top="580" left="274" width="461" height="20" font="0">arthritis (PsA) (new starts): patient had an inadequate response, </text>
<text top="600" left="274" width="524" height="20" font="0">intolerance, or contraindication to two of the following products: Enbrel </text>
<text top="621" left="274" width="535" height="20" font="0">(etanercept), Humira (adalimumab), Skyrizi (risankizumab-rzaa), Xeljanz </text>
<text top="642" left="274" width="535" height="20" font="0">(tofacitinib)/Xeljanz XR (tofacitinib extended-release). For moderately to </text>
<text top="662" left="274" width="510" height="20" font="0">severely active Crohn's disease (new starts): patient had an inadequate </text>
<text top="683" left="274" width="519" height="20" font="0">response, intolerance, or contraindication to Humira (adalimumab). For </text>
<text top="704" left="274" width="539" height="20" font="0">moderately to severely active ulcerative colitis (new starts): patient had an </text>
<text top="724" left="274" width="462" height="20" font="0">inadequate response, intolerance, or contraindication to Humira </text>
<text top="745" left="274" width="110" height="20" font="0">(adalimumab). </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="843" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="941" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="941" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">259 </text>
</page>
<page number="260" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="113" height="27" font="4"><b>TIVARGA</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Stivarga </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="484" height="20" font="0">Progressive gastrointestinal stromal tumors (GIST), osteosarcoma, </text>
<text top="378" left="274" width="518" height="20" font="0">glioblastoma, angiosarcoma, retroperitoneal/intra-abdominal soft tissue </text>
<text top="399" left="274" width="493" height="20" font="0">sarcoma, rhabdomyosarcoma, solitary fibrous tumor, and soft tissue </text>
<text top="419" left="274" width="471" height="20" font="0">sarcomas of the extremities, body wall, head and neck, advanced </text>
<text top="440" left="274" width="131" height="20" font="0">colorectal cancer. </text>
<text top="479" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="500" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="479" left="274" width="35" height="20" font="0">N/A </text>
<text top="538" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="559" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="580" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="538" left="274" width="513" height="20" font="0">For gastrointestinal stromal tumors: The disease is progressive, locally </text>
<text top="559" left="274" width="277" height="20" font="0">advanced, unresectable, or metastatic. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">260 </text>
</page>
<page number="261" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="83" height="27" font="4"><b>UTENT</b></text>
<text top="119" left="207" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="125" height="20" font="0">Sunitinib Malate </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="51" height="20" font="0">Sutent </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="540" height="20" font="0">Thyroid carcinoma (follicular, medullary, papillary, and Hurthle cell), soft </text>
<text top="400" left="274" width="515" height="20" font="0">tissue sarcoma (angiosarcoma, solitary fibrous tumor, and alveolar soft </text>
<text top="421" left="274" width="464" height="20" font="0">part sarcoma subtypes), recurrent chordoma, thymic carcinoma. </text>
<text top="459" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="480" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="459" left="274" width="35" height="20" font="0">N/A </text>
<text top="519" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="539" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="560" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="519" left="274" width="519" height="20" font="0">For renal cell carcinoma, the disease is relapsed, advanced, or stage IV. </text>
<text top="599" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="599" left="274" width="35" height="20" font="0">N/A </text>
<text top="638" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="658" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="638" left="274" width="35" height="20" font="0">N/A </text>
<text top="697" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="718" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="697" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="756" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="756" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">261 </text>
</page>
<page number="262" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="83" height="27" font="4"><b>YMLIN</b></text>
<text top="119" left="207" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="114" height="20" font="0">Symlinpen 120 </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="105" height="20" font="0">Symlinpen 60 </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="35" height="20" font="0">N/A </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">262 </text>
</page>
<page number="263" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="123" height="27" font="4"><b>YMPAZAN</b></text>
<text top="119" left="247" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="80" height="20" font="0">Sympazan </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="166" height="20" font="0">2 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">263 </text>
</page>
<page number="264" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="17" height="33" font="1"><b>S</b></text>
<text top="123" left="125" width="96" height="27" font="4"><b>YNRIBO</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Synribo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="509" height="20" font="0">Follow-up therapy for chronic myeloid leukemia (CML) patients after </text>
<text top="378" left="274" width="313" height="20" font="0">hematopoietic stem cell transplant (HSCT) </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="35" height="20" font="0">N/A </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">264 </text>
</page>
<page number="265" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="117" height="27" font="4"><b>ABRECTA</b></text>
<text top="119" left="245" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Tabrecta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="533" height="20" font="0">Treatment of recurrent or advanced non-small cell lung cancer (NSCLC). </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="502" height="20" font="0">For recurrent, advanced, or metastatic NSCLC: Tumor is positive for </text>
<text top="476" left="274" width="505" height="20" font="0">mesenchymal-epithelial transition (MET) exon 14 skipping mutation. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">265 </text>
</page>
<page number="266" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="131" height="27" font="4"><b>ADALAFIL </b></text>
<text top="118" left="260" width="10" height="33" font="1"><b>(</b></text>
<text top="123" left="269" width="51" height="27" font="4"><b>PAH</b></text>
<text top="118" left="320" width="10" height="33" font="1"><b>)</b></text>
<text top="113" left="330" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="41" height="20" font="0">Alyq </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="171" height="20" font="0">Tadalafil TABS 20MG </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="525" height="20" font="0">For pulmonary arterial hypertension (PAH) (World Health Organization </text>
<text top="498" left="274" width="538" height="20" font="0">[WHO] Group 1): Diagnosis was confirmed by right heart catheterization. </text>
<text top="519" left="274" width="486" height="20" font="0">For PAH new starts only: 1) Pretreatment mean pulmonary arterial </text>
<text top="539" left="274" width="518" height="20" font="0">pressure is greater than 20 mmHg, 2) Pretreatment pulmonary capillary </text>
<text top="560" left="274" width="509" height="20" font="0">wedge pressure is less than or equal to 15 mmHg, and 3) Pretreatment </text>
<text top="581" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="620" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="620" left="274" width="35" height="20" font="0">N/A </text>
<text top="658" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="679" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="658" left="274" width="35" height="20" font="0">N/A </text>
<text top="718" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="738" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="718" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="777" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="777" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">266 </text>
</page>
<page number="267" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="109" height="27" font="4"><b>AFINLAR</b></text>
<text top="119" left="237" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Tafinlar </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="460" height="20" font="0">Brain metastases from melanoma, thyroid carcinoma (papillary </text>
<text top="378" left="274" width="502" height="20" font="0">carcinoma, follicular carcinoma, and Hurthle cell carcinoma), central </text>
<text top="399" left="274" width="512" height="20" font="0">nervous system (CNS) cancer (i.e., glioma, meningioma, astrocytoma) </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="518" height="20" font="0">For brain metastases from melanoma, adjuvant treatment of melanoma, </text>
<text top="518" left="274" width="498" height="20" font="0">and central nervous system (CNS) cancer (i.e., glioma, meningioma, </text>
<text top="538" left="274" width="490" height="20" font="0">astrocytoma): 1) The tumor is positive for a BRAF V600 activating </text>
<text top="559" left="274" width="537" height="20" font="0">mutation (e.g., V600E or V600K), and 2) The requested drug will be used </text>
<text top="580" left="274" width="538" height="20" font="0">in combination with trametinib. For unresectable or metastatic melanoma: </text>
<text top="600" left="274" width="496" height="20" font="0">1) The tumor is positive for a BRAF V600 activating mutation (e.g., </text>
<text top="621" left="274" width="507" height="20" font="0">V600E or V600K), and 2) The requested drug will be used as a single </text>
<text top="642" left="274" width="525" height="20" font="0">agent or in combination with trametinib. For non-small cell lung cancer: </text>
<text top="662" left="274" width="478" height="20" font="0">1) The tumor is positive for a BRAF V600E mutation, and 2) The </text>
<text top="683" left="274" width="521" height="20" font="0">requested drug will be used in combination with trametinib. For thyroid </text>
<text top="704" left="274" width="516" height="20" font="0">carcinoma with papillary, follicular, or Hurthle histology: The tumor is </text>
<text top="724" left="274" width="466" height="20" font="0">positive for BRAF activating mutation (e.g., V600E or V600K). </text>
<text top="763" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="763" left="274" width="35" height="20" font="0">N/A </text>
<text top="802" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="823" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="802" left="274" width="35" height="20" font="0">N/A </text>
<text top="861" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="882" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="861" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="921" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="921" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">267 </text>
</page>
<page number="268" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="108" height="27" font="4"><b>AGRISSO</b></text>
<text top="119" left="236" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="67" height="20" font="0">Tagrisso </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="520" height="20" font="0">Sensitizing epidermal growth factor receptor (EGFR) mutation-positive </text>
<text top="378" left="274" width="477" height="20" font="0">recurrent or advanced non-small cell lung cancer (NSCLC), brain </text>
<text top="399" left="274" width="451" height="20" font="0">metastases from sensitizing EGFR mutation-positive NSCLC, </text>
<text top="419" left="274" width="481" height="20" font="0">leptomeningeal metastases from EGFR mutation-positive NSCLC </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="522" height="20" font="0">For NSCLC, the requested drug is used in any of the following settings: </text>
<text top="538" left="274" width="496" height="20" font="0">1) The patient meets both of the following: a) patient has metastatic, </text>
<text top="559" left="274" width="514" height="20" font="0">advanced, or recurrent NSCLC (including brain and/or leptomeningeal </text>
<text top="580" left="274" width="534" height="20" font="0">metastases from NSCLC) and b) patient has a sensitizing EGFR mutation </text>
<text top="600" left="274" width="495" height="20" font="0">OR 2) Patient meets both of the following: a) request is for adjuvant </text>
<text top="621" left="274" width="528" height="20" font="0">treatment of NSCLC following tumor resection and b) patient has EGFR </text>
<text top="642" left="274" width="192" height="20" font="0">mutation-positive disease. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">268 </text>
</page>
<page number="269" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="65" height="27" font="4"><b>ALTZ</b></text>
<text top="119" left="193" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="42" height="20" font="0">Taltz </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="528" height="20" font="0">For moderate to severe plaque psoriasis (new starts only): 1) At least 3% </text>
<text top="476" left="274" width="523" height="20" font="0">of body surface area (BSA) is affected OR crucial body areas (e.g., feet, </text>
<text top="497" left="274" width="518" height="20" font="0">hands, face, neck, groin, intertriginous areas) are affected at the time of </text>
<text top="518" left="274" width="530" height="20" font="0">diagnosis AND 2) the patient had an inadequate response, intolerance, or </text>
<text top="538" left="274" width="510" height="20" font="0">contraindication to one of the following products: Enbrel (etanercept), </text>
<text top="559" left="274" width="540" height="20" font="0">Humira (adalimumab), Skyrizi (risankizumab-rzaa). For active ankylosing </text>
<text top="580" left="274" width="500" height="20" font="0">spondylitis (new starts only): the patient had an inadequate response, </text>
<text top="600" left="274" width="516" height="20" font="0">intolerance, or contraindication to either Enbrel (etanercept) or Humira </text>
<text top="621" left="274" width="517" height="20" font="0">(adalimumab). For active psoriatic arthritis (PsA) (new starts only): the </text>
<text top="642" left="274" width="539" height="20" font="0">patient had an inadequate response, intolerance, or contraindication to one </text>
<text top="662" left="274" width="509" height="20" font="0">of the following products: Enbrel (etanercept), Humira (adalimumab), </text>
<text top="683" left="274" width="536" height="20" font="0">Skyrizi (risankizumab-rzaa), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib </text>
<text top="704" left="274" width="509" height="20" font="0">extended-release). For active axial spondyloarthritis (new starts only): </text>
<text top="724" left="274" width="538" height="20" font="0">Patient meets any of the following: 1) has had an inadequate response to a </text>
<text top="745" left="274" width="466" height="20" font="0">non-steroidal anti-inflammatory drug (NSAID) trial or 2) has an </text>
<text top="766" left="274" width="315" height="20" font="0">intolerance or contraindication to NSAIDs. </text>
<text top="805" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="805" left="274" width="35" height="20" font="0">N/A </text>
<text top="843" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="864" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="843" left="274" width="35" height="20" font="0">N/A </text>
<text top="903" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="923" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="903" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="962" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="962" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">269 </text>
</page>
<page number="270" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="117" height="27" font="4"><b>ALZENNA</b></text>
<text top="119" left="245" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="232" height="20" font="0">Talzenna CAPS 0.25MG, 1MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="511" height="20" font="0">Recurrent germline breast cancer susceptibility gene (BRCA)-mutated </text>
<text top="378" left="274" width="99" height="20" font="0">breast cancer </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="518" height="20" font="0">For germline BRCA-mutated (gBRCAm) metastatic or recurrent breast </text>
<text top="497" left="274" width="509" height="20" font="0">cancer, the patient experienced an unacceptable toxicity with a trial of </text>
<text top="518" left="274" width="152" height="20" font="0">Lynparza (olaparib). </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">270 </text>
</page>
<page number="271" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="135" height="27" font="4"><b>ARGRETIN </b></text>
<text top="118" left="263" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="283" width="93" height="27" font="4"><b>OPICAL</b></text>
<text top="119" left="377" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="111" height="20" font="0">Targretin GEL </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="397" height="20" font="0">Mycosis fungoides, chronic or smoldering adult T-cell </text>
<text top="378" left="274" width="488" height="20" font="0">leukemia/lymphoma, primary cutaneous marginal zone lymphoma, </text>
<text top="399" left="274" width="328" height="20" font="0">primary cutaneous follicle center lymphoma. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">271 </text>
</page>
<page number="272" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="93" height="27" font="4"><b>ASIGNA</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Tasigna </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="512" height="20" font="0">Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ </text>
<text top="378" left="274" width="327" height="20" font="0">ALL), gastrointestinal stromal tumor (GIST) </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="516" height="20" font="0">For chronic myeloid leukemia (CML) or acute lymphoblastic leukemia </text>
<text top="497" left="274" width="473" height="20" font="0">(ALL), diagnosis was confirmed by detection of the Philadelphia </text>
<text top="518" left="274" width="501" height="20" font="0">chromosome or BCR-ABL gene. For CML, including patients newly </text>
<text top="538" left="274" width="507" height="20" font="0">diagnosed with CML and patients who have received a hematopoietic </text>
<text top="559" left="274" width="521" height="20" font="0">stem cell transplant: patient has experienced resistance or intolerance to </text>
<text top="580" left="274" width="515" height="20" font="0">imatinib or dasatinib. If patient experienced resistance to an alternative </text>
<text top="600" left="274" width="529" height="20" font="0">tyrosine kinase inhibitor for CML, patient is negative for T315I, Y253H, </text>
<text top="621" left="274" width="481" height="20" font="0">E255K/V, and F359V/C/I mutations. For GIST, patient must have </text>
<text top="642" left="274" width="368" height="20" font="0">progressed on imatinib, sunitinib, and regorafenib. </text>
<text top="680" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="680" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="740" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="719" left="274" width="35" height="20" font="0">N/A </text>
<text top="778" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="799" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="778" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="838" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="838" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">272 </text>
</page>
<page number="273" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="152" height="27" font="4"><b>AZAROTENE</b></text>
<text top="119" left="280" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="137" height="20" font="0">Tazarotene CREA </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="166" height="20" font="0">Tazorac CREA 0.05% </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="513" height="20" font="0">For plaque psoriasis: 1) The requested drug is being prescribed to treat </text>
<text top="498" left="274" width="537" height="20" font="0">less than 20 percent of the patient's body surface area AND 2) The patient </text>
<text top="519" left="274" width="513" height="20" font="0">experienced an inadequate treatment response or intolerance to at least </text>
<text top="539" left="274" width="534" height="20" font="0">one topical corticosteroid OR has a contraindication that would prohibit a </text>
<text top="560" left="274" width="222" height="20" font="0">trial of topical corticosteroids. </text>
<text top="599" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="599" left="274" width="35" height="20" font="0">N/A </text>
<text top="638" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="658" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="638" left="274" width="35" height="20" font="0">N/A </text>
<text top="697" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="718" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="697" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="756" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="756" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">273 </text>
</page>
<page number="274" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="112" height="27" font="4"><b>AZVERIK</b></text>
<text top="119" left="240" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Tazverik </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="517" height="20" font="0">Epithelioid sarcoma: 16 years of age or older, Follicular lymphoma: 18 </text>
<text top="556" left="274" width="152" height="20" font="0">years of age or older </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">274 </text>
</page>
<page number="275" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="128" height="27" font="4"><b>ECENTRIQ</b></text>
<text top="119" left="256" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="74" height="20" font="0">Tecentriq </text>
<text top="1096" left="783" width="32" height="20" font="0">275 </text>
</page>
<page number="276" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="524" height="20" font="0">Recurrent or advanced non-small cell lung cancer, PD-L1 positive triple </text>
<text top="234" left="274" width="515" height="20" font="0">negative recurrent breast cancer in combination with paclitaxel protein-</text>
<text top="254" left="274" width="50" height="20" font="0">bound </text>
<text top="293" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="314" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="293" left="274" width="35" height="20" font="0">N/A </text>
<text top="352" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="373" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="394" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="352" left="274" width="518" height="20" font="0">For urothelial carcinoma, patient meets one of the following criteria: 1) </text>
<text top="373" left="274" width="490" height="20" font="0">Patient is ineligible for cisplatin therapy and tumors express PD-L1 </text>
<text top="394" left="274" width="526" height="20" font="0">(defined as PD-L1 stained tumor-infiltrating immune cells [IC] covering </text>
<text top="414" left="274" width="496" height="20" font="0">greater than or equal to 5 percent of the tumor area) OR 2) Patient is </text>
<text top="435" left="274" width="525" height="20" font="0">ineligible for any platinum containing chemotherapy. For non-small cell </text>
<text top="456" left="274" width="539" height="20" font="0">lung cancer (NSCLC): 1) the patient has recurrent, advanced or metastatic </text>
<text top="476" left="274" width="523" height="20" font="0">disease AND the requested drug will be used as any of the following: a) </text>
<text top="497" left="274" width="534" height="20" font="0">first-line treatment of tumors with high PD-L1 expression (defined as PD-</text>
<text top="518" left="274" width="509" height="20" font="0">L1 stained greater than or equal to 50 percent of tumor cells or PD-L1 </text>
<text top="539" left="274" width="498" height="20" font="0">stained tumor-infiltrating immune cells [IC] covering greater than or </text>
<text top="559" left="274" width="507" height="20" font="0">equal to 10 percent of the tumor area) and no EGFR or ALK genomic </text>
<text top="580" left="274" width="512" height="20" font="0">tumor aberrations, b) used in combination with carboplatin, paclitaxel, </text>
<text top="601" left="274" width="534" height="20" font="0">and bevacizumab, or in combination with carboplatin and albumin-bound </text>
<text top="621" left="274" width="537" height="20" font="0">paclitaxel for nonsquamous NSCLC, or c) the requested drug will be used </text>
<text top="642" left="274" width="510" height="20" font="0">as subsequent therapy or continuation maintenance therapy, OR 2) the </text>
<text top="663" left="274" width="523" height="20" font="0">patient has stage II to IIIA disease AND the requested drug will be used </text>
<text top="684" left="274" width="448" height="20" font="0">as adjuvant treatment following resection and platinum-based </text>
<text top="704" left="274" width="533" height="20" font="0">chemotherapy for tumors with PD-L1 expression on greater than or equal </text>
<text top="725" left="274" width="518" height="20" font="0">to 1 percent of tumor cells. For hepatocellular carcinoma, the requested </text>
<text top="746" left="274" width="521" height="20" font="0">drug will be used as initial treatment in combination with bevacizumab. </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="844" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="942" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="942" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">276 </text>
</page>
<page number="277" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="125" height="27" font="4"><b>ECFIDERA</b></text>
<text top="119" left="253" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Tecfidera </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="165" height="20" font="0">Tecfidera Starter Pack </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="35" height="20" font="0">N/A </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">277 </text>
</page>
<page number="278" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="149" height="27" font="4"><b>EMAZEPAM </b></text>
<text top="118" left="277" width="30" height="33" font="1"><b>30</b></text>
<text top="123" left="307" width="47" height="27" font="4"><b>MG </b></text>
<text top="118" left="354" width="46" height="33" font="1"><b>- 65</b></text>
<text top="113" left="400" width="15" height="39" font="11"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="193" height="20" font="0">Temazepam CAPS 30MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="470" height="20" font="0">Prescriber must acknowledge that the benefit of therapy with the </text>
<text top="476" left="274" width="515" height="20" font="0">requested drug outweighs the potential risks for the patient. (Note: The </text>
<text top="497" left="274" width="490" height="20" font="0">American Geriatrics Society identifies the use of this medication as </text>
<text top="518" left="274" width="491" height="20" font="0">potentially inappropriate in older adults, meaning it is best avoided, </text>
<text top="538" left="274" width="456" height="20" font="0">prescribed at reduced dosage, or used with caution or carefully </text>
<text top="559" left="274" width="471" height="20" font="0">monitored.) The patient has experienced an inadequate treatment </text>
<text top="580" left="274" width="504" height="20" font="0">response, intolerance, or has a contraindication to doxepin (3 mg or 6 </text>
<text top="600" left="274" width="38" height="20" font="0">mg). </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="528" height="20" font="0">This Prior Authorization requirement only applies to patients 65 years of </text>
<text top="817" left="274" width="95" height="20" font="0">age or older. </text>
<text top="1096" left="783" width="32" height="20" font="0">278 </text>
</page>
<page number="279" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="123" height="27" font="4"><b>EPMETKO</b></text>
<text top="119" left="251" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="78" height="20" font="0">Tepmetko </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">279 </text>
</page>
<page number="280" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="185" height="27" font="4"><b>ESTOSTERONE </b></text>
<text top="118" left="313" width="22" height="33" font="1"><b>C</b></text>
<text top="123" left="334" width="133" height="27" font="4"><b>YPIONATE </b></text>
<text top="118" left="467" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="479" width="29" height="27" font="4"><b>NJ</b></text>
<text top="119" left="508" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="205" height="20" font="0">Testosterone Cypionate INJ </text>
<text top="221" left="149" width="190" height="20" font="0">100MG/ML, 200MG/ML </text>
<text top="297" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="297" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="339" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="339" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="378" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="378" left="274" width="137" height="20" font="0">Gender Dysphoria </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="457" height="20" font="0">Primary or hypogonadotropic hypogonadism: 1) Request is for </text>
<text top="497" left="274" width="526" height="20" font="0">continuation of testosterone therapy and the patient had a confirmed low </text>
<text top="518" left="274" width="504" height="20" font="0">morning testosterone level according to current practice guidelines or </text>
<text top="538" left="274" width="509" height="20" font="0">your standard lab reference values before starting testosterone therapy </text>
<text top="559" left="274" width="524" height="20" font="0">[Note: Safety and efficacy of testosterone products in patients with &#34;age-</text>
<text top="580" left="274" width="516" height="20" font="0">related hypogonadism&#34; (also referred to as &#34;late-onset hypogonadism&#34;) </text>
<text top="600" left="274" width="494" height="20" font="0">have not been established.] OR 2) Request is not for continuation of </text>
<text top="621" left="274" width="484" height="20" font="0">testosterone therapy and the patient has at least two confirmed low </text>
<text top="642" left="274" width="511" height="20" font="0">morning testosterone levels according to current practice guidelines or </text>
<text top="662" left="274" width="465" height="20" font="0">your standard lab reference values [Note: Safety and efficacy of </text>
<text top="683" left="274" width="522" height="20" font="0">testosterone products in patients with &#34;age-related hypogonadism&#34; (also </text>
<text top="704" left="274" width="509" height="20" font="0">referred to as &#34;late-onset hypogonadism&#34;) have not been established.]. </text>
<text top="724" left="274" width="512" height="20" font="0">Gender dysphoria: The patient is able to make an informed decision to </text>
<text top="745" left="274" width="205" height="20" font="0">engage in hormone therapy. </text>
<text top="784" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="784" left="274" width="35" height="20" font="0">N/A </text>
<text top="823" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="843" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="823" left="274" width="35" height="20" font="0">N/A </text>
<text top="882" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="903" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="882" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="941" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="941" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">280 </text>
</page>
<page number="281" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="185" height="27" font="4"><b>ESTOSTERONE </b></text>
<text top="118" left="313" width="20" height="33" font="1"><b>E</b></text>
<text top="123" left="333" width="142" height="27" font="4"><b>NANTHATE </b></text>
<text top="118" left="475" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="487" width="29" height="27" font="4"><b>NJ</b></text>
<text top="119" left="516" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="203" height="20" font="0">Testosterone Enanthate INJ </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="137" height="20" font="0">Gender Dysphoria </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="457" height="20" font="0">Primary or hypogonadotropic hypogonadism: 1) Request is for </text>
<text top="476" left="274" width="526" height="20" font="0">continuation of testosterone therapy and the patient had a confirmed low </text>
<text top="497" left="274" width="504" height="20" font="0">morning testosterone level according to current practice guidelines or </text>
<text top="518" left="274" width="509" height="20" font="0">your standard lab reference values before starting testosterone therapy </text>
<text top="538" left="274" width="524" height="20" font="0">[Note: Safety and efficacy of testosterone products in patients with &#34;age-</text>
<text top="559" left="274" width="516" height="20" font="0">related hypogonadism&#34; (also referred to as &#34;late-onset hypogonadism&#34;) </text>
<text top="580" left="274" width="494" height="20" font="0">have not been established.] OR 2) Request is not for continuation of </text>
<text top="600" left="274" width="484" height="20" font="0">testosterone therapy and the patient has at least two confirmed low </text>
<text top="621" left="274" width="511" height="20" font="0">morning testosterone levels according to current practice guidelines or </text>
<text top="642" left="274" width="465" height="20" font="0">your standard lab reference values [Note: Safety and efficacy of </text>
<text top="662" left="274" width="522" height="20" font="0">testosterone products in patients with &#34;age-related hypogonadism&#34; (also </text>
<text top="683" left="274" width="509" height="20" font="0">referred to as &#34;late-onset hypogonadism&#34;) have not been established.]. </text>
<text top="704" left="274" width="512" height="20" font="0">Gender dysphoria: The patient is able to make an informed decision to </text>
<text top="724" left="274" width="205" height="20" font="0">engage in hormone therapy. </text>
<text top="763" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="763" left="274" width="35" height="20" font="0">N/A </text>
<text top="802" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="823" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="802" left="274" width="35" height="20" font="0">N/A </text>
<text top="861" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="882" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="861" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="921" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="921" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">281 </text>
</page>
<page number="282" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="192" height="27" font="4"><b>ETRABENAZINE</b></text>
<text top="119" left="320" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="106" height="20" font="0">Tetrabenazine </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="515" height="20" font="0">Tic disorders, tardive dyskinesia, hemiballismus, chorea not associated </text>
<text top="378" left="274" width="194" height="20" font="0">with Huntington's disease. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="533" height="20" font="0">For treatment of chorea associated with Huntington's disease: The patient </text>
<text top="497" left="274" width="520" height="20" font="0">must have a prior inadequate response or intolerable adverse event with </text>
<text top="518" left="274" width="537" height="20" font="0">deutetrabenazine therapy. For treatment of tardive dyskinesia: The patient </text>
<text top="538" left="274" width="520" height="20" font="0">must have a prior inadequate response or intolerable adverse event with </text>
<text top="559" left="274" width="299" height="20" font="0">deutetrabenazine or valbenazine therapy. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">282 </text>
</page>
<page number="283" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>HALOMID</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="75" height="20" font="0">Thalomid </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="509" height="20" font="0">Myelofibrosis-related anemia, recurrent aphthous stomatitis, recurrent </text>
<text top="378" left="274" width="483" height="20" font="0">human immunodeficiency virus (HIV)-associated aphthous ulcers, </text>
<text top="399" left="274" width="538" height="20" font="0">cachexia, HIV-associated diarrhea, acquired immunodeficiency syndrome </text>
<text top="419" left="274" width="491" height="20" font="0">(AIDS)-related Kaposi's sarcoma, Behcet's syndrome, chronic graft-</text>
<text top="440" left="274" width="511" height="20" font="0">versus-host disease, Crohn's disease, multicentric Castleman's disease. </text>
<text top="479" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="500" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="479" left="274" width="35" height="20" font="0">N/A </text>
<text top="538" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="559" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="580" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="538" left="274" width="464" height="20" font="0">For cachexia: Cachexia must be due to cancer or HIV infection. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">283 </text>
</page>
<page number="284" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="93" height="27" font="4"><b>IBSOVO</b></text>
<text top="119" left="221" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Tibsovo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="455" height="20" font="0">Conventional (grades 1-3) or dedifferentiated chondrosarcoma </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="528" height="20" font="0">Patient has disease with a susceptible isocitrate dehydrogenase-1 (IDH1) </text>
<text top="476" left="274" width="492" height="20" font="0">mutation. For acute myeloid leukemia (AML): 1) patient has newly-</text>
<text top="497" left="274" width="507" height="20" font="0">diagnosed AML and meets one of the following: a) 75 years of age or </text>
<text top="518" left="274" width="539" height="20" font="0">older, b) patient has comorbidities that preclude use of intensive induction </text>
<text top="538" left="274" width="513" height="20" font="0">chemotherapy, or c) patient is 60 physiologic years of age or older and </text>
<text top="559" left="274" width="458" height="20" font="0">declines intensive induction chemotherapy, OR 2) patient is 60 </text>
<text top="580" left="274" width="520" height="20" font="0">physiologic years of age or older and the requested drug will be used as </text>
<text top="600" left="274" width="521" height="20" font="0">post-induction therapy following response to induction therapy with the </text>
<text top="621" left="274" width="484" height="20" font="0">requested drug, OR 3) patient has relapsed or refractory AML. For </text>
<text top="642" left="274" width="538" height="20" font="0">unresectable or metastatic cholangiocarcinoma: the requested drug will be </text>
<text top="662" left="274" width="475" height="20" font="0">used as subsequent treatment for progression on or after systemic </text>
<text top="683" left="274" width="77" height="20" font="0">treatment. </text>
<text top="722" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="722" left="274" width="35" height="20" font="0">N/A </text>
<text top="760" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="781" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="760" left="274" width="35" height="20" font="0">N/A </text>
<text top="820" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="841" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="820" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="879" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="879" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">284 </text>
</page>
<page number="285" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="153" height="27" font="4"><b>OBRAMYCIN</b></text>
<text top="119" left="281" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="247" height="20" font="0">Tobramycin NEBU 300MG/5ML </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="249" height="20" font="0">Non-cystic fibrosis bronchiectasis </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="534" height="20" font="0">For cystic fibrosis and non-cystic fibrosis bronchiectasis, the patient must </text>
<text top="476" left="274" width="519" height="20" font="0">meet one of the following: 1) Pseudomonas aeruginosa is present in the </text>
<text top="497" left="274" width="531" height="20" font="0">patient's airway cultures, OR 2) the patient has a history of Pseudomonas </text>
<text top="518" left="274" width="374" height="20" font="0">aeruginosa infection or colonization in the airways. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="35" height="20" font="0">N/A </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="734" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="755" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">285 </text>
</page>
<page number="286" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="99" height="27" font="4"><b>OPICAL </b></text>
<text top="118" left="227" width="22" height="33" font="1"><b>D</b></text>
<text top="123" left="249" width="93" height="27" font="4"><b>OXEPIN</b></text>
<text top="119" left="343" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="228" height="20" font="0">Doxepin Hydrochloride CREA </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="462" height="20" font="0">The patient has experienced an inadequate response to a topical </text>
<text top="476" left="274" width="472" height="20" font="0">corticosteroid or a topical calcineurin inhibitor (e.g., tacrolimus). </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="64" height="20" font="0">1 month </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">286 </text>
</page>
<page number="287" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="99" height="27" font="4"><b>OPICAL </b></text>
<text top="118" left="227" width="20" height="33" font="1"><b>L</b></text>
<text top="123" left="247" width="123" height="27" font="4"><b>IDOCAINE</b></text>
<text top="119" left="370" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="152" height="20" font="0">Lidocaine OINT 5% </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="9" height="23" font="6">  </text>
<text top="222" left="149" width="258" height="20" font="0">Lidocaine Hcl EXTERNAL SOLN </text>
<text top="242" left="149" width="28" height="20" font="0">4% </text>
<text top="262" left="122" width="8" height="22" font="5">•</text>
<text top="262" left="130" width="9" height="23" font="6">  </text>
<text top="264" left="149" width="206" height="20" font="0">Lidocaine/prilocaine CREA </text>
<text top="341" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="341" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="383" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="383" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="422" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="422" left="274" width="35" height="20" font="0">N/A </text>
<text top="461" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="481" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="461" left="274" width="35" height="20" font="0">N/A </text>
<text top="520" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="541" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="561" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="520" left="274" width="529" height="20" font="0">1) The requested drug is being used for topical anesthesia, AND 2) If the </text>
<text top="541" left="274" width="532" height="20" font="0">requested drug will be used as part of a compounded product, then all the </text>
<text top="561" left="274" width="474" height="20" font="0">active ingredients in the compounded product are Food and Drug </text>
<text top="582" left="274" width="349" height="20" font="0">Administration (FDA) approved for topical use. </text>
<text top="621" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="621" left="274" width="35" height="20" font="0">N/A </text>
<text top="660" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="680" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="719" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="740" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="719" left="274" width="71" height="20" font="0">3 months </text>
<text top="778" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="778" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="799" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="820" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">287 </text>
</page>
<page number="288" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="99" height="27" font="4"><b>OPICAL </b></text>
<text top="118" left="227" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="247" width="192" height="27" font="4"><b>ESTOSTERONES</b></text>
<text top="119" left="440" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="226" height="20" font="0">Androderm PT24 2MG/24HR, </text>
<text top="221" left="149" width="91" height="20" font="0">4MG/24HR </text>
<text top="240" left="122" width="8" height="22" font="5">•</text>
<text top="240" left="130" width="9" height="23" font="6">  </text>
<text top="242" left="149" width="233" height="20" font="0">Testosterone GEL 10MG/ACT, </text>
<text top="263" left="149" width="207" height="20" font="0">25MG/2.5GM, 50MG/5GM </text>
<text top="283" left="122" width="8" height="22" font="5">•</text>
<text top="282" left="130" width="9" height="23" font="6">  </text>
<text top="285" left="149" width="211" height="20" font="0">Testosterone Pump GEL 1% </text>
<text top="305" left="122" width="8" height="22" font="5">•</text>
<text top="304" left="130" width="9" height="23" font="6">  </text>
<text top="307" left="149" width="222" height="20" font="0">Testosterone Topical Solution </text>
<text top="384" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="384" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="426" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="426" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="465" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="465" left="274" width="137" height="20" font="0">Gender Dysphoria </text>
<text top="503" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="524" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="503" left="274" width="35" height="20" font="0">N/A </text>
<text top="563" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="583" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="604" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="563" left="274" width="457" height="20" font="0">Primary or hypogonadotropic hypogonadism: 1) Request is for </text>
<text top="583" left="274" width="526" height="20" font="0">continuation of testosterone therapy and the patient had a confirmed low </text>
<text top="604" left="274" width="504" height="20" font="0">morning testosterone level according to current practice guidelines or </text>
<text top="625" left="274" width="509" height="20" font="0">your standard lab reference values before starting testosterone therapy </text>
<text top="646" left="274" width="524" height="20" font="0">[Note: Safety and efficacy of testosterone products in patients with &#34;age-</text>
<text top="666" left="274" width="516" height="20" font="0">related hypogonadism&#34; (also referred to as &#34;late-onset hypogonadism&#34;) </text>
<text top="687" left="274" width="494" height="20" font="0">have not been established.] OR 2) Request is not for continuation of </text>
<text top="708" left="274" width="484" height="20" font="0">testosterone therapy and the patient has at least two confirmed low </text>
<text top="728" left="274" width="511" height="20" font="0">morning testosterone levels according to current practice guidelines or </text>
<text top="749" left="274" width="465" height="20" font="0">your standard lab reference values [Note: Safety and efficacy of </text>
<text top="770" left="274" width="522" height="20" font="0">testosterone products in patients with &#34;age-related hypogonadism&#34; (also </text>
<text top="790" left="274" width="509" height="20" font="0">referred to as &#34;late-onset hypogonadism&#34;) have not been established.]. </text>
<text top="811" left="274" width="512" height="20" font="0">Gender dysphoria: The patient is able to make an informed decision to </text>
<text top="832" left="274" width="205" height="20" font="0">engage in hormone therapy. </text>
<text top="871" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="871" left="274" width="35" height="20" font="0">N/A </text>
<text top="909" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="930" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="909" left="274" width="35" height="20" font="0">N/A </text>
<text top="969" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="989" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="969" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1028" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1028" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">288 </text>
</page>
<page number="289" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="99" height="27" font="4"><b>OPICAL </b></text>
<text top="118" left="227" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="247" width="121" height="27" font="4"><b>RETINOIN</b></text>
<text top="119" left="369" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="124" height="20" font="0">Tretinoin CREA </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="111" height="20" font="0">Tretinoin GEL </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="167" height="20" font="0">Tretinoin Microsphere </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="213" height="20" font="0">Tretinoin Microsphere Pump </text>
<text top="343" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="343" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="385" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="385" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="423" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="423" left="274" width="35" height="20" font="0">N/A </text>
<text top="462" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="483" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="462" left="274" width="35" height="20" font="0">N/A </text>
<text top="521" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="542" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="563" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="521" left="274" width="35" height="20" font="0">N/A </text>
<text top="601" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="601" left="274" width="35" height="20" font="0">N/A </text>
<text top="640" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="661" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="700" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="720" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="700" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="759" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="759" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">289 </text>
</page>
<page number="290" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="148" height="27" font="4"><b>OREMIFENE</b></text>
<text top="119" left="276" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="142" height="20" font="0">Toremifene Citrate </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="522" height="20" font="0">Congenital/acquired QT prolongation (long QT syndrome), uncorrected </text>
<text top="417" left="274" width="346" height="20" font="0">hypokalemia, or uncorrected hypomagnesemia. </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">290 </text>
</page>
<page number="291" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="113" height="27" font="4"><b>RELSTAR</b></text>
<text top="119" left="241" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="230" height="20" font="0">Trelstar Mixject INJ 11.25MG, </text>
<text top="221" left="149" width="65" height="20" font="0">3.75MG </text>
<text top="297" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="297" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="339" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="339" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="378" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="378" left="274" width="133" height="20" font="0">Gender dysphoria </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="538" height="20" font="0">For gender dysphoria, patient meets either of the following (1 or 2): 1) the </text>
<text top="497" left="274" width="509" height="20" font="0">requested drug is used to suppress puberty and the patient is at Tanner </text>
<text top="518" left="274" width="526" height="20" font="0">stage 2 or greater, OR 2) patient is undergoing gender transition, and the </text>
<text top="538" left="274" width="479" height="20" font="0">patient will receive the requested drug concomitantly with gender-</text>
<text top="559" left="274" width="153" height="20" font="0">affirming hormones. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">291 </text>
</page>
<page number="292" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="171" height="27" font="4"><b>REPROSTINIL </b></text>
<text top="118" left="299" width="12" height="33" font="1"><b>I</b></text>
<text top="123" left="311" width="29" height="27" font="4"><b>NJ</b></text>
<text top="119" left="340" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="89" height="20" font="0">Treprostinil </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="532" height="20" font="0">For pulmonary arterial hypertension (World Health Organization [WHO] </text>
<text top="476" left="274" width="530" height="20" font="0">Group 1), the diagnosis was confirmed by right heart catheterization. For </text>
<text top="497" left="274" width="496" height="20" font="0">new starts only: 1) pretreatment mean pulmonary arterial pressure is </text>
<text top="518" left="274" width="488" height="20" font="0">greater than 20 mmHg, 2) pretreatment pulmonary capillary wedge </text>
<text top="538" left="274" width="469" height="20" font="0">pressure is less than or equal to 15 mmHg, AND 3) pretreatment </text>
<text top="559" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="776" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="796" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">292 </text>
</page>
<page number="293" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="119" height="27" font="4"><b>RIENTINE</b></text>
<text top="119" left="247" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="180" height="20" font="0">Trientine Hydrochloride </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">293 </text>
</page>
<page number="294" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="111" height="27" font="4"><b>RIKAFTA</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Trikafta </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="500" height="20" font="0">The requested medication will not be used in combination with other </text>
<text top="476" left="274" width="245" height="20" font="0">medications containing ivacaftor. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="166" height="20" font="0">6 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">294 </text>
</page>
<page number="295" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="120" height="27" font="4"><b>RODELVY</b></text>
<text top="119" left="248" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Trodelvy </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="284" height="20" font="0">Recurrent triple-negative breast cancer </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">295 </text>
</page>
<page number="296" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="124" height="27" font="4"><b>RUSELTIQ</b></text>
<text top="119" left="252" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Truseltiq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">296 </text>
</page>
<page number="297" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="84" height="27" font="4"><b>UKYSA</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="57" height="20" font="0">Tukysa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="509" height="20" font="0">Recurrent human epidermal growth factor receptor 2 (HER2)-positive </text>
<text top="378" left="274" width="540" height="20" font="0">breast cancer, including patients with brain metastases, who have received </text>
<text top="399" left="274" width="540" height="20" font="0">one or more lines of prior HER2-targeted therapy in the metastatic setting. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="35" height="20" font="0">N/A </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">297 </text>
</page>
<page number="298" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>T</b></text>
<text top="123" left="128" width="96" height="27" font="4"><b>URALIO</b></text>
<text top="119" left="224" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Turalio </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">298 </text>
</page>
<page number="299" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>U</b></text>
<text top="123" left="130" width="100" height="27" font="4"><b>BRELVY</b></text>
<text top="119" left="230" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Ubrelvy </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="454" height="20" font="0">The patient has experienced an inadequate treatment response, </text>
<text top="476" left="274" width="504" height="20" font="0">intolerance, or the patient has a contraindication to one triptan 5-HT1 </text>
<text top="497" left="274" width="125" height="20" font="0">receptor agonist. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">299 </text>
</page>
<page number="300" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>U</b></text>
<text top="123" left="130" width="83" height="27" font="4"><b>KONIQ</b></text>
<text top="119" left="212" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="59" height="20" font="0">Ukoniq </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">300 </text>
</page>
<page number="301" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="121" height="27" font="4"><b>ALCHLOR</b></text>
<text top="119" left="251" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Valchlor </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="540" height="20" font="0">Chronic or smoldering adult T-cell leukemia/lymphoma, Stage 2 or higher </text>
<text top="378" left="274" width="518" height="20" font="0">mycosis fungoides/Sezary syndrome, primary cutaneous marginal zone </text>
<text top="399" left="274" width="523" height="20" font="0">lymphoma, primary cutaneous follicle center lymphoma, lymphomatoid </text>
<text top="419" left="274" width="77" height="20" font="0">papulosis. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="99" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="35" height="20" font="0">N/A </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">301 </text>
</page>
<page number="302" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="104" height="27" font="4"><b>ALTOCO</b></text>
<text top="119" left="234" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="62" height="20" font="0">Valtoco </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="166" height="20" font="0">6 years of age or older </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">302 </text>
</page>
<page number="303" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="100" height="27" font="4"><b>ELCADE</b></text>
<text top="119" left="230" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="89" height="20" font="0">Bortezomib </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="63" height="20" font="0">Velcade </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="359" height="20" font="0">Systemic light chain amyloidosis, Waldenstrom's </text>
<text top="400" left="274" width="468" height="20" font="0">macroglobulinemia/lymphoplasmacytic lymphoma, multicentric </text>
<text top="421" left="274" width="439" height="20" font="0">Castleman's disease, adult T-cell leukemia/lymphoma, acute </text>
<text top="441" left="274" width="485" height="20" font="0">lymphoblastic leukemia, AIDS-related Kaposi's sarcoma, Hodgkin </text>
<text top="462" left="274" width="226" height="20" font="0">lymphoma, POEMS syndrome </text>
<text top="501" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="521" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="501" left="274" width="35" height="20" font="0">N/A </text>
<text top="560" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="581" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="602" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="560" left="274" width="35" height="20" font="0">N/A </text>
<text top="640" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="640" left="274" width="35" height="20" font="0">N/A </text>
<text top="679" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="700" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="679" left="274" width="35" height="20" font="0">N/A </text>
<text top="738" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="759" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="738" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="798" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="798" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="819" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="839" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">303 </text>
</page>
<page number="304" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="109" height="27" font="4"><b>ELTASSA</b></text>
<text top="119" left="239" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Veltassa </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="454" height="20" font="0">The patient has experienced an inadequate treatment response, </text>
<text top="476" left="274" width="362" height="20" font="0">intolerance, or has a contraindication to Lokelma. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">304 </text>
</page>
<page number="305" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="133" height="27" font="4"><b>ENCLEXTA</b></text>
<text top="119" left="263" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="78" height="20" font="0">Venclexta </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="179" height="20" font="0">Venclexta Starting Pack </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="496" height="20" font="0">Mantle cell lymphoma, blastic plasmacytoid dendritic cell neoplasm </text>
<text top="400" left="274" width="487" height="20" font="0">(BPDCN), multiple myeloma, relapsed or refractory acute myeloid </text>
<text top="421" left="274" width="523" height="20" font="0">leukemia (AML), AML in patients 60 physiologic years of age or older. </text>
<text top="459" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="480" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="459" left="274" width="35" height="20" font="0">N/A </text>
<text top="519" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="539" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="560" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="519" left="274" width="534" height="20" font="0">For acute myeloid leukemia (AML), any of the following criteria must be </text>
<text top="539" left="274" width="531" height="20" font="0">met: 1) the patient's physiologic age is 60 years of age or older OR 2) the </text>
<text top="560" left="274" width="483" height="20" font="0">requested drug will be used as a component of repeating the initial </text>
<text top="581" left="274" width="473" height="20" font="0">successful induction regimen if late relapse OR 3) the patient has </text>
<text top="602" left="274" width="527" height="20" font="0">comorbidities that preclude use of intensive induction chemotherapy OR </text>
<text top="622" left="274" width="524" height="20" font="0">4) the requested drug will be used for relapsed or refractory disease. For </text>
<text top="643" left="274" width="482" height="20" font="0">blastic plasmacytoid dendritic cell neoplasm (BPDCN), any of the </text>
<text top="664" left="274" width="506" height="20" font="0">following criteria must be met: 1) patient has systemic disease treated </text>
<text top="684" left="274" width="534" height="20" font="0">with palliative intent OR 2) patient has relapsed or refractory disease. For </text>
<text top="705" left="274" width="500" height="20" font="0">multiple myeloma, all of the following must be met: 1) the disease is </text>
<text top="726" left="274" width="482" height="20" font="0">relapsed or progressive AND 2) the requested drug will be used in </text>
<text top="747" left="274" width="454" height="20" font="0">combination with dexamethasone AND 3) patient has t(11:14) </text>
<text top="767" left="274" width="102" height="20" font="0">translocation. </text>
<text top="806" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="806" left="274" width="35" height="20" font="0">N/A </text>
<text top="845" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="865" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="845" left="274" width="35" height="20" font="0">N/A </text>
<text top="904" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="925" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="904" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="963" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="963" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">305 </text>
</page>
<page number="306" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="107" height="27" font="4"><b>ENTAVIS</b></text>
<text top="119" left="237" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="69" height="20" font="0">Ventavis </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="532" height="20" font="0">For pulmonary arterial hypertension (World Health Organization [WHO] </text>
<text top="476" left="274" width="530" height="20" font="0">Group 1), the diagnosis was confirmed by right heart catheterization. For </text>
<text top="497" left="274" width="496" height="20" font="0">new starts only: 1) pretreatment mean pulmonary arterial pressure is </text>
<text top="518" left="274" width="488" height="20" font="0">greater than 20 mmHg, 2) pretreatment pulmonary capillary wedge </text>
<text top="538" left="274" width="469" height="20" font="0">pressure is less than or equal to 15 mmHg, AND 3) pretreatment </text>
<text top="559" left="274" width="516" height="20" font="0">pulmonary vascular resistance is greater than or equal to 3 Wood units. </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="776" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="796" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">306 </text>
</page>
<page number="307" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="132" height="27" font="4"><b>ERSACLOZ</b></text>
<text top="119" left="262" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="77" height="20" font="0">Versacloz </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="538" height="20" font="0">For the treatment of a severely ill patient with schizophrenia who failed to </text>
<text top="476" left="274" width="512" height="20" font="0">respond adequately to standard antipsychotic treatment (i.e., treatment-</text>
<text top="497" left="274" width="474" height="20" font="0">resistant schizophrenia), 1) the patient experienced an inadequate </text>
<text top="518" left="274" width="469" height="20" font="0">treatment response, intolerance, or contraindication to one of the </text>
<text top="538" left="274" width="534" height="20" font="0">following generic products: A) aripiprazole, B) asenapine, C) olanzapine, </text>
<text top="559" left="274" width="476" height="20" font="0">D) quetiapine, E) risperidone, F) ziprasidone AND 2) The patient </text>
<text top="580" left="274" width="448" height="20" font="0">experienced an inadequate treatment response, intolerance, or </text>
<text top="600" left="274" width="513" height="20" font="0">contraindication to one of the following brand products: A) Latuda, B) </text>
<text top="621" left="274" width="154" height="20" font="0">Rexulti, C) Secuado. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">307 </text>
</page>
<page number="308" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="111" height="27" font="4"><b>ERZENIO</b></text>
<text top="119" left="240" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="71" height="20" font="0">Verzenio </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="502" height="20" font="0">Recurrent hormone receptor (HR)-positive, human epidermal growth </text>
<text top="378" left="274" width="500" height="20" font="0">factor receptor 2 (HER2)-negative breast cancer in combination with </text>
<text top="399" left="274" width="540" height="20" font="0">fulvestrant or an aromatase inhibitor, or as a single agent if progression on </text>
<text top="419" left="274" width="529" height="20" font="0">prior endocrine therapy and prior chemotherapy in the metastatic setting. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="35" height="20" font="0">N/A </text>
<text top="598" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="598" left="274" width="35" height="20" font="0">N/A </text>
<text top="636" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="657" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="636" left="274" width="35" height="20" font="0">N/A </text>
<text top="696" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="716" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="696" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="755" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="755" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">308 </text>
</page>
<page number="309" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="139" height="27" font="4"><b>IGABATRIN</b></text>
<text top="119" left="268" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="82" height="20" font="0">Vigabatrin </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="81" height="20" font="0">Vigadrone </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="536" height="20" font="0">For complex partial seizures (CPS): patient had an inadequate response to </text>
<text top="498" left="274" width="273" height="20" font="0">at least 2 antiepileptic drugs for CPS. </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">309 </text>
</page>
<page number="310" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="105" height="27" font="4"><b>ITRAKVI</b></text>
<text top="119" left="235" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Vitrakvi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="522" height="20" font="0">Advanced, recurrent, or persistent neurotrophic tyrosine receptor kinase </text>
<text top="378" left="274" width="527" height="20" font="0">(NTRK) gene fusion-positive solid tumors, first-line treatment of NTRK </text>
<text top="399" left="274" width="249" height="20" font="0">gene fusion-positive solid tumors. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="480" height="20" font="0">For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-</text>
<text top="518" left="274" width="527" height="20" font="0">positive solid tumors, the disease is without a known acquired resistance </text>
<text top="538" left="274" width="73" height="20" font="0">mutation. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">310 </text>
</page>
<page number="311" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="108" height="27" font="4"><b>IZIMPRO</b></text>
<text top="119" left="238" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="73" height="20" font="0">Vizimpro </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="441" height="20" font="0">Recurrent or advanced non-small cell lung cancer (NSCLC). </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="497" height="20" font="0">For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, </text>
<text top="476" left="274" width="534" height="20" font="0">advanced or metastatic, and 2) the patient has sensitizing EGFR mutation-</text>
<text top="497" left="274" width="122" height="20" font="0">positive disease. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">311 </text>
</page>
<page number="312" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="183" height="27" font="4"><b>ORICONAZOLE</b></text>
<text top="119" left="312" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="132" height="20" font="0">Voriconazole INJ </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="151" height="20" font="0">Voriconazole SUSR </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="457" height="20" font="0">The patient will use the requested drug orally or intravenously. </text>
<text top="557" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="557" left="274" width="35" height="20" font="0">N/A </text>
<text top="596" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="617" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="596" left="274" width="35" height="20" font="0">N/A </text>
<text top="656" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="676" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="656" left="274" width="71" height="20" font="0">6 months </text>
<text top="715" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="715" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">312 </text>
</page>
<page number="313" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="75" height="27" font="4"><b>OSEVI</b></text>
<text top="119" left="204" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="55" height="20" font="0">Vosevi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="522" height="20" font="0">Decompensated cirrhosis/moderate or severe hepatic impairment (Child </text>
<text top="417" left="274" width="205" height="20" font="0">Turcotte Pugh class B or C) </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="504" height="20" font="0">For hepatitis C: Infection confirmed by presence of HCV RNA in the </text>
<text top="476" left="274" width="520" height="20" font="0">serum prior to starting treatment. Planned treatment regimen, genotype, </text>
<text top="497" left="274" width="529" height="20" font="0">prior treatment history, presence or absence of cirrhosis (compensated or </text>
<text top="518" left="274" width="530" height="20" font="0">decompensated [Child Turcotte Pugh class B or C]), presence or absence </text>
<text top="538" left="274" width="469" height="20" font="0">of HIV coinfection, presence or absence of resistance-associated </text>
<text top="559" left="274" width="521" height="20" font="0">substitutions where applicable, liver and kidney transplantation status if </text>
<text top="580" left="274" width="539" height="20" font="0">applicable. Coverage conditions and specific durations of approval will be </text>
<text top="600" left="274" width="343" height="20" font="0">based on current AASLD treatment guidelines. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="526" height="20" font="0">Criteria will be applied consistent with current AASLD-IDSA guidance. </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">313 </text>
</page>
<page number="314" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>V</b></text>
<text top="123" left="130" width="111" height="27" font="4"><b>OTRIENT</b></text>
<text top="119" left="240" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="64" height="20" font="0">Votrient </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="498" height="20" font="0">Thyroid carcinoma (follicular, papillary, Hurthle cell, or medullary), </text>
<text top="378" left="274" width="123" height="20" font="0">uterine sarcoma. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="525" height="20" font="0">For renal cell carcinoma: The disease is advanced, relapsed, or stage IV. </text>
<text top="497" left="274" width="514" height="20" font="0">For soft tissue sarcoma (STS): The patient does not have an adipocytic </text>
<text top="518" left="274" width="494" height="20" font="0">soft tissue sarcoma. For uterine sarcoma: The disease is recurrent or </text>
<text top="538" left="274" width="82" height="20" font="0">metastatic. </text>
<text top="577" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="577" left="274" width="35" height="20" font="0">N/A </text>
<text top="616" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="636" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="616" left="274" width="35" height="20" font="0">N/A </text>
<text top="675" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="696" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="675" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="734" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="734" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">314 </text>
</page>
<page number="315" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="30" height="33" font="1"><b>W</b></text>
<text top="123" left="138" width="93" height="27" font="4"><b>ELIREG</b></text>
<text top="119" left="231" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Welireg </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">315 </text>
</page>
<page number="316" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="97" height="27" font="4"><b>ALKORI</b></text>
<text top="119" left="227" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Xalkori </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="526" height="20" font="0">Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level </text>
<text top="378" left="274" width="509" height="20" font="0">MET amplification or MET exon 14 skipping mutation, inflammatory </text>
<text top="399" left="274" width="227" height="20" font="0">myofibroblastic tumors (IMT). </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="35" height="20" font="0">N/A </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="522" height="20" font="0">For NSCLC, the requested drug is used in any of the following settings: </text>
<text top="518" left="274" width="476" height="20" font="0">1) the patient has recurrent, advanced or metastatic ALK-positive </text>
<text top="538" left="274" width="493" height="20" font="0">NSCLC, 2) the patient has recurrent, advanced or metastatic ROS-1 </text>
<text top="559" left="274" width="495" height="20" font="0">positive NSCLC, or 3) the patient has NSCLC with high-level MET </text>
<text top="580" left="274" width="535" height="20" font="0">amplification or MET exon 14 skipping mutation. For IMT, the disease is </text>
<text top="600" left="274" width="536" height="20" font="0">ALK-positive. For anaplastic large cell lymphoma, the disease is relapsed </text>
<text top="621" left="274" width="234" height="20" font="0">or refractory and ALK-positive. </text>
<text top="660" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="660" left="274" width="35" height="20" font="0">N/A </text>
<text top="698" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="719" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="698" left="274" width="35" height="20" font="0">N/A </text>
<text top="758" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="778" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="758" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="817" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="817" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">316 </text>
</page>
<page number="317" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="95" height="27" font="4"><b>ELJANZ</b></text>
<text top="119" left="224" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Xeljanz </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="84" height="20" font="0">Xeljanz Xr </text>
<text top="299" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="299" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="341" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="341" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="379" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="379" left="274" width="35" height="20" font="0">N/A </text>
<text top="418" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="439" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="418" left="274" width="35" height="20" font="0">N/A </text>
<text top="477" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="498" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="519" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="477" left="274" width="523" height="20" font="0">For moderately to severely active rheumatoid arthritis (new starts only): </text>
<text top="498" left="274" width="517" height="20" font="0">1) Inadequate response, intolerance or contraindication to methotrexate </text>
<text top="519" left="274" width="499" height="20" font="0">(MTX), OR 2) Inadequate response or intolerance to a prior biologic </text>
<text top="539" left="274" width="526" height="20" font="0">disease-modifying antirheumatic drug (DMARD) or a targeted synthetic </text>
<text top="560" left="274" width="516" height="20" font="0">DMARD. For active psoriatic arthritis (new starts only): The requested </text>
<text top="581" left="274" width="535" height="20" font="0">drug is used in combination with a nonbiologic DMARD. For moderately </text>
<text top="602" left="274" width="540" height="20" font="0">to severely active ulcerative colitis (new starts only): Inadequate response, </text>
<text top="622" left="274" width="527" height="20" font="0">intolerance or contraindication to a tumor necrosis factor (TNF) blocker. </text>
<text top="661" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="661" left="274" width="35" height="20" font="0">N/A </text>
<text top="700" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="720" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="700" left="274" width="35" height="20" font="0">N/A </text>
<text top="759" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="780" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="759" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="819" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="819" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">317 </text>
</page>
<page number="318" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="107" height="27" font="4"><b>ERMELO</b></text>
<text top="119" left="236" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="68" height="20" font="0">Xermelo </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">318 </text>
</page>
<page number="319" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="69" height="27" font="4"><b>GEVA</b></text>
<text top="119" left="199" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="51" height="20" font="0">Xgeva </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="523" height="20" font="0">For hypercalcemia of malignancy: condition is refractory to intravenous </text>
<text top="476" left="274" width="495" height="20" font="0">(IV) bisphosphonate therapy or there is a clinical reason to avoid IV </text>
<text top="497" left="274" width="179" height="20" font="0">bisphosphonate therapy. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="526" height="20" font="0">Coverage under Part D will be denied if coverage is available under Part </text>
<text top="714" left="274" width="536" height="20" font="0">A or Part B as the medication is prescribed and dispensed or administered </text>
<text top="734" left="274" width="134" height="20" font="0">for the individual. </text>
<text top="1096" left="783" width="32" height="20" font="0">319 </text>
</page>
<page number="320" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="93" height="27" font="4"><b>IFAXAN</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="173" height="20" font="0">Xifaxan TABS 550MG </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="493" height="20" font="0">1) The requested drug is being prescribed to reduce the risk of overt </text>
<text top="476" left="274" width="485" height="20" font="0">hepatic encephalopathy (HE) recurrence OR 2) The patient has the </text>
<text top="497" left="274" width="520" height="20" font="0">diagnosis of irritable bowel syndrome with diarrhea (IBS-D) AND 3) If </text>
<text top="518" left="274" width="532" height="20" font="0">the patient has previously received treatment with the requested drug, the </text>
<text top="538" left="274" width="513" height="20" font="0">patient has experienced a recurrence of symptoms AND 4) The patient </text>
<text top="559" left="274" width="507" height="20" font="0">has not already received an initial 14-day course of treatment and two </text>
<text top="580" left="274" width="537" height="20" font="0">additional 14-day courses of treatment with the requested drug OR 5) The </text>
<text top="600" left="274" width="506" height="20" font="0">patient has not previously received treatment with the requested drug. </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="495" height="20" font="0">Reduction in risk of overt HE recurrence: 6 months, IBS-D: 14 days </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">320 </text>
</page>
<page number="321" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="79" height="27" font="4"><b>OLAIR</b></text>
<text top="119" left="208" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="50" height="20" font="0">Xolair </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="507" height="20" font="0">For allergic asthma initial therapy: 1) Patient has positive skin test (or </text>
<text top="476" left="274" width="534" height="20" font="0">blood test) to at least 1 perennial aeroallergen, 2) Patient has baseline IgE </text>
<text top="497" left="274" width="507" height="20" font="0">level greater than or equal to 30 IU/mL, and 3) Patient has inadequate </text>
<text top="518" left="274" width="488" height="20" font="0">asthma control despite current treatment with both of the following </text>
<text top="538" left="274" width="470" height="20" font="0">medications at optimized doses: a) Inhaled corticosteroid, and b) </text>
<text top="559" left="274" width="529" height="20" font="0">Additional controller (long acting beta2-agonist, leukotriene modifier, or </text>
<text top="580" left="274" width="485" height="20" font="0">sustained-release theophylline) unless patient has an intolerance or </text>
<text top="600" left="274" width="489" height="20" font="0">contraindication to such therapies. For allergic asthma continuation </text>
<text top="621" left="274" width="535" height="20" font="0">therapy only: Patient's asthma control has improved on treatment with the </text>
<text top="642" left="274" width="533" height="20" font="0">requested drug since initiation of therapy. For chronic idiopathic urticaria </text>
<text top="662" left="274" width="510" height="20" font="0">(CIU) initial therapy: 1) Patient has been evaluated for other causes of </text>
<text top="683" left="274" width="517" height="20" font="0">urticaria, including bradykinin-related angioedema and IL-1-associated </text>
<text top="704" left="274" width="525" height="20" font="0">urticarial syndromes (auto-inflammatory disorders, urticarial vasculitis), </text>
<text top="724" left="274" width="451" height="20" font="0">and 2) Patient has experienced a spontaneous onset of wheals, </text>
<text top="745" left="274" width="527" height="20" font="0">angioedema, or both, for at least 6 weeks. For CIU continuation therapy: </text>
<text top="766" left="274" width="495" height="20" font="0">Patient has experienced a response (e.g., improved symptoms) since </text>
<text top="787" left="274" width="152" height="20" font="0">initiation of therapy. </text>
<text top="825" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="825" left="274" width="522" height="20" font="0">For CIU: 12 years of age or older. For allergic asthma: 6 years of age or </text>
<text top="846" left="274" width="354" height="20" font="0">older. For nasal polyps: 18 years of age or older. </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="905" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="944" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="944" left="274" width="527" height="20" font="0">Allergic asthma and nasal polyps: Plan Year. CIU initial: 6 months. CIU </text>
<text top="965" left="274" width="175" height="20" font="0">continuation: Plan Year </text>
<text top="1003" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1003" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">321 </text>
</page>
<page number="322" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="97" height="27" font="4"><b>OSPATA</b></text>
<text top="119" left="227" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="63" height="20" font="0">Xospata </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="513" height="20" font="0">Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and </text>
<text top="378" left="274" width="154" height="20" font="0">FLT3 rearrangement </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="541" height="20" font="0">For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and </text>
<text top="497" left="274" width="443" height="20" font="0">FLT3 rearrangement: the disease is in chronic or blast phase. </text>
<text top="556" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="556" left="274" width="175" height="20" font="0">18 years of age or older </text>
<text top="595" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="616" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="595" left="274" width="35" height="20" font="0">N/A </text>
<text top="654" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="675" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="654" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="714" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="714" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">322 </text>
</page>
<page number="323" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="79" height="27" font="4"><b>POVIO</b></text>
<text top="119" left="208" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="59" height="20" font="0">Xpovio </text>
<text top="220" left="122" width="8" height="22" font="5">•</text>
<text top="219" left="130" width="5" height="23" font="6"> </text>
<text top="222" left="149" width="223" height="20" font="0">Xpovio 100 Mg Once Weekly </text>
<text top="242" left="122" width="8" height="22" font="5">•</text>
<text top="241" left="130" width="5" height="23" font="6"> </text>
<text top="244" left="149" width="214" height="20" font="0">Xpovio 40 Mg Once Weekly </text>
<text top="264" left="122" width="8" height="22" font="5">•</text>
<text top="263" left="130" width="5" height="23" font="6"> </text>
<text top="266" left="149" width="221" height="20" font="0">Xpovio 40 Mg Twice Weekly </text>
<text top="286" left="122" width="8" height="22" font="5">•</text>
<text top="285" left="130" width="5" height="23" font="6"> </text>
<text top="288" left="149" width="214" height="20" font="0">Xpovio 60 Mg Once Weekly </text>
<text top="308" left="122" width="8" height="22" font="5">•</text>
<text top="307" left="130" width="5" height="23" font="6"> </text>
<text top="310" left="149" width="221" height="20" font="0">Xpovio 60 Mg Twice Weekly </text>
<text top="330" left="122" width="8" height="22" font="5">•</text>
<text top="329" left="130" width="5" height="23" font="6"> </text>
<text top="332" left="149" width="214" height="20" font="0">Xpovio 80 Mg Once Weekly </text>
<text top="352" left="122" width="8" height="22" font="5">•</text>
<text top="351" left="130" width="5" height="23" font="6"> </text>
<text top="354" left="149" width="221" height="20" font="0">Xpovio 80 Mg Twice Weekly </text>
<text top="431" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="431" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="473" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="473" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="511" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="511" left="274" width="35" height="20" font="0">N/A </text>
<text top="550" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="571" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="550" left="274" width="35" height="20" font="0">N/A </text>
<text top="609" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="630" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="651" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="609" left="274" width="35" height="20" font="0">N/A </text>
<text top="689" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="689" left="274" width="35" height="20" font="0">N/A </text>
<text top="728" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="749" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="728" left="274" width="35" height="20" font="0">N/A </text>
<text top="788" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="808" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="788" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="847" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="847" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">323 </text>
</page>
<page number="324" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="77" height="27" font="4"><b>TANDI</b></text>
<text top="119" left="207" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="53" height="20" font="0">Xtandi </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="499" height="20" font="0">The requested drug will be used in combination with a gonadotropin-</text>
<text top="476" left="274" width="473" height="20" font="0">releasing hormone (GnRH) analog or after bilateral orchiectomy. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">324 </text>
</page>
<page number="325" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>X</b></text>
<text top="123" left="130" width="73" height="27" font="4"><b>YREM</b></text>
<text top="119" left="203" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="54" height="20" font="0">Xyrem </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="521" height="20" font="0">1) The requested drug is being prescribed for the treatment of excessive </text>
<text top="476" left="274" width="509" height="20" font="0">daytime sleepiness in a patient 7 years of age or older with narcolepsy </text>
<text top="497" left="274" width="527" height="20" font="0">AND 2) The diagnosis has been confirmed by sleep lab evaluation AND </text>
<text top="518" left="274" width="540" height="20" font="0">3)The patient experienced an inadequate treatment response or intolerance </text>
<text top="538" left="274" width="475" height="20" font="0">to at least one central nervous system (CNS) stimulant drug (e.g., </text>
<text top="559" left="274" width="478" height="20" font="0">amphetamine, dextroamphetamine, or methylphenidate) OR has a </text>
<text top="580" left="274" width="499" height="20" font="0">contraindication that would prohibit a trial of central nervous system </text>
<text top="600" left="274" width="486" height="20" font="0">(CNS) stimulant drugs (e.g., amphetamine, dextroamphetamine, or </text>
<text top="621" left="274" width="513" height="20" font="0">methylphenidate) [Note: Coverage of amphetamines may require prior </text>
<text top="642" left="274" width="492" height="20" font="0">authorization.] AND 4) If the patient is 18 years of age or older, the </text>
<text top="662" left="274" width="529" height="20" font="0">patient experienced an inadequate treatment response or intolerance to at </text>
<text top="683" left="274" width="540" height="20" font="0">least one central nervous system (CNS) wakefulness promoting drug (e.g., </text>
<text top="704" left="274" width="494" height="20" font="0">armodafinil) OR has a contraindication that would prohibit a trial of </text>
<text top="724" left="274" width="479" height="20" font="0">central nervous system (CNS) wakefulness promoting drugs (e.g., </text>
<text top="745" left="274" width="453" height="20" font="0">armodafinil) [Note: coverage of armodafinil may require prior </text>
<text top="766" left="274" width="495" height="20" font="0">authorization.] OR 5) The requested drug is being prescribed for the </text>
<text top="787" left="274" width="535" height="20" font="0">treatment of cataplexy in a patient 7 years of age or older with narcolepsy </text>
<text top="807" left="274" width="488" height="20" font="0">AND 6) The diagnosis has been confirmed by sleep lab evaluation. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="166" height="20" font="0">7 years of age or older </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="905" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="478" height="20" font="0">Prescribed by or in consultation with a sleep disorder specialist or </text>
<text top="905" left="274" width="90" height="20" font="0">neurologist. </text>
<text top="944" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="944" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1003" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1003" left="274" width="538" height="20" font="0">If the request is for a continuation of therapy, then the patient experienced </text>
<text top="1024" left="274" width="473" height="20" font="0">a decrease in daytime sleepiness with narcolepsy or a decrease in </text>
<text top="1045" left="274" width="263" height="20" font="0">cataplexy episodes with narcolepsy. </text>
<text top="1096" left="783" width="32" height="20" font="0">325 </text>
</page>
<page number="326" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1096" left="783" width="27" height="20" font="0">326</text>
<text top="1093" left="810" width="9" height="23" font="6"> </text>
</page>
<page number="327" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="22" height="33" font="1"><b>Y</b></text>
<text top="123" left="130" width="87" height="27" font="4"><b>ERVOY</b></text>
<text top="119" left="216" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="58" height="20" font="0">Yervoy </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="263" height="20" font="0">All Medically-accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">327 </text>
</page>
<page number="328" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="80" height="27" font="4"><b>ARXIO</b></text>
<text top="119" left="208" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="53" height="20" font="0">Zarxio </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="498" height="20" font="0">Neutropenia in myelodysplastic syndromes (MDS), agranulocytosis, </text>
<text top="378" left="274" width="512" height="20" font="0">neutropenia in aplastic anemia, human immunodeficiency virus (HIV)-</text>
<text top="399" left="274" width="429" height="20" font="0">related neutropenia, neutropenia related to renal transplant. </text>
<text top="437" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="458" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="437" left="274" width="481" height="20" font="0">Use of the requested product within 24 hours prior to or following </text>
<text top="458" left="274" width="111" height="20" font="0">chemotherapy. </text>
<text top="497" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="518" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="538" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="497" left="274" width="533" height="20" font="0">For prophylaxis or treatment of myelosuppressive chemotherapy-induced </text>
<text top="518" left="274" width="494" height="20" font="0">febrile neutropenia (FN) patient must meet both of the following: 1) </text>
<text top="538" left="274" width="487" height="20" font="0">Patient has a solid tumor or non-myeloid cancer, and 2) Patient has </text>
<text top="559" left="274" width="486" height="20" font="0">received, is currently receiving, or will be receiving treatment with </text>
<text top="580" left="274" width="281" height="20" font="0">myelosuppressive anti-cancer therapy. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="71" height="20" font="0">6 months </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">328 </text>
</page>
<page number="329" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="79" height="27" font="4"><b>EJULA</b></text>
<text top="119" left="207" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="51" height="20" font="0">Zejula </text>
<text top="1096" left="783" width="32" height="20" font="0">329 </text>
</page>
<page number="330" position="absolute" top="0" left="0" height="1188" width="918">
<text top="132" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="132" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="174" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="174" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="213" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="213" left="274" width="509" height="20" font="0">In combination with bevacizumab for persistent or recurrent epithelial </text>
<text top="234" left="274" width="476" height="20" font="0">ovarian, fallopian tube, or primary peritoneal cancer for platinum-</text>
<text top="254" left="274" width="128" height="20" font="0">sensitive disease. </text>
<text top="293" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="314" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="293" left="274" width="35" height="20" font="0">N/A </text>
<text top="352" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="373" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="394" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="352" left="274" width="514" height="20" font="0">For ovarian, fallopian tube, or primary peritoneal cancer, the requested </text>
<text top="373" left="274" width="532" height="20" font="0">drug is used in any of the following settings: 1) as maintenance treatment </text>
<text top="394" left="274" width="503" height="20" font="0">of stage II-IV epithelial ovarian, fallopian tube, or primary peritoneal </text>
<text top="414" left="274" width="517" height="20" font="0">cancer in patients who are in a complete or partial response to first-line </text>
<text top="435" left="274" width="505" height="20" font="0">platinum-based chemotherapy AND if it is known that the patient has </text>
<text top="456" left="274" width="508" height="20" font="0">breast cancer susceptibility gene (BRCA)-mutated disease, the patient </text>
<text top="476" left="274" width="525" height="20" font="0">experienced an unacceptable toxicity with a trial of Lynparza (olaparib), </text>
<text top="497" left="274" width="539" height="20" font="0">2) as maintenance treatment of recurrent epithelial ovarian, fallopian tube, </text>
<text top="518" left="274" width="521" height="20" font="0">or primary peritoneal cancer in patients who are in a complete or partial </text>
<text top="539" left="274" width="527" height="20" font="0">response to chemotherapy AND the patient experienced an unacceptable </text>
<text top="559" left="274" width="522" height="20" font="0">toxicity with a trial of Lynparza (olaparib), 3) as treatment of advanced, </text>
<text top="580" left="274" width="496" height="20" font="0">persistent, or recurrent ovarian, fallopian tube, or primary peritoneal </text>
<text top="601" left="274" width="538" height="20" font="0">cancer in patients treated with three or more prior chemotherapy regimens </text>
<text top="621" left="274" width="466" height="20" font="0">and whose cancer is associated with homologous recombination </text>
<text top="642" left="274" width="501" height="20" font="0">deficiency (HRD) positive status defined by either a) a deleterious or </text>
<text top="663" left="274" width="521" height="20" font="0">suspected deleterious BRCA mutation AND if prescribed for advanced, </text>
<text top="684" left="274" width="491" height="20" font="0">persistent, or recurrent ovarian cancer with deleterious or suspected </text>
<text top="704" left="274" width="471" height="20" font="0">deleterious germline BRCA mutation, the patient experienced an </text>
<text top="725" left="274" width="518" height="20" font="0">unacceptable toxicity with a trial of Lynparza (olaparib), or b) genomic </text>
<text top="746" left="274" width="535" height="20" font="0">instability and progression more than six months after response to the last </text>
<text top="766" left="274" width="540" height="20" font="0">platinum-based chemotherapy, or 4) in combination with bevacizumab for </text>
<text top="787" left="274" width="503" height="20" font="0">platinum-sensitive persistent or recurrent epithelial ovarian, fallopian </text>
<text top="808" left="274" width="253" height="20" font="0">tube, or primary peritoneal cancer. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="906" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="945" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="945" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1004" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1004" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">330 </text>
</page>
<page number="331" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="116" height="27" font="4"><b>ELBORAF</b></text>
<text top="119" left="244" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="66" height="20" font="0">Zelboraf </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="523" height="20" font="0">Non-small cell lung cancer, hairy cell leukemia, thyroid carcinoma (i.e., </text>
<text top="378" left="274" width="517" height="20" font="0">papillary carcinoma, follicular carcinoma, and Hurthle cell carcinoma), </text>
<text top="399" left="274" width="519" height="20" font="0">central nervous system cancer (i.e., glioma, meningioma, astrocytoma), </text>
<text top="419" left="274" width="378" height="20" font="0">adjuvant systemic therapy for cutaneous melanoma. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="523" height="20" font="0">For adjuvant treatment of melanoma, and central nervous system (CNS) </text>
<text top="538" left="274" width="527" height="20" font="0">cancer (i.e., glioma, meningioma, astrocytoma): 1) The tumor is positive </text>
<text top="559" left="274" width="527" height="20" font="0">for BRAF V600 activating mutation (e.g., V600E or V600K) and 2) The </text>
<text top="580" left="274" width="476" height="20" font="0">requested drug will be used in combination with cobimetinib. For </text>
<text top="600" left="274" width="530" height="20" font="0">unresectable or metastatic melanoma: 1) The tumor is positive for BRAF </text>
<text top="621" left="274" width="518" height="20" font="0">V600 activating mutation (e.g., V600E or V600K) and 2) the requested </text>
<text top="642" left="274" width="516" height="20" font="0">drug will be used as a single agent, or in combination with cobimetinib </text>
<text top="662" left="274" width="525" height="20" font="0">(with or without atezolizumab). For Erdheim-Chester Disease: Tumor is </text>
<text top="683" left="274" width="505" height="20" font="0">positive for BRAF V600 mutation. For non-small cell lung cancer: 1) </text>
<text top="704" left="274" width="528" height="20" font="0">Tumor is positive for the BRAF V600E mutation, and 2) The patient has </text>
<text top="724" left="274" width="499" height="20" font="0">recurrent, advanced, or metastatic disease. For thyroid carcinoma: 1) </text>
<text top="745" left="274" width="501" height="20" font="0">Tumor is positive for BRAF mutation, and 2) Patient has radioiodine </text>
<text top="766" left="274" width="503" height="20" font="0">refractory follicular, Hurthle cell, or papillary thyroid carcinoma. For </text>
<text top="787" left="274" width="492" height="20" font="0">hairy cell leukemia: The requested drug will be used for subsequent </text>
<text top="807" left="274" width="63" height="20" font="0">therapy. </text>
<text top="846" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="846" left="274" width="35" height="20" font="0">N/A </text>
<text top="885" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="905" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="885" left="274" width="35" height="20" font="0">N/A </text>
<text top="944" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="965" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="944" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="1003" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="1003" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">331 </text>
</page>
<page number="332" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="113" height="27" font="4"><b>EPZELCA</b></text>
<text top="119" left="241" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="70" height="20" font="0">Zepzelca </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="496" height="20" font="0">Relapsed small cell lung cancer, primary progressive small cell lung </text>
<text top="378" left="274" width="56" height="20" font="0">cancer. </text>
<text top="417" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="437" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="417" left="274" width="35" height="20" font="0">N/A </text>
<text top="476" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="497" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="518" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="476" left="274" width="504" height="20" font="0">For small cell lung cancer: the requested medication will be used as a </text>
<text top="497" left="274" width="520" height="20" font="0">single agent in one of the following settings: 1) the disease has relapsed </text>
<text top="518" left="274" width="488" height="20" font="0">following complete or partial response or stable disease with initial </text>
<text top="538" left="274" width="534" height="20" font="0">treatment, 2) the patient has primary progressive disease, or 3) the patient </text>
<text top="559" left="274" width="531" height="20" font="0">has metastatic disease following disease progression on or after platinum-</text>
<text top="580" left="274" width="156" height="20" font="0">based chemotherapy. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">332 </text>
</page>
<page number="333" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="95" height="27" font="4"><b>OLINZA</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="60" height="20" font="0">Zolinza </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="279" height="20" font="0">Mycosis fungoides, Sezary syndrome. </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="35" height="20" font="0">N/A </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">333 </text>
</page>
<page number="334" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="95" height="27" font="4"><b>YDELIG</b></text>
<text top="119" left="223" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="61" height="20" font="0">Zydelig </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="483" height="20" font="0">Relapsed or refractory chronic lymphocytic leukemia (CLL)/small </text>
<text top="378" left="274" width="459" height="20" font="0">lymphocytic lymphoma (SLL), relapsed or refractory follicular </text>
<text top="399" left="274" width="469" height="20" font="0">lymphoma, and marginal zone lymphomas [nodal marginal zone </text>
<text top="419" left="274" width="463" height="20" font="0">lymphoma, gastric mucosa associated lymphoid tissue (MALT) </text>
<text top="440" left="274" width="506" height="20" font="0">lymphoma, non-gastric MALT lymphoma, and splenic marginal zone </text>
<text top="461" left="274" width="92" height="20" font="0">lymphoma]. </text>
<text top="500" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="520" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="500" left="274" width="35" height="20" font="0">N/A </text>
<text top="559" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="580" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="600" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="559" left="274" width="35" height="20" font="0">N/A </text>
<text top="639" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="639" left="274" width="35" height="20" font="0">N/A </text>
<text top="678" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="698" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="678" left="274" width="35" height="20" font="0">N/A </text>
<text top="737" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="758" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="737" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="796" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="796" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">334 </text>
</page>
<page number="335" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="97" height="27" font="4"><b>YKADIA</b></text>
<text top="119" left="225" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="114" height="20" font="0">Zykadia TABS </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="509" height="20" font="0">All FDA-approved Indications, Some Medically accepted Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="467" height="20" font="0">Recurrent or advanced ALK-positive non-small cell lung cancer </text>
<text top="378" left="274" width="505" height="20" font="0">(NSCLC), recurrent, advanced, or metastatic ROS1-positive NSCLC, </text>
<text top="399" left="274" width="485" height="20" font="0">inflammatory myofibroblastic tumor (IMT), brain metastases from </text>
<text top="419" left="274" width="67" height="20" font="0">NSCLC. </text>
<text top="458" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="479" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="458" left="274" width="35" height="20" font="0">N/A </text>
<text top="518" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="538" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="559" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="518" left="274" width="496" height="20" font="0">For NSCLC: the patient has recurrent, advanced, or metastatic ALK-</text>
<text top="538" left="274" width="504" height="20" font="0">positive or ROS1-positive disease. For inflammatory myofibroblastic </text>
<text top="559" left="274" width="520" height="20" font="0">tumor: the disease is ALK-positive. For brain metastases from NSCLC: </text>
<text top="580" left="274" width="280" height="20" font="0">the patient has ALK-positive NSCLC. </text>
<text top="618" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="618" left="274" width="35" height="20" font="0">N/A </text>
<text top="657" left="126" width="86" height="20" font="7"><b>Prescriber </b></text>
<text top="678" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="657" left="274" width="35" height="20" font="0">N/A </text>
<text top="716" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="737" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="716" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="776" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="776" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">335 </text>
</page>
<page number="336" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="20" height="33" font="1"><b>Z</b></text>
<text top="123" left="128" width="106" height="27" font="4"><b>YPREXA </b></text>
<text top="118" left="234" width="22" height="33" font="1"><b>R</b></text>
<text top="123" left="256" width="115" height="27" font="4"><b>ELPREVV</b></text>
<text top="119" left="370" width="12" height="31" font="10"> </text>
<text top="174" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="5" height="23" font="6"> </text>
<text top="200" left="149" width="135" height="20" font="0">Zyprexa Relprevv </text>
<text top="277" left="126" width="111" height="23" font="2"><b>PA Criteria </b></text>
<text top="277" left="274" width="145" height="23" font="2"><b>Criteria Details </b></text>
<text top="319" left="126" width="91" height="20" font="7"><b>Indications </b></text>
<text top="319" left="274" width="230" height="20" font="0">All FDA-approved Indications. </text>
<text top="357" left="126" width="120" height="20" font="7"><b>Off-Label Uses </b></text>
<text top="357" left="274" width="35" height="20" font="0">N/A </text>
<text top="396" left="126" width="80" height="20" font="7"><b>Exclusion </b></text>
<text top="417" left="126" width="66" height="20" font="7"><b>Criteria </b></text>
<text top="396" left="274" width="35" height="20" font="0">N/A </text>
<text top="455" left="126" width="77" height="20" font="7"><b>Required </b></text>
<text top="476" left="126" width="67" height="20" font="7"><b>Medical </b></text>
<text top="497" left="126" width="98" height="20" font="7"><b>Information </b></text>
<text top="455" left="274" width="397" height="20" font="0">Tolerability with oral olanzapine has been established. </text>
<text top="536" left="126" width="131" height="20" font="7"><b>Age Restrictions </b></text>
<text top="536" left="274" width="35" height="20" font="0">N/A </text>
<text top="574" left="126" width="85" height="20" font="7"><b>Prescriber </b></text>
<text top="595" left="126" width="97" height="20" font="7"><b>Restrictions </b></text>
<text top="574" left="274" width="35" height="20" font="0">N/A </text>
<text top="634" left="126" width="77" height="20" font="7"><b>Coverage </b></text>
<text top="654" left="126" width="74" height="20" font="7"><b>Duration </b></text>
<text top="634" left="274" width="76" height="20" font="0">Plan Year </text>
<text top="693" left="126" width="117" height="20" font="7"><b>Other Criteria </b></text>
<text top="693" left="274" width="35" height="20" font="0">N/A </text>
<text top="1096" left="783" width="32" height="20" font="0">336 </text>
</page>
<page number="337" position="absolute" top="0" left="0" height="1188" width="918">
<text top="118" left="108" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="126" width="57" height="27" font="4"><b>ART </b></text>
<text top="118" left="183" width="48" height="33" font="1"><b>B V</b></text>
<text top="123" left="231" width="83" height="27" font="4"><b>ERSUS </b></text>
<text top="118" left="314" width="18" height="33" font="1"><b>P</b></text>
<text top="123" left="332" width="57" height="27" font="4"><b>ART </b></text>
<text top="118" left="389" width="22" height="33" font="1"><b>D</b></text>
<text top="113" left="411" width="15" height="39" font="11"> </text>
<text top="1096" left="783" width="32" height="20" font="0">337 </text>
</page>
<page number="338" position="absolute" top="0" left="0" height="1188" width="918">
<text top="109" left="116" width="167" height="23" font="2"><b>Products Affected </b></text>
<text top="132" left="122" width="8" height="22" font="5">•</text>
<text top="131" left="130" width="9" height="23" font="6">  </text>
<text top="134" left="149" width="60" height="20" font="0">Abelcet </text>
<text top="154" left="122" width="8" height="22" font="5">•</text>
<text top="153" left="130" width="9" height="23" font="6">  </text>
<text top="156" left="149" width="279" height="20" font="0">Acetylcysteine INHALATION SOLN </text>
<text top="176" left="122" width="8" height="22" font="5">•</text>
<text top="175" left="130" width="9" height="23" font="6">  </text>
<text top="178" left="149" width="251" height="20" font="0">Acyclovir Sodium INJ 50MG/ML </text>
<text top="198" left="122" width="8" height="22" font="5">•</text>
<text top="197" left="130" width="9" height="23" font="6">  </text>
<text top="200" left="149" width="247" height="20" font="0">Albuterol Sulfate NEBU 0.083%, </text>
<text top="221" left="149" width="221" height="20" font="0">0.63MG/3ML, 1.25MG/3ML, </text>
<text top="242" left="149" width="111" height="20" font="0">2.5MG/0.5ML </text>
<text top="262" left="122" width="8" height="22" font="5">•</text>
<text top="261" left="130" width="9" height="23" font="6">  </text>
<text top="264" left="149" width="84" height="20" font="0">Ambisome </text>
<text top="284" left="122" width="8" height="22" font="5">•</text>
<text top="283" left="130" width="9" height="23" font="6">  </text>
<text top="286" left="149" width="256" height="20" font="0">Aminosyn-pf 7% INJ 32.5MEQ/L; </text>
<text top="306" left="149" width="249" height="20" font="0">490MG/100ML; 861MG/100ML; </text>
<text top="327" left="149" width="249" height="20" font="0">370MG/100ML; 576MG/100ML; </text>
<text top="348" left="149" width="249" height="20" font="0">270MG/100ML; 220MG/100ML; </text>
<text top="368" left="149" width="249" height="20" font="0">534MG/100ML; 831MG/100ML; </text>
<text top="389" left="149" width="249" height="20" font="0">475MG/100ML; 125MG/100ML; </text>
<text top="410" left="149" width="220" height="20" font="0">10.69GM/L; 300MG/100ML; </text>
<text top="430" left="149" width="197" height="20" font="0">570MG/100ML; 70GM/L; </text>
<text top="451" left="149" width="240" height="20" font="0">347MG/100ML; 50MG/100ML; </text>
<text top="472" left="149" width="249" height="20" font="0">360MG/100ML; 125MG/100ML; </text>
<text top="493" left="149" width="235" height="20" font="0">44MG/100ML; 452MG/100ML </text>
<text top="512" left="122" width="8" height="22" font="5">•</text>
<text top="512" left="130" width="9" height="23" font="6">  </text>
<text top="515" left="149" width="151" height="20" font="0">Amphotericin B INJ </text>
<text top="534" left="122" width="8" height="22" font="5">•</text>
<text top="534" left="130" width="9" height="23" font="6">  </text>
<text top="537" left="149" width="131" height="20" font="0">Aprepitant CAPS </text>
<text top="557" left="122" width="8" height="22" font="5">•</text>
<text top="556" left="130" width="9" height="23" font="6">  </text>
<text top="559" left="149" width="129" height="20" font="0">Azathioprine INJ </text>
<text top="578" left="122" width="8" height="22" font="5">•</text>
<text top="578" left="130" width="9" height="23" font="6">  </text>
<text top="581" left="149" width="200" height="20" font="0">Azathioprine TABS 50MG </text>
<text top="600" left="122" width="8" height="22" font="5">•</text>
<text top="600" left="130" width="9" height="23" font="6">  </text>
<text top="602" left="149" width="170" height="20" font="0">Bleomycin Sulfate INJ </text>
<text top="623" left="122" width="8" height="22" font="5">•</text>
<text top="622" left="130" width="9" height="23" font="6">  </text>
<text top="625" left="149" width="137" height="20" font="0">Budesonide SUSP </text>
<text top="644" left="122" width="8" height="22" font="5">•</text>
<text top="644" left="130" width="9" height="23" font="6">  </text>
<text top="647" left="149" width="80" height="20" font="0">Cladribine </text>
<text top="666" left="122" width="8" height="22" font="5">•</text>
<text top="666" left="130" width="9" height="23" font="6">  </text>
<text top="668" left="149" width="223" height="20" font="0">Clinimix 4.25%/dextrose 10% </text>
<text top="688" left="122" width="8" height="22" font="5">•</text>
<text top="688" left="130" width="9" height="23" font="6">  </text>
<text top="691" left="149" width="214" height="20" font="0">Clinimix 4.25%/dextrose 5% </text>
<text top="710" left="122" width="8" height="22" font="5">•</text>
<text top="710" left="130" width="9" height="23" font="6">  </text>
<text top="712" left="149" width="200" height="20" font="0">Clinimix 5%/dextrose 15% </text>
<text top="732" left="122" width="8" height="22" font="5">•</text>
<text top="732" left="130" width="9" height="23" font="6">  </text>
<text top="734" left="149" width="200" height="20" font="0">Clinimix 5%/dextrose 20% </text>
<text top="754" left="122" width="8" height="22" font="5">•</text>
<text top="754" left="130" width="9" height="23" font="6">  </text>
<text top="756" left="149" width="96" height="20" font="0">Clinimix 6/5 </text>
<text top="776" left="122" width="8" height="22" font="5">•</text>
<text top="776" left="130" width="9" height="23" font="6">  </text>
<text top="778" left="149" width="105" height="20" font="0">Clinimix 8/10 </text>
<text top="798" left="122" width="8" height="22" font="5">•</text>
<text top="798" left="130" width="9" height="23" font="6">  </text>
<text top="800" left="149" width="105" height="20" font="0">Clinimix 8/14 </text>
<text top="820" left="122" width="8" height="22" font="5">•</text>
<text top="820" left="130" width="9" height="23" font="6">  </text>
<text top="822" left="149" width="119" height="20" font="0">Clinisol Sf 15% </text>
<text top="842" left="122" width="8" height="22" font="5">•</text>
<text top="842" left="130" width="9" height="23" font="6">  </text>
<text top="844" left="149" width="78" height="20" font="0">Clinolipid </text>
<text top="864" left="122" width="8" height="22" font="5">•</text>
<text top="864" left="130" width="9" height="23" font="6">  </text>
<text top="866" left="149" width="192" height="20" font="0">Cromolyn Sodium NEBU </text>
<text top="886" left="122" width="8" height="22" font="5">•</text>
<text top="886" left="130" width="9" height="23" font="6">  </text>
<text top="888" left="149" width="193" height="20" font="0">Cyclophosphamide CAPS </text>
<text top="908" left="122" width="8" height="22" font="5">•</text>
<text top="908" left="130" width="9" height="23" font="6">  </text>
<text top="910" left="149" width="194" height="20" font="0">Cyclophosphamide TABS </text>
<text top="930" left="122" width="8" height="22" font="5">•</text>
<text top="929" left="130" width="9" height="23" font="6">  </text>
<text top="932" left="149" width="150" height="20" font="0">Cyclosporine CAPS </text>
<text top="952" left="122" width="8" height="22" font="5">•</text>
<text top="952" left="130" width="9" height="23" font="6">  </text>
<text top="954" left="149" width="131" height="20" font="0">Cyclosporine INJ </text>
<text top="974" left="122" width="8" height="22" font="5">•</text>
<text top="974" left="130" width="9" height="23" font="6">  </text>
<text top="976" left="149" width="172" height="20" font="0">Cyclosporine Modified </text>
<text top="996" left="122" width="8" height="22" font="5">•</text>
<text top="995" left="130" width="9" height="23" font="6">  </text>
<text top="998" left="149" width="206" height="20" font="0">Cytarabine INJ 100MG/ML </text>
<text top="1018" left="122" width="8" height="22" font="5">•</text>
<text top="1018" left="130" width="9" height="23" font="6">  </text>
<text top="1020" left="149" width="152" height="20" font="0">Cytarabine Aqueous </text>
<text top="1057" left="783" width="32" height="20" font="0">338 </text>
</page>
<page number="339" position="absolute" top="0" left="0" height="1188" width="918">
<text top="117" left="122" width="8" height="22" font="5">•</text>
<text top="116" left="130" width="9" height="23" font="6">  </text>
<text top="119" left="149" width="107" height="20" font="0">Dextrose 50% </text>
<text top="139" left="122" width="8" height="22" font="5">•</text>
<text top="138" left="130" width="9" height="23" font="6">  </text>
<text top="141" left="149" width="107" height="20" font="0">Dextrose 70% </text>
<text top="161" left="122" width="8" height="22" font="5">•</text>
<text top="160" left="130" width="9" height="23" font="6">  </text>
<text top="163" left="149" width="275" height="20" font="0">Diphtheria/tetanus Toxoids Adsorbed </text>
<text top="183" left="149" width="69" height="20" font="0">Pediatric </text>
<text top="203" left="122" width="8" height="22" font="5">•</text>
<text top="203" left="130" width="9" height="23" font="6">  </text>
<text top="205" left="149" width="105" height="20" font="0">Emend SUSR </text>
<text top="225" left="122" width="8" height="22" font="5">•</text>
<text top="224" left="130" width="9" height="23" font="6">  </text>
<text top="227" left="149" width="77" height="20" font="0">Engerix-b </text>
<text top="247" left="122" width="8" height="22" font="5">•</text>
<text top="246" left="130" width="9" height="23" font="6">  </text>
<text top="249" left="149" width="161" height="20" font="0">Epoprostenol Sodium </text>
<text top="269" left="122" width="8" height="22" font="5">•</text>
<text top="269" left="130" width="9" height="23" font="6">  </text>
<text top="271" left="149" width="268" height="20" font="0">Everolimus TABS 0.25MG, 0.5MG, </text>
<text top="292" left="149" width="112" height="20" font="0">0.75MG, 1MG </text>
<text top="312" left="122" width="8" height="22" font="5">•</text>
<text top="311" left="130" width="9" height="23" font="6">  </text>
<text top="314" left="149" width="221" height="20" font="0">Fluorouracil INJ 1GM/20ML, </text>
<text top="335" left="149" width="226" height="20" font="0">2.5GM/50ML, 500MG/10ML, </text>
<text top="355" left="149" width="102" height="20" font="0">5GM/100ML </text>
<text top="375" left="122" width="8" height="22" font="5">•</text>
<text top="375" left="130" width="9" height="23" font="6">  </text>
<text top="377" left="149" width="149" height="20" font="0">Freamine Hbc 6.9% </text>
<text top="397" left="122" width="8" height="22" font="5">•</text>
<text top="397" left="130" width="9" height="23" font="6">  </text>
<text top="399" left="149" width="209" height="20" font="0">Freamine III INJ 89MEQ/L; </text>
<text top="420" left="149" width="249" height="20" font="0">710MG/100ML; 950MG/100ML; </text>
<text top="441" left="149" width="190" height="20" font="0">3MEQ/L; 24MG/100ML; </text>
<text top="462" left="149" width="258" height="20" font="0">1400MG/100ML; 280MG/100ML; </text>
<text top="482" left="149" width="249" height="20" font="0">690MG/100ML; 910MG/100ML; </text>
<text top="503" left="149" width="249" height="20" font="0">730MG/100ML; 530MG/100ML; </text>
<text top="524" left="149" width="235" height="20" font="0">560MG/100ML; 10MMOLE/L; </text>
<text top="544" left="149" width="258" height="20" font="0">120MG/100ML; 1120MG/100ML; </text>
<text top="565" left="149" width="208" height="20" font="0">590MG/100ML; 10MEQ/L; </text>
<text top="586" left="149" width="249" height="20" font="0">400MG/100ML; 150MG/100ML; </text>
<text top="606" left="149" width="120" height="20" font="0">660MG/100ML </text>
<text top="626" left="122" width="8" height="22" font="5">•</text>
<text top="626" left="130" width="9" height="23" font="6">  </text>
<text top="628" left="149" width="77" height="20" font="0">Gamastan </text>
<text top="648" left="122" width="8" height="22" font="5">•</text>
<text top="648" left="130" width="9" height="23" font="6">  </text>
<text top="650" left="149" width="185" height="20" font="0">Ganciclovir INJ 500MG, </text>
<text top="671" left="149" width="111" height="20" font="0">500MG/10ML </text>
<text top="691" left="122" width="8" height="22" font="5">•</text>
<text top="690" left="130" width="9" height="23" font="6">  </text>
<text top="693" left="149" width="230" height="20" font="0">Gengraf CAPS 100MG, 25MG </text>
<text top="713" left="122" width="8" height="22" font="5">•</text>
<text top="712" left="130" width="9" height="23" font="6">  </text>
<text top="715" left="149" width="115" height="20" font="0">Gengraf SOLN </text>
<text top="735" left="122" width="8" height="22" font="5">•</text>
<text top="734" left="130" width="9" height="23" font="6">  </text>
<text top="737" left="149" width="170" height="20" font="0">Granisetron Hcl TABS </text>
<text top="757" left="122" width="8" height="22" font="5">•</text>
<text top="756" left="130" width="9" height="23" font="6">  </text>
<text top="759" left="149" width="205" height="20" font="0">Hepatamine INJ 62MEQ/L; </text>
<text top="780" left="149" width="249" height="20" font="0">770MG/100ML; 600MG/100ML; </text>
<text top="801" left="149" width="190" height="20" font="0">3MEQ/L; 20MG/100ML; </text>
<text top="821" left="149" width="249" height="20" font="0">900MG/100ML; 240MG/100ML; </text>
<text top="842" left="149" width="258" height="20" font="0">900MG/100ML; 1100MG/100ML; </text>
<text top="863" left="149" width="249" height="20" font="0">610MG/100ML; 100MG/100ML; </text>
<text top="883" left="149" width="249" height="20" font="0">100MG/100ML; 115MG/100ML; </text>
<text top="904" left="149" width="249" height="20" font="0">800MG/100ML; 500MG/100ML; </text>
<text top="925" left="149" width="240" height="20" font="0">450MG/100ML; 66MG/100ML; </text>
<text top="945" left="149" width="120" height="20" font="0">840MG/100ML </text>
<text top="965" left="122" width="8" height="22" font="5">•</text>
<text top="965" left="130" width="9" height="23" font="6">  </text>
<text top="967" left="149" width="244" height="20" font="0">Humulin R U-500 (concentrated) </text>
<text top="987" left="122" width="8" height="22" font="5">•</text>
<text top="986" left="130" width="9" height="23" font="6">  </text>
<text top="989" left="149" width="273" height="20" font="0">Hydromorphone Hcl INJ 10MG/ML, </text>
<text top="1010" left="149" width="154" height="20" font="0">1MG/ML, 4MG/ML </text>
<text top="1096" left="783" width="32" height="20" font="0">339 </text>
</page>
<page number="340" position="absolute" top="0" left="0" height="1188" width="918">
</page>
<page number="341" position="absolute" top="0" left="0" height="1188" width="918">
<text top="117" left="122" width="8" height="22" font="5">•</text>
<text top="116" left="130" width="9" height="23" font="6">  </text>
<text top="119" left="149" width="217" height="20" font="0">Plenamine INJ 147.4MEQ/L; </text>
<text top="139" left="149" width="258" height="20" font="0">2.17GM/100ML; 1.47GM/100ML; </text>
<text top="160" left="149" width="249" height="20" font="0">434MG/100ML; 749MG/100ML; </text>
<text top="181" left="149" width="253" height="20" font="0">1.04GM/100ML; 894MG/100ML; </text>
<text top="202" left="149" width="254" height="20" font="0">749MG/100ML; 1.04GM/100ML; </text>
<text top="222" left="149" width="253" height="20" font="0">1.18GM/100ML; 749MG/100ML; </text>
<text top="243" left="149" width="253" height="20" font="0">1.04GM/100ML; 894MG/100ML; </text>
<text top="264" left="149" width="249" height="20" font="0">592MG/100ML; 749MG/100ML; </text>
<text top="284" left="149" width="240" height="20" font="0">250MG/100ML; 39MG/100ML; </text>
<text top="305" left="149" width="120" height="20" font="0">960MG/100ML </text>
<text top="325" left="122" width="8" height="22" font="5">•</text>
<text top="324" left="130" width="9" height="23" font="6">  </text>
<text top="327" left="149" width="150" height="20" font="0">Prednisolone SOLN </text>
<text top="347" left="122" width="8" height="22" font="5">•</text>
<text top="346" left="130" width="9" height="23" font="6">  </text>
<text top="349" left="149" width="238" height="20" font="0">Prednisolone Sodium Phosphate </text>
<text top="370" left="149" width="202" height="20" font="0">ORAL SOLN 10MG/5ML, </text>
<text top="390" left="149" width="194" height="20" font="0">15MG/5ML, 20MG/5ML, </text>
<text top="411" left="149" width="181" height="20" font="0">25MG/5ML, 5MG/5ML </text>
<text top="431" left="122" width="8" height="22" font="5">•</text>
<text top="430" left="130" width="9" height="23" font="6">  </text>
<text top="433" left="149" width="136" height="20" font="0">Prednisone SOLN </text>
<text top="453" left="122" width="8" height="22" font="5">•</text>
<text top="452" left="130" width="9" height="23" font="6">  </text>
<text top="455" left="149" width="238" height="20" font="0">Prednisone TABS 10MG, 1MG, </text>
<text top="476" left="149" width="215" height="20" font="0">2.5MG, 20MG, 50MG, 5MG </text>
<text top="496" left="122" width="8" height="22" font="5">•</text>
<text top="495" left="130" width="9" height="23" font="6">  </text>
<text top="498" left="149" width="147" height="20" font="0">Prednisone Intensol </text>
<text top="518" left="122" width="8" height="22" font="5">•</text>
<text top="517" left="130" width="9" height="23" font="6">  </text>
<text top="520" left="149" width="185" height="20" font="0">Premasol INJ 52MEQ/L; </text>
<text top="540" left="149" width="258" height="20" font="0">1760MG/100ML; 880MG/100ML; </text>
<text top="561" left="149" width="217" height="20" font="0">34MEQ/L; 1760MG/100ML; </text>
<text top="582" left="149" width="249" height="20" font="0">372MG/100ML; 406MG/100ML; </text>
<text top="603" left="149" width="249" height="20" font="0">526MG/100ML; 492MG/100ML; </text>
<text top="623" left="149" width="249" height="20" font="0">492MG/100ML; 526MG/100ML; </text>
<text top="644" left="149" width="249" height="20" font="0">356MG/100ML; 356MG/100ML; </text>
<text top="665" left="149" width="240" height="20" font="0">390MG/100ML; 34MG/100ML; </text>
<text top="685" left="149" width="120" height="20" font="0">152MG/100ML </text>
<text top="705" left="122" width="8" height="22" font="5">•</text>
<text top="704" left="130" width="9" height="23" font="6">  </text>
<text top="707" left="149" width="95" height="20" font="0">Procalamine </text>
<text top="727" left="122" width="8" height="22" font="5">•</text>
<text top="726" left="130" width="9" height="23" font="6">  </text>
<text top="729" left="149" width="111" height="20" font="0">Prograf PACK </text>
<text top="749" left="122" width="8" height="22" font="5">•</text>
<text top="748" left="130" width="9" height="23" font="6">  </text>
<text top="751" left="149" width="51" height="20" font="0">Prosol </text>
<text top="771" left="122" width="8" height="22" font="5">•</text>
<text top="770" left="130" width="9" height="23" font="6">  </text>
<text top="773" left="149" width="70" height="20" font="0">Rabavert </text>
<text top="793" left="122" width="8" height="22" font="5">•</text>
<text top="792" left="130" width="9" height="23" font="6">  </text>
<text top="795" left="149" width="122" height="20" font="0">Recombivax Hb </text>
<text top="815" left="122" width="8" height="22" font="5">•</text>
<text top="814" left="130" width="9" height="23" font="6">  </text>
<text top="817" left="149" width="151" height="20" font="0">Sandimmune SOLN </text>
<text top="837" left="122" width="8" height="22" font="5">•</text>
<text top="836" left="130" width="9" height="23" font="6">  </text>
<text top="839" left="149" width="126" height="20" font="0">Sirolimus SOLN </text>
<text top="859" left="122" width="8" height="22" font="5">•</text>
<text top="858" left="130" width="9" height="23" font="6">  </text>
<text top="861" left="149" width="125" height="20" font="0">Sirolimus TABS </text>
<text top="881" left="122" width="8" height="22" font="5">•</text>
<text top="880" left="130" width="9" height="23" font="6">  </text>
<text top="883" left="149" width="136" height="20" font="0">Tacrolimus CAPS </text>
<text top="903" left="122" width="8" height="22" font="5">•</text>
<text top="902" left="130" width="9" height="23" font="6">  </text>
<text top="905" left="149" width="50" height="20" font="0">Tdvax </text>
<text top="925" left="122" width="8" height="22" font="5">•</text>
<text top="924" left="130" width="9" height="23" font="6">  </text>
<text top="927" left="149" width="62" height="20" font="0">Tenivac </text>
<text top="947" left="122" width="8" height="22" font="5">•</text>
<text top="946" left="130" width="9" height="23" font="6">  </text>
<text top="949" left="149" width="155" height="20" font="0">Tpn Electrolytes INJ </text>
<text top="970" left="149" width="253" height="20" font="0">29.5MEQ/20ML; 4.5MEQ/20ML; </text>
<text top="991" left="149" width="226" height="20" font="0">35MEQ/20ML; 5MEQ/20ML; </text>
<text top="1011" left="149" width="230" height="20" font="0">20MEQ/20ML; 35MEQ/20ML </text>
<text top="1096" left="783" width="32" height="20" font="0">341 </text>
</page>
<page number="342" position="absolute" top="0" left="0" height="1188" width="918">
<text top="117" left="122" width="8" height="22" font="5">•</text>
<text top="116" left="130" width="9" height="23" font="6">  </text>
<text top="119" left="149" width="182" height="20" font="0">Travasol INJ 52MEQ/L; </text>
<text top="116" left="330" width="5" height="23" font="6"></text>
<text top="139" left="149" width="258" height="20" font="0">1760MG/100ML; 880MG/100ML; </text>
<text top="137" left="406" width="5" height="23" font="6"></text>
<text top="160" left="149" width="217" height="20" font="0">34MEQ/L; 1760MG/100ML; </text>
<text top="157" left="366" width="5" height="23" font="6"></text>
<text top="181" left="149" width="249" height="20" font="0">372MG/100ML; 406MG/100ML; </text>
<text top="178" left="397" width="5" height="23" font="6"></text>
<text top="202" left="149" width="249" height="20" font="0">526MG/100ML; 492MG/100ML; </text>
<text top="199" left="397" width="5" height="23" font="6"></text>
<text top="222" left="149" width="249" height="20" font="0">492MG/100ML; 526MG/100ML; </text>
<text top="219" left="397" width="5" height="23" font="6"></text>
<text top="243" left="149" width="249" height="20" font="0">356MG/100ML; 500MG/100ML; </text>
<text top="240" left="397" width="5" height="23" font="6"></text>
<text top="264" left="149" width="249" height="20" font="0">356MG/100ML; 390MG/100ML; </text>
<text top="261" left="397" width="5" height="23" font="6"></text>
<text top="284" left="149" width="230" height="20" font="0">34MG/100ML; 152MG/100ML</text>
<text top="281" left="379" width="9" height="23" font="6"> </text>
<text top="304" left="122" width="8" height="22" font="5">•</text>
<text top="303" left="130" width="9" height="23" font="6">  </text>
<text top="306" left="149" width="206" height="20" font="0">Trophamine INJ 97MEQ/L; </text>
<text top="303" left="355" width="5" height="23" font="6"></text>
<text top="327" left="149" width="245" height="20" font="0">0.54GM/100ML; 1.2GM/100ML;</text>
<text top="324" left="393" width="9" height="23" font="6"> </text>
<text top="348" left="149" width="162" height="20" font="0">0.32GM/100ML; 0; 0;</text>
<text top="345" left="310" width="9" height="23" font="6"> </text>
<text top="368" left="149" width="245" height="20" font="0">0.5GM/100ML; 0.36GM/100ML;</text>
<text top="366" left="393" width="9" height="23" font="6"> </text>
<text top="389" left="149" width="254" height="20" font="0">0.48GM/100ML; 0.82GM/100ML;</text>
<text top="386" left="402" width="9" height="23" font="6"> </text>
<text top="410" left="149" width="236" height="20" font="0">1.4GM/100ML; 1.2GM/100ML;</text>
<text top="407" left="384" width="9" height="23" font="6"> </text>
<text top="430" left="149" width="254" height="20" font="0">0.34GM/100ML; 0.48GM/100ML;</text>
<text top="428" left="402" width="9" height="23" font="6"> </text>
<text top="451" left="149" width="254" height="20" font="0">0.68GM/100ML; 0.38GM/100ML;</text>
<text top="448" left="402" width="9" height="23" font="6"> </text>
<text top="472" left="149" width="208" height="20" font="0">5MEQ/L; 0.025GM/100ML;</text>
<text top="469" left="357" width="9" height="23" font="6"> </text>
<text top="493" left="149" width="245" height="20" font="0">0.42GM/100ML; 0.2GM/100ML;</text>
<text top="490" left="393" width="9" height="23" font="6"> </text>
<text top="513" left="149" width="249" height="20" font="0">0.24GM/100ML; 0.78GM/100ML</text>
<text top="510" left="397" width="9" height="23" font="6"> </text>
<text top="533" left="122" width="8" height="22" font="5">•</text>
<text top="532" left="130" width="9" height="23" font="6">  </text>
<text top="535" left="149" width="248" height="20" font="0">Vinblastine Sulfate INJ 1MG/ML </text>
<text top="555" left="122" width="8" height="22" font="5">•</text>
<text top="554" left="130" width="9" height="23" font="6">  </text>
<text top="557" left="149" width="171" height="20" font="0">Vincristine Sulfate INJ </text>
<text top="577" left="122" width="8" height="22" font="5">•</text>
<text top="576" left="130" width="9" height="23" font="6">  </text>
<text top="579" left="149" width="156" height="20" font="0">Zortress TABS 1MG </text>
<text top="662" left="108" width="67" height="23" font="2"><b>Details </b></text>
<text top="710" left="108" width="706" height="20" font="0">This  drug  may  be  covered  under  Medicare  Part  B  or  D  depending  upon  the  circumstances. </text>
<text top="731" left="108" width="706" height="20" font="0">Information  may  need  to  be  submitted  describing  the  use  and  setting  of  the  drug  to  make  the </text>
<text top="752" left="108" width="109" height="20" font="0">determination. </text>
<text top="1096" left="783" width="32" height="20" font="0">342 </text>
</page>
<page number="343" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="12" size="18" family="BCDIEE+TimesNewRomanPS" color="#000000"/>
	<fontspec id="13" size="18" family="BCDJEE+Calibri" color="#000000"/>
<text top="55" left="108" width="5" height="20" font="0"> </text>
<text top="79" left="108" width="5" height="20" font="0"> </text>
<text top="1096" left="783" width="32" height="20" font="0">343 </text>
<text top="118" left="61" width="77" height="27" font="4"><b>INDEX</b></text>
<text top="184" left="62" width="12" height="20" font="12"><i><b>A</b></i></text>
<text top="186" left="74" width="4" height="18" font="13"><i> </i></text>
<text top="217" left="62" width="56" height="20" font="0">Abelcet</text>
<text top="217" left="404" width="27" height="20" font="0">338</text>
<text top="240" left="62" width="86" height="20" font="0">Abiraterone</text>
<text top="240" left="422" width="9" height="20" font="0">1</text>
<text top="264" left="62" width="145" height="20" font="0">Abiraterone Acetate</text>
<text top="264" left="422" width="9" height="20" font="0">1</text>
<text top="288" left="62" width="68" height="20" font="0">Accutane</text>
<text top="288" left="404" width="27" height="20" font="0">153</text>
<text top="312" left="62" width="107" height="20" font="0">Acetylcysteine</text>
<text top="312" left="404" width="27" height="20" font="0">338</text>
<text top="336" left="62" width="64" height="20" font="0">Acitretin</text>
<text top="336" left="422" width="9" height="20" font="0">3</text>
<text top="359" left="62" width="85" height="20" font="0">Actimmune</text>
<text top="359" left="422" width="9" height="20" font="0">4</text>
<text top="383" left="62" width="132" height="20" font="0">Acyclovir Sodium</text>
<text top="383" left="404" width="27" height="20" font="0">338</text>
<text top="407" left="62" width="68" height="20" font="0">Adempas</text>
<text top="407" left="422" width="9" height="20" font="0">5</text>
<text top="431" left="62" width="58" height="20" font="0">Afinitor</text>
<text top="431" left="413" width="18" height="20" font="0">83</text>
<text top="455" left="62" width="118" height="20" font="0">Afinitor Disperz</text>
<text top="455" left="413" width="18" height="20" font="0">83</text>
<text top="478" left="62" width="64" height="20" font="0">Aimovig</text>
<text top="478" left="422" width="9" height="20" font="0">6</text>
<text top="502" left="62" width="125" height="20" font="0">Albuterol Sulfate</text>
<text top="502" left="404" width="27" height="20" font="0">338</text>
<text top="526" left="62" width="66" height="20" font="0">Alecensa</text>
<text top="526" left="422" width="9" height="20" font="0">7</text>
<text top="550" left="62" width="71" height="20" font="0">Alosetron</text>
<text top="550" left="422" width="9" height="20" font="0">8</text>
<text top="574" left="62" width="180" height="20" font="0">Alosetron Hydrochloride</text>
<text top="574" left="422" width="9" height="20" font="0">8</text>
<text top="598" left="62" width="201" height="20" font="0">Alpha1-proteinase Inhibitor</text>
<text top="598" left="422" width="9" height="20" font="0">9</text>
<text top="621" left="62" width="65" height="20" font="0">Alunbrig</text>
<text top="621" left="413" width="18" height="20" font="0">10</text>
<text top="645" left="62" width="36" height="20" font="0">Alyq</text>
<text top="645" left="404" width="27" height="20" font="0">266</text>
<text top="669" left="62" width="79" height="20" font="0">Ambisome</text>
<text top="669" left="404" width="27" height="20" font="0">338</text>
<text top="693" left="62" width="93" height="20" font="0">Ambrisentan</text>
<text top="693" left="413" width="18" height="20" font="0">11</text>
<text top="717" left="62" width="124" height="20" font="0">Aminosyn-pf 7%</text>
<text top="717" left="404" width="27" height="20" font="0">338</text>
<text top="740" left="62" width="128" height="20" font="0">Amitriptyline Hcl</text>
<text top="740" left="404" width="27" height="20" font="0">127</text>
<text top="764" left="62" width="207" height="20" font="0">Amitriptyline Hydrochloride</text>
<text top="764" left="404" width="27" height="20" font="0">127</text>
<text top="788" left="62" width="86" height="20" font="0">Amnesteem</text>
<text top="788" left="404" width="27" height="20" font="0">153</text>
<text top="812" left="62" width="116" height="20" font="0">Amphotericin B</text>
<text top="812" left="404" width="27" height="20" font="0">338</text>
<text top="836" left="62" width="83" height="20" font="0">Androderm</text>
<text top="836" left="404" width="27" height="20" font="0">288</text>
<text top="859" left="62" width="117" height="20" font="0">Apo-varenicline</text>
<text top="859" left="413" width="18" height="20" font="0">45</text>
<text top="883" left="62" width="77" height="20" font="0">Aprepitant</text>
<text top="883" left="404" width="27" height="20" font="0">338</text>
<text top="907" left="62" width="61" height="20" font="0">Arcalyst</text>
<text top="907" left="413" width="18" height="20" font="0">12</text>
<text top="931" left="62" width="89" height="20" font="0">Armodafinil</text>
<text top="931" left="413" width="18" height="20" font="0">13</text>
<text top="955" left="62" width="63" height="20" font="0">Asparlas</text>
<text top="955" left="413" width="18" height="20" font="0">14</text>
<text top="978" left="62" width="88" height="20" font="0">Atovaquone</text>
<text top="978" left="404" width="27" height="20" font="0">187</text>
<text top="1002" left="62" width="60" height="20" font="0">Austedo</text>
<text top="1002" left="413" width="18" height="20" font="0">15</text>
<text top="1026" left="62" width="57" height="20" font="0">Avonex</text>
<text top="1026" left="413" width="18" height="20" font="0">16</text>
<text top="1050" left="62" width="88" height="20" font="0">Avonex Pen</text>
<text top="1050" left="413" width="18" height="20" font="0">16</text>
<text top="217" left="118" width="287" height="20" font="0"> .............................................................. </text>
<text top="217" left="431" width="5" height="20" font="0"> </text>
<text top="240" left="148" width="288" height="20" font="0"> ............................................................   </text>
<text top="264" left="207" width="229" height="20" font="0">...............................................   </text>
<text top="288" left="130" width="276" height="20" font="0"> ............................................................ </text>
<text top="288" left="431" width="5" height="20" font="0"> </text>
<text top="312" left="169" width="236" height="20" font="0"> ................................................... </text>
<text top="312" left="431" width="5" height="20" font="0"> </text>
<text top="336" left="126" width="310" height="20" font="0"> .................................................................   </text>
<text top="359" left="147" width="289" height="20" font="0"> ............................................................   </text>
<text top="383" left="194" width="211" height="20" font="0"> ............................................. </text>
<text top="383" left="431" width="5" height="20" font="0"> </text>
<text top="407" left="130" width="306" height="20" font="0"> ................................................................   </text>
<text top="431" left="120" width="316" height="20" font="0"> ................................................................   </text>
<text top="455" left="180" width="256" height="20" font="0">...................................................   </text>
<text top="478" left="126" width="310" height="20" font="0"> .................................................................   </text>
<text top="502" left="186" width="219" height="20" font="0"> ............................................... </text>
<text top="502" left="431" width="5" height="20" font="0"> </text>
<text top="526" left="128" width="308" height="20" font="0"> ................................................................   </text>
<text top="550" left="133" width="303" height="20" font="0"> ...............................................................   </text>
<text top="574" left="242" width="194" height="20" font="0"> .......................................   </text>
<text top="598" left="262" width="174" height="20" font="0"> ..................................   </text>
<text top="621" left="127" width="309" height="20" font="0"> ..............................................................   </text>
<text top="645" left="98" width="307" height="20" font="0"> ................................................................... </text>
<text top="645" left="431" width="5" height="20" font="0"> </text>
<text top="669" left="141" width="264" height="20" font="0"> ......................................................... </text>
<text top="669" left="431" width="5" height="20" font="0"> </text>
<text top="693" left="155" width="281" height="20" font="0"> ........................................................   </text>
<text top="717" left="186" width="219" height="20" font="0"> ............................................... </text>
<text top="717" left="431" width="5" height="20" font="0"> </text>
<text top="740" left="190" width="215" height="20" font="0"> .............................................. </text>
<text top="740" left="431" width="5" height="20" font="0"> </text>
<text top="764" left="269" width="136" height="20" font="0"> ............................. </text>
<text top="764" left="431" width="5" height="20" font="0"> </text>
<text top="788" left="148" width="258" height="20" font="0"> ........................................................ </text>
<text top="788" left="431" width="5" height="20" font="0"> </text>
<text top="812" left="178" width="227" height="20" font="0"> ................................................. </text>
<text top="812" left="431" width="5" height="20" font="0"> </text>
<text top="836" left="145" width="260" height="20" font="0"> ........................................................ </text>
<text top="836" left="431" width="5" height="20" font="0"> </text>
<text top="859" left="179" width="257" height="20" font="0"> ...................................................   </text>
<text top="883" left="139" width="267" height="20" font="0"> .......................................................... </text>
<text top="883" left="431" width="5" height="20" font="0"> </text>
<text top="907" left="123" width="313" height="20" font="0"> ...............................................................   </text>
<text top="931" left="151" width="285" height="20" font="0"> .........................................................   </text>
<text top="955" left="125" width="311" height="20" font="0"> ...............................................................   </text>
<text top="978" left="150" width="255" height="20" font="0"> ....................................................... </text>
<text top="978" left="431" width="5" height="20" font="0"> </text>
<text top="1002" left="122" width="314" height="20" font="0"> ...............................................................   </text>
<text top="1026" left="119" width="317" height="20" font="0"> ................................................................   </text>
<text top="1050" left="150" width="286" height="20" font="0"> .........................................................   </text>
<text top="184" left="486" width="58" height="20" font="0">Ayvakit</text>
<text top="184" left="838" width="18" height="20" font="0">17</text>
<text top="208" left="486" width="94" height="20" font="0">Azathioprine</text>
<text top="208" left="829" width="27" height="20" font="0">338</text>
<text top="240" left="486" width="12" height="20" font="12"><i><b>B</b></i></text>
<text top="243" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="273" left="486" width="63" height="20" font="0">Balversa</text>
<text top="273" left="838" width="18" height="20" font="0">18</text>
<text top="297" left="486" width="50" height="20" font="0">Banzel</text>
<text top="297" left="838" width="18" height="20" font="0">19</text>
<text top="321" left="486" width="68" height="20" font="0">Beleodaq</text>
<text top="321" left="838" width="18" height="20" font="0">20</text>
<text top="345" left="486" width="63" height="20" font="0">Benlysta</text>
<text top="345" left="837" width="19" height="20" font="0"> 21</text>
<text top="368" left="486" width="158" height="20" font="0">Benztropine Mesylate</text>
<text top="368" left="829" width="27" height="20" font="0">116</text>
<text top="392" left="486" width="60" height="20" font="0">Besremi</text>
<text top="392" left="838" width="18" height="20" font="0">22</text>
<text top="416" left="486" width="72" height="20" font="0">Betaseron</text>
<text top="416" left="838" width="18" height="20" font="0">23</text>
<text top="440" left="486" width="98" height="20" font="0">Bevacizumab</text>
<text top="440" left="838" width="18" height="20" font="0">24</text>
<text top="464" left="486" width="82" height="20" font="0">Bexarotene</text>
<text top="464" left="838" width="18" height="20" font="0">26</text>
<text top="487" left="486" width="62" height="20" font="0">Bivigam</text>
<text top="487" left="829" width="27" height="20" font="0">156</text>
<text top="511" left="486" width="57" height="20" font="0">Blenrep</text>
<text top="511" left="838" width="18" height="20" font="0">27</text>
<text top="535" left="486" width="135" height="20" font="0">Bleomycin Sulfate</text>
<text top="535" left="829" width="27" height="20" font="0">338</text>
<text top="559" left="486" width="85" height="20" font="0">Bortezomib</text>
<text top="559" left="829" width="27" height="20" font="0">303</text>
<text top="583" left="486" width="67" height="20" font="0">Bosentan</text>
<text top="583" left="838" width="18" height="20" font="0">28</text>
<text top="607" left="486" width="53" height="20" font="0">Bosulif</text>
<text top="607" left="838" width="18" height="20" font="0">29</text>
<text top="630" left="486" width="60" height="20" font="0">Braftovi</text>
<text top="630" left="838" width="18" height="20" font="0">30</text>
<text top="654" left="486" width="58" height="20" font="0">Briviact</text>
<text top="654" left="811" width="45" height="20" font="0">31, 32</text>
<text top="678" left="486" width="82" height="20" font="0">Briviact Inj</text>
<text top="678" left="838" width="18" height="20" font="0">32</text>
<text top="702" left="486" width="65" height="20" font="0">Brukinsa</text>
<text top="702" left="838" width="18" height="20" font="0">33</text>
<text top="726" left="486" width="85" height="20" font="0">Budesonide</text>
<text top="726" left="829" width="27" height="20" font="0">338</text>
<text top="749" left="486" width="108" height="20" font="0">Buprenorphine</text>
<text top="749" left="811" width="45" height="20" font="0">34, 35</text>
<text top="773" left="486" width="138" height="20" font="0">Buprenorphine Hcl</text>
<text top="773" left="838" width="18" height="20" font="0">34</text>
<text top="797" left="486" width="153" height="20" font="0">Buprenorphine Patch</text>
<text top="797" left="838" width="18" height="20" font="0">35</text>
<text top="830" left="486" width="12" height="20" font="12"><i><b>C</b></i></text>
<text top="832" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="863" left="486" width="83" height="20" font="0">Cabometyx</text>
<text top="863" left="838" width="18" height="20" font="0">36</text>
<text top="886" left="486" width="97" height="20" font="0">Calcipotriene</text>
<text top="886" left="838" width="18" height="20" font="0">37</text>
<text top="910" left="486" width="308" height="20" font="0">Calcipotriene/betamethasone Dipropionate</text>
<text top="910" left="838" width="18" height="20" font="0">37</text>
<text top="934" left="486" width="68" height="20" font="0">Calcitriol</text>
<text top="934" left="838" width="18" height="20" font="0">37</text>
<text top="958" left="486" width="76" height="20" font="0">Calquence</text>
<text top="958" left="838" width="18" height="20" font="0">38</text>
<text top="982" left="486" width="56" height="20" font="0">Caplyta</text>
<text top="982" left="838" width="18" height="20" font="0">39</text>
<text top="1005" left="486" width="63" height="20" font="0">Caprelsa</text>
<text top="1005" left="838" width="18" height="20" font="0">40</text>
<text top="1029" left="486" width="42" height="20" font="0">Carac</text>
<text top="1029" left="838" width="18" height="20" font="0">41</text>
<text top="1053" left="486" width="66" height="20" font="0">Carbaglu</text>
<text top="1053" left="838" width="18" height="20" font="0">42</text>
<text top="184" left="544" width="316" height="20" font="0"> .................................................................   </text>
<text top="208" left="580" width="253" height="20" font="0"> ....................................................... </text>
<text top="208" left="856" width="5" height="20" font="0"> </text>
<text top="273" left="549" width="311" height="20" font="0">................................................................   </text>
<text top="297" left="536" width="324" height="20" font="0"> ..................................................................   </text>
<text top="321" left="554" width="306" height="20" font="0"> ..............................................................   </text>
<text top="345" left="549" width="311" height="20" font="0">................................................................  </text>
<text top="368" left="644" width="188" height="20" font="0"> ........................................ </text>
<text top="368" left="856" width="5" height="20" font="0"> </text>
<text top="392" left="546" width="314" height="20" font="0"> ................................................................   </text>
<text top="416" left="558" width="302" height="20" font="0">..............................................................   </text>
<text top="440" left="584" width="276" height="20" font="0"> ........................................................   </text>
<text top="464" left="568" width="292" height="20" font="0"> ...........................................................   </text>
<text top="487" left="548" width="285" height="20" font="0"> .............................................................. </text>
<text top="487" left="856" width="5" height="20" font="0"> </text>
<text top="511" left="543" width="317" height="20" font="0"> .................................................................   </text>
<text top="535" left="621" width="212" height="20" font="0"> .............................................. </text>
<text top="535" left="856" width="5" height="20" font="0"> </text>
<text top="559" left="571" width="262" height="20" font="0"> ......................................................... </text>
<text top="559" left="856" width="5" height="20" font="0"> </text>
<text top="583" left="553" width="307" height="20" font="0"> ...............................................................   </text>
<text top="607" left="539" width="321" height="20" font="0"> ..................................................................   </text>
<text top="630" left="546" width="314" height="20" font="0"> ................................................................   </text>
<text top="654" left="544" width="271" height="20" font="0"> ........................................................... </text>
<text top="654" left="856" width="5" height="20" font="0"> </text>
<text top="678" left="569" width="292" height="20" font="0"> ...........................................................   </text>
<text top="702" left="551" width="309" height="20" font="0"> ...............................................................   </text>
<text top="726" left="571" width="262" height="20" font="0"> ......................................................... </text>
<text top="726" left="856" width="5" height="20" font="0"> </text>
<text top="749" left="594" width="221" height="20" font="0">................................................ </text>
<text top="749" left="856" width="5" height="20" font="0"> </text>
<text top="773" left="625" width="236" height="20" font="0"> ...............................................   </text>
<text top="797" left="639" width="222" height="20" font="0"> ............................................   </text>
<text top="863" left="569" width="291" height="20" font="0"> ...........................................................   </text>
<text top="886" left="583" width="277" height="20" font="0"> ........................................................   </text>
<text top="910" left="794" width="66" height="20" font="0"> .........   </text>
<text top="934" left="554" width="306" height="20" font="0"> ..............................................................   </text>
<text top="958" left="562" width="298" height="20" font="0"> .............................................................   </text>
<text top="982" left="542" width="318" height="20" font="0"> .................................................................   </text>
<text top="1005" left="549" width="311" height="20" font="0">................................................................   </text>
<text top="1029" left="528" width="332" height="20" font="0"> ....................................................................   </text>
<text top="1053" left="552" width="308" height="20" font="0"> ...............................................................   </text>
</page>
<page number="344" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">344 </text>
<text top="96" left="62" width="174" height="20" font="0">Carbinoxamine Maleate</text>
<text top="96" left="404" width="27" height="20" font="0">129</text>
<text top="120" left="62" width="59" height="20" font="0">Cayston</text>
<text top="120" left="413" width="18" height="20" font="0">43</text>
<text top="143" left="62" width="65" height="20" font="0">Cerdelga</text>
<text top="143" left="413" width="18" height="20" font="0">44</text>
<text top="167" left="62" width="57" height="20" font="0">Chantix</text>
<text top="167" left="413" width="18" height="20" font="0">45</text>
<text top="191" left="62" width="226" height="20" font="0">Chantix Continuing Month Pak</text>
<text top="191" left="413" width="18" height="20" font="0">45</text>
<text top="215" left="62" width="202" height="20" font="0">Chantix Starting Month Pak</text>
<text top="215" left="413" width="18" height="20" font="0">45</text>
<text top="239" left="62" width="161" height="20" font="0">Chlordiazepoxide - 65</text>
<text top="239" left="413" width="18" height="20" font="0">46</text>
<text top="262" left="62" width="158" height="20" font="0">Chlordiazepoxide Hcl</text>
<text top="262" left="413" width="18" height="20" font="0">46</text>
<text top="286" left="62" width="237" height="20" font="0">Chlordiazepoxide Hydrochloride</text>
<text top="286" left="413" width="18" height="20" font="0">46</text>
<text top="310" left="62" width="226" height="20" font="0">Chlordiazepoxide/amitriptyline</text>
<text top="310" left="404" width="27" height="20" font="0">110</text>
<text top="334" left="62" width="109" height="20" font="0">Chlorzoxazone</text>
<text top="334" left="404" width="27" height="20" font="0">133</text>
<text top="358" left="62" width="76" height="20" font="0">Cladribine</text>
<text top="358" left="404" width="27" height="20" font="0">338</text>
<text top="381" left="62" width="60" height="20" font="0">Claravis</text>
<text top="381" left="404" width="27" height="20" font="0">153</text>
<text top="405" left="62" width="153" height="20" font="0">Clemastine Fumarate</text>
<text top="405" left="404" width="27" height="20" font="0">130</text>
<text top="429" left="62" width="219" height="20" font="0">Clinimix 4.25%/dextrose 10%</text>
<text top="429" left="404" width="27" height="20" font="0">338</text>
<text top="453" left="62" width="210" height="20" font="0">Clinimix 4.25%/dextrose 5%</text>
<text top="453" left="404" width="27" height="20" font="0">338</text>
<text top="477" left="62" width="196" height="20" font="0">Clinimix 5%/dextrose 15%</text>
<text top="477" left="404" width="27" height="20" font="0">338</text>
<text top="501" left="62" width="196" height="20" font="0">Clinimix 5%/dextrose 20%</text>
<text top="501" left="404" width="27" height="20" font="0">338</text>
<text top="524" left="62" width="92" height="20" font="0">Clinimix 6/5</text>
<text top="524" left="404" width="27" height="20" font="0">338</text>
<text top="548" left="62" width="100" height="20" font="0">Clinimix 8/10</text>
<text top="548" left="404" width="27" height="20" font="0">338</text>
<text top="572" left="62" width="100" height="20" font="0">Clinimix 8/14</text>
<text top="572" left="404" width="27" height="20" font="0">338</text>
<text top="596" left="62" width="115" height="20" font="0">Clinisol Sf 15%</text>
<text top="596" left="404" width="27" height="20" font="0">338</text>
<text top="620" left="62" width="73" height="20" font="0">Clinolipid</text>
<text top="620" left="404" width="27" height="20" font="0">338</text>
<text top="643" left="62" width="73" height="20" font="0">Clobazam</text>
<text top="643" left="413" width="18" height="20" font="0">47</text>
<text top="667" left="62" width="104" height="20" font="0">Clomipramine</text>
<text top="667" left="413" width="18" height="20" font="0">48</text>
<text top="691" left="62" width="134" height="20" font="0">Clomipramine Hcl</text>
<text top="691" left="413" width="18" height="20" font="0">48</text>
<text top="715" left="62" width="86" height="20" font="0">Clorazepate</text>
<text top="715" left="413" width="18" height="20" font="0">49</text>
<text top="739" left="62" width="181" height="20" font="0">Clorazepate Dipotassium</text>
<text top="739" left="413" width="18" height="20" font="0">49</text>
<text top="762" left="62" width="104" height="20" font="0">Clozapine Odt</text>
<text top="762" left="413" width="18" height="20" font="0">50</text>
<text top="786" left="62" width="166" height="20" font="0">Colistimethate Sodium</text>
<text top="786" left="413" width="18" height="20" font="0">51</text>
<text top="810" left="62" width="86" height="20" font="0">Coly-mycin</text>
<text top="810" left="413" width="18" height="20" font="0">51</text>
<text top="834" left="62" width="68" height="20" font="0">Cometriq</text>
<text top="834" left="413" width="18" height="20" font="0">52</text>
<text top="858" left="62" width="73" height="20" font="0">Copaxone</text>
<text top="858" left="404" width="27" height="20" font="0">101</text>
<text top="881" left="62" width="63" height="20" font="0">Copiktra</text>
<text top="881" left="413" width="18" height="20" font="0">53</text>
<text top="905" left="62" width="57" height="20" font="0">Cotellic</text>
<text top="905" left="413" width="18" height="20" font="0">54</text>
<text top="929" left="62" width="133" height="20" font="0">Cromolyn Sodium</text>
<text top="929" left="404" width="27" height="20" font="0">338</text>
<text top="953" left="62" width="231" height="20" font="0">Cyclobenzaprine Hydrochloride</text>
<text top="953" left="404" width="27" height="20" font="0">133</text>
<text top="977" left="62" width="139" height="20" font="0">Cyclophosphamide</text>
<text top="977" left="404" width="27" height="20" font="0">338</text>
<text top="1000" left="62" width="96" height="20" font="0">Cyclosporine</text>
<text top="1000" left="404" width="27" height="20" font="0">338</text>
<text top="1024" left="62" width="168" height="20" font="0">Cyclosporine Modified</text>
<text top="1024" left="404" width="27" height="20" font="0">338</text>
<text top="1048" left="62" width="145" height="20" font="0">Cyproheptadine Hcl</text>
<text top="1048" left="404" width="27" height="20" font="0">118</text>
<text top="1072" left="62" width="224" height="20" font="0">Cyproheptadine Hydrochloride</text>
<text top="1072" left="404" width="27" height="20" font="0">118</text>
<text top="1096" left="62" width="68" height="20" font="0">Cystagon</text>
<text top="1096" left="413" width="18" height="20" font="0">55</text>
<text top="96" left="235" width="170" height="20" font="0"> .................................... </text>
<text top="96" left="431" width="5" height="20" font="0"> </text>
<text top="120" left="121" width="315" height="20" font="0"> ................................................................   </text>
<text top="143" left="127" width="309" height="20" font="0"> ..............................................................   </text>
<text top="167" left="119" width="317" height="20" font="0"> ................................................................   </text>
<text top="191" left="288" width="148" height="20" font="0"> ..........................   </text>
<text top="215" left="264" width="172" height="20" font="0"> ................................   </text>
<text top="239" left="223" width="213" height="20" font="0"> .........................................   </text>
<text top="262" left="220" width="216" height="20" font="0"> ..........................................   </text>
<text top="286" left="299" width="137" height="20" font="0"> ........................   </text>
<text top="310" left="287" width="118" height="20" font="0"> ......................... </text>
<text top="310" left="431" width="5" height="20" font="0"> </text>
<text top="334" left="171" width="234" height="20" font="0"> ................................................... </text>
<text top="334" left="431" width="5" height="20" font="0"> </text>
<text top="358" left="138" width="268" height="20" font="0"> .......................................................... </text>
<text top="358" left="431" width="5" height="20" font="0"> </text>
<text top="381" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="381" left="431" width="5" height="20" font="0"> </text>
<text top="405" left="215" width="190" height="20" font="0"> ......................................... </text>
<text top="405" left="431" width="5" height="20" font="0"> </text>
<text top="429" left="280" width="125" height="20" font="0"> .......................... </text>
<text top="429" left="431" width="5" height="20" font="0"> </text>
<text top="453" left="271" width="134" height="20" font="0"> ............................ </text>
<text top="453" left="431" width="5" height="20" font="0"> </text>
<text top="477" left="258" width="147" height="20" font="0"> ............................... </text>
<text top="477" left="431" width="5" height="20" font="0"> </text>
<text top="501" left="258" width="147" height="20" font="0"> ............................... </text>
<text top="501" left="431" width="5" height="20" font="0"> </text>
<text top="524" left="153" width="252" height="20" font="0"> ...................................................... </text>
<text top="524" left="431" width="5" height="20" font="0"> </text>
<text top="548" left="162" width="243" height="20" font="0"> .................................................... </text>
<text top="548" left="431" width="5" height="20" font="0"> </text>
<text top="572" left="162" width="243" height="20" font="0"> .................................................... </text>
<text top="572" left="431" width="5" height="20" font="0"> </text>
<text top="596" left="177" width="228" height="20" font="0"> ................................................. </text>
<text top="596" left="431" width="5" height="20" font="0"> </text>
<text top="620" left="135" width="270" height="20" font="0"> ........................................................... </text>
<text top="620" left="431" width="5" height="20" font="0"> </text>
<text top="643" left="135" width="301" height="20" font="0"> .............................................................   </text>
<text top="667" left="166" width="270" height="20" font="0"> ......................................................   </text>
<text top="691" left="196" width="240" height="20" font="0"> ...............................................   </text>
<text top="715" left="148" width="288" height="20" font="0"> ..........................................................   </text>
<text top="739" left="243" width="193" height="20" font="0">.....................................   </text>
<text top="762" left="166" width="270" height="20" font="0"> ......................................................   </text>
<text top="786" left="227" width="209" height="20" font="0"> ........................................   </text>
<text top="810" left="148" width="288" height="20" font="0"> ..........................................................   </text>
<text top="834" left="130" width="306" height="20" font="0"> ..............................................................   </text>
<text top="858" left="135" width="270" height="20" font="0"> ........................................................... </text>
<text top="858" left="431" width="5" height="20" font="0"> </text>
<text top="881" left="125" width="311" height="20" font="0"> ...............................................................   </text>
<text top="905" left="119" width="317" height="20" font="0"> ................................................................   </text>
<text top="929" left="195" width="210" height="20" font="0"> ............................................. </text>
<text top="929" left="431" width="5" height="20" font="0"> </text>
<text top="953" left="293" width="112" height="20" font="0"> ....................... </text>
<text top="953" left="431" width="5" height="20" font="0"> </text>
<text top="977" left="201" width="204" height="20" font="0"> ............................................ </text>
<text top="977" left="431" width="5" height="20" font="0"> </text>
<text top="1000" left="158" width="247" height="20" font="0"> ..................................................... </text>
<text top="1000" left="431" width="5" height="20" font="0"> </text>
<text top="1024" left="229" width="176" height="20" font="0"> ...................................... </text>
<text top="1024" left="431" width="5" height="20" font="0"> </text>
<text top="1048" left="207" width="198" height="20" font="0">........................................... </text>
<text top="1048" left="431" width="5" height="20" font="0"> </text>
<text top="1072" left="286" width="119" height="20" font="0"> ......................... </text>
<text top="1072" left="431" width="5" height="20" font="0"> </text>
<text top="1096" left="130" width="306" height="20" font="0"> ..............................................................   </text>
<text top="96" left="486" width="351" height="20" font="0">Cystaran ...............................................................</text>
<text top="120" left="565" width="268" height="20" font="0"> .......................................................... </text>
<text top="143" left="633" width="199" height="20" font="0"> ........................................... </text>
<text top="209" left="591" width="251" height="20" font="0"> ...................................................... </text>
<text top="233" left="613" width="229" height="20" font="0"> ................................................. </text>
<text top="257" left="558" width="279" height="20" font="0">..............................................................</text>
<text top="280" left="572" width="265" height="20" font="0">...........................................................</text>
<text top="304" left="545" width="293" height="20" font="0">.................................................................</text>
<text top="328" left="689" width="139" height="20" font="0">...............................</text>
<text top="352" left="599" width="238" height="20" font="0">.....................................................</text>
<text top="376" left="621" width="216" height="20" font="0">................................................</text>
<text top="399" left="590" width="238" height="20" font="0">.....................................................</text>
<text top="423" left="590" width="238" height="20" font="0">.....................................................</text>
<text top="447" left="563" width="274" height="20" font="0">.............................................................</text>
<text top="471" left="554" width="283" height="20" font="0">...............................................................</text>
<text top="495" left="563" width="274" height="20" font="0">.............................................................</text>
<text top="519" left="626" width="211" height="20" font="0">...............................................</text>
<text top="542" left="626" width="212" height="20" font="0">...............................................</text>
<text top="566" left="603" width="234" height="20" font="0">....................................................</text>
<text top="590" left="612" width="216" height="20" font="0">................................................</text>
<text top="614" left="689" width="139" height="20" font="0">...............................</text>
<text top="638" left="698" width="103" height="20" font="0">.......................</text>
<text top="661" left="648" width="180" height="20" font="0">........................................</text>
<text top="709" left="590" width="239" height="20" font="0">.....................................................</text>
<text top="733" left="671" width="158" height="20" font="0">...................................</text>
<text top="757" left="549" width="288" height="20" font="0">................................................................</text>
<text top="780" left="581" width="247" height="20" font="0">.......................................................</text>
<text top="804" left="662" width="130" height="20" font="0">.............................</text>
<text top="828" left="581" width="247" height="20" font="0">.......................................................</text>
<text top="852" left="554" width="283" height="20" font="0">...............................................................</text>
<text top="876" left="621" width="216" height="20" font="0">................................................</text>
<text top="899" left="572" width="265" height="20" font="0">...........................................................</text>
<text top="923" left="567" width="261" height="20" font="0">..........................................................</text>
<text top="947" left="540" width="297" height="20" font="0">..................................................................</text>
<text top="1013" left="540" width="288" height="20" font="0">................................................................</text>
<text top="1036" left="684" width="144" height="20" font="0">................................</text>
<text top="1036" left="540" width="144" height="20" font="0">................................</text>
<text top="1060" left="536" width="288" height="20" font="0">................................................................</text>
<text top="1084" left="720" width="117" height="20" font="0">..........................</text>
<text top="1084" left="576" width="144" height="20" font="0">................................</text>
<text top="1036" left="828" width="9" height="20" font="0">..</text>
<text top="1060" left="824" width="14" height="20" font="0">...</text>
<text top="96" left="837" width="23" height="20" font="0"> 56 </text>
<text top="120" left="486" width="79" height="20" font="0">Cytarabine</text>
<text top="120" left="829" width="32" height="20" font="0">338 </text>
<text top="143" left="486" width="147" height="20" font="0">Cytarabine Aqueous</text>
<text top="143" left="829" width="32" height="20" font="0">338 </text>
<text top="176" left="486" width="13" height="20" font="12"><i><b>D</b></i></text>
<text top="179" left="499" width="4" height="18" font="13"><i> </i></text>
<text top="209" left="486" width="105" height="20" font="0">Dalfampridine</text>
<text top="209" left="838" width="23" height="20" font="0">57 </text>
<text top="233" left="486" width="126" height="20" font="0">Dalfampridine Er</text>
<text top="233" left="838" width="23" height="20" font="0">57 </text>
<text top="257" left="486" width="76" height="20" font="0">Daurismo </text>
<text top="257" left="837" width="23" height="20" font="0"> 58 </text>
<text top="280" left="486" width="89" height="20" font="0">Deferasirox </text>
<text top="280" left="837" width="23" height="20" font="0"> 59 </text>
<text top="304" left="486" width="60" height="20" font="0">Demser </text>
<text top="304" left="837" width="23" height="20" font="0"> 60 </text>
<text top="328" left="486" width="206" height="20" font="0">Desipramine Hydrochloride </text>
<text top="328" left="828" width="32" height="20" font="0"> 127 </text>
<text top="352" left="486" width="116" height="20" font="0">Desvenlafaxine </text>
<text top="352" left="837" width="23" height="20" font="0"> 61 </text>
<text top="376" left="486" width="138" height="20" font="0">Desvenlafaxine Er </text>
<text top="376" left="837" width="23" height="20" font="0"> 61 </text>
<text top="399" left="486" width="107" height="20" font="0">Dextrose 50% </text>
<text top="399" left="828" width="32" height="20" font="0"> 339 </text>
<text top="423" left="486" width="107" height="20" font="0">Dextrose 70% </text>
<text top="423" left="828" width="32" height="20" font="0"> 339 </text>
<text top="447" left="486" width="80" height="20" font="0">Dhe Nasal </text>
<text top="447" left="837" width="23" height="20" font="0"> 62 </text>
<text top="471" left="486" width="71" height="20" font="0">Diacomit </text>
<text top="471" left="837" width="23" height="20" font="0"> 63 </text>
<text top="495" left="486" width="77" height="20" font="0">Diazepam </text>
<text top="495" left="837" width="23" height="20" font="0"> 64 </text>
<text top="519" left="486" width="142" height="20" font="0">Diclofenac Gel 1% </text>
<text top="519" left="837" width="23" height="20" font="0"> 65 </text>
<text top="542" left="486" width="144" height="20" font="0">Diclofenac Sodium </text>
<text top="542" left="837" width="23" height="20" font="0"> 65 </text>
<text top="566" left="486" width="121" height="20" font="0">Diclofenac Soln </text>
<text top="566" left="837" width="23" height="20" font="0"> 66 </text>
<text top="590" left="486" width="128" height="20" font="0">Dicyclomine Hcl </text>
<text top="590" left="828" width="32" height="20" font="0"> 110 </text>
<text top="614" left="486" width="207" height="20" font="0">Dicyclomine Hydrochloride </text>
<text top="614" left="828" width="32" height="20" font="0"> 110 </text>
<text top="638" left="486" width="212" height="20" font="0">Dihydroergotamine Mesylate</text>
<text top="638" left="801" width="59" height="20" font="0"> 62, 110 </text>
<text top="661" left="486" width="165" height="20" font="0">Diphenhydramine Hcl </text>
<text top="661" left="828" width="32" height="20" font="0"> 110 </text>
<text top="685" left="486" width="374" height="20" font="0">Diphtheria/tetanus Toxoids Adsorbed Pediatric 339 </text>
<text top="709" left="486" width="104" height="20" font="0">Dipyridamole </text>
<text top="709" left="828" width="32" height="20" font="0"> 110 </text>
<text top="733" left="486" width="185" height="20" font="0">Disopyramide Phosphate </text>
<text top="733" left="828" width="32" height="20" font="0"> 110 </text>
<text top="757" left="486" width="67" height="20" font="0">Doptelet </text>
<text top="757" left="837" width="23" height="20" font="0"> 67 </text>
<text top="780" left="486" width="97" height="20" font="0">Doxepin Hcl </text>
<text top="780" left="828" width="32" height="20" font="0"> 119 </text>
<text top="804" left="486" width="176" height="20" font="0">Doxepin Hydrochloride </text>
<text top="804" left="792" width="68" height="20" font="0"> 119, 286 </text>
<text top="828" left="486" width="96" height="20" font="0">Doxycycline </text>
<text top="828" left="828" width="32" height="20" font="0"> 208 </text>
<text top="852" left="486" width="71" height="20" font="0">Drizalma </text>
<text top="852" left="837" width="23" height="20" font="0"> 68 </text>
<text top="876" left="486" width="137" height="20" font="0">Drizalma Sprinkle </text>
<text top="876" left="837" width="23" height="20" font="0"> 68 </text>
<text top="899" left="486" width="86" height="20" font="0">Dronabinol </text>
<text top="899" left="837" width="23" height="20" font="0"> 69 </text>
<text top="923" left="486" width="81" height="20" font="0">Droxidopa </text>
<text top="923" left="828" width="32" height="20" font="0"> 198 </text>
<text top="947" left="486" width="56" height="20" font="0">Duexis </text>
<text top="947" left="837" width="23" height="20" font="0"> 70 </text>
<text top="980" left="486" width="12" height="20" font="12"><i><b>E</b></i></text>
<text top="982" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="1013" left="486" width="55" height="20" font="0">Emend </text>
<text top="1013" left="828" width="32" height="20" font="0"> 339 </text>
<text top="1036" left="486" width="54" height="20" font="0">Emsam</text>
<text top="1036" left="837" width="23" height="20" font="0"> 71 </text>
<text top="1060" left="486" width="52" height="20" font="0">Enbrel </text>
<text top="1060" left="837" width="23" height="20" font="0"> 72 </text>
<text top="1084" left="486" width="92" height="20" font="0">Enbrel Mini </text>
<text top="1084" left="837" width="23" height="20" font="0"> 72 </text>
</page>
<page number="345" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">345 </text>
<text top="96" left="62" width="352" height="20" font="0">Enbrel Sureclick .................................................. </text>
<text top="120" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="143" left="122" width="293" height="20" font="0">................................................................ </text>
<text top="167" left="118" width="296" height="20" font="0"> ................................................................ </text>
<text top="191" left="119" width="295" height="20" font="0"> ................................................................ </text>
<text top="215" left="132" width="282" height="20" font="0"> ............................................................. </text>
<text top="239" left="95" width="126" height="20" font="0">............................</text>
<text top="239" left="374" width="41" height="20" font="0">........ </text>
<text top="262" left="374" width="32" height="20" font="0">...... </text>
<text top="286" left="198" width="23" height="20" font="0">.....</text>
<text top="286" left="374" width="41" height="20" font="0">........ </text>
<text top="310" left="117" width="104" height="20" font="0">.......................</text>
<text top="310" left="374" width="41" height="20" font="0">........ </text>
<text top="334" left="157" width="63" height="20" font="0">..............</text>
<text top="334" left="374" width="41" height="20" font="0">........ </text>
<text top="358" left="374" width="41" height="20" font="0">........ </text>
<text top="381" left="112" width="108" height="20" font="0">........................</text>
<text top="381" left="374" width="41" height="20" font="0">........ </text>
<text top="405" left="149" width="71" height="20" font="0"> ...............</text>
<text top="405" left="374" width="32" height="20" font="0">...... </text>
<text top="429" left="148" width="230" height="20" font="0">.................................................. </text>
<text top="453" left="126" width="288" height="20" font="0">............................................................... </text>
<text top="519" left="112" width="302" height="20" font="0">.................................................................. </text>
<text top="542" left="221" width="194" height="20" font="0">.......................................... </text>
<text top="566" left="121" width="293" height="20" font="0">................................................................ </text>
<text top="590" left="266" width="149" height="20" font="0">................................ </text>
<text top="590" left="121" width="144" height="20" font="0">................................</text>
<text top="614" left="153" width="261" height="20" font="0">......................................................... </text>
<text top="638" left="270" width="144" height="20" font="0">............................... </text>
<text top="638" left="126" width="144" height="20" font="0">................................</text>
<text top="661" left="324" width="81" height="20" font="0">................. </text>
<text top="685" left="171" width="243" height="20" font="0">..................................................... </text>
<text top="709" left="122" width="293" height="20" font="0">................................................................ </text>
<text top="733" left="230" width="185" height="20" font="0">........................................ </text>
<text top="757" left="266" width="149" height="20" font="0">................................ </text>
<text top="757" left="122" width="144" height="20" font="0">................................</text>
<text top="780" left="185" width="220" height="20" font="0">................................................ </text>
<text top="804" left="144" width="270" height="20" font="0">........................................................... </text>
<text top="828" left="297" width="54" height="20" font="0">........... </text>
<text top="828" left="153" width="144" height="20" font="0">................................</text>
<text top="852" left="198" width="216" height="20" font="0">............................................... </text>
<text top="876" left="257" width="157" height="20" font="0">.................................. </text>
<text top="876" left="113" width="144" height="20" font="0">................................</text>
<text top="899" left="117" width="297" height="20" font="0">................................................................. </text>
<text top="923" left="207" width="198" height="20" font="0">........................................... </text>
<text top="947" left="153" width="252" height="20" font="0">....................................................... </text>
<text top="971" left="275" width="139" height="20" font="0">.............................. </text>
<text top="971" left="131" width="144" height="20" font="0">................................</text>
<text top="1036" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="1060" left="207" width="198" height="20" font="0">........................................... </text>
<text top="1084" left="356" width="49" height="20" font="0">.......... </text>
<text top="239" left="221" width="153" height="20" font="0">..................................</text>
<text top="262" left="347" width="27" height="20" font="0">......</text>
<text top="286" left="221" width="54" height="20" font="0">............</text>
<text top="310" left="221" width="41" height="20" font="0">.........</text>
<text top="262" left="221" width="126" height="20" font="0">............................</text>
<text top="286" left="275" width="77" height="20" font="0">.................</text>
<text top="310" left="261" width="90" height="20" font="0">....................</text>
<text top="286" left="131" width="67" height="20" font="0">...............</text>
<text top="286" left="351" width="23" height="20" font="0">.....</text>
<text top="310" left="351" width="23" height="20" font="0">.....</text>
<text top="334" left="351" width="23" height="20" font="0">.....</text>
<text top="334" left="270" width="81" height="20" font="0">..................</text>
<text top="334" left="221" width="50" height="20" font="0">...........</text>
<text top="334" left="126" width="32" height="20" font="0">.......</text>
<text top="358" left="239" width="135" height="20" font="0">..............................</text>
<text top="381" left="221" width="153" height="20" font="0">..................................</text>
<text top="405" left="297" width="77" height="20" font="0">.................</text>
<text top="405" left="221" width="77" height="20" font="0">.................</text>
<text top="262" left="218" width="5" height="20" font="0"> </text>
<text top="358" left="235" width="5" height="20" font="0"> </text>
<text top="96" left="413" width="23" height="20" font="0">72 </text>
<text top="120" left="62" width="77" height="20" font="0">Engerix-b </text>
<text top="120" left="404" width="32" height="20" font="0">339 </text>
<text top="143" left="62" width="61" height="20" font="0">Enhertu </text>
<text top="143" left="413" width="23" height="20" font="0">74 </text>
<text top="167" left="62" width="56" height="20" font="0">Enstilar</text>
<text top="167" left="413" width="23" height="20" font="0">37 </text>
<text top="191" left="62" width="57" height="20" font="0">Epclusa</text>
<text top="191" left="413" width="23" height="20" font="0">75 </text>
<text top="215" left="62" width="70" height="20" font="0">Epidiolex</text>
<text top="215" left="413" width="23" height="20" font="0">76 </text>
<text top="239" left="62" width="33" height="20" font="0">Epo </text>
<text top="239" left="413" width="23" height="20" font="0">77 </text>
<text top="262" left="62" width="157" height="20" font="0">Epoprostenol Sodium</text>
<text top="262" left="404" width="32" height="20" font="0">339 </text>
<text top="286" left="62" width="69" height="20" font="0">Erivedge </text>
<text top="286" left="413" width="23" height="20" font="0">79 </text>
<text top="310" left="62" width="59" height="20" font="0">Erleada </text>
<text top="310" left="413" width="23" height="20" font="0">80 </text>
<text top="334" left="62" width="68" height="20" font="0">Erlotinib </text>
<text top="334" left="413" width="23" height="20" font="0">81 </text>
<text top="358" left="62" width="173" height="20" font="0">Erlotinib Hydrochloride</text>
<text top="358" left="413" width="23" height="20" font="0">81 </text>
<text top="381" left="62" width="51" height="20" font="0">Esbriet</text>
<text top="381" left="413" width="23" height="20" font="0">82 </text>
<text top="405" left="62" width="88" height="20" font="0">Eszopiclone</text>
<text top="405" left="404" width="32" height="20" font="0">113 </text>
<text top="429" left="62" width="87" height="20" font="0">Everolimus </text>
<text top="429" left="377" width="59" height="20" font="0">83, 339 </text>
<text top="453" left="62" width="67" height="20" font="0">Exkivity </text>
<text top="453" left="413" width="23" height="20" font="0">84 </text>
<text top="486" left="62" width="12" height="20" font="12"><i><b>F</b></i></text>
<text top="488" left="74" width="4" height="18" font="13"><i> </i></text>
<text top="519" left="62" width="53" height="20" font="0">Fanapt </text>
<text top="519" left="413" width="23" height="20" font="0">85 </text>
<text top="542" left="62" width="161" height="20" font="0">Fanapt Titration Pack </text>
<text top="542" left="413" width="23" height="20" font="0">85 </text>
<text top="566" left="62" width="63" height="20" font="0">Farydak </text>
<text top="566" left="413" width="23" height="20" font="0">86 </text>
<text top="590" left="62" width="60" height="20" font="0">Fasenra </text>
<text top="590" left="413" width="23" height="20" font="0">87 </text>
<text top="614" left="62" width="92" height="20" font="0">Fasenra Pen </text>
<text top="614" left="413" width="23" height="20" font="0">87 </text>
<text top="638" left="62" width="67" height="20" font="0">Fentanyl </text>
<text top="638" left="413" width="23" height="20" font="0">88 </text>
<text top="661" left="62" width="263" height="20" font="0">Fentanyl Citrate Oral Transmucosal </text>
<text top="661" left="404" width="31" height="20" font="0">209 </text>
<text top="685" left="62" width="112" height="20" font="0">Fentanyl Patch </text>
<text top="685" left="413" width="23" height="20" font="0">88 </text>
<text top="709" left="62" width="62" height="20" font="0">Fetzima </text>
<text top="709" left="413" width="23" height="20" font="0">89 </text>
<text top="733" left="62" width="170" height="20" font="0">Fetzima Titration Pack </text>
<text top="733" left="413" width="23" height="20" font="0">89 </text>
<text top="757" left="62" width="63" height="20" font="0">Fintepla </text>
<text top="757" left="413" width="23" height="20" font="0">90 </text>
<text top="780" left="62" width="127" height="20" font="0">Flebogamma Dif </text>
<text top="780" left="404" width="32" height="20" font="0">156 </text>
<text top="804" left="62" width="84" height="20" font="0">Fluoroplex </text>
<text top="804" left="413" width="23" height="20" font="0">91 </text>
<text top="828" left="62" width="94" height="20" font="0">Fluorouracil </text>
<text top="828" left="350" width="86" height="20" font="0">41, 91, 339 </text>
<text top="852" left="62" width="140" height="20" font="0">Fortamet/glumetza </text>
<text top="852" left="413" width="23" height="20" font="0">92 </text>
<text top="876" left="62" width="51" height="20" font="0">Forteo </text>
<text top="876" left="413" width="23" height="20" font="0">93 </text>
<text top="899" left="62" width="59" height="20" font="0">Fotivda </text>
<text top="899" left="413" width="23" height="20" font="0">95 </text>
<text top="923" left="62" width="149" height="20" font="0">Freamine Hbc 6.9% </text>
<text top="923" left="404" width="32" height="20" font="0">339 </text>
<text top="947" left="62" width="95" height="20" font="0">Freamine III </text>
<text top="947" left="404" width="32" height="20" font="0">339 </text>
<text top="971" left="62" width="71" height="20" font="0">Fycompa </text>
<text top="971" left="413" width="23" height="20" font="0">96 </text>
<text top="1004" left="62" width="13" height="20" font="12"><i><b>G</b></i></text>
<text top="1006" left="75" width="4" height="18" font="13"><i> </i></text>
<text top="1036" left="62" width="77" height="20" font="0">Gamastan </text>
<text top="1036" left="404" width="32" height="20" font="0">339 </text>
<text top="1060" left="62" width="146" height="20" font="0">Gammagard Liquid </text>
<text top="1060" left="404" width="32" height="20" font="0">156 </text>
<text top="1084" left="62" width="297" height="20" font="0">Gammagard S/d Iga Less Than 1mcg/ml </text>
<text top="1084" left="404" width="31" height="20" font="0">156 </text>
<text top="96" left="486" width="342" height="20" font="0">Gammaked .........................................................</text>
<text top="120" left="574" width="254" height="20" font="0"> ........................................................</text>
<text top="143" left="570" width="258" height="20" font="0"> .........................................................</text>
<text top="167" left="571" width="257" height="20" font="0"> .........................................................</text>
<text top="191" left="534" width="303" height="20" font="0"> ...................................................................</text>
<text top="215" left="544" width="298" height="20" font="0"> ................................................................. </text>
<text top="239" left="545" width="288" height="20" font="0"> .............................................................. </text>
<text top="262" left="568" width="265" height="20" font="0"> ......................................................... </text>
<text top="286" left="648" width="180" height="20" font="0">........................................</text>
<text top="310" left="545" width="288" height="20" font="0">................................................................</text>
<text top="334" left="540" width="288" height="20" font="0">................................................................</text>
<text top="358" left="567" width="261" height="20" font="0">..........................................................</text>
<text top="381" left="603" width="225" height="20" font="0">..................................................</text>
<text top="405" left="617" width="211" height="20" font="0">...............................................</text>
<text top="429" left="594" width="234" height="20" font="0">....................................................</text>
<text top="453" left="603" width="225" height="20" font="0">..................................................</text>
<text top="477" left="680" width="149" height="20" font="0">.................................</text>
<text top="542" left="558" width="270" height="20" font="0">............................................................</text>
<text top="566" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="590" left="576" width="252" height="20" font="0">........................................................</text>
<text top="614" left="621" width="207" height="20" font="0">..............................................</text>
<text top="638" left="540" width="288" height="20" font="0">................................................................</text>
<text top="661" left="567" width="261" height="20" font="0">..........................................................</text>
<text top="685" left="680" width="149" height="20" font="0">.................................</text>
<text top="709" left="684" width="144" height="20" font="0">................................</text>
<text top="733" left="644" width="184" height="20" font="0">.........................................</text>
<text top="757" left="662" width="167" height="20" font="0">.....................................</text>
<text top="780" left="657" width="171" height="20" font="0">......................................</text>
<text top="804" left="671" width="162" height="20" font="0">................................... </text>
<text top="828" left="617" width="212" height="20" font="0">...............................................</text>
<text top="852" left="648" width="180" height="20" font="0">........................................</text>
<text top="876" left="675" width="158" height="20" font="0">.................................. </text>
<text top="899" left="801" width="27" height="20" font="0">......</text>
<text top="899" left="657" width="144" height="20" font="0">................................</text>
<text top="923" left="657" width="144" height="20" font="0">................................</text>
<text top="923" left="828" width="5" height="20" font="0"> </text>
<text top="923" left="801" width="27" height="20" font="0">......</text>
<text top="947" left="797" width="32" height="20" font="0">.......</text>
<text top="947" left="653" width="144" height="20" font="0">................................</text>
<text top="971" left="653" width="176" height="20" font="0">.......................................</text>
<text top="995" left="648" width="180" height="20" font="0">........................................</text>
<text top="1018" left="720" width="108" height="20" font="0">........................</text>
<text top="1018" left="576" width="144" height="20" font="0">................................</text>
<text top="1042" left="747" width="81" height="20" font="0">..................</text>
<text top="1066" left="689" width="140" height="20" font="0">...............................</text>
<text top="1066" left="545" width="144" height="20" font="0">................................</text>
<text top="1090" left="818" width="10" height="20" font="0"> ..</text>
<text top="96" left="828" width="32" height="20" font="0"> 156 </text>
<text top="120" left="486" width="88" height="20" font="0">Gammaplex</text>
<text top="120" left="828" width="32" height="20" font="0"> 156 </text>
<text top="143" left="486" width="84" height="20" font="0">Gamunex-c</text>
<text top="143" left="828" width="32" height="20" font="0"> 156 </text>
<text top="167" left="486" width="85" height="20" font="0">Ganciclovir</text>
<text top="167" left="828" width="32" height="20" font="0"> 339 </text>
<text top="191" left="486" width="48" height="20" font="0">Gattex</text>
<text top="191" left="837" width="23" height="20" font="0"> 97 </text>
<text top="215" left="486" width="58" height="20" font="0">Gavreto</text>
<text top="215" left="838" width="23" height="20" font="0">98 </text>
<text top="239" left="486" width="59" height="20" font="0">Gengraf</text>
<text top="239" left="829" width="32" height="20" font="0">339 </text>
<text top="262" left="486" width="82" height="20" font="0">Genotropin</text>
<text top="262" left="829" width="32" height="20" font="0">102 </text>
<text top="286" left="486" width="166" height="20" font="0">Genotropin Miniquick </text>
<text top="286" left="828" width="32" height="20" font="0"> 102 </text>
<text top="310" left="486" width="61" height="20" font="0">Gilenya </text>
<text top="310" left="833" width="28" height="20" font="0">. 99 </text>
<text top="334" left="486" width="54" height="20" font="0">Gilotrif</text>
<text top="334" left="828" width="32" height="20" font="0"> 100 </text>
<text top="358" left="486" width="82" height="20" font="0">Glatiramer </text>
<text top="358" left="828" width="32" height="20" font="0"> 101 </text>
<text top="381" left="486" width="120" height="20" font="0">Granisetron Hcl </text>
<text top="381" left="828" width="32" height="20" font="0"> 339 </text>
<text top="405" left="486" width="132" height="20" font="0">Growth Hormone </text>
<text top="405" left="828" width="32" height="20" font="0"> 102 </text>
<text top="429" left="486" width="109" height="20" font="0">Guanfacine Er </text>
<text top="429" left="828" width="32" height="20" font="0"> 110 </text>
<text top="453" left="486" width="118" height="20" font="0">Guanfacine Hcl </text>
<text top="453" left="828" width="32" height="20" font="0"> 110 </text>
<text top="477" left="486" width="197" height="20" font="0">Guanfacine Hydrochloride </text>
<text top="477" left="828" width="32" height="20" font="0"> 110 </text>
<text top="510" left="486" width="14" height="20" font="12"><i><b>H</b></i></text>
<text top="512" left="500" width="4" height="18" font="13"><i> </i></text>
<text top="542" left="486" width="73" height="20" font="0">Haegarda </text>
<text top="542" left="828" width="32" height="20" font="0"> 105 </text>
<text top="566" left="486" width="63" height="20" font="0">Harvoni </text>
<text top="566" left="828" width="32" height="20" font="0"> 106 </text>
<text top="590" left="486" width="91" height="20" font="0">Hepatamine </text>
<text top="590" left="828" width="32" height="20" font="0"> 339 </text>
<text top="614" left="486" width="136" height="20" font="0">Herceptin Hylecta </text>
<text top="614" left="828" width="32" height="20" font="0"> 107 </text>
<text top="638" left="486" width="58" height="20" font="0">Hetlioz </text>
<text top="638" left="828" width="32" height="20" font="0"> 108 </text>
<text top="661" left="486" width="82" height="20" font="0">Hetlioz Lq </text>
<text top="661" left="828" width="32" height="20" font="0"> 109 </text>
<text top="685" left="486" width="198" height="20" font="0">High Risk Medication - 65 </text>
<text top="685" left="828" width="32" height="20" font="0"> 110 </text>
<text top="709" left="486" width="198" height="20" font="0">Hrm - Anticonvulsants - 65</text>
<text top="709" left="828" width="32" height="20" font="0"> 112 </text>
<text top="733" left="486" width="159" height="20" font="0">Hrm - Hypnotics - 65 </text>
<text top="733" left="828" width="32" height="20" font="0"> 113 </text>
<text top="757" left="486" width="179" height="20" font="0">Hrm - Scopolamine - 65 </text>
<text top="757" left="828" width="32" height="20" font="0"> 115 </text>
<text top="780" left="486" width="174" height="20" font="0">Hrm-antiparkinson - 65 </text>
<text top="780" left="828" width="32" height="20" font="0"> 116 </text>
<text top="804" left="486" width="187" height="20" font="0">Hrm-cyproheptadine - 65 </text>
<text top="804" left="829" width="32" height="20" font="0">118 </text>
<text top="828" left="486" width="135" height="20" font="0">Hrm-doxepin - 65 </text>
<text top="828" left="828" width="32" height="20" font="0"> 119 </text>
<text top="852" left="486" width="162" height="20" font="0">Hrm-hydroxyzine - 65</text>
<text top="852" left="828" width="32" height="20" font="0"> 121 </text>
<text top="876" left="486" width="191" height="20" font="0">Hrm-hydroxyzine Inj - 65 </text>
<text top="876" left="829" width="32" height="20" font="0">123 </text>
<text top="899" left="486" width="174" height="20" font="0">Hrm-promethazine - 65 </text>
<text top="899" left="828" width="32" height="20" font="0"> 125 </text>
<text top="923" left="486" width="175" height="20" font="0">Hrms - Antidepressants </text>
<text top="923" left="829" width="32" height="20" font="0">127 </text>
<text top="947" left="486" width="170" height="20" font="0">Hrms - Carbinoxamine </text>
<text top="947" left="828" width="32" height="20" font="0"> 129 </text>
<text top="971" left="486" width="169" height="20" font="0">Hrms - Clemastine- 65 </text>
<text top="971" left="828" width="32" height="20" font="0"> 130 </text>
<text top="995" left="486" width="164" height="20" font="0">Hrms - Meclizine - 65 </text>
<text top="995" left="828" width="32" height="20" font="0"> 131 </text>
<text top="1018" left="486" width="94" height="20" font="0">Hrms - Tcas </text>
<text top="1018" left="828" width="32" height="20" font="0"> 132 </text>
<text top="1042" left="486" width="264" height="20" font="0">Hrm-skeletal Muscle Relaxants - 65 </text>
<text top="1042" left="828" width="32" height="20" font="0"> 133 </text>
<text top="1066" left="486" width="59" height="20" font="0">Humira </text>
<text top="1066" left="828" width="32" height="20" font="0"> 134 </text>
<text top="1090" left="486" width="374" height="20" font="0">Humira Pediatric Crohns Disease Starter Pack  134 </text>
</page>
<page number="346" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">346 </text>
<text top="96" left="62" width="343" height="20" font="0">Humira Pen ........................................................ </text>
<text top="120" left="270" width="135" height="20" font="0">............................. </text>
<text top="143" left="338" width="67" height="20" font="0">.............. </text>
<text top="167" left="248" width="157" height="20" font="0">.................................. </text>
<text top="191" left="302" width="103" height="20" font="0">...................... </text>
<text top="215" left="257" width="148" height="20" font="0">................................ </text>
<text top="239" left="212" width="193" height="20" font="0">.......................................... </text>
<text top="262" left="293" width="112" height="20" font="0">........................ </text>
<text top="286" left="189" width="180" height="20" font="0">....................................... </text>
<text top="310" left="266" width="104" height="20" font="0">...................... </text>
<text top="334" left="225" width="180" height="20" font="0">....................................... </text>
<text top="358" left="158" width="243" height="20" font="0">......................................................</text>
<text top="381" left="288" width="117" height="20" font="0">......................... </text>
<text top="405" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="471" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="495" left="216" width="198" height="20" font="0">........................................... </text>
<text top="519" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="542" left="185" width="221" height="20" font="0">................................................ </text>
<text top="566" left="112" width="293" height="20" font="0">................................................................ </text>
<text top="590" left="108" width="297" height="20" font="0">................................................................. </text>
<text top="614" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="638" left="194" width="212" height="20" font="0">.............................................. </text>
<text top="661" left="139" width="266" height="20" font="0">.......................................................... </text>
<text top="685" left="180" width="225" height="20" font="0">................................................. </text>
<text top="709" left="257" width="149" height="20" font="0">................................ </text>
<text top="733" left="216" width="189" height="20" font="0">......................................... </text>
<text top="757" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="780" left="243" width="162" height="20" font="0">................................... </text>
<text top="804" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="828" left="103" width="302" height="20" font="0">.................................................................. </text>
<text top="852" left="112" width="293" height="20" font="0">................................................................ </text>
<text top="876" left="112" width="293" height="20" font="0">................................................................ </text>
<text top="899" left="216" width="189" height="20" font="0">......................................... </text>
<text top="923" left="342" width="63" height="20" font="0">............. </text>
<text top="947" left="149" width="257" height="20" font="0">........................................................ </text>
<text top="971" left="248" width="158" height="20" font="0">.................................. </text>
<text top="971" left="103" width="144" height="20" font="0">................................</text>
<text top="995" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="1018" left="176" width="230" height="20" font="0">.................................................. </text>
<text top="1042" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="1066" left="297" width="108" height="20" font="0">....................... </text>
<text top="1066" left="153" width="144" height="20" font="0">................................</text>
<text top="1090" left="139" width="266" height="20" font="0">.......................................................... </text>
<text top="96" left="404" width="32" height="20" font="0">134 </text>
<text top="120" left="62" width="209" height="20" font="0">Humira Pen-cd/uc/hs Starter </text>
<text top="120" left="404" width="32" height="20" font="0">134 </text>
<text top="143" left="62" width="278" height="20" font="0">Humira Pen-pediatric Uc Starter Pack </text>
<text top="143" left="404" width="32" height="20" font="0">134 </text>
<text top="167" left="62" width="188" height="20" font="0">Humira Pen-ps/uv Starter </text>
<text top="167" left="404" width="32" height="20" font="0">134 </text>
<text top="191" left="62" width="244" height="20" font="0">Humulin R U-500 (concentrated) </text>
<text top="191" left="404" width="32" height="20" font="0">339 </text>
<text top="215" left="62" width="197" height="20" font="0">Hydrocodone Bitartrate Er </text>
<text top="215" left="404" width="32" height="20" font="0">150 </text>
<text top="239" left="62" width="154" height="20" font="0">Hydromorphone Hcl </text>
<text top="239" left="404" width="32" height="20" font="0">339 </text>
<text top="262" left="62" width="233" height="20" font="0">Hydromorphone Hydrochloride </text>
<text top="262" left="404" width="32" height="20" font="0">340 </text>
<text top="286" left="62" width="129" height="20" font="0">Hydroxyzine Hcl </text>
<text top="286" left="368" width="68" height="20" font="0">121, 123 </text>
<text top="310" left="62" width="208" height="20" font="0">Hydroxyzine Hydrochloride </text>
<text top="310" left="368" width="68" height="20" font="0">121, 123 </text>
<text top="334" left="62" width="165" height="20" font="0">Hydroxyzine Pamoate </text>
<text top="334" left="404" width="32" height="20" font="0">121 </text>
<text top="358" left="62" width="96" height="20" font="0">Hyperlyte-cr </text>
<text top="358" left="401" width="35" height="20" font="0"> 340 </text>
<text top="381" left="62" width="229" height="20" font="0">Hypnotic-benzodiazepines - 65 </text>
<text top="381" left="404" width="31" height="20" font="0">136 </text>
<text top="405" left="62" width="91" height="20" font="0">Hysingla Er </text>
<text top="405" left="404" width="32" height="20" font="0">150 </text>
<text top="438" left="62" width="7" height="20" font="12"><i><b>I</b></i></text>
<text top="441" left="69" width="4" height="18" font="13"><i> </i></text>
<text top="471" left="62" width="58" height="20" font="0">Ibrance </text>
<text top="471" left="404" width="32" height="20" font="0">137 </text>
<text top="495" left="62" width="158" height="20" font="0">Ibuprofen/famotidine </text>
<text top="495" left="413" width="23" height="20" font="0">70 </text>
<text top="519" left="62" width="68" height="20" font="0">Icatibant </text>
<text top="519" left="404" width="32" height="20" font="0">138 </text>
<text top="542" left="62" width="127" height="20" font="0">Icatibant Acetate </text>
<text top="542" left="404" width="32" height="20" font="0">138 </text>
<text top="566" left="62" width="53" height="20" font="0">Iclusig </text>
<text top="566" left="404" width="32" height="20" font="0">139 </text>
<text top="590" left="62" width="48" height="20" font="0">Idhifa </text>
<text top="590" left="404" width="32" height="20" font="0">140 </text>
<text top="614" left="62" width="66" height="20" font="0">Imatinib </text>
<text top="614" left="404" width="32" height="20" font="0">141 </text>
<text top="638" left="62" width="136" height="20" font="0">Imatinib Mesylate </text>
<text top="638" left="404" width="32" height="20" font="0">141 </text>
<text top="661" left="62" width="78" height="20" font="0">Imbruvica </text>
<text top="661" left="404" width="32" height="20" font="0">142 </text>
<text top="685" left="62" width="119" height="20" font="0">Imipramine Hcl </text>
<text top="685" left="404" width="32" height="20" font="0">127 </text>
<text top="709" left="62" width="198" height="20" font="0">Imipramine Hydrochloride </text>
<text top="709" left="404" width="32" height="20" font="0">127 </text>
<text top="733" left="62" width="155" height="20" font="0">Imipramine Pamoate </text>
<text top="733" left="404" width="32" height="20" font="0">127 </text>
<text top="757" left="62" width="60" height="20" font="0">Imlygic </text>
<text top="757" left="404" width="32" height="20" font="0">145 </text>
<text top="780" left="62" width="182" height="20" font="0">Imovax Rabies (h.d.c.v.) </text>
<text top="780" left="404" width="32" height="20" font="0">340 </text>
<text top="804" left="62" width="63" height="20" font="0">Increlex </text>
<text top="804" left="404" width="32" height="20" font="0">146 </text>
<text top="828" left="62" width="42" height="20" font="0">Inlyta</text>
<text top="828" left="404" width="32" height="20" font="0">147 </text>
<text top="852" left="62" width="51" height="20" font="0">Inqovi </text>
<text top="852" left="404" width="32" height="20" font="0">148 </text>
<text top="876" left="62" width="51" height="20" font="0">Inrebic</text>
<text top="876" left="404" width="32" height="20" font="0">149 </text>
<text top="899" left="62" width="158" height="20" font="0">Ipratropium Bromide </text>
<text top="899" left="404" width="32" height="20" font="0">340 </text>
<text top="923" left="62" width="282" height="20" font="0">Ipratropium Bromide/albuterol Sulfate </text>
<text top="923" left="404" width="32" height="20" font="0">340 </text>
<text top="947" left="62" width="87" height="20" font="0">Ir Before Er</text>
<text top="947" left="404" width="32" height="20" font="0">150 </text>
<text top="971" left="62" width="42" height="20" font="0">Iressa</text>
<text top="971" left="404" width="32" height="20" font="0">152 </text>
<text top="995" left="62" width="67" height="20" font="0">Isolyte-s </text>
<text top="995" left="404" width="32" height="20" font="0">340 </text>
<text top="1018" left="62" width="117" height="20" font="0">Isolyte-s Ph 7.4 </text>
<text top="1018" left="404" width="32" height="20" font="0">340 </text>
<text top="1042" left="62" width="87" height="20" font="0">Isotretinoin </text>
<text top="1042" left="404" width="32" height="20" font="0">153 </text>
<text top="1066" left="62" width="93" height="20" font="0">Itraconazole </text>
<text top="1066" left="404" width="32" height="20" font="0">154 </text>
<text top="1090" left="62" width="78" height="20" font="0">Ivermectin</text>
<text top="1090" left="404" width="32" height="20" font="0">155 </text>
<text top="96" left="486" width="347" height="20" font="0">Ivermectin Tab ................................................... </text>
<text top="120" left="518" width="310" height="20" font="0">.....................................................................</text>
<text top="185" left="531" width="297" height="20" font="0">..................................................................</text>
<text top="251" left="558" width="270" height="20" font="0">............................................................</text>
<text top="275" left="558" width="270" height="20" font="0">............................................................</text>
<text top="298" left="585" width="243" height="20" font="0">......................................................</text>
<text top="322" left="671" width="158" height="20" font="0">...................................</text>
<text top="346" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="370" left="558" width="270" height="20" font="0">............................................................</text>
<text top="394" left="540" width="288" height="20" font="0">................................................................</text>
<text top="417" left="671" width="158" height="20" font="0">...................................</text>
<text top="441" left="671" width="158" height="20" font="0">...................................</text>
<text top="465" left="671" width="158" height="20" font="0">...................................</text>
<text top="489" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="513" left="563" width="265" height="20" font="0">...........................................................</text>
<text top="537" left="536" width="288" height="20" font="0">................................................................</text>
<text top="560" left="558" width="270" height="20" font="0">............................................................</text>
<text top="626" left="558" width="270" height="20" font="0">............................................................</text>
<text top="650" left="635" width="193" height="20" font="0">...........................................</text>
<text top="674" left="554" width="275" height="20" font="0">.............................................................</text>
<text top="697" left="689" width="139" height="20" font="0">...............................</text>
<text top="721" left="684" width="144" height="20" font="0">................................</text>
<text top="745" left="689" width="139" height="20" font="0">...............................</text>
<text top="769" left="689" width="139" height="20" font="0">...............................</text>
<text top="793" left="689" width="139" height="20" font="0">...............................</text>
<text top="816" left="689" width="139" height="20" font="0">...............................</text>
<text top="840" left="680" width="144" height="20" font="0">................................</text>
<text top="864" left="680" width="144" height="20" font="0">................................</text>
<text top="888" left="567" width="261" height="20" font="0">..........................................................</text>
<text top="912" left="626" width="202" height="20" font="0">.............................................</text>
<text top="935" left="581" width="248" height="20" font="0">.......................................................</text>
<text top="959" left="612" width="216" height="20" font="0">................................................</text>
<text top="983" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="1007" left="558" width="234" height="20" font="0">....................................................</text>
<text top="1031" left="590" width="238" height="20" font="0">.....................................................</text>
<text top="1054" left="765" width="63" height="20" font="0">..............</text>
<text top="1054" left="621" width="144" height="20" font="0">................................</text>
<text top="1078" left="639" width="189" height="20" font="0">..........................................</text>
<text top="1102" left="702" width="126" height="20" font="0">............................</text>
<text top="1102" left="558" width="144" height="20" font="0">................................</text>
<text top="537" left="824" width="5" height="20" font="0">.</text>
<text top="840" left="824" width="5" height="20" font="0">.</text>
<text top="864" left="824" width="5" height="20" font="0">.</text>
<text top="96" left="829" width="32" height="20" font="0">155 </text>
<text top="120" left="486" width="33" height="20" font="0">Ivig </text>
<text top="120" left="828" width="32" height="20" font="0"> 156 </text>
<text top="152" left="486" width="9" height="20" font="12"><i><b>J</b></i></text>
<text top="155" left="495" width="4" height="18" font="13"><i> </i></text>
<text top="185" left="486" width="48" height="20" font="0">Jakafi </text>
<text top="185" left="828" width="32" height="20" font="0"> 158 </text>
<text top="218" left="486" width="12" height="20" font="12"><i><b>K</b></i></text>
<text top="221" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="251" left="486" width="73" height="20" font="0">Kalydeco </text>
<text top="251" left="828" width="32" height="20" font="0"> 159 </text>
<text top="275" left="486" width="73" height="20" font="0">Kesimpta </text>
<text top="275" left="828" width="32" height="20" font="0"> 160 </text>
<text top="298" left="486" width="99" height="20" font="0">Ketoconazole</text>
<text top="298" left="828" width="32" height="20" font="0"> 161 </text>
<text top="322" left="486" width="186" height="20" font="0">Ketorolac Tromethamine </text>
<text top="322" left="828" width="32" height="20" font="0"> 110 </text>
<text top="346" left="486" width="71" height="20" font="0">Keytruda </text>
<text top="346" left="828" width="32" height="20" font="0"> 162 </text>
<text top="370" left="486" width="76" height="20" font="0">Khapzory </text>
<text top="370" left="828" width="32" height="20" font="0"> 340 </text>
<text top="394" left="486" width="57" height="20" font="0">Kisqali </text>
<text top="394" left="828" width="32" height="20" font="0"> 163 </text>
<text top="417" left="486" width="188" height="20" font="0">Kisqali Femara 200 Dose </text>
<text top="417" left="828" width="32" height="20" font="0"> 163 </text>
<text top="441" left="486" width="188" height="20" font="0">Kisqali Femara 400 Dose </text>
<text top="441" left="828" width="32" height="20" font="0"> 163 </text>
<text top="465" left="486" width="188" height="20" font="0">Kisqali Femara 600 Dose </text>
<text top="465" left="828" width="32" height="20" font="0"> 163 </text>
<text top="489" left="486" width="60" height="20" font="0">Korlym </text>
<text top="489" left="828" width="32" height="20" font="0"> 165 </text>
<text top="513" left="486" width="77" height="20" font="0">Kristalose </text>
<text top="513" left="828" width="32" height="20" font="0"> 166 </text>
<text top="537" left="486" width="52" height="20" font="0">Kuvan </text>
<text top="537" left="828" width="32" height="20" font="0"> 167 </text>
<text top="560" left="486" width="73" height="20" font="0">Kynmobi </text>
<text top="560" left="828" width="32" height="20" font="0"> 168 </text>
<text top="593" left="486" width="11" height="20" font="12"><i><b>L</b></i></text>
<text top="596" left="497" width="4" height="18" font="13"><i> </i></text>
<text top="626" left="486" width="73" height="20" font="0">Lapatinib </text>
<text top="626" left="828" width="32" height="20" font="0"> 169 </text>
<text top="650" left="486" width="152" height="20" font="0">Lapatinib Ditosylate </text>
<text top="650" left="828" width="32" height="20" font="0"> 169 </text>
<text top="674" left="486" width="68" height="20" font="0">Lenvima </text>
<text top="674" left="828" width="32" height="20" font="0"> 170 </text>
<text top="697" left="486" width="207" height="20" font="0">Lenvima 10 Mg Daily Dose </text>
<text top="697" left="828" width="32" height="20" font="0"> 170 </text>
<text top="721" left="486" width="200" height="20" font="0">Lenvima 12mg Daily Dose </text>
<text top="721" left="828" width="32" height="20" font="0"> 170 </text>
<text top="745" left="486" width="207" height="20" font="0">Lenvima 14 Mg Daily Dose </text>
<text top="745" left="828" width="32" height="20" font="0"> 170 </text>
<text top="769" left="486" width="207" height="20" font="0">Lenvima 18 Mg Daily Dose </text>
<text top="769" left="828" width="32" height="20" font="0"> 170 </text>
<text top="793" left="486" width="207" height="20" font="0">Lenvima 20 Mg Daily Dose </text>
<text top="793" left="828" width="32" height="20" font="0"> 170 </text>
<text top="816" left="486" width="207" height="20" font="0">Lenvima 24 Mg Daily Dose </text>
<text top="816" left="828" width="32" height="20" font="0"> 170 </text>
<text top="840" left="486" width="198" height="20" font="0">Lenvima 4 Mg Daily Dose </text>
<text top="840" left="828" width="32" height="20" font="0"> 170 </text>
<text top="864" left="486" width="198" height="20" font="0">Lenvima 8 Mg Daily Dose </text>
<text top="864" left="828" width="32" height="20" font="0"> 170 </text>
<text top="888" left="486" width="83" height="20" font="0">Leuprolide </text>
<text top="888" left="828" width="32" height="20" font="0"> 171 </text>
<text top="912" left="486" width="143" height="20" font="0">Leuprolide Acetate </text>
<text top="912" left="828" width="32" height="20" font="0"> 171 </text>
<text top="935" left="486" width="96" height="20" font="0">Levalbuterol </text>
<text top="935" left="828" width="32" height="20" font="0"> 340 </text>
<text top="959" left="486" width="127" height="20" font="0">Levalbuterol Hcl </text>
<text top="959" left="828" width="32" height="20" font="0"> 340 </text>
<text top="983" left="486" width="60" height="20" font="0">Libtayo </text>
<text top="983" left="828" width="32" height="20" font="0"> 172 </text>
<text top="1007" left="486" width="72" height="20" font="0">Lidocaine</text>
<text top="1007" left="792" width="68" height="20" font="0"> 173, 287 </text>
<text top="1031" left="486" width="107" height="20" font="0">Lidocaine Hcl </text>
<text top="1031" left="828" width="32" height="20" font="0"> 287 </text>
<text top="1054" left="486" width="136" height="20" font="0">Lidocaine Patches </text>
<text top="1054" left="828" width="32" height="20" font="0"> 173 </text>
<text top="1078" left="486" width="153" height="20" font="0">Lidocaine/prilocaine </text>
<text top="1078" left="828" width="32" height="20" font="0"> 287 </text>
<text top="1102" left="486" width="73" height="20" font="0">Linezolid </text>
<text top="1102" left="828" width="32" height="20" font="0"> 174 </text>
</page>
<page number="347" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">347 </text>
<text top="96" left="62" width="343" height="20" font="0">Lonsurf .............................................................. </text>
<text top="120" left="275" width="131" height="20" font="0">............................ </text>
<text top="120" left="130" width="144" height="20" font="0">................................</text>
<text top="143" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="167" left="275" width="131" height="20" font="0">............................ </text>
<text top="167" left="130" width="144" height="20" font="0">................................</text>
<text top="191" left="243" width="162" height="20" font="0">................................... </text>
<text top="215" left="243" width="162" height="20" font="0">................................... </text>
<text top="239" left="275" width="131" height="20" font="0">............................ </text>
<text top="262" left="275" width="131" height="20" font="0">............................ </text>
<text top="286" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="310" left="225" width="180" height="20" font="0">....................................... </text>
<text top="334" left="275" width="131" height="20" font="0">............................ </text>
<text top="334" left="130" width="144" height="20" font="0">................................</text>
<text top="358" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="423" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="447" left="167" width="239" height="20" font="0">.................................................... </text>
<text top="471" left="243" width="162" height="20" font="0">................................... </text>
<text top="495" left="270" width="135" height="20" font="0">............................. </text>
<text top="495" left="126" width="144" height="20" font="0">................................</text>
<text top="519" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="542" left="284" width="122" height="20" font="0">.......................... </text>
<text top="542" left="139" width="144" height="20" font="0">................................</text>
<text top="566" left="144" width="261" height="20" font="0">......................................................... </text>
<text top="590" left="275" width="131" height="20" font="0">............................ </text>
<text top="614" left="257" width="149" height="20" font="0">................................ </text>
<text top="638" left="279" width="126" height="20" font="0">........................... </text>
<text top="661" left="162" width="243" height="20" font="0">..................................................... </text>
<text top="685" left="266" width="140" height="20" font="0">.............................. </text>
<text top="685" left="121" width="144" height="20" font="0">................................</text>
<text top="709" left="275" width="140" height="20" font="0">.............................. </text>
<text top="733" left="176" width="230" height="20" font="0">.................................................. </text>
<text top="757" left="257" width="149" height="20" font="0">................................ </text>
<text top="780" left="261" width="144" height="20" font="0">............................... </text>
<text top="804" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="828" left="207" width="198" height="20" font="0">........................................... </text>
<text top="852" left="270" width="135" height="20" font="0">............................. </text>
<text top="876" left="342" width="63" height="20" font="0">............. </text>
<text top="899" left="338" width="67" height="20" font="0">.............. </text>
<text top="923" left="288" width="126" height="20" font="0">........................... </text>
<text top="923" left="144" width="144" height="20" font="0">................................</text>
<text top="947" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="971" left="270" width="135" height="20" font="0">............................. </text>
<text top="971" left="126" width="144" height="20" font="0">................................</text>
<text top="995" left="189" width="216" height="20" font="0">............................................... </text>
<text top="1018" left="212" width="193" height="20" font="0">.......................................... </text>
<text top="1042" left="234" width="171" height="20" font="0">..................................... </text>
<text top="1066" left="230" width="175" height="20" font="0">...................................... </text>
<text top="1090" left="275" width="130" height="20" font="0">............................ </text>
<text top="1090" left="131" width="144" height="20" font="0">................................</text>
<text top="96" left="404" width="32" height="20" font="0">175 </text>
<text top="120" left="62" width="70" height="20" font="0">Lorbrena </text>
<text top="120" left="404" width="32" height="20" font="0">176 </text>
<text top="143" left="62" width="77" height="20" font="0">Lumakras </text>
<text top="143" left="404" width="32" height="20" font="0">177 </text>
<text top="167" left="62" width="71" height="20" font="0">Lumoxiti </text>
<text top="167" left="404" width="32" height="20" font="0">178 </text>
<text top="191" left="62" width="183" height="20" font="0">Lupron Depot (1-month) </text>
<text top="191" left="404" width="32" height="20" font="0">180 </text>
<text top="215" left="62" width="183" height="20" font="0">Lupron Depot (3-month) </text>
<text top="215" left="404" width="32" height="20" font="0">180 </text>
<text top="239" left="62" width="215" height="20" font="0">Lupron Depot-ped (1-month) </text>
<text top="239" left="404" width="32" height="20" font="0">179 </text>
<text top="262" left="62" width="215" height="20" font="0">Lupron Depot-ped (3-month) </text>
<text top="262" left="404" width="32" height="20" font="0">179 </text>
<text top="286" left="62" width="89" height="20" font="0">Lupron Ped </text>
<text top="286" left="404" width="32" height="20" font="0">179 </text>
<text top="310" left="62" width="164" height="20" font="0">Lupron-endometriosis </text>
<text top="310" left="404" width="32" height="20" font="0">180 </text>
<text top="334" left="62" width="72" height="20" font="0">Lynparza </text>
<text top="334" left="404" width="32" height="20" font="0">181 </text>
<text top="358" left="62" width="74" height="20" font="0">Lyrica Cr </text>
<text top="358" left="404" width="32" height="20" font="0">182 </text>
<text top="390" left="62" width="16" height="20" font="12"><i><b>M</b></i></text>
<text top="393" left="78" width="4" height="18" font="13"><i> </i></text>
<text top="423" left="62" width="66" height="20" font="0">Mavyret </text>
<text top="423" left="404" width="32" height="20" font="0">183 </text>
<text top="447" left="62" width="107" height="20" font="0">Meclizine Hcl </text>
<text top="447" left="404" width="32" height="20" font="0">131 </text>
<text top="471" left="62" width="181" height="20" font="0">Meclizine Hydrochloride</text>
<text top="471" left="404" width="32" height="20" font="0">131 </text>
<text top="495" left="62" width="68" height="20" font="0">Mekinist </text>
<text top="495" left="404" width="32" height="20" font="0">184 </text>
<text top="519" left="62" width="66" height="20" font="0">Mektovi </text>
<text top="519" left="404" width="32" height="20" font="0">185 </text>
<text top="542" left="62" width="81" height="20" font="0">Melphalan </text>
<text top="542" left="404" width="32" height="20" font="0">340 </text>
<text top="566" left="62" width="86" height="20" font="0">Memantine </text>
<text top="566" left="404" width="32" height="20" font="0">186 </text>
<text top="590" left="62" width="216" height="20" font="0">Memantine Hcl Titration Pak </text>
<text top="590" left="404" width="32" height="20" font="0">186 </text>
<text top="614" left="62" width="196" height="20" font="0">Memantine Hydrochloride </text>
<text top="614" left="404" width="32" height="20" font="0">186 </text>
<text top="638" left="62" width="218" height="20" font="0">Memantine Hydrochloride Er </text>
<text top="638" left="404" width="32" height="20" font="0">186 </text>
<text top="661" left="62" width="104" height="20" font="0">Meprobamate </text>
<text top="661" left="404" width="32" height="20" font="0">110 </text>
<text top="685" left="62" width="61" height="20" font="0">Mepron </text>
<text top="685" left="404" width="32" height="20" font="0">187 </text>
<text top="709" left="62" width="214" height="20" font="0">Metformin Hydrochloride Er </text>
<text top="709" left="413" width="23" height="20" font="0">92 </text>
<text top="733" left="62" width="116" height="20" font="0">Methadone Hcl </text>
<text top="733" left="404" width="32" height="20" font="0">150 </text>
<text top="757" left="62" width="195" height="20" font="0">Methadone Hydrochloride </text>
<text top="757" left="404" width="32" height="20" font="0">150 </text>
<text top="780" left="62" width="201" height="20" font="0">Methscopolamine Bromide </text>
<text top="780" left="404" width="32" height="20" font="0">110 </text>
<text top="804" left="62" width="87" height="20" font="0">Methyldopa</text>
<text top="804" left="404" width="32" height="20" font="0">110 </text>
<text top="828" left="62" width="150" height="20" font="0">Methylprednisolone </text>
<text top="828" left="404" width="32" height="20" font="0">340 </text>
<text top="852" left="62" width="209" height="20" font="0">Methylprednisolone Acetate </text>
<text top="852" left="404" width="32" height="20" font="0">340 </text>
<text top="876" left="62" width="284" height="20" font="0">Methylprednisolone Sodium Succinate </text>
<text top="876" left="404" width="32" height="20" font="0">340 </text>
<text top="899" left="62" width="277" height="20" font="0">Methylprednisolone Sodiumsuccinate </text>
<text top="899" left="404" width="32" height="20" font="0">340 </text>
<text top="923" left="62" width="86" height="20" font="0">Metyrosine </text>
<text top="923" left="413" width="23" height="20" font="0">60 </text>
<text top="947" left="62" width="76" height="20" font="0">Modafinil </text>
<text top="947" left="404" width="32" height="20" font="0">188 </text>
<text top="971" left="62" width="67" height="20" font="0">Monjuvi </text>
<text top="971" left="404" width="32" height="20" font="0">189 </text>
<text top="995" left="62" width="131" height="20" font="0">Morphine Sulfate </text>
<text top="995" left="404" width="32" height="20" font="0">340 </text>
<text top="1018" left="62" width="152" height="20" font="0">Morphine Sulfate Er </text>
<text top="1018" left="404" width="32" height="20" font="0">150 </text>
<text top="1042" left="62" width="175" height="20" font="0">Mycophenolate Mofetil </text>
<text top="1042" left="404" width="32" height="20" font="0">340 </text>
<text top="1066" left="62" width="171" height="20" font="0">Mycophenolic Acid Dr </text>
<text top="1066" left="404" width="31" height="20" font="0">340 </text>
<text top="1090" left="62" width="71" height="20" font="0">Mylotarg </text>
<text top="1090" left="404" width="32" height="20" font="0">190 </text>
<text top="96" left="486" width="347" height="20" font="0">Myorisan ............................................................ </text>
<text top="161" left="752" width="76" height="20" font="0">.................</text>
<text top="185" left="666" width="167" height="20" font="0">.................................... </text>
<text top="209" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="233" left="558" width="270" height="20" font="0">............................................................</text>
<text top="257" left="576" width="252" height="20" font="0">........................................................</text>
<text top="280" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="304" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="328" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="352" left="563" width="265" height="20" font="0">...........................................................</text>
<text top="376" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="399" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="423" left="558" width="270" height="20" font="0">............................................................</text>
<text top="447" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="471" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="495" left="558" width="270" height="20" font="0">............................................................</text>
<text top="560" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="584" left="563" width="265" height="20" font="0">...........................................................</text>
<text top="608" left="626" width="202" height="20" font="0">.............................................</text>
<text top="632" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="656" left="522" width="306" height="20" font="0">....................................................................</text>
<text top="679" left="558" width="270" height="20" font="0">............................................................</text>
<text top="703" left="612" width="216" height="20" font="0">................................................</text>
<text top="727" left="689" width="139" height="20" font="0">...............................</text>
<text top="751" left="612" width="216" height="20" font="0">................................................</text>
<text top="775" left="540" width="288" height="20" font="0">................................................................</text>
<text top="798" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="822" left="540" width="288" height="20" font="0">................................................................</text>
<text top="846" left="662" width="166" height="20" font="0">.....................................</text>
<text top="870" left="554" width="275" height="20" font="0">.............................................................</text>
<text top="894" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="917" left="581" width="247" height="20" font="0">.......................................................</text>
<text top="941" left="711" width="117" height="20" font="0">..........................</text>
<text top="941" left="567" width="144" height="20" font="0">................................</text>
<text top="965" left="599" width="229" height="20" font="0">...................................................</text>
<text top="96" left="829" width="32" height="20" font="0">153 </text>
<text top="129" left="486" width="13" height="20" font="12"><i><b>N</b></i></text>
<text top="131" left="499" width="4" height="18" font="13"><i> </i></text>
<text top="161" left="486" width="269" height="20" font="0">Naproxen/esomeprazole Magnesium </text>
<text top="161" left="828" width="32" height="20" font="0"> 191 </text>
<text top="185" left="486" width="180" height="20" font="0">Naproxen-esomeprazole </text>
<text top="185" left="829" width="32" height="20" font="0">191 </text>
<text top="209" left="486" width="61" height="20" font="0">Natpara </text>
<text top="209" left="828" width="32" height="20" font="0"> 192 </text>
<text top="233" left="486" width="74" height="20" font="0">Nayzilam </text>
<text top="233" left="828" width="32" height="20" font="0"> 193 </text>
<text top="257" left="486" width="93" height="20" font="0">Nephramine </text>
<text top="257" left="828" width="32" height="20" font="0"> 340 </text>
<text top="280" left="486" width="63" height="20" font="0">Nerlynx </text>
<text top="280" left="828" width="32" height="20" font="0"> 194 </text>
<text top="304" left="486" width="65" height="20" font="0">Nexavar </text>
<text top="304" left="828" width="32" height="20" font="0"> 195 </text>
<text top="328" left="486" width="59" height="20" font="0">Ninlaro </text>
<text top="328" left="828" width="32" height="20" font="0"> 196 </text>
<text top="352" left="486" width="79" height="20" font="0">Nitisinone </text>
<text top="352" left="828" width="32" height="20" font="0"> 197 </text>
<text top="376" left="486" width="68" height="20" font="0">Northera </text>
<text top="376" left="828" width="32" height="20" font="0"> 198 </text>
<text top="399" left="486" width="60" height="20" font="0">Nubeqa </text>
<text top="399" left="828" width="32" height="20" font="0"> 199 </text>
<text top="423" left="486" width="73" height="20" font="0">Nuedexta </text>
<text top="423" left="828" width="32" height="20" font="0"> 200 </text>
<text top="447" left="486" width="59" height="20" font="0">Nulojix </text>
<text top="447" left="828" width="32" height="20" font="0"> 340 </text>
<text top="471" left="486" width="70" height="20" font="0">Nuplazid </text>
<text top="471" left="828" width="32" height="20" font="0"> 201 </text>
<text top="495" left="486" width="76" height="20" font="0">Nutrilipid </text>
<text top="495" left="828" width="32" height="20" font="0"> 340 </text>
<text top="528" left="486" width="13" height="20" font="12"><i><b>O</b></i></text>
<text top="530" left="499" width="4" height="18" font="13"><i> </i></text>
<text top="560" left="486" width="69" height="20" font="0">Octagam </text>
<text top="560" left="828" width="32" height="20" font="0"> 156 </text>
<text top="584" left="486" width="80" height="20" font="0">Octreotide </text>
<text top="584" left="828" width="32" height="20" font="0"> 202 </text>
<text top="608" left="486" width="140" height="20" font="0">Octreotide Acetate </text>
<text top="608" left="828" width="32" height="20" font="0"> 202 </text>
<text top="632" left="486" width="67" height="20" font="0">Odomzo </text>
<text top="632" left="828" width="32" height="20" font="0"> 203 </text>
<text top="656" left="486" width="36" height="20" font="0">Ofev</text>
<text top="656" left="828" width="32" height="20" font="0"> 204 </text>
<text top="679" left="486" width="72" height="20" font="0">Oncaspar </text>
<text top="679" left="828" width="32" height="20" font="0"> 205 </text>
<text top="703" left="486" width="127" height="20" font="0">Ondansetron Hcl </text>
<text top="703" left="828" width="32" height="20" font="0"> 340 </text>
<text top="727" left="486" width="206" height="20" font="0">Ondansetron Hydrochloride </text>
<text top="727" left="828" width="32" height="20" font="0"> 340 </text>
<text top="751" left="486" width="128" height="20" font="0">Ondansetron Odt </text>
<text top="751" left="828" width="32" height="20" font="0"> 340 </text>
<text top="775" left="486" width="54" height="20" font="0">Onureg</text>
<text top="775" left="828" width="32" height="20" font="0"> 206 </text>
<text top="798" left="486" width="67" height="20" font="0">Opsumit </text>
<text top="798" left="828" width="32" height="20" font="0"> 207 </text>
<text top="822" left="486" width="55" height="20" font="0">Oracea </text>
<text top="822" left="828" width="32" height="20" font="0"> 208 </text>
<text top="846" left="486" width="180" height="20" font="0">Oral-intranasal Fentanyl </text>
<text top="846" left="828" width="32" height="20" font="0"> 209 </text>
<text top="870" left="486" width="68" height="20" font="0">Orgovyx </text>
<text top="870" left="828" width="32" height="20" font="0"> 210 </text>
<text top="894" left="486" width="68" height="20" font="0">Orkambi </text>
<text top="894" left="828" width="32" height="20" font="0"> 211 </text>
<text top="917" left="486" width="98" height="20" font="0">Oxandrolone </text>
<text top="917" left="828" width="32" height="20" font="0"> 212 </text>
<text top="941" left="486" width="81" height="20" font="0">Oxazepam </text>
<text top="941" left="828" width="32" height="20" font="0"> 213 </text>
<text top="965" left="486" width="114" height="20" font="0">Oxazepam - 65 </text>
<text top="965" left="828" width="32" height="20" font="0"> 213 </text>
<text top="998" left="486" width="11" height="20" font="12"><i><b>P</b></i></text>
<text top="1000" left="497" width="4" height="18" font="13"><i> </i></text>
<text top="1031" left="486" width="347" height="20" font="0">Padcev ................................................................ </text>
<text top="1054" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="1078" left="639" width="189" height="20" font="0">..........................................</text>
<text top="1102" left="689" width="140" height="20" font="0">...............................</text>
<text top="1102" left="545" width="144" height="20" font="0">................................</text>
<text top="1031" left="829" width="32" height="20" font="0">214 </text>
<text top="1054" left="486" width="66" height="20" font="0">Panzyga </text>
<text top="1054" left="828" width="32" height="20" font="0"> 156 </text>
<text top="1078" left="486" width="155" height="20" font="0">Part B Versus Part D </text>
<text top="1078" left="828" width="32" height="20" font="0"> 337 </text>
<text top="1102" left="486" width="62" height="20" font="0">Pegasys </text>
<text top="1102" left="828" width="32" height="20" font="0"> 215 </text>
</page>
<page number="348" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">348 </text>
<text top="96" left="62" width="343" height="20" font="0">Pemazyre ........................................................... </text>
<text top="120" left="131" width="284" height="20" font="0">.............................................................. </text>
<text top="143" left="239" width="167" height="20" font="0">.................................... </text>
<text top="167" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="191" left="257" width="149" height="20" font="0">................................ </text>
<text top="215" left="162" width="243" height="20" font="0">..................................................... </text>
<text top="239" left="225" width="180" height="20" font="0">....................................... </text>
<text top="262" left="171" width="234" height="20" font="0">................................................... </text>
<text top="286" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="310" left="112" width="293" height="20" font="0">................................................................ </text>
<text top="334" left="252" width="153" height="20" font="0">................................. </text>
<text top="358" left="252" width="153" height="20" font="0">................................. </text>
<text top="381" left="252" width="153" height="20" font="0">................................. </text>
<text top="405" left="139" width="266" height="20" font="0">.......................................................... </text>
<text top="429" left="112" width="293" height="20" font="0">................................................................ </text>
<text top="453" left="130" width="275" height="20" font="0">............................................................ </text>
<text top="477" left="130" width="275" height="20" font="0">............................................................ </text>
<text top="501" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="524" left="157" width="248" height="20" font="0">...................................................... </text>
<text top="548" left="297" width="108" height="20" font="0">....................... </text>
<text top="572" left="144" width="261" height="20" font="0">......................................................... </text>
<text top="596" left="207" width="198" height="20" font="0">........................................... </text>
<text top="620" left="139" width="266" height="20" font="0">.......................................................... </text>
<text top="643" left="162" width="243" height="20" font="0">..................................................... </text>
<text top="667" left="130" width="275" height="20" font="0">............................................................ </text>
<text top="691" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="715" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="739" left="153" width="252" height="20" font="0">....................................................... </text>
<text top="762" left="112" width="302" height="20" font="0">.................................................................. </text>
<text top="786" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="810" left="284" width="140" height="20" font="0">.............................. </text>
<text top="810" left="139" width="144" height="20" font="0">................................</text>
<text top="834" left="130" width="275" height="20" font="0">............................................................ </text>
<text top="858" left="194" width="212" height="20" font="0">.............................................. </text>
<text top="881" left="234" width="171" height="20" font="0">..................................... </text>
<text top="905" left="270" width="135" height="20" font="0">............................. </text>
<text top="929" left="157" width="248" height="20" font="0">...................................................... </text>
<text top="953" left="252" width="153" height="20" font="0">................................. </text>
<text top="953" left="108" width="144" height="20" font="0">................................</text>
<text top="977" left="185" width="221" height="20" font="0">................................................ </text>
<text top="1000" left="148" width="257" height="20" font="0">........................................................ </text>
<text top="1066" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="1090" left="239" width="167" height="20" font="0">.................................... </text>
<text top="96" left="404" width="32" height="20" font="0">216 </text>
<text top="120" left="62" width="69" height="20" font="0">Pennsaid </text>
<text top="120" left="413" width="23" height="20" font="0">66 </text>
<text top="143" left="62" width="178" height="20" font="0">Pentamidine Isethionate </text>
<text top="143" left="404" width="32" height="20" font="0">340 </text>
<text top="167" left="62" width="62" height="20" font="0">Pepaxto </text>
<text top="167" left="404" width="32" height="20" font="0">217 </text>
<text top="191" left="62" width="195" height="20" font="0">Perphenazine/amitriptyline</text>
<text top="191" left="404" width="32" height="20" font="0">110 </text>
<text top="215" left="62" width="104" height="20" font="0">Phenobarbital </text>
<text top="215" left="404" width="32" height="20" font="0">112 </text>
<text top="239" left="62" width="165" height="20" font="0">Phenobarbital Sodium </text>
<text top="239" left="404" width="32" height="20" font="0">112 </text>
<text top="262" left="62" width="114" height="20" font="0">Phenylbutyrate </text>
<text top="262" left="404" width="32" height="20" font="0">218 </text>
<text top="286" left="62" width="57" height="20" font="0">Phesgo </text>
<text top="286" left="404" width="32" height="20" font="0">219 </text>
<text top="310" left="62" width="51" height="20" font="0">Piqray </text>
<text top="310" left="404" width="32" height="20" font="0">220 </text>
<text top="334" left="62" width="192" height="20" font="0">Piqray 200mg Daily Dose </text>
<text top="334" left="404" width="32" height="20" font="0">220 </text>
<text top="358" left="62" width="192" height="20" font="0">Piqray 250mg Daily Dose </text>
<text top="358" left="404" width="32" height="20" font="0">220 </text>
<text top="381" left="62" width="192" height="20" font="0">Piqray 300mg Daily Dose </text>
<text top="381" left="404" width="32" height="20" font="0">220 </text>
<text top="405" left="62" width="80" height="20" font="0">Plenamine </text>
<text top="405" left="404" width="32" height="20" font="0">341 </text>
<text top="429" left="62" width="51" height="20" font="0">Polivy </text>
<text top="429" left="404" width="32" height="20" font="0">221 </text>
<text top="453" left="62" width="72" height="20" font="0">Pomalyst </text>
<text top="453" left="404" width="32" height="20" font="0">222 </text>
<text top="477" left="62" width="72" height="20" font="0">Poteligeo </text>
<text top="477" left="404" width="32" height="20" font="0">223 </text>
<text top="501" left="62" width="60" height="20" font="0">Praluent</text>
<text top="501" left="404" width="32" height="20" font="0">224 </text>
<text top="524" left="62" width="99" height="20" font="0">Prednisolone </text>
<text top="524" left="404" width="32" height="20" font="0">341 </text>
<text top="548" left="62" width="238" height="20" font="0">Prednisolone Sodium Phosphate </text>
<text top="548" left="404" width="32" height="20" font="0">341 </text>
<text top="572" left="62" width="85" height="20" font="0">Prednisone </text>
<text top="572" left="404" width="32" height="20" font="0">341 </text>
<text top="596" left="62" width="147" height="20" font="0">Prednisone Intensol </text>
<text top="596" left="404" width="32" height="20" font="0">341 </text>
<text top="620" left="62" width="81" height="20" font="0">Pregabalin </text>
<text top="620" left="404" width="32" height="20" font="0">225 </text>
<text top="643" left="62" width="103" height="20" font="0">Pregabalin Er </text>
<text top="643" left="404" width="32" height="20" font="0">182 </text>
<text top="667" left="62" width="71" height="20" font="0">Premasol </text>
<text top="667" left="404" width="32" height="20" font="0">341 </text>
<text top="691" left="62" width="87" height="20" font="0">Pretomanid </text>
<text top="691" left="404" width="32" height="20" font="0">226 </text>
<text top="715" left="62" width="66" height="20" font="0">Privigen </text>
<text top="715" left="404" width="32" height="20" font="0">156 </text>
<text top="739" left="62" width="95" height="20" font="0">Procalamine </text>
<text top="739" left="404" width="32" height="20" font="0">341 </text>
<text top="762" left="62" width="53" height="20" font="0">Procrit </text>
<text top="762" left="413" width="23" height="20" font="0">77 </text>
<text top="786" left="62" width="59" height="20" font="0">Prograf </text>
<text top="786" left="404" width="32" height="20" font="0">341 </text>
<text top="810" left="62" width="78" height="20" font="0">Prolastin-c</text>
<text top="810" left="422" width="14" height="20" font="0">9 </text>
<text top="834" left="62" width="72" height="20" font="0">Promacta </text>
<text top="834" left="404" width="32" height="20" font="0">227 </text>
<text top="858" left="62" width="134" height="20" font="0">Promethazine Hcl </text>
<text top="858" left="404" width="32" height="20" font="0">125 </text>
<text top="881" left="62" width="176" height="20" font="0">Promethazine Hcl Plain </text>
<text top="881" left="404" width="32" height="20" font="0">125 </text>
<text top="905" left="62" width="208" height="20" font="0">Promethazine Hydrochloride</text>
<text top="905" left="404" width="32" height="20" font="0">125 </text>
<text top="929" left="62" width="99" height="20" font="0">Promethegan </text>
<text top="929" left="404" width="32" height="20" font="0">125 </text>
<text top="953" left="62" width="50" height="20" font="0">Prosol </text>
<text top="953" left="404" width="32" height="20" font="0">341 </text>
<text top="977" left="62" width="126" height="20" font="0">Protriptyline Hcl </text>
<text top="977" left="404" width="32" height="20" font="0">132 </text>
<text top="1000" left="62" width="90" height="20" font="0">Pulmozyme </text>
<text top="1000" left="404" width="32" height="20" font="0">230 </text>
<text top="1033" left="62" width="13" height="20" font="12"><i><b>Q</b></i></text>
<text top="1036" left="75" width="4" height="18" font="13"><i> </i></text>
<text top="1066" left="62" width="62" height="20" font="0">Qinlock </text>
<text top="1066" left="404" width="32" height="20" font="0">231 </text>
<text top="1090" left="62" width="177" height="20" font="0">Quetiapine Fumarate Er </text>
<text top="1090" left="404" width="32" height="20" font="0">232 </text>
<text top="96" left="486" width="347" height="20" font="0">Quetiapine Xr ..................................................... </text>
<text top="120" left="603" width="225" height="20" font="0">..................................................</text>
<text top="185" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="209" left="608" width="220" height="20" font="0">.................................................</text>
<text top="233" left="558" width="270" height="20" font="0">............................................................</text>
<text top="257" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="280" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="304" left="558" width="270" height="20" font="0">............................................................</text>
<text top="328" left="540" width="288" height="20" font="0">................................................................</text>
<text top="352" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="376" left="599" width="229" height="20" font="0">...................................................</text>
<text top="399" left="563" width="265" height="20" font="0">...........................................................</text>
<text top="423" left="558" width="270" height="20" font="0">............................................................</text>
<text top="447" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="471" left="572" width="265" height="20" font="0">...........................................................</text>
<text top="495" left="558" width="270" height="20" font="0">............................................................</text>
<text top="519" left="540" width="288" height="20" font="0">................................................................</text>
<text top="584" left="540" width="288" height="20" font="0">................................................................</text>
<text top="608" left="585" width="243" height="20" font="0">......................................................</text>
<text top="632" left="603" width="225" height="20" font="0">..................................................</text>
<text top="656" left="648" width="180" height="20" font="0">........................................</text>
<text top="679" left="698" width="131" height="20" font="0">.............................</text>
<text top="703" left="545" width="284" height="20" font="0">...............................................................</text>
<text top="727" left="558" width="270" height="20" font="0">............................................................</text>
<text top="751" left="581" width="247" height="20" font="0">.......................................................</text>
<text top="775" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="798" left="558" width="270" height="20" font="0">............................................................</text>
<text top="822" left="612" width="216" height="20" font="0">................................................</text>
<text top="846" left="558" width="270" height="20" font="0">............................................................</text>
<text top="870" left="540" width="288" height="20" font="0">................................................................</text>
<text top="894" left="540" width="288" height="20" font="0">................................................................</text>
<text top="917" left="572" width="256" height="20" font="0">.........................................................</text>
<text top="941" left="657" width="171" height="20" font="0">......................................</text>
<text top="965" left="617" width="212" height="20" font="0">...............................................</text>
<text top="989" left="558" width="270" height="20" font="0">............................................................</text>
<text top="1013" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="1036" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="1060" left="540" width="288" height="20" font="0">................................................................</text>
<text top="1084" left="693" width="135" height="20" font="0">..............................</text>
<text top="1084" left="549" width="144" height="20" font="0">................................</text>
<text top="96" left="829" width="32" height="20" font="0">232 </text>
<text top="120" left="486" width="118" height="20" font="0">Quinine Sulfate </text>
<text top="120" left="828" width="32" height="20" font="0"> 233 </text>
<text top="152" left="486" width="12" height="20" font="12"><i><b>R</b></i></text>
<text top="155" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="185" left="486" width="69" height="20" font="0">Rabavert </text>
<text top="185" left="828" width="32" height="20" font="0"> 341 </text>
<text top="209" left="486" width="122" height="20" font="0">Recombivax Hb </text>
<text top="209" left="828" width="32" height="20" font="0"> 341 </text>
<text top="233" left="486" width="73" height="20" font="0">Regranex </text>
<text top="233" left="828" width="32" height="20" font="0"> 234 </text>
<text top="257" left="486" width="69" height="20" font="0">Retevmo </text>
<text top="257" left="828" width="32" height="20" font="0"> 235 </text>
<text top="280" left="486" width="71" height="20" font="0">Revlimid </text>
<text top="280" left="828" width="32" height="20" font="0"> 236 </text>
<text top="304" left="486" width="73" height="20" font="0">Rezurock </text>
<text top="304" left="828" width="32" height="20" font="0"> 238 </text>
<text top="328" left="486" width="58" height="20" font="0">Rinvoq </text>
<text top="328" left="828" width="32" height="20" font="0"> 239 </text>
<text top="352" left="486" width="61" height="20" font="0">Rituxan </text>
<text top="352" left="828" width="32" height="20" font="0"> 241 </text>
<text top="376" left="486" width="117" height="20" font="0">Rituxan Hycela </text>
<text top="376" left="828" width="32" height="20" font="0"> 240 </text>
<text top="399" left="486" width="80" height="20" font="0">Rituximab </text>
<text top="399" left="828" width="32" height="20" font="0"> 241 </text>
<text top="423" left="486" width="76" height="20" font="0">Rozlytrek </text>
<text top="423" left="828" width="32" height="20" font="0"> 244 </text>
<text top="447" left="486" width="64" height="20" font="0">Rubraca </text>
<text top="447" left="828" width="32" height="20" font="0"> 245 </text>
<text top="471" left="486" width="89" height="20" font="0">Rufinamide </text>
<text top="471" left="837" width="23" height="20" font="0"> 19 </text>
<text top="495" left="486" width="72" height="20" font="0">Ruxience </text>
<text top="495" left="828" width="32" height="20" font="0"> 241 </text>
<text top="519" left="486" width="57" height="20" font="0">Rydapt </text>
<text top="519" left="828" width="32" height="20" font="0"> 246 </text>
<text top="551" left="486" width="10" height="20" font="12"><i><b>S</b></i></text>
<text top="554" left="496" width="4" height="18" font="13"><i> </i></text>
<text top="584" left="486" width="54" height="20" font="0">Sajazir </text>
<text top="584" left="828" width="32" height="20" font="0"> 138 </text>
<text top="608" left="486" width="100" height="20" font="0">Sandimmune </text>
<text top="608" left="828" width="32" height="20" font="0"> 341 </text>
<text top="632" left="486" width="118" height="20" font="0">Sandostatin Lar </text>
<text top="632" left="828" width="32" height="20" font="0"> 247 </text>
<text top="656" left="486" width="166" height="20" font="0">Sandostatin Lar Depot </text>
<text top="656" left="828" width="32" height="20" font="0"> 247 </text>
<text top="679" left="486" width="212" height="20" font="0">Sapropterin Dihydrochloride </text>
<text top="679" left="828" width="32" height="20" font="0"> 167 </text>
<text top="703" left="486" width="61" height="20" font="0">Sarclisa </text>
<text top="703" left="828" width="32" height="20" font="0"> 249 </text>
<text top="727" left="486" width="72" height="20" font="0">Scemblix </text>
<text top="727" left="828" width="32" height="20" font="0"> 250 </text>
<text top="751" left="486" width="98" height="20" font="0">Scopolamine </text>
<text top="751" left="828" width="32" height="20" font="0"> 115 </text>
<text top="775" left="486" width="64" height="20" font="0">Signifor </text>
<text top="775" left="828" width="32" height="20" font="0"> 251 </text>
<text top="798" left="486" width="75" height="20" font="0">Sildenafil </text>
<text top="798" left="828" width="32" height="20" font="0"> 252 </text>
<text top="822" left="486" width="128" height="20" font="0">Sildenafil Citrate </text>
<text top="822" left="828" width="32" height="20" font="0"> 252 </text>
<text top="846" left="486" width="75" height="20" font="0">Sirolimus </text>
<text top="846" left="828" width="32" height="20" font="0"> 341 </text>
<text top="870" left="486" width="55" height="20" font="0">Sirturo </text>
<text top="870" left="828" width="32" height="20" font="0"> 253 </text>
<text top="894" left="486" width="57" height="20" font="0">Skyrizi </text>
<text top="894" left="828" width="32" height="20" font="0"> 254 </text>
<text top="917" left="486" width="88" height="20" font="0">Skyrizi Pen </text>
<text top="917" left="828" width="32" height="20" font="0"> 254 </text>
<text top="941" left="486" width="174" height="20" font="0">Sodium Phenylbutyrate </text>
<text top="941" left="828" width="32" height="20" font="0"> 218 </text>
<text top="965" left="486" width="130" height="20" font="0">Somatuline Depot</text>
<text top="965" left="828" width="32" height="20" font="0"> 255 </text>
<text top="989" left="486" width="73" height="20" font="0">Somavert </text>
<text top="989" left="828" width="32" height="20" font="0"> 256 </text>
<text top="1013" left="486" width="61" height="20" font="0">Spritam </text>
<text top="1013" left="828" width="32" height="20" font="0"> 257 </text>
<text top="1036" left="486" width="59" height="20" font="0">Sprycel </text>
<text top="1036" left="828" width="32" height="20" font="0"> 258 </text>
<text top="1060" left="486" width="54" height="20" font="0">Stelara </text>
<text top="1060" left="828" width="32" height="20" font="0"> 259 </text>
<text top="1084" left="486" width="64" height="20" font="0">Stivarga </text>
<text top="1084" left="828" width="32" height="20" font="0"> 260 </text>
</page>
<page number="349" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">349 </text>
<text top="96" left="62" width="343" height="20" font="0">Sunitinib Malate ................................................ </text>
<text top="120" left="108" width="297" height="20" font="0">................................................................. </text>
<text top="143" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="167" left="176" width="229" height="20" font="0">.................................................. </text>
<text top="191" left="167" width="238" height="20" font="0">.................................................... </text>
<text top="215" left="140" width="266" height="20" font="0">.......................................................... </text>
<text top="239" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="304" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="328" left="144" width="261" height="20" font="0">......................................................... </text>
<text top="352" left="131" width="275" height="20" font="0">............................................................ </text>
<text top="376" left="171" width="234" height="20" font="0">................................................... </text>
<text top="399" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="423" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="447" left="99" width="306" height="20" font="0">................................................................... </text>
<text top="471" left="131" width="275" height="20" font="0">............................................................ </text>
<text top="495" left="131" width="275" height="20" font="0">............................................................ </text>
<text top="519" left="189" width="216" height="20" font="0">............................................... </text>
<text top="542" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="566" left="144" width="261" height="20" font="0">......................................................... </text>
<text top="590" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="614" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="638" left="108" width="297" height="20" font="0">................................................................. </text>
<text top="661" left="275" width="131" height="20" font="0">............................ </text>
<text top="661" left="130" width="144" height="20" font="0">................................</text>
<text top="685" left="130" width="275" height="20" font="0">............................................................ </text>
<text top="709" left="225" width="180" height="20" font="0">....................................... </text>
<text top="733" left="153" width="216" height="20" font="0">............................................... </text>
<text top="757" left="230" width="176" height="20" font="0">...................................... </text>
<text top="780" left="121" width="284" height="20" font="0">.............................................................. </text>
<text top="804" left="279" width="126" height="20" font="0">........................... </text>
<text top="804" left="135" width="144" height="20" font="0">................................</text>
<text top="828" left="157" width="248" height="20" font="0">...................................................... </text>
<text top="852" left="234" width="171" height="20" font="0">..................................... </text>
<text top="876" left="261" width="144" height="20" font="0">............................... </text>
<text top="899" left="234" width="171" height="20" font="0">..................................... </text>
<text top="923" left="257" width="149" height="20" font="0">................................ </text>
<text top="947" left="203" width="203" height="20" font="0">............................................ </text>
<text top="971" left="279" width="126" height="20" font="0">........................... </text>
<text top="995" left="167" width="239" height="20" font="0">.................................................... </text>
<text top="1018" left="279" width="126" height="20" font="0">........................... </text>
<text top="1018" left="135" width="144" height="20" font="0">................................</text>
<text top="1042" left="185" width="221" height="20" font="0">................................................ </text>
<text top="1066" left="266" width="140" height="20" font="0">.............................. </text>
<text top="1066" left="121" width="144" height="20" font="0">................................</text>
<text top="1090" left="153" width="252" height="20" font="0">....................................................... </text>
<text top="96" left="404" width="32" height="20" font="0">261 </text>
<text top="120" left="62" width="50" height="20" font="0">Sutent </text>
<text top="120" left="404" width="32" height="20" font="0">261 </text>
<text top="143" left="62" width="57" height="20" font="0">Symlin </text>
<text top="143" left="404" width="32" height="20" font="0">262 </text>
<text top="167" left="62" width="114" height="20" font="0">Symlinpen 120 </text>
<text top="167" left="404" width="32" height="20" font="0">262 </text>
<text top="191" left="62" width="105" height="20" font="0">Symlinpen 60 </text>
<text top="191" left="404" width="32" height="20" font="0">262 </text>
<text top="215" left="62" width="79" height="20" font="0">Sympazan </text>
<text top="215" left="404" width="32" height="20" font="0">263 </text>
<text top="239" left="62" width="61" height="20" font="0">Synribo </text>
<text top="239" left="404" width="32" height="20" font="0">264 </text>
<text top="271" left="62" width="11" height="20" font="12"><i><b>T</b></i></text>
<text top="274" left="73" width="4" height="18" font="13"><i> </i></text>
<text top="304" left="62" width="67" height="20" font="0">Tabrecta </text>
<text top="304" left="404" width="32" height="20" font="0">265 </text>
<text top="328" left="62" width="86" height="20" font="0">Tacrolimus </text>
<text top="328" left="404" width="32" height="20" font="0">341 </text>
<text top="352" left="62" width="69" height="20" font="0">Tadalafil </text>
<text top="352" left="404" width="32" height="20" font="0">266 </text>
<text top="376" left="62" width="112" height="20" font="0">Tadalafil (pah) </text>
<text top="376" left="404" width="32" height="20" font="0">266 </text>
<text top="399" left="62" width="62" height="20" font="0">Tafinlar </text>
<text top="399" left="404" width="32" height="20" font="0">267 </text>
<text top="423" left="62" width="67" height="20" font="0">Tagrisso </text>
<text top="423" left="404" width="32" height="20" font="0">268 </text>
<text top="447" left="62" width="41" height="20" font="0">Taltz </text>
<text top="447" left="404" width="32" height="20" font="0">269 </text>
<text top="471" left="62" width="70" height="20" font="0">Talzenna </text>
<text top="471" left="404" width="32" height="20" font="0">270 </text>
<text top="495" left="62" width="71" height="20" font="0">Targretin </text>
<text top="495" left="404" width="32" height="20" font="0">271 </text>
<text top="519" left="62" width="131" height="20" font="0">Targretin Topical </text>
<text top="519" left="404" width="32" height="20" font="0">271 </text>
<text top="542" left="62" width="61" height="20" font="0">Tasigna </text>
<text top="542" left="404" width="32" height="20" font="0">272 </text>
<text top="566" left="62" width="84" height="20" font="0">Tazarotene </text>
<text top="566" left="404" width="32" height="20" font="0">273 </text>
<text top="590" left="62" width="62" height="20" font="0">Tazorac </text>
<text top="590" left="404" width="32" height="20" font="0">273 </text>
<text top="614" left="62" width="68" height="20" font="0">Tazverik </text>
<text top="614" left="404" width="32" height="20" font="0">274 </text>
<text top="638" left="62" width="50" height="20" font="0">Tdvax </text>
<text top="638" left="404" width="32" height="20" font="0">341 </text>
<text top="661" left="62" width="69" height="20" font="0">Tecentriq</text>
<text top="661" left="404" width="32" height="20" font="0">275 </text>
<text top="685" left="62" width="69" height="20" font="0">Tecfidera</text>
<text top="685" left="404" width="32" height="20" font="0">277 </text>
<text top="709" left="62" width="165" height="20" font="0">Tecfidera Starter Pack </text>
<text top="709" left="404" width="32" height="20" font="0">277 </text>
<text top="733" left="62" width="92" height="20" font="0">Temazepam </text>
<text top="733" left="368" width="68" height="20" font="0">136, 278 </text>
<text top="757" left="62" width="171" height="20" font="0">Temazepam 30mg - 65 </text>
<text top="757" left="404" width="32" height="20" font="0">278 </text>
<text top="780" left="62" width="62" height="20" font="0">Tenivac </text>
<text top="780" left="404" width="32" height="20" font="0">341 </text>
<text top="804" left="62" width="77" height="20" font="0">Tepmetko </text>
<text top="804" left="404" width="32" height="20" font="0">279 </text>
<text top="828" left="62" width="96" height="20" font="0">Testosterone </text>
<text top="828" left="404" width="32" height="20" font="0">288 </text>
<text top="852" left="62" width="175" height="20" font="0">Testosterone Cypionate </text>
<text top="852" left="404" width="32" height="20" font="0">280 </text>
<text top="876" left="62" width="200" height="20" font="0">Testosterone Cypionate Inj </text>
<text top="876" left="404" width="32" height="20" font="0">280 </text>
<text top="899" left="62" width="173" height="20" font="0">Testosterone Enanthate </text>
<text top="899" left="404" width="32" height="20" font="0">281 </text>
<text top="923" left="62" width="197" height="20" font="0">Testosterone Enanthate Inj </text>
<text top="923" left="404" width="32" height="20" font="0">281 </text>
<text top="947" left="62" width="143" height="20" font="0">Testosterone Pump </text>
<text top="947" left="404" width="32" height="20" font="0">288 </text>
<text top="971" left="62" width="222" height="20" font="0">Testosterone Topical Solution </text>
<text top="971" left="404" width="32" height="20" font="0">288 </text>
<text top="995" left="62" width="107" height="20" font="0">Tetrabenazine </text>
<text top="995" left="404" width="32" height="20" font="0">282 </text>
<text top="1018" left="62" width="75" height="20" font="0">Thalomid </text>
<text top="1018" left="404" width="32" height="20" font="0">283 </text>
<text top="1042" left="62" width="127" height="20" font="0">Thioridazine Hcl </text>
<text top="1042" left="404" width="32" height="20" font="0">110 </text>
<text top="1066" left="62" width="64" height="20" font="0">Tibsovo </text>
<text top="1066" left="404" width="32" height="20" font="0">284 </text>
<text top="1090" left="62" width="92" height="20" font="0">Tobramycin </text>
<text top="1090" left="404" width="32" height="20" font="0">285 </text>
<text top="96" left="486" width="347" height="20" font="0">Topical Doxepin ................................................. </text>
<text top="120" left="621" width="207" height="20" font="0">..............................................</text>
<text top="143" left="648" width="180" height="20" font="0">........................................</text>
<text top="167" left="617" width="212" height="20" font="0">...............................................</text>
<text top="191" left="572" width="256" height="20" font="0">.........................................................</text>
<text top="215" left="626" width="202" height="20" font="0">.............................................</text>
<text top="239" left="608" width="221" height="20" font="0">.................................................</text>
<text top="262" left="549" width="288" height="20" font="0">................................................................</text>
<text top="286" left="612" width="216" height="20" font="0">................................................</text>
<text top="310" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="334" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="358" left="603" width="225" height="20" font="0">..................................................</text>
<text top="381" left="572" width="256" height="20" font="0">.........................................................</text>
<text top="405" left="599" width="229" height="20" font="0">...................................................</text>
<text top="429" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="453" left="653" width="175" height="20" font="0">.......................................</text>
<text top="477" left="698" width="131" height="20" font="0">.............................</text>
<text top="501" left="563" width="266" height="20" font="0">...........................................................</text>
<text top="524" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="548" left="662" width="166" height="20" font="0">.....................................</text>
<text top="572" left="639" width="189" height="20" font="0">..........................................</text>
<text top="596" left="716" width="113" height="20" font="0">.........................</text>
<text top="620" left="545" width="284" height="20" font="0">...............................................................</text>
<text top="643" left="743" width="85" height="20" font="0">...................</text>
<text top="667" left="653" width="175" height="20" font="0">.......................................</text>
<text top="691" left="554" width="275" height="20" font="0">.............................................................</text>
<text top="715" left="576" width="252" height="20" font="0">........................................................</text>
<text top="739" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="762" left="540" width="288" height="20" font="0">................................................................</text>
<text top="786" left="540" width="288" height="20" font="0">................................................................</text>
<text top="852" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="876" left="540" width="288" height="20" font="0">................................................................</text>
<text top="941" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="965" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="989" left="635" width="202" height="20" font="0">.............................................</text>
<text top="1013" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="1036" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="1060" left="707" width="121" height="20" font="0">...........................</text>
<text top="1084" left="662" width="166" height="20" font="0">.....................................</text>
<text top="1060" left="563" width="144" height="20" font="0">................................</text>
<text top="96" left="829" width="32" height="20" font="0">286 </text>
<text top="120" left="486" width="136" height="20" font="0">Topical Lidocaine </text>
<text top="120" left="828" width="32" height="20" font="0"> 287 </text>
<text top="143" left="486" width="163" height="20" font="0">Topical Testosterones </text>
<text top="143" left="828" width="32" height="20" font="0"> 288 </text>
<text top="167" left="486" width="131" height="20" font="0">Topical Tretinoin </text>
<text top="167" left="828" width="32" height="20" font="0"> 289 </text>
<text top="191" left="486" width="88" height="20" font="0">Toremifene </text>
<text top="191" left="828" width="32" height="20" font="0"> 290 </text>
<text top="215" left="486" width="142" height="20" font="0">Toremifene Citrate </text>
<text top="215" left="828" width="32" height="20" font="0"> 290 </text>
<text top="239" left="486" width="124" height="20" font="0">Tpn Electrolytes </text>
<text top="239" left="828" width="32" height="20" font="0"> 341 </text>
<text top="262" left="486" width="64" height="20" font="0">Tracleer </text>
<text top="262" left="837" width="23" height="20" font="0"> 28 </text>
<text top="286" left="486" width="126" height="20" font="0">Tramadol Hcl Er </text>
<text top="286" left="828" width="32" height="20" font="0"> 150 </text>
<text top="310" left="486" width="63" height="20" font="0">Travasol</text>
<text top="310" left="828" width="32" height="20" font="0"> 342 </text>
<text top="334" left="486" width="60" height="20" font="0">Trelstar </text>
<text top="334" left="828" width="32" height="20" font="0"> 291 </text>
<text top="358" left="486" width="121" height="20" font="0">Trelstar Mixject </text>
<text top="358" left="828" width="32" height="20" font="0"> 291 </text>
<text top="381" left="486" width="89" height="20" font="0">Treprostinil </text>
<text top="381" left="828" width="32" height="20" font="0"> 292 </text>
<text top="405" left="486" width="114" height="20" font="0">Treprostinil Inj </text>
<text top="405" left="828" width="32" height="20" font="0"> 292 </text>
<text top="429" left="486" width="71" height="20" font="0">Tretinoin </text>
<text top="429" left="828" width="32" height="20" font="0"> 289 </text>
<text top="453" left="486" width="167" height="20" font="0">Tretinoin Microsphere </text>
<text top="453" left="828" width="32" height="20" font="0"> 289 </text>
<text top="477" left="486" width="213" height="20" font="0">Tretinoin Microsphere Pump </text>
<text top="477" left="828" width="32" height="20" font="0"> 289 </text>
<text top="501" left="486" width="78" height="20" font="0">Triazolam </text>
<text top="501" left="828" width="32" height="20" font="0"> 136 </text>
<text top="524" left="486" width="70" height="20" font="0">Trientine </text>
<text top="524" left="828" width="32" height="20" font="0"> 293 </text>
<text top="548" left="486" width="180" height="20" font="0">Trientine Hydrochloride </text>
<text top="548" left="828" width="32" height="20" font="0"> 293 </text>
<text top="572" left="486" width="155" height="20" font="0">Trihexyphenidyl Hcl </text>
<text top="572" left="828" width="32" height="20" font="0"> 116 </text>
<text top="596" left="486" width="234" height="20" font="0">Trihexyphenidyl Hydrochloride </text>
<text top="596" left="828" width="32" height="20" font="0"> 116 </text>
<text top="620" left="486" width="62" height="20" font="0">Trikafta </text>
<text top="620" left="828" width="32" height="20" font="0"> 294 </text>
<text top="643" left="486" width="259" height="20" font="0">Trimethobenzamide Hydrochloride </text>
<text top="643" left="828" width="32" height="20" font="0"> 110 </text>
<text top="667" left="486" width="167" height="20" font="0">Trimipramine Maleate </text>
<text top="667" left="828" width="32" height="20" font="0"> 132 </text>
<text top="691" left="486" width="70" height="20" font="0">Trodelvy </text>
<text top="691" left="828" width="32" height="20" font="0"> 295 </text>
<text top="715" left="486" width="92" height="20" font="0">Trophamine </text>
<text top="715" left="828" width="32" height="20" font="0"> 342 </text>
<text top="739" left="486" width="69" height="20" font="0">Truseltiq </text>
<text top="739" left="828" width="32" height="20" font="0"> 296 </text>
<text top="762" left="486" width="58" height="20" font="0">Tukysa </text>
<text top="762" left="828" width="32" height="20" font="0"> 297 </text>
<text top="786" left="486" width="58" height="20" font="0">Turalio </text>
<text top="786" left="828" width="32" height="20" font="0"> 298 </text>
<text top="819" left="486" width="13" height="20" font="12"><i><b>U</b></i></text>
<text top="821" left="499" width="4" height="18" font="13"><i> </i></text>
<text top="852" left="486" width="63" height="20" font="0">Ubrelvy </text>
<text top="852" left="828" width="32" height="20" font="0"> 299 </text>
<text top="876" left="486" width="54" height="20" font="0">Ukoniq</text>
<text top="876" left="828" width="32" height="20" font="0"> 300 </text>
<text top="908" left="486" width="12" height="20" font="12"><i><b>V</b></i></text>
<text top="911" left="498" width="4" height="18" font="13"><i> </i></text>
<text top="941" left="486" width="63" height="20" font="0">Valchlor</text>
<text top="941" left="828" width="32" height="20" font="0"> 301 </text>
<text top="965" left="486" width="61" height="20" font="0">Valtoco </text>
<text top="965" left="828" width="32" height="20" font="0"> 302 </text>
<text top="989" left="486" width="150" height="20" font="0">Varenicline Tartrate </text>
<text top="989" left="837" width="23" height="20" font="0"> 45 </text>
<text top="1013" left="486" width="63" height="20" font="0">Velcade </text>
<text top="1013" left="828" width="32" height="20" font="0"> 303 </text>
<text top="1036" left="486" width="66" height="20" font="0">Veltassa </text>
<text top="1036" left="828" width="32" height="20" font="0"> 304 </text>
<text top="1060" left="486" width="77" height="20" font="0">Venclexta </text>
<text top="1060" left="828" width="32" height="20" font="0"> 305 </text>
<text top="1084" left="486" width="178" height="20" font="0">Venclexta Starting Pack </text>
<text top="1084" left="828" width="32" height="20" font="0"> 305 </text>
</page>
<page number="350" position="absolute" top="0" left="0" height="1188" width="918">
<text top="33" left="62" width="5" height="20" font="0"> </text>
<text top="57" left="62" width="5" height="20" font="0"> </text>
<text top="1128" left="830" width="32" height="20" font="0">350 </text>
<text top="96" left="62" width="343" height="20" font="0">Ventavis ............................................................. </text>
<text top="120" left="135" width="270" height="20" font="0">........................................................... </text>
<text top="143" left="131" width="275" height="20" font="0">............................................................ </text>
<text top="167" left="140" width="266" height="20" font="0">.......................................................... </text>
<text top="191" left="140" width="266" height="20" font="0">.......................................................... </text>
<text top="215" left="203" width="202" height="20" font="0">............................................ </text>
<text top="239" left="198" width="207" height="20" font="0">............................................. </text>
<text top="262" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="286" left="131" width="275" height="20" font="0">............................................................ </text>
<text top="310" left="162" width="243" height="20" font="0">..................................................... </text>
<text top="334" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="358" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="423" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="489" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="513" left="122" width="284" height="20" font="0">.............................................................. </text>
<text top="537" left="144" width="261" height="20" font="0">......................................................... </text>
<text top="560" left="126" width="279" height="20" font="0">............................................................. </text>
<text top="584" left="113" width="293" height="20" font="0">................................................................ </text>
<text top="608" left="266" width="140" height="20" font="0">.............................. </text>
<text top="608" left="121" width="144" height="20" font="0">................................</text>
<text top="632" left="108" width="297" height="20" font="0">................................................................. </text>
<text top="656" left="266" width="140" height="20" font="0">.............................. </text>
<text top="656" left="121" width="144" height="20" font="0">................................</text>
<text top="679" left="117" width="288" height="20" font="0">............................................................... </text>
<text top="703" left="284" width="122" height="20" font="0">.......................... </text>
<text top="96" left="404" width="32" height="20" font="0">306 </text>
<text top="120" left="62" width="76" height="20" font="0">Versacloz </text>
<text top="120" left="404" width="32" height="20" font="0">307 </text>
<text top="143" left="62" width="70" height="20" font="0">Verzenio </text>
<text top="143" left="404" width="32" height="20" font="0">308 </text>
<text top="167" left="62" width="81" height="20" font="0">Vigabatrin </text>
<text top="167" left="404" width="32" height="20" font="0">309 </text>
<text top="191" left="62" width="80" height="20" font="0">Vigadrone </text>
<text top="191" left="404" width="32" height="20" font="0">309 </text>
<text top="215" left="62" width="143" height="20" font="0">Vinblastine Sulfate </text>
<text top="215" left="404" width="32" height="20" font="0">342 </text>
<text top="239" left="62" width="140" height="20" font="0">Vincristine Sulfate </text>
<text top="239" left="404" width="32" height="20" font="0">342 </text>
<text top="262" left="62" width="60" height="20" font="0">Vitrakvi</text>
<text top="262" left="404" width="32" height="20" font="0">310 </text>
<text top="286" left="62" width="69" height="20" font="0">Vizimpro</text>
<text top="286" left="404" width="32" height="20" font="0">311 </text>
<text top="310" left="62" width="101" height="20" font="0">Voriconazole </text>
<text top="310" left="404" width="32" height="20" font="0">312 </text>
<text top="334" left="62" width="56" height="20" font="0">Vosevi </text>
<text top="334" left="404" width="32" height="20" font="0">313 </text>
<text top="358" left="62" width="60" height="20" font="0">Votrient</text>
<text top="358" left="404" width="32" height="20" font="0">314 </text>
<text top="390" left="62" width="16" height="20" font="12"><i><b>W</b></i></text>
<text top="393" left="78" width="4" height="18" font="13"><i> </i></text>
<text top="423" left="62" width="62" height="20" font="0">Welireg </text>
<text top="423" left="404" width="32" height="20" font="0">315 </text>
<text top="456" left="62" width="12" height="20" font="12"><i><b>X</b></i></text>
<text top="459" left="74" width="4" height="18" font="13"><i> </i></text>
<text top="489" left="62" width="59" height="20" font="0">Xalkori </text>
<text top="489" left="404" width="32" height="20" font="0">316 </text>
<text top="513" left="62" width="60" height="20" font="0">Xeljanz </text>
<text top="513" left="404" width="32" height="20" font="0">317 </text>
<text top="537" left="62" width="84" height="20" font="0">Xeljanz Xr </text>
<text top="537" left="404" width="32" height="20" font="0">317 </text>
<text top="560" left="62" width="68" height="20" font="0">Xermelo </text>
<text top="560" left="404" width="32" height="20" font="0">318 </text>
<text top="584" left="62" width="51" height="20" font="0">Xgeva </text>
<text top="584" left="404" width="32" height="20" font="0">319 </text>
<text top="608" left="62" width="62" height="20" font="0">Xifaxan </text>
<text top="608" left="404" width="32" height="20" font="0">320 </text>
<text top="632" left="62" width="50" height="20" font="0">Xolair </text>
<text top="632" left="404" width="32" height="20" font="0">321 </text>
<text top="656" left="62" width="63" height="20" font="0">Xospata </text>
<text top="656" left="404" width="32" height="20" font="0">322 </text>
<text top="679" left="62" width="58" height="20" font="0">Xpovio </text>
<text top="679" left="404" width="32" height="20" font="0">323 </text>
<text top="703" left="62" width="223" height="20" font="0">Xpovio 100 Mg Once Weekly </text>
<text top="703" left="404" width="32" height="20" font="0">323 </text>
<text top="96" left="486" width="342" height="20" font="0">Xpovio 40 Mg Once Weekly .............................</text>
<text top="120" left="702" width="126" height="20" font="0">............................</text>
<text top="143" left="698" width="130" height="20" font="0">.............................</text>
<text top="167" left="702" width="126" height="20" font="0">............................</text>
<text top="191" left="698" width="130" height="20" font="0">.............................</text>
<text top="215" left="702" width="126" height="20" font="0">............................</text>
<text top="239" left="536" width="288" height="20" font="0">................................................................</text>
<text top="262" left="540" width="288" height="20" font="0">................................................................</text>
<text top="328" left="540" width="288" height="20" font="0">................................................................</text>
<text top="394" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="417" left="536" width="288" height="20" font="0">................................................................</text>
<text top="441" left="536" width="288" height="20" font="0">................................................................</text>
<text top="465" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="489" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="513" left="554" width="274" height="20" font="0">.............................................................</text>
<text top="537" left="545" width="288" height="20" font="0">................................................................</text>
<text top="560" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="584" left="621" width="207" height="20" font="0">..............................................</text>
<text top="608" left="549" width="279" height="20" font="0">..............................................................</text>
<text top="632" left="545" width="283" height="20" font="0">...............................................................</text>
<text top="656" left="693" width="135" height="20" font="0">..............................</text>
<text top="656" left="549" width="144" height="20" font="0">................................</text>
<text top="679" left="617" width="211" height="20" font="0">...............................................</text>
<text top="703" left="680" width="144" height="20" font="0">................................</text>
<text top="703" left="536" width="144" height="20" font="0">................................</text>
<text top="703" left="824" width="23" height="20" font="0">.....</text>
<text top="537" left="833" width="5" height="20" font="0">.</text>
<text top="441" left="824" width="5" height="20" font="0">.</text>
<text top="417" left="824" width="5" height="20" font="0">.</text>
<text top="239" left="824" width="5" height="20" font="0">.</text>
<text top="96" left="828" width="32" height="20" font="0"> 323 </text>
<text top="120" left="486" width="216" height="20" font="0">Xpovio 40 Mg Twice Weekly</text>
<text top="120" left="828" width="32" height="20" font="0"> 323 </text>
<text top="143" left="486" width="213" height="20" font="0">Xpovio 60 Mg Once Weekly </text>
<text top="143" left="828" width="32" height="20" font="0"> 323 </text>
<text top="167" left="486" width="216" height="20" font="0">Xpovio 60 Mg Twice Weekly</text>
<text top="167" left="828" width="32" height="20" font="0"> 323 </text>
<text top="191" left="486" width="213" height="20" font="0">Xpovio 80 Mg Once Weekly </text>
<text top="191" left="828" width="32" height="20" font="0"> 323 </text>
<text top="215" left="486" width="216" height="20" font="0">Xpovio 80 Mg Twice Weekly</text>
<text top="215" left="828" width="32" height="20" font="0"> 323 </text>
<text top="239" left="486" width="53" height="20" font="0">Xtandi </text>
<text top="239" left="828" width="32" height="20" font="0"> 324 </text>
<text top="262" left="486" width="54" height="20" font="0">Xyrem </text>
<text top="262" left="828" width="32" height="20" font="0"> 325 </text>
<text top="295" left="486" width="11" height="20" font="12"><i><b>Y</b></i></text>
<text top="298" left="497" width="4" height="18" font="13"><i> </i></text>
<text top="328" left="486" width="54" height="20" font="0">Yervoy</text>
<text top="328" left="828" width="32" height="20" font="0"> 327 </text>
<text top="361" left="486" width="11" height="20" font="12"><i><b>Z</b></i></text>
<text top="363" left="497" width="4" height="18" font="13"><i> </i></text>
<text top="394" left="486" width="68" height="20" font="0">Zaleplon </text>
<text top="394" left="828" width="32" height="20" font="0"> 113 </text>
<text top="417" left="486" width="52" height="20" font="0">Zarxio </text>
<text top="417" left="828" width="32" height="20" font="0"> 328 </text>
<text top="441" left="486" width="50" height="20" font="0">Zejula </text>
<text top="441" left="828" width="32" height="20" font="0"> 329 </text>
<text top="465" left="486" width="66" height="20" font="0">Zelboraf </text>
<text top="465" left="828" width="32" height="20" font="0"> 331 </text>
<text top="489" left="486" width="70" height="20" font="0">Zenatane </text>
<text top="489" left="828" width="32" height="20" font="0"> 153 </text>
<text top="513" left="486" width="69" height="20" font="0">Zepzelca </text>
<text top="513" left="828" width="32" height="20" font="0"> 332 </text>
<text top="537" left="486" width="60" height="20" font="0">Zirabev </text>
<text top="537" left="837" width="23" height="20" font="0"> 24 </text>
<text top="560" left="486" width="59" height="20" font="0">Zolinza </text>
<text top="560" left="828" width="32" height="20" font="0"> 333 </text>
<text top="584" left="486" width="136" height="20" font="0">Zolpidem Tartrate </text>
<text top="584" left="828" width="32" height="20" font="0"> 113 </text>
<text top="608" left="486" width="63" height="20" font="0">Zortress </text>
<text top="608" left="828" width="32" height="20" font="0"> 342 </text>
<text top="632" left="486" width="60" height="20" font="0">Zydelig </text>
<text top="632" left="828" width="32" height="20" font="0"> 334 </text>
<text top="656" left="486" width="63" height="20" font="0">Zykadia </text>
<text top="656" left="828" width="32" height="20" font="0"> 335 </text>
<text top="679" left="486" width="135" height="20" font="0">Zyprexa Relprevv </text>
<text top="679" left="828" width="32" height="20" font="0"> 336 </text>
<text top="703" left="486" width="51" height="20" font="0">Zytiga </text>
<text top="703" left="846" width="14" height="20" font="0"> 1 </text>
<text top="727" left="62" width="5" height="20" font="0"> </text>
<text top="766" left="62" width="6" height="27" font="4"><b> </b></text>
</page>
<outline>
<item page="1">ABIRATERONE </item>
<item page="3">ACITRETIN  </item>
<item page="4">ACTIMMUNE</item>
<item page="5">ADEMPAS</item>
<item page="6">AIMOVIG</item>
<item page="7">ALECENSA  </item>
<item page="8">ALOSETRON</item>
<item page="9">ALPHA1-PROTEINASE  INHIBITOR </item>
<item page="10">ALUNBRIG  </item>
<item page="11">AMBRISENTAN  </item>
<item page="12">ARCALYST</item>
<item page="13">ARMODAFINIL  </item>
<item page="14">ASPARLAS</item>
<item page="15">AUSTEDO</item>
<item page="16">AVONEX.  </item>
<item page="17">AYVAKIT </item>
<item page="18">BALVERSA</item>
<item page="19">BANZEL</item>
<item page="20">BELEODAQ</item>
<item page="21">BENLYSTA</item>
<item page="22">BESREMI </item>
<item page="23">BETASERON</item>
<item page="24">BEVACIZUMAB </item>
<item page="26">BEXAROTENE </item>
<item page="27">BLENREP</item>
<item page="28">BOSENTAN </item>
<item page="29">BOSULIF </item>
<item page="30">BRAFTOVI  </item>
<item page="31">BRIVIACT  </item>
<item page="32">BRIVIACT INJ  </item>
<item page="33">BRUKINSA </item>
<item page="34">BUPRENORPHINE </item>
<item page="35">BUPRENORPHINE PATCH </item>
<item page="36">CABOMETYX  </item>
<item page="37">CALCIPOTRIENE </item>
<item page="38">CALQUENCE  </item>
<item page="39">CAPLYTA  </item>
<item page="40">CAPRELSA </item>
<item page="41">CARAC  </item>
<item page="42">CARBAGLU  </item>
<item page="43">CAYSTON  </item>
<item page="44">CERDELGA </item>
<item page="45">CHANTIX  </item>
<item page="46">CHLORDIAZEPOXIDE - 65  </item>
<item page="47">CLOBAZAM  </item>
<item page="48">CLOMIPRAMINE  </item>
<item page="49">CLORAZEPATE </item>
<item page="50">CLOZAPINE ODT  </item>
<item page="51">COLY-MYCIN </item>
<item page="52">COMETRIQ</item>
<item page="53">COPIKTRA</item>
<item page="54">COTELLIC </item>
<item page="55">CYSTAGON  </item>
<item page="56">CYSTARAN  </item>
<item page="58">DAURISMO  </item>
<item page="59">DEFERASIROX  </item>
<item page="60">DEMSER </item>
<item page="57">DALFAMPRIDINE  </item>
<item page="61">DESVENLAFAXINE</item>
<item page="62">DHE NASAL  </item>
<item page="63">DIACOMIT  </item>
<item page="64">DIAZEPAM  </item>
<item page="65">DICLOFENAC GEL  1% </item>
<item page="66">DICLOFENAC SOLN  </item>
<item page="67">DOPTELET</item>
<item page="68">DRIZALMA</item>
<item page="69">DRONABINOL </item>
<item page="70">DUEXIS  </item>
<item page="71">EMSAM </item>
<item page="72">ENBREL  </item>
<item page="74">ENHERTU</item>
<item page="75">EPCLUSA </item>
<item page="76">EPIDIOLEX  </item>
<item page="77">EPO </item>
<item page="79">ERIVEDGE</item>
<item page="80">ERLEADA</item>
<item page="81">ERLOTINIB  </item>
<item page="82">ESBRIET  </item>
<item page="83">EVEROLIMUS  </item>
<item page="84">EXKIVITY  </item>
<item page="85">FANAPT  </item>
<item page="86">FARYDAK  </item>
<item page="87">FASENRA  </item>
<item page="88">FENTANYL PATCH  </item>
<item page="89">FETZIMA</item>
<item page="90">FINTEPLA  </item>
<item page="91">FLUOROURACIL  </item>
<item page="92">FORTAMET/GLUMETZA  </item>
<item page="93">FORTEO  </item>
<item page="95">FOTIVDA  </item>
<item page="96">FYCOMPA </item>
<item page="97">GATTEX</item>
<item page="98">GAVRETO </item>
<item page="99">GILENYA </item>
<item page="100">GILOTRIF  </item>
<item page="101">GLATIRAMER  </item>
<item page="102">GROWTH HORMONE</item>
<item page="105">HAEGARDA </item>
<item page="106">HARVONI  </item>
<item page="107">HERCEPTIN HYLECTA </item>
<item page="108">HETLIOZ  </item>
<item page="109">HETLIOZ LQ  </item>
<item page="110">HIGH RISK  MEDICATION - 65  </item>
<item page="112">HRM - ANTICONVULSANTS - 65  </item>
<item page="113">HRM - HYPNOTICS - 65 </item>
<item page="115">HRM - SCOPOLAMINE  - 65 </item>
<item page="116">HRM-ANTIPARKINSON - 65  </item>
<item page="118">HRM-CYPROHEPTADINE - 65 </item>
<item page="119">HRM-DOXEPIN - 65  </item>
<item page="121">HRM-HYDROXYZINE  - 65  </item>
<item page="123">HRM-HYDROXYZINE  INJ  - 65 </item>
<item page="125">HRM-PROMETHAZINE - 65  </item>
<item page="127">HRMS - ANTIDEPRESSANTS  </item>
<item page="129">HRMS - CARBINOXAMINE  </item>
<item page="130">HRMS - CLEMASTINE- 65  </item>
<item page="131">HRMS - MECLIZINE - 65  </item>
<item page="132">HRMS - TCAS  </item>
<item page="133">HRM-SKELETAL MUSCLE  RELAXANTS - 65  </item>
<item page="134">HUMIRA  </item>
<item page="136">HYPNOTIC-BENZODIAZEPINES - 65  </item>
<item page="137">IBRANCE  </item>
<item page="138">ICATIBANT  </item>
<item page="139">ICLUSIG  </item>
<item page="140">IDHIFA  </item>
<item page="141">IMATINIB  </item>
<item page="142">IMBRUVICA  </item>
<item page="145">IMLYGIC  </item>
<item page="146">INCRELEX  </item>
<item page="147">INLYTA  </item>
<item page="148">INQOVI  </item>
<item page="149">INREBIC </item>
<item page="150">IR BEFORE  ER </item>
<item page="152">IRESSA  </item>
<item page="153">ISOTRETINOIN</item>
<item page="154">ITRACONAZOLE</item>
<item page="155">IVERMECTIN TAB  </item>
<item page="156">IVIG  </item>
<item page="158">JAKAFI  </item>
<item page="159">KALYDECO</item>
<item page="160">KESIMPTA </item>
<item page="161">KETOCONAZOLE </item>
<item page="162">KEYTRUDA  </item>
<item page="163">KISQALI </item>
<item page="165">KORLYM  </item>
<item page="166">KRISTALOSE</item>
<item page="167">KUVAN  </item>
<item page="168">KYNMOBI</item>
<item page="169">LAPATINIB  </item>
<item page="170">LENVIMA </item>
<item page="171">LEUPROLIDE</item>
<item page="172">LIBTAYO  </item>
<item page="173">LIDOCAINE PATCHES</item>
<item page="174">LINEZOLID  </item>
<item page="175">LONSURF  </item>
<item page="176">LORBRENA  </item>
<item page="177">LUMAKRAS  </item>
<item page="178">LUMOXITI</item>
<item page="179">LUPRON PED</item>
<item page="180">LUPRON-ENDOMETRIOSIS  </item>
<item page="181">LYNPARZA </item>
<item page="182">LYRICA CR</item>
<item page="183">MAVYRET </item>
<item page="184">MEKINIST  </item>
<item page="185">MEKTOVI  </item>
<item page="186">MEMANTINE </item>
<item page="187">MEPRON </item>
<item page="188">MODAFINIL </item>
<item page="189">MONJUVI </item>
<item page="190">MYLOTARG </item>
<item page="191">NAPROXEN-ESOMEPRAZOLE </item>
<item page="192">NATPARA </item>
<item page="193">NAYZILAM </item>
<item page="194">NERLYNX</item>
<item page="195">NEXAVAR</item>
<item page="196">NINLARO  </item>
<item page="197">NITISINONE  </item>
<item page="198">NORTHERA  </item>
<item page="199">NUBEQA </item>
<item page="200">NUEDEXTA  </item>
<item page="201">NUPLAZID  </item>
<item page="202">OCTREOTIDE</item>
<item page="203">ODOMZO</item>
<item page="204">OFEV  </item>
<item page="205">ONCASPAR  </item>
<item page="206">ONUREG  </item>
<item page="207">OPSUMIT</item>
<item page="208">ORACEA  </item>
<item page="209">ORAL-INTRANASAL FENTANYL  </item>
<item page="210">ORGOVYX  </item>
<item page="211">ORKAMBI  </item>
<item page="212">OXANDROLONE  </item>
<item page="213">OXAZEPAM - 65 </item>
<item page="214">PADCEV  </item>
<item page="215">PEGASYS  </item>
<item page="216">PEMAZYRE  </item>
<item page="217">PEPAXTO </item>
<item page="218">PHENYLBUTYRATE  </item>
<item page="219">PHESGO  </item>
<item page="220"> PIQRAY</item>
<item page="221"> POLIVY  </item>
<item page="222">POMALYST </item>
<item page="223">POTELIGEO </item>
<item page="224">PRALUENT  </item>
<item page="225"> PREGABALIN  </item>
<item page="226">PRETOMANID </item>
<item page="227">PROMACTA  </item>
<item page="230">PULMOZYME</item>
<item page="231">QINLOCK </item>
<item page="232">QUETIAPINE XR  </item>
<item page="233">QUININE SULFATE  </item>
<item page="234">REGRANEX  </item>
<item page="235">RETEVMO  </item>
<item page="236">REVLIMID  </item>
<item page="238">REZUROCK  </item>
<item page="239">RINVOQ  </item>
<item page="240">RITUXAN HYCELA  </item>
<item page="241">RITUXIMAB  </item>
<item page="244">ROZLYTREK  </item>
<item page="245">RUBRACA  </item>
<item page="246">RYDAPT  </item>
<item page="247">SANDOSTATIN  LAR  </item>
<item page="249">SARCLISA  </item>
<item page="250">SCEMBLIX  </item>
<item page="253">SIRTURO </item>
<item page="254">SKYRIZI  </item>
<item page="256">SOMAVERT </item>
<item page="257">SPRITAM  </item>
<item page="258">SPRYCEL </item>
<item page="259">STELARA  </item>
<item page="260">STIVARGA  </item>
<item page="261">SUTENT</item>
<item page="263">SYMPAZAN  </item>
<item page="264">SYNRIBO </item>
<item page="265">TABRECTA </item>
<item page="267">TAFINLAR </item>
<item page="268">TAGRISSO  </item>
<item page="269">TALTZ</item>
<item page="270">TALZENNA  </item>
<item page="271">TARGRETIN TOPICAL </item>
<item page="272">TASIGNA </item>
<item page="273">TAZAROTENE</item>
<item page="274">TAZVERIK </item>
<item page="275">TECENTRIQ </item>
<item page="277">TECFIDERA  </item>
<item page="278">TEMAZEPAM 30MG  - 65  </item>
<item page="279">TEPMETKO </item>
<item page="280">TESTOSTERONE CYPIONATE  INJ  </item>
<item page="281">TESTOSTERONE ENANTHATE  INJ</item>
<item page="282">TETRABENAZINE  </item>
<item page="283">THALOMID  </item>
<item page="284">TIBSOVO  </item>
<item page="285">TOBRAMYCIN  </item>
<item page="286">TOPICAL DOXEPIN  </item>
<item page="287">TOPICAL LIDOCAINE  </item>
<item page="288">TOPICAL TESTOSTERONES  </item>
<item page="289">TOPICAL TRETINOIN  </item>
<item page="290">TOREMIFENE </item>
<item page="291">TRELSTAR  </item>
<item page="292">TREPROSTINIL INJ </item>
<item page="293">TRIENTINE  </item>
<item page="294">TRIKAFTA  </item>
<item page="295">TRODELVY  </item>
<item page="296">TRUSELTIQ  </item>
<item page="297">TUKYSA  </item>
<item page="298">TURALIO  </item>
<item page="299">UBRELVY  </item>
<item page="300">UKONIQ  </item>
<item page="301">VALCHLOR  </item>
<item page="302">VALTOCO  </item>
<item page="303">VELCADE  </item>
<item page="304">VELTASSA  </item>
<item page="305">VENCLEXTA  </item>
<item page="306">VENTAVIS </item>
<item page="307">VERSACLOZ</item>
<item page="308">VERZENIO  </item>
<item page="309">VIGABATRIN  </item>
<item page="310">VITRAKVI  </item>
<item page="311">VIZIMPRO  </item>
<item page="312">VORICONAZOLE  </item>
<item page="313">VOSEVI  </item>
<item page="314">VOTRIENT  </item>
<item page="315">WELIREG  </item>
<item page="316">XALKORI  </item>
<item page="317">XELJANZ  </item>
<item page="318">XERMELO </item>
<item page="319">XGEVA </item>
<item page="320">XIFAXAN  </item>
<item page="321">XOLAIR  </item>
<item page="322">XOSPATA </item>
<item page="323">XPOVIO  </item>
<item page="324">XTANDI  </item>
<item page="325">XYREM  </item>
<item page="327">YERVOY  </item>
<item page="328">ZARXIO  </item>
<item page="329">ZEJULA.  </item>
<item page="331">ZELBORAF  </item>
<item page="332">ZEPZELCA </item>
<item page="333">ZOLINZA  </item>
<item page="334">ZYDELIG  </item>
<item page="335">ZYKADIA  </item>
<item page="336">ZYPREXA RELPREVV  </item>
<item page="337">PART B  VERSUS PART D  </item>
<item page="343">INDEX</item>
</outline>
</pdf2xml>
